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Cholesterol is a vital component of the cell membrane that is crucial for 
the central nervous system (CNS) function. As the brain cholesterol metabolism 
is tightly regulated, any metabolic changes may perturb normal brain 
physiological functions. Aberrant levels of cholesterol and its derivatives such 
as oxysterols, has been implicated in neurological pathologies such as 
Alzheimer’s disease (AD) and stroke. However, little is known regarding the 
potential regulatory roles of cholesterol or oxysterols in gene expression when 
they exist in excessive levels in such pathologies. This study was therefore 
conducted using microarray-based approaches to elucidate the effects of 
cholesterol or oxysterols on gene expression changes in the brain and cerebral 
vessels, which may contribute to the CNS disorders mentioned above.  
After 1-day post-intracortical injection of cholesterol or oxysterols i.e. 
7β-hydroxycholesterol (7β-HC) and 7-ketocholesterol (7-KC) at low dose in the 
rat prefrontal cortex (PFC), microarray analyses has identified 1365 
differentially expressed genes (DEGs), which were commonly affected by both 
7β-HC and 7-KC treatments. Among these DEGs, downregulation was the 
primary trend and genes encoding G-protein coupled receptors (GPCRs) 
encompassed the majority of the genes found in the top network based on 
Ingenuity Pathway Analysis (IPA). Downregulation of oxytocin receptor 
(OXTR) was validated by real-time PCR and Western blot. Electron 





terminals. Thus, increased oxysterols may affect synaptic function through 
transcriptional repression of GPCRs. 
Besides that, comprehensive gene expression profiles in the middle 
cerebral artery (MCA) of New Zealand White (NZW) rabbits exposed to two 
stroke risk factors i.e. hypercholesterolemia and/or hypertension, by dietary 
supplementation with cholesterol and/or the 2-kidney, 1-clip (2K1C) method, 
was elucidated. Microarray and IPA analyses of the MCA from the 
hypercholesterolemic rabbits showed DEGs related to similar ‘node molecules’ 
as the hypertensive rabbits, despite relatively low percentage of ‘common 
genes’ between the two conditions. Upregulated common genes were related to 
‘node molecules’ like hepatocyte nuclear factor 4A (HNF4A), serpin peptidase 
inhibitor, clade B, member 2 (SERPINB2), and amyloid precursor protein 
(APP). Increased levels of HNF4A mRNA and protein were verified in the 
aorta. 
In addition, hypercholesterolemia and hypertension are also risk factors 
for AD. Using the same animal models of hypercholesterolemia and 
hypertension, gene expression alterations were analyzed in the frontal cortex 
(FC). In FC, hypercholesterolemia induced more gene expression changes than 
hypertension. The comparison between gene expression profiles of the FC and 
MCA, surprisingly, revealed a majority of the downregulated DEGs in FC were 
found in MCA of the same hypercholesterolemic rabbits. Likewise, common 
‘node molecules’ were also noted in these tissues after exposure to 
hypercholesterolemia. Interestingly, ‘node molecules’ that were affected by 





associated with various pathways involving APP and its proteolytic fragments. 
A significantly increased Aβ-immunolabeled neurons was observed in the FC 
of ‘hypercholesterolemia plus sham/hypertension’ rabbits. 
To investigate the possible regulation of APP and its related genes by 
the sterol regulatory element binding protein (SREBP) signaling, which may be 
affected during hypercholesterolemia, expression of APP/amyloid-β (Aβ) and 
SERPINB2 after treatment with SREBP inhibitors were studied in vitro. 
Increased expression of APP/Aβ and SERPINB2 induced by SREBP inhibition 
were observed in the human endothelial and neuroblastoma cell lines, thus, 
implying a possible regulation of SREBP in the expression of these genes. 
In conclusion, cholesterol exerted different acute and chronic effects on 
gene expression changes in the brain and cerebral vessels in present study. 
Acute intracortical administration of oxysterols at low concentration were 
capable of inducing more severe gene expression changes compared with 
cholesterol. In contrast, consumption of a high cholesterol diet for an extended 
period chronically induced massive gene expression changes in the brain and 
cerebral vessels, possibly through the mediation of SREBP signaling, and it 
might affect similar pathways in both of these tissues. Therefore, current results 
could shed light on the link between cholesterol and neurological disorders, as 
well as open new research avenue for elucidation of potential pathological 
mechanisms.  
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Sterol lipids are the main non-polar cell membranes lipids with 
cholesterol predominates in mammals (van Meer et al., 2008). Cholesterol is an 
essential structural component of eukaryotic cellular membrane, vital for 
membrane organization, dynamics and function (Liscum and Underwood, 1995; 
Liu et al., 2010). It modulates fluid membrane rigidity by limiting passive 
permeability and enhancing lipid bilayer’s mechanical durability (Simons and 
Ikonen, 2000). Lipid rafts are membrane regions with dynamic nanoscale 
assemblies enriched in sphingolipid, cholesterol and 
glycosylphosphatidylinositol (GPI)-anchored proteins (Hancock, 2006). They 
are thought to serve as a platform to co-localize proteins that participate in 
intracellular signaling pathways (Calder and Yaqoob, 2007), ion channel 
activities (Koyrakh et al., 2005) and vesicular exocytosis aided by secretory 
proteins assembly (e.g. soluble N-ethylmaleimide-sensitive factor attachment 
protein receptors (SNAREs)) into lipid rafts (Ong et al., 2010). Cholesterol is 
responsible for lipid rafts maintenance in a liquid-ordered phase (Marwali et al., 
2003). It maintains the raft assembly together and as a molecular spacer between 
sphingolipids hydrocarbon chains (Simons and Toomre, 2000). Besides that, 
cholesterol’s interaction with distinct classes of membrane protein within lipid 
rafts affects the assembly, stability and function of the membrane proteins (Lee, 
2004). In contrast, removal of cholesterol from lipid rafts by cyclodextrin 
(membrane depleting agent), promotes disassociation of raft proteins from the 
lipids and renders these proteins non-functional (Simons and Toomre, 2000).  
Cholesterol participates in a numerous biological processes like 
regulation of homeostasis and transmembrane communication within or 
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between cellular compartments (Liu et al., 2010). It plays important role in 
cellular metabolism and signal transduction through interaction with membrane 
proteins and enzymes (Pfrieger, 2003b). Furthermore, it modulates the function 
and organization of membrane proteins and enzymes (Burger et al., 2000). In 
addition, cholesterol is an essential precursor and a source of bioactive 
molecules for diverse biological processes regulated in both the periphery and 
central nervous system (CNS). For example, cholesterol is required for the 
biosynthesis of oxysterol, sterol hormones, vitamin D and bile acids (Simons 
and Ikonen, 2000; Liu et al., 2010). 
 
 Physicochemical Properties of Cholesterol 
Cholesterol structure is composed of three regions: a hydrocarbon tail 
(lateral chain), a ring structure region with four hydrocarbon rings (A, B, C and 
D) and a hydroxyl group (Figure 1.1) (Yeagle, 1985; Vejux et al., 2008). 
Cholesterol is mainly a hydrophobic molecule due to the steroid ring backbone, 
sterane. However, cholesterol’s amphiphilic nature (due to the presence of 3-β 
hydroxyl moiety), causes cholesterol to be arranged in the membrane bilayer 
with its long axis vertical to the membrane’s plane. The hydroxyl group is 
orientated to face the aqueous surroundings while the hydrophobic ring is 











Figure 1.1. Structure of cholesterol.  (Vejux et al., 2008) 
Cholesterol is asymmetrically distributed across the plane of the 
membrane with higher levels present in the cytosolic leaflet (Bach and Wachtel, 
2003). In addition, it is more abundant in plasma membrane and late secretory 
pathways than in membranes of a certain subcellular organelles such as 
mitochondria (Brown and London, 2000).  
 
 Cholesterol in the Brain  
The brain is the most cholesterol-rich organ in the body (Björkhem and 
Meaney, 2004). Although the human brain only accounts for 2% of the total 
body weight, it contains about 25% of the total body cholesterol and cholesterol 
derivatives (~20 mg/g). More than 99.5% of the brain cholesterol is present in 
the form of unesterified, free cholesterol (Björkhem and Meaney, 2004; 
Dietschy and Turley, 2004; Vaya and Schipper, 2007). In the brain, cholesterol 
is divided into two pools: major pool with 70% of the brain cholesterol residing 
in myelin sheaths, and minor pool with the 30% residing in plasma membranes 
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of glial cells (20%) and neurons (10%) (Dietschy and Turley, 2004). For the 
former, cholesterol enrichment in myelin sheaths is needed for electrical signal 
transmission along axons (Dietschy and Turley, 2004). On the other hand, 
cholesterol in the neural membranes is essential in membrane organization, 
dynamics, function and sorting (Simons and Ikonen, 2000). Besides, it is also 
associated with the assembly and maintenance of lipid rafts (Simons and 
Ehehalt, 2002). Lipid rafts are involved in various activities in the CNS such as 
neuronal excitability and synaptic transmission (Tsui-Pierchala et al., 2002). 
Moreover, cholesterol is required for the development and function of neuron 
and synapse (Sun et al., 2014), as well as optimal neuroplasticity and behavior 
(Farooqui, 2011). Chelation of cholesterol by cyclodextrin has been shown to 
impair neuronal synaptic transmission and plasticity associated with activation 
of alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA), N-
methyl-D-aspartate (NMDA) and kainic acid (KA) receptors (Frank et al., 
2008).  
Furthermore, cholesterol is a precursor for oxysterols and neurosteroids 
biosynthesis (Simons and Ikonen, 2000). Apart from regulating the activities of 
membrane-bound enzymes, receptors and ion channel (Simons and Ikonen, 
2000), cholesterol also involves in endocytosis and antigen expression 
(Farooqui, 2011). In addition, cholesterol regulates various signaling molecules 
in CNS, neuronal function (e.g. memory and neural oxidative stress reactions) 
as well as development of neurodegenerative diseases (Pfrieger, 2003a; Nelson 
and Alkon, 2005). 
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1.2.1. Biosynthesis of Cholesterol  
Unlike cholesterol in the peripheral organs, cholesterol in the brain is 
neither derived from dietary uptake nor hepatic synthesis due to its inability to 
cross the blood brain barrier (BBB) (Jurevics and Morell, 1995). BBB is formed 
by tight junctions between capillary endothelial cells, separating circulating 
blood from extracellular fluid in CNS (Orth and Bellosta, 2012). Hence, brain 
cholesterol is supplied by de novo synthesis (Farooqui, 2011). The highest rate 
of cholesterol biosynthesis in the brain is found in the first postnatal weeks in 
humans and this may be associated with the development of CNS (Farooqui, 
2011). In contrast, cholesterol production is reduced in adult as cholesterol is 
recycled efficiently (Dietschy and Turley, 2001) and the half-life of brain 
cholesterol is around 170 days (Andersson et al., 1990). At cellular level, 
oligodendrocytes possess the highest capacity for cholesterol biosynthesis, 
followed by astrocytes and neurons (Farooqui, 2011). The endoplasmic 
recticulum (ER) is the major intracellular site for cholesterol biosynthesis while 
some are synthesized in the peroxisomes (Kovacs et al., 2001). This is an 
energy-consuming process that involves multiple intermediates and enzymes 
(Farooqui, 2011). 
The first step of cholesterol biosynthesis involves the transformation of 
acetyl-CoA and acetoacetyl-CoA into 3-hydroxyl-3 methyl-glutaryl-CoA 
(HMG-CoA), which is then converted to mevalonate by HMG-CoA reductase 
(Farooqui, 2011). The conversion of HMG-CoA into mevalonate is the rate-
limiting step in cholesterol biosynthesis (Farooqui, 2011). Mevalonate is 
phosphorylated to isopentenyl pyrophosphate (IPP) and other active isoprenoid 
units. These units are then condensed to form geranyl pyrophosphate (GPP) and 
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farnesyl pyrophosphate (FPP) through reactions that are catalyzed by farnesyl 
pyrophosphate synthase (Farooqui, 2011). The synthesis of squalene starts from 
the formation of FPP in a reaction that is catalyzed by squalene synthase, and 
squalene is further converted to lanosterol by lanosterol synthase (Farooqui, 
2011). Subsequently, cholesterol biosynthesis is divided into two alternative 
pathways, namely the Bloch pathway and Kandutsch-Russell pathway 
(Farooqui, 2011). The former involves the conversion of lanosterol to 
zymosterol, followed by desmosterol and cholesterol. In contrast, the latter (the 
primary route of cholesterol biosynthesis in humans (Kandutsch and Chen, 
1975)) requires the conversion of lanosterol to lathosterol, and finally to 7-
dehydrocholesterol before producing cholesterol (Lutjohann et al., 2002; Thelen 
et al., 2006). Besides that, CYP51 catalyzes the conversion of lanosterol to 
cholesterol (Farooqui, 2011). The cholesterol biosynthesis pathway is illustrated 



























Figure 1.2. Cholesterol biosynthesis pathway. [Adapted from (Farooqui, 2011)]. 
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1.2.2. Regulation of Cholesterol Biosynthesis 
Cholesterol levels of neural membranes are tightly regulated in order to 
maintain cholesterol homeostasis. One of the regulatory mechanisms involves 
insulin-induce genes (INSIGs) and sterol regulatory element binding proteins 
(SREBPs) (DeBose-Boyd, 2008). This mechanism is controlled through 
feedback regulation by sterol, including cholesterol per-se (Brown and 
Goldstein, 1997; Farooqui, 2011). High level of cholesterol is known to inhibit 
the maturation of the SREBP.  
SREBPs are membrane-bound transcription factors. There are two genes 
that encode three known mammalian SREBP isoforms (SREBP-1a, SREBP-1c, 
and SREBP-2) (Brown and Goldstein, 1999). SREBP-1a is involved in fatty 
acid and cholesterol synthesis, SREBP-1c in fatty acid synthesis, and SREBP-2 
in cholesterol synthesis and uptake (Goldstein et al., 2006). In cells with low 
cholesterol level, SREBP forms a complex with SREBP cleavage activation 
protein (SCAP). The SREBP-SCAP complex is transported from the ER to 
Golgi to undergo a sequential proteolytic cleavage by Site-1 protease (S1P) and 
Site-2 protease (S2P) (Figure 1.3). This subsequently releases the N-terminus 
of SREBP which is also known as the mature SREBP (mSREBP). mSREBP is 
further transported from the Golgi into the nucleus (Figure 1.3) where it 
activates gene transcription by binding to sterol regulatory element (SRE) 
sequences in the promoter region of target genes. A classic example of a SREBP 
target gene is the HMG-CoA reductase (Figure 1.3) (Brown and Goldstein, 
1999; Osborne and Espenshade, 2009). On the other hand, excess ER 
cholesterol inhibits the translocation of SREBP-SCAP complex through the 
binding of cholesterol to SCAP, and SCAP to INSIG (an ER-resident protein) 
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(Osborne and Espenshade, 2009). Besides, oxysterols can promote the retention 
of SREBP-SCAP complex in the ER by binding independently to INSIG 
(Osborne and Espenshade, 2009). Additionally, sterols can selectively inhibit 
the S1P-mediated SREBP cleavage while indirectly regulate the activity of S2P 















Figure 1.3. SREBP activation pathway.In ER, SREBP forms a complex with 
SCAP and it is transported to Golgi for S1P- and S2P-mediated proteolytic 
cleavage. This releases soluble mSREBP into the nucleus and it binds to the 
SRE at the promoter region for transcription of target genes involved in fatty 
acid synthesis, and cholesterol synthesis and uptake.  
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1.2.3. Transport and Storage of Cholesterol 
The rate of cholesterol synthesis in the brain is relatively low in adults 
(Björkhem and Meaney, 2004) with the half-life of cholesterol in the mature 
brain is at least 5 years (Bjorkhem et al., 1998). While the cholesterol in the 
myelin sheaths are produced by oligodendrocytes, astrocytes are responsible for 
brain cholesterol synthesis in the adult nervous system (Farooqui, 2011). 
Astocytes produce two to three times more cholesterol than neurons. Astrocyte 
secrete cholesterol together with lipoprotein particles such as apolipoprotein E 
(APOE), where APOE acts as a cholesterol carrier (DeMattos et al., 2001; 
Björkhem and Meaney, 2004; Vance et al., 2005). The APOE-cholesterol 
complexes are transported out of the astrocytes through the cholesterol efflux 
regulatory proteins, ATP-binding cassette, subfamily A, member 1 (ABCA1) 
and ATP-binding cassette, subfamily G, member 1 (ABCG1). These complexes 
are accepted by low-density lipoprotein receptors (LDLRs) in neurons (Vance 
et al., 2005) and may enter the neuron via receptor-mediated endocytosis. Free 
cholesterol is released into the cell and it can be stored in the cytoplasm lipid 
droplets after being esterified by acyl-coenzyme-A cholesterol acyltransferase 
(ACAT) in the ER (Brown and Jessup, 2009). 
 
1.2.4. Elimination of Cholesterol  
The degradation of brain cholesterol is dependent on the liver function 
as both neurons and glial cells are incapable of this process (Sun et al., 2014). 
Four cytochrome P450-dependent hydroxylases: CYPs 7A1, 27A1, 11A1 AND 
46A1, are present in both neural and non-neural tissues (Farooqui, 2011). These 
enzymes are vital in the elimination of excess cholesterol in the brain through 
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BBB into the bloodstream from where it is further transported to the liver by 
plasma lipoproteins. CYP46A1, a microsomal enzyme, is the key player of 
cholesterol turnover in the CNS, accounting for the majority of the cholesterol 
elimination process from the brain (Farooqui, 2011). It converts excess brain 
cholesterol into 24S-hydroxycholesterol (24S-HC) which is subsequently 
metabolized in the liver (Saucier et al., 1993). In the liver, 24S-HC is converted 
to bile acids and they are excreted in bile (Pikuleva, 2006). 24S-HC is a vital 
metabolite in cholesterol metabolism (Russell, 2000; He et al., 2006) and 
plasma levels of 24S-HC are used as an index for elimination of brain 
cholesterol (Lutjohann et al., 1996). Besides 24S-HC, other naturally occurring 
oxysterols in the body are 27-hydroxycholesterol (27-HC) and 25-
hydroxycholesterol (25-HC). 24S-HC is a brain-specific oxysterol while 27-HC 
is synthesized in the periphery (Farooqui, 2011).  
 
1.2.5. Cholesterol and Blood Brain Barrier (BBB) 
Cholesterol transport between the circulation and the cerebrospinal fluid 
(CSF) is deterred by the presence of BBB (Dietschy, 2009) and only a little 
amount of smaller high-density lipoproteins (HDLs) is able to traverse BBB into 
the brain (Wang and Eckel, 2014). Therefore, cholesterol homeostasis in the 
brain is not influenced by unmodified cholesterol in the circulation. On the other 
hand, oxysterols such as 24S-HC and 27-HC are able to cross the BBB easily 
(Sun et al., 2014). 24S-HC is also suggested to modulate cholesterol 
biosynthesis as reduction of this oxysterol is associated with decreased 
biosynthesis (Lund et al., 2003). In contrast to 24S-HC, 27-HC can be 
transported from the circulation into the brain through BBB (Heverin et al., 
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2005). CYP27A1 enzyme produces 27-HC. Although CYP27A1 gene exists in 
most organs and tissues, it is only present in small amount in the brain (Heverin 
et al., 2005). 27-HC can be metabolized by CYP7B enzyme into 7α-hydroxy-3-
oxo-4-cholestenoic acid (7-HOCA) in neurons. 7-HOCA is able to cross the 
BBB and it can be transported out from the brain into the liver for further 
metabolism (Martin et al., 1997; Meaney et al., 2007).  
  




Oxysterols are 27-carbon atom cholesterol oxidation products that are 
generated either by enzymatic oxidation or direct oxidation of cholesterol, 
called autoxidation (Vejux et al., 2008). Like cholesterol, oxysterols are 
composed of a hydrocarbon tail (lateral or side-chain), a ring structure region 
with four hydrocarbon rings and a hydroxyl group (Figure 1.4). Oxidation of 
cholesterol occurs on the side-chain or on the sterol ring structure (Vejux et al., 
2008). In general, side-chain oxygenated sterols are usually originated from 
enzymatic oxidation whereas ring oxygenated sterols are likely to be produced 
by autoxidation (Brown and Jessup, 2009).  




Figure 1.4. Structures of major oxysterols. (Vejux et al., 2008) 
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Enzymatic oxidation of cholesterol requires the activity of cytochrome 
P450-dependent hydroxylases that is responsible for the generation of 
endogenous oxysterols. These oxysterols include hepatic 7α-
hydroxycholesterol (produced by CYP7A1), 24S-HC in brain and retina 
(produced by CYP46A1), and 27-HC in most tissues (produced by CYP27A1) 
(Vejux et al., 2008). An exception is 25-HC which is produced by cholesterol 
25-hydroxylase, a non-heme iron protein enzyme (Bjorkhem, 1992).  
In contrast, autoxidation of cholesterol usually occurs at position 4, 5, 6 
and 7. These are the most responsive sites for autoxidation due to the presence 
of a double bond on the B hydrocarbon ring which is prone to free radical attacks 
(Vejux et al., 2008). For example, cholesterol autoxidation involves a direct 
radical attack by reactive oxygen species (ROS) such as hydroxyl radical, 
leading to an abstraction of an allylic hydrogen atom at position 7 (Brown and 
Jessup, 2009). This eventually forms cholesterol hydroperoxides like 7α-
hydroperoxycholesterol (7α-OOHC) and 7β-hydroperoxycholesterol (7β-
OOHC) (Brown and Jessup, 2009) with the former being the major oxysterol 
synthesized at the early steps of cholesterol autoxidation (Brown et al., 1997). 
They can be further processed by both enzymatic and non-enzymatic pathways. 
Following the non-enzymatic pathway, 7α-hydroxycholesterol (7α-HC), 7β-
hydroxycholesterol (7β-HC) and 7-ketocholesterol (7-KC) are produced 
(Brown and Jessup, 2009). These are the main non-enzymatically generated 
oxysterols that are found in most tissues (Brown and Jessup, 1999). Other 
oxysterols produced by autoxidation are 5α,6α-epoxycholesterol, 5β,6β-
epoxycholesterol, and cholestane-3β,5β,6β-triol (Vejux et al., 2008). 
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 Distribution of Oxysterols 
Oxysterols are maintained at 103- to 106-fold lower levels than 
cholesterol under physiological conditions (Björkhem and Diczfalusy, 2002; 
Brown and Jessup, 2009). They differ from cholesterol in the presence of an 
additional polar moiety, which facilitates their transport through cellular 
membranes (Brown and Jessup, 2009; Jusakul et al., 2011). Similar to 
cholesterol, many oxysterols are hydrophobic to a large extent and restricted to 
non-polar locations within the cells such as membranes and lipid droplets 
(Brown and Jessup, 2009). Incorporation of these polar moieties into the 
hydrophobic regions of cell membrane induces local re-arrangement of acyl 
chains (Meaney et al., 2002; Jusakul et al., 2011). Small modification in the 
structures of oxysterols relative to cholesterol may affect their interaction with 
other membrane lipids and this may create significant effects on membrane 
structure (Wang et al., 2004; Massey and Pownall, 2005). In addition, oxysterols 
have been reported to increase the fluidity of brain synaptic plasma membrane 
(Wood et al., 1995).  
 
 Metabolism of Oxysterols 
Similar to cholesterol, oxysterols participate in various enzymatic 
metabolic pathways (Gill et al., 2008). Firstly, ACAT and lecithin-cholesterol 
acyltransferase (LCAT) can efficiently esterify oxysterol in cells and plasma, 
respectively. For example, 7-KC is esterified to form 7-ketocholesteryl ester 
(Brown and Jessup, 2009). Secondly, both cholesterol and some ring-
oxygenated oxysterol are targets of sterol 27-hydroxylase (CYP27A1) (Brown 
and Jessup, 2009). Metabolism of 7-KC to 27-hydroxylated 7-KC by CYP27A1 
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and subsequently to more polar metabolites, may facilitate their removal from 
the cell (Brown et al., 2000; Lyons and Brown, 2001). Metabolites of 7-KC have 
reduced toxicity and they are more easily eliminated compared with the parent 
oxysterol (Brown and Jessup, 2009). Thirdly, 11β-hydroxycholesteroid 
dehydrogenase type 1 (CYP11β), a P450 enzyme, can catalyze the reduction of 
7-KC to 7β-HC (Jessup and Brown, 2005). Lastly, many oxysterols including 
both ring-oxygenated (Fuda et al., 2007) and side-chain oxygenated (Chen et 
al., 2007) oxysterols, are substrates of the cholesterol sulfotransferase 
(SULT2B1b) enzyme (Brown and Jessup, 2009). This may be an important 
mode of oxysterol clearance as expression of SULT2B1b seems to confer 
cellular protection against toxic effects of some autoxidatively generated 
oxysterols (Fuda et al., 2007). Besides, SULT2B1b also inhibits cellular liver X 
receptor (LXR) signaling induced by endogenous side-chain oxysterols (Chen 
et al., 2007; Ma et al., 2008). 
 
 Elimination of Oxysterols 
The elimination process oxysterols requires their removal from cells to 
lipophilic acceptors through the activities of specific membrane lipid 
transporters such as ABCA1, ABCG1 and scavenger receptor BI (SRBI) 
(Jessup et al., 2006). These elimination routes are used by most oxysterols 
except for 24S-HC and 27-HC (Bjorkhem, 2006). ABCA1 is involved in the 
export of oxysterols to apolipoprotein A1 (APOA1), the key constituent of HDL 
(Brown and Jessup, 2009). ABCG1 is thought to promote 7β-HC and 7-KC 
efflux to HDL and protect cells against the impairment of endothelial cell 
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function and apoptotic effects induced by these autoxidatively generated 
oxysterols (Engel et al., 2007; Terasaka et al., 2007). 
 
 Oxysterols and Cholesterol Homeostasis 
The pivotal roles of cholesterol in normal cell function is very well-
known but excess of cholesterol can be deleterious (Brown and Jessup, 2009). 
Various mechanisms exist to control cholesterol accumulation including the 
involvement of oxysterols in cholesterol homeostasis. Oxysterols are important 
in the detection and regulation of excess cholesterol (Brown and Jessup, 2009). 
Firstly, HMG-CoA reductase degradation can be accelerated by certain 
oxysterols in addition to the involvement of other regulators in the cholesterol 
biosynthetic pathway (DeBose-Boyd, 2008). Secondly, oxysterols suppress the 
SREBP activation pathway. As mentioned above, SREBP activation requires 
the translocation from the ER to Golgi where it undergoes sequential proteolytic 
cleavage by two proteases before being imported into the nucleus for the 
transcription of target genes (Brown and Jessup, 2009). When cholesterol levels 
exceed a critical threshold (5% of total ER lipid) (Radhakrishnan et al., 2008), 
retention of SREBP-SCAP complex in ER by INSIG is governed by the binding 
of cholesterol to SCAP (Radhakrishnan et al., 2004) and oxysterols to INSIG 
(Radhakrishnan et al., 2007). As a result, lipogenic gene expression is arrested 
(Brown and Jessup, 2009). Thirdly, oxysterols help to enhance cholesterol 
efflux by activating LXR. Oxysterols such as 24S-HC and 27-HC, are natural 
ligands for LXR nuclear receptors, which are responsible for the expression of 
genes that encode cholesterol export proteins (i.e. ABCA1, ABCG1 and APOE) 
(Björkhem and Meaney, 2004; Brown and Jessup, 2009). Besides that, 
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oxysterols such as 25-HC, promote cholesterol storage as ester whereas 24S,25-
epoxycholesterol has special role in monitoring and modulating cholesterol 
synthesis (Brown and Jessup, 2009). Furthermore, oxysterol-membrane 
interactions may regulate cholesterol homeostasis in cells through the 
modulation of the lipid environment properties, in which INSIG and SCAP are 
located (Brown and Jessup, 2009). Together, oxysterols play supporting roles 
to cholesterol and are suggested to exert more or less influence in different 
tissues under different physiological conditions (Gill et al., 2008). 
 
 Other Roles of Oxysterols in the Brain 
Specific oxysterols are important in various physiological functions in 
the brain. Other than being involved in sterol transport between tissues, bile acid 
biosynthesis and gene transcription, oxysterols are implicated in neural cell 
differentiation in different neural cell types (Farooqui, 2011). Cellular 
differentiation is a process that involves the transformation of a generic cell into 
a specific cell type following specific triggers from the body or the cell per-se 
(Farooqui, 2011). For example, 22R-hydroxycholesterol, an intermediate in the 
pathway of pregnenolone synthesis from cholesterol, is able to induce neurite 
outgrowth in vitro (Farooqui, 2011). This establishes an association between the 
modulation of progesterone synthesis by 22R-hydroxycholesterol with neuronal 
plasticity, cognitive function and neurodegeneration (Guarneri et al., 2000).  
In addition, oxysterols are also associated with exocytosis and apoptosis. 
Exocytosis is a process that releases soluble proteins, lipids, and 
neurotransmitters from the intracellular vesicles into the extracellular 
compartment (Farooqui, 2011). Enhanced exocytosis has been observed in rat 
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pheochromocytoma PC12 cells after being treated with 7-KC, 24S-HC or 5β,6β-
epoxycholesterol (Ma et al., 2010). 7-KC-induced neurotransmitter release is 
dependent on the integrity of cholesterol-rich lipid domains on cellular 
membranes as well as the increased levels of intracellular calcium (Ma et al., 
2010). On the other hand, apoptosis is one of the normal developmental 
processes and cellular responses to stress (Oppenheim, 1991). The presence of 
nuclear chromatin condensation, DNA fragmentation, cell shrinkage, bleb and 
apoptotic body formation are characteristics of apoptosis (Farooqui et al., 2004). 
Cytotoxic effects of oxysterols have been demonstrated in human 
neuroblastoma cell line, SH-SY5Y, oligodendrocyte cell line (158N) and 
endothelial cells (Farooqui, 2011). 7β-HC, 7-KC and 25-HC are toxic to neural 
cell cultures (Chang et al., 1998; Ong et al., 2003). Additionally, both 7β-HC 
and 7-KC control interleukin-1β (IL-1β) secretion and the active form of this 
cytokine aids apoptosis (Farooqui, 2011). 
 Besides that, 7-KC generates synergistic effects with 1-methyl-4-
phenylpyridinium (MPP+) which is selectively toxic to dopaminergic neurons. 
MPP+ has been extensively studied as a model of Parkinson's disease (PD) 
(Nakamura et al., 2000; Farooqui, 2011). Enhanced MPP+-mediated nuclear 
damage, decreased mitochondrial transmembrane potential, elevated cytosolic 
cytochrome c accumulation, activated caspase-3, increased ROS synthesis and 
depleted glutathione have been shown to be induced by 7-KC in differentiated 
PC12 cells (Kim et al., 2006). Furthermore, aberrant calcium channel functions 
may potentially mediate cytotoxicity induced by autoxidatively generated 
oxysterols. Interestingly, antioxidant, nitric oxide scavengers (Han et al., 2007; 
Luthra et al., 2008) and calcium channel blocker treatments (Lemaire-Ewing et 
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al., 2005; Ryan et al., 2006) are able to alleviate these cytotoxic effects of 
oxysterols. Although the exact mechanism that underlies the toxicity of 
autoxidatively generated oxysterols is yet to be elucidated, these effects are 
related to apoptotic cell death (Lizard et al., 2000). Additionally, the presence 
of 24S-HC and 25-HC is plasma is associated with neurodegeneration in the 
brain (Farooqui, 2011). 
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3. Cholesterol, Oxysterols and Neurological Disorders 
 Excitotoxicity and Neurodegeneration 
Excitotoxicity is defined as a pathological process where neurons are 
damaged and destroyed, due to enhanced release of excitatory neurotransmitters 
(i.e. glutamate and its analogs) from injured neurons (Ong et al., 2010). 
Glutamate is the most abundant excitatory neurotransmitter in the CNS and it is 
released from the synaptic vesicles in both pre- and post-synaptic neurons. 
Excitotoxicity is the result of an over-activation of glutamate receptors which 
include AMPA and NMDA receptors (Ong et al., 2010). The binding of 
glutamate and its analogs to these receptors induce excitotoxicity through a 
large influx of calcium into the cell (Lipton and Rosenberg, 1994). Increased 
intracellular calcium will give rise to a series of aberrant downstream 
biochemical reactions that involve calcium-dependent proteases, protein 
kinases, nucleases and phospholipases (Berger and Garnier, 1999; Meldrum, 
2000). These reactions are related to free radical production and mitochondrial 
dysfunction that will eventually cause cell death (Farooqui and Horrocks, 1991; 
Arundine and Tymianski, 2003).  
Neurodegeneration is a collection of neurological symptoms that 
encompasses a region-specific, premature and gradual death of certain groups 
of neurons in the brain (Leker and Shohami, 2002). A prominent feature of 
neurodegenerative diseases is the accumulation of intracellular or extracellular 
cerebral deposits of misfolded proteins. For instance, accumulation of amyloid-
β (Aβ), α-synuclein and huntingtin are demonstrated in Alzheimer’s disease 
(AD), PD and Huntington’s disease, respectively (Farooqui, 2010). 
Excitotoxicity has a pivotal role in the progression of neurodegenerative 
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diseases as unregulated release of excitatory neurotransmitters is a vital 
characteristic of neuronal damage in various neurological disorders (Doble, 
1999). Neurochemical alterations induced by excitotoxicity resonate the 
changes observed in both acute neuronal damage (e.g. stroke, spinal cord injury 
and traumatic brain injury) and chronic neurodegenerative diseases (e.g. AD) 
(Wang et al., 2005; Farooqui et al., 2008). In acute neuronal injury, neurons 
degenerate quickly (minutes to hours) due to immense glutamate release, 
sudden hypoxia and ATP depletion, aberrant ion homeostasis as well as 
induction of apoptosis via mitochondrial release of cytochrome c (Farooqui and 
Horrocks, 1994). However, in neurodegenerative diseases, ion homeostasis is 
maintained to a restricted extent and neuronal death may need a longer duration 
(Farooqui and Horrocks, 2007). Besides, pathological protein aggregation can 
exacerbate the interaction among excitotoxicity, oxidative stress and 
neuroinflammation (Farooqui and Horrocks, 2007). 
 
3.1.1. Cholesterol and Oxysterols in KA-Induced Excitotoxicity and 
Neurodegeneration 
KA is a non-degradable glutamate analog that causes the loss of neurons, 
especially in the striatal and hippocampal region (Farooqui et al., 2008). The 
effects of KA are mediated through KA receptors. Administration of KA in 
rodents is a well-known animal model for excitotoxicity and neurodegeneration 
(Farooqui et al., 2008). Intracerebroventricular injection of KA in rats has 
demonstrated increased cholesterol immunostaining (Ong et al., 2003), reduced 
expression of SREBP2 and HMG-CoA reductase, enhanced cholesterol esters 
as well as elevated expression of ACAT1 and ABCA1 in the lesioned 
Chapter I - Introduction 
 
25 
hippocampus (Kim and Ong, 2009; Ong et al., 2010; Kim et al., 2011). 
Alterations in cholesterol biosynthesis, esterification and transport may play a 
role in cholesterol accumulation after KA lesion (Ong et al., 2010).  
Furthermore, gas chromatograph-mass spectrometry (GC-MS) analysis 
of the hippocampus has revealed enhanced cholesterol accumulation and 
oxysterol levels after KA treatment. These oxysterols included the 
autoxidatively formed species such as 7β-HC, 7-KC and cholesterol epoxides 
(Ong et al., 2003; He et al., 2006; Kim et al., 2010; Kim et al., 2011). Under 
normal condition, oxysterols produced from autoxidation are found in trace 
amount in human tissues (Iuliano et al., 2003; Lee et al., 2008a). However, their 
levels are elevated in oxidative stress associated diseases (Ong et al., 2010). 
Hence, autoxidatively formed oxysterols are thought to be useful biomarkers of 
oxidative damage in the brain (Ong et al., 2010). Besides that, oxysterols have 
the capacity to produce cytotoxic and apoptotic damages in various cell types 
including neurons (Ryan et al., 2004). Elevated cholesterol and oxysterol levels 
(i.e. 7β-HC and 7-KC) following KA treatment may exacerbate neuronal 
oxidative damage after KA-induced excitotoxicity (Ong et al., 2010). Since 
oxysterols are able to promote membrane fusion and exocytosis, increased 
oxysterol levels after KA injury may enhance exocytosis from axon terminals 
of surviving neurons, leading to further glutamatergic stimulation and 
excitotoxicity (Ma et al., 2010; Ong et al., 2010). Additionally, treatment of KA 
with lovastatin in organotypic slices from rat hippocampus were able to lower 
the cholesterol, 24S-HC and 7-KC levels, compared with those that were treated 
with KA alone (He et al., 2006). Brain-permeable statins such as lovastatin may 
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also confer neuroprotection by limiting the levels of cholesterol or oxysterols in 
neurodegenerative brain regions (Ong et al., 2010).  
Together, these studies have highlighted that excess levels of cholesterol 
and oxysterols following KA excitotoxicity could result in disrupted neuronal 
ion homeostasis, enhanced neurotransmitter release and further propagation of 
excitotoxicity (Ong et al., 2010). 
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 Intracranial Large Artery Disease (ICLAD) 
Stroke is one of the global leading causes of disability and mortality 
according to epidemiological studies. It is classically characterized as 
neurological deficits resulted from acute focal injury of the CNS by vascular 
cause (Sacco et al., 2013). The clinical presentation of stroke can be categorized 
as ischemic or hemorrhagic stroke (Bornstein, 2009). ICLAD is defined as 
atherosclerotic stenosis of large arteries at the base of the brain. It is a major 
cause of stroke especially in Asians, Hispanics and Africans (Wong, 2006) and 
is responsible for about 10% of all ischemic strokes (Mazighi et al., 2008; 
Qureshi and Caplan, 2014). In Chinese population, ICLAD is estimated to 
account for 33-50% of stroke and more than 50% of transient ischemic attack 
(TIA) (Wong, 2006). It affects about 47%, 48% and 56% of stroke patients in 
Thailand, Singapore and Korea, respectively (Wong, 2006). Together with the 
people of Hispanic and African ancestries that constitute the majority of the 
global population, ICLAD is possibly the most common vascular lesion in the 
world (Gorelick et al., 2008). In addition, ICLAD carries a poor prognosis in 
terms of subsequent vascular event and death, and there is 25-30% incidence of 
recurrence within 2 years after the first stroke (Wong and Li, 2003; Mazighi et 
al., 2006). The disease is also prevalent among 53% of vascular dementia and 
18% of AD patients of Asian ethnicity (Wong, 2006; De Silva et al., 2009). 
Intracranial atherosclerotic lesions could range from mild wall 
thickening and non-stenosing plaques to severe luminal narrowing (Qureshi and 
Caplan, 2014). These usually occur in intracranial arteries enclosed by cranial 
bones and dura, or those localized in the subarachnoid space (Qureshi and 
Caplan, 2014). The most commonly affected artery by ICLAD is the middle 
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cerebral artery (MCA) (Wong, 2006; Mohammad et al., 2010). Other major 
vessels involved are the intracranial portion of the internal carotid artery, 
vertebrobasilar artery, and posterior and anterior cerebral arteries (Wong, 2006).  
 
3.2.1. Middle Cerebral Artery (MCA) 
The MCA is the largest branch of the internal carotid artery (Rowland et 
al., 2010), supplying blood to a portion of the frontal lobe and the lateral surface 
of the temporal and parietal lobes (Figure 1.5). These regions include the 
primary motor and sensory areas of the face, hand and arm as well as the 
dominant hemisphere (i.e. the areas for speech) (Bornstein, 2009). Similar to 
other intracranial arteries, the MCA is made of three layers that contain 
endothelium, smooth muscle cells and an extracellular matrix comprising of 
collagen and elastin fibers (Mohammad et al., 2010). The luminal tunica intima 
has a single layer of endothelial cells overlying connective tissue which is 
supported by a dense elastic band, called the internal elastic lamina (Mohammad 
et al., 2010). The middle layer or intima media is composed of smooth muscle 
cells. Tunica adventitia which is the outermost layer, mainly contains collagen 
and is surrounded only by CSF (Mohammad et al., 2010). 
Besides being the most commonly affected artery by ICLAD (Wong, 
2006; Mohammad et al., 2010), MCA is also the most prone region to 
atherosclerotic narrowing within the anterior circulation (Caplan, 2008). The 
mainstream (M1) segment of the MCA is the most frequently implicated region, 
followed by the upper division (M2) branch. In contrast, the inferior division is 
usually unaffected (Caplan, 2008). M1 segment supplies blood to the basal 
ganglia and internal capsule through its penetrating arteries (Bornstein, 2009). 
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Hence, stenosis within MCA is mainly associated with infarction in the deep 
territory supplied by these penetrating artery branches (Caplan, 2008). Various 
consequences could arise from stroke involving MCA, including motor and 
sensory deficits, motor and sensory aphasias, and contralateral hemiparesis or 
hemiplegia (Bornstein, 2009). In addition, it is also common to observe 
significant atherosclerotic lesions in the contralateral MCA when one MCA is 
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Figure 1.5. The arteries of the base of the brain. (Standring, 2008) 
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3.2.2. Mechanisms of Intracranial Atherosclerosis 
Atherosclerosis is a progressive disease that develops early in life, 
leading to vascular remodeling and manifested as coronary artery disease 
(CAD), cerebrovascular disorders or peripheral arterial disease (Pu et al., 2014). 
ICLAD may occur in isolation or alongside with systemic atherosclerotic 
disease in coronary, extracranial and other peripheral arteries (Qureshi and 
Caplan, 2014). As mentioned earlier, ICLAD is a vital contributor to ischemic 
stroke (Natori et al., 2014); thus, it is not surprising that atherosclerotic plaques 
are commonly observed at autopsy in the intracranial arteries of patients with 
fatal stroke (Mazighi et al., 2008).  
The process of atherosclerosis can be categorized into four major steps. 
The first step is the initiation of endothelial activation and inflammation. 
Initiation begins in predisposed areas where slow flow promotes partial 
endothelial activation (Hopkins, 2013). Vascular smooth muscle cells (VSMCs) 
that are localized at predisposed sites, induce intimal thickening prior to foam 
cell formation (Hopkins, 2013). The action of VSMCs may be a response to 
platelet-derived growth factor (PDGF) synthesized by activated endothelial 
cells (Allahverdian et al., 2012). Endothelial activation is further exacerbated 
by other risk factors. The activation of endothelial cells triggers a series of 
innate immune responses involving adhesion molecules and monocytes/ 
macrophages. Monocytes attach to the endothelium and move into the 
subendothelial space where they are transformed into macrophages. 
Macrophages are further activated to intensify the innate immune response 
(Hopkins, 2013).  
Chapter I - Introduction 
 
31 
The second step involves the promotion of intimal lipoprotein 
deposition, retention, modification, and foam cell formation (Hopkins, 2013). 
In this step, retained and modified lipoproteins are captured by macrophages 
and VSMC. This induces the formation of foam cell, the hallmark of the 
growing atherosclerotic lesion. The accumulation of foam cells subsequently 
forms fatty streaks, which is the earliest observable abnormality of the vessel 
wall (Yanni, 2004). The levels of LDL cholesterol, HDL cholesterol, APOA1 
or apolipoprotein B (APOB) play important roles in the formation of foam cells 
(Hopkins, 2013). 
The third step includes the progression of complex plaques by plaque 
development, expansion of the necrotic core, fibrosis, thrombosis, and 
remodeling (Hopkins, 2013). As the lipid-rich plaque develops, the 
accumulation of macrophages and activated endothelial cells secrete an array of 
proinflammatory cytokines, matrix metalloproteinases and cathepsins, which 
promote plaque fragility (Hopkins, 2013). Moreover, interferon gamma 
suppresses collagen production by VSMCs, which further weakens both plaque 
and newly generated fibrous cap (Libby, 2009). This may result in thrombosis 
or tissue infarction. Prior to thrombotic events, outward remodeling of the 
arterial wall may take place in order to accommodate the developing plaque 
without affecting the luminal diameter and blood supply (Hopkins, 2013; Pu et 
al., 2014). However, as the plaque burden increases, the artery can no longer 
compensate by expanding outward. This may eventually lead to stenosis of 
blood vessel diameter, hemodynamics alterations and finally, occlusion (Pu et 
al., 2014). Thus, precipitation of acute ischemic events attributed to plaque 
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destabilization and thrombosis, are regarded as the final step in atherogenesis 
(Hopkins, 2013).  
There are various risk factors that play vital roles in aggravating more 
than one steps in atherosclerosis. For example, hyperlipidemia contributes to 
endothelial activation, reduction of nitric oxide synthesis or availability, foam 
cell formation, induction of platelet activation and thrombotic potential, and 
promotion of reversible plaque destabilization (Hopkins, 2013). In general, 
ICLAD is a process of dynamic changes where the progress for each stenosis is 
different and the rate is approximately 9-12% for 6 months (Pu et al., 2014). 
The risk of vascular events may influence the progression of stenosis (Pu et al., 
2014).  
 
3.2.3. Pathological Characteristics of ICLAD 
The initial pathological features of intracranial atherosclerosis begin at 
an early age. Fatty streaks and fibrous plaques can be detected by 24 years old 
(Velican and Velican, 1982) while more advanced features such as intimal 
necrosis and thickenings, are observed in older individuals (Stehbens, 1975). In 
intracranial atherosclerosis, proliferative fibrosis of the intima or adventitia is 
more predominant than lipid infiltration (Baker and Iannone, 1959). Well-
characterized plaques are commonly identified in elderlies (Velican et al., 
1982). Neovascularization is often associated with intraplaque hemorrhage 
(Takaba et al., 1998). Besides that, dense mineral deposits such as calcium, are 
more commonly detected in degenerated media of intracranial arteries than in 
coronary arteries (Mathur et al., 1963; Yanai et al., 1994). Ischemia is related to 
plaques with high lipid content, intraplaque hemorrhage, neovasculature, and 
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macrophage and T lymphocyte infiltration (Chen et al., 2008b; Labadzhyan et 
al., 2011). Furthermore, intracranial arteries are more prone to inflammatory 
modifications and plaque instability due to lack of inflammatory inhibitors 
(Tulamo et al., 2010), higher expression of proinflammatory proteasomes (Sun 
et al., 2012) and deficiency of an external elastic lamina (Masuoka et al., 2010). 
 
3.2.4. ICLAD and Stroke 
Intracranial atherosclerosis can cause thromboembolism with or without 
hypoperfusion, and induce transient or permanent cerebral ischemic events 
(Qureshi and Caplan, 2014). The clinical outcome of ICLAD can be 
asymptomatic or symptomatic which is presented as ischemic stroke and TIA 
(Mansour et al., 2014; Pu et al., 2014). Intracranial plaques and stenosis are 
observed in the autopsies of 45-62% patients of ischemic stroke (Chen et al., 
2008b; Mazighi et al., 2008).  
Some underlying mechanisms of ischemic stroke associated with 
intracranial stenosis are in-situ thrombosis from plaque disruption, distal 
thromboembolism, perforator artery occlusion by plaque within the parent 
artery, and hemodynamic impairment (Mohammad et al., 2010; Qureshi and 
Caplan, 2014). Hypoperfusion induced by progressive narrowing of the large 
atherosclerotic arteries may lead to gradual generation of leptomeningeal 
collaterals (Mansour et al., 2014). The failure of these collaterals in supplying 
adequate perfusion to terminal areas promotes the development of infarctions 
in border zone territories (Mansour et al., 2014). Border zone or watershed 
infarcts are ischemic lesions that occur in distinctive locations at the junction 
between two main arterial territories, which constitute approximately 10% of 
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all brain infarcts (Mangla et al., 2011). Both internal and cortical border zone 
infarctions of the MCA have been reported to be the outcome of ICLAD 
(Yamauchi et al., 2009).  
Together, the interplay among progressive arterial narrowing, plaque 
instability and thromboembolism, and/or exhausted collateral flow with 
impaired vasomotor reactivity, contributes to ICLAD-associated ischemic 
stroke (Mohammad et al., 2010). 
 
3.2.5. Risk Factors of ICLAD 
3.2.5.1. Hypercholesterolemia  
Hypercholesterolemia is defined as the presence of high cholesterol 
concentration in the blood. Cholesterol is a key constituent of atheroma plaques 
in atherosclerosis (Silva et al., 2013). A close relationship between 
hypercholesterolemia and atheroma plaques formation has been established, 
where the patency of the intracranial blood vessels is gradually reduced and 
eventually causing hypoperfusion and ischemic brain damage (Silva et al., 
2013). Thus, it is not surprising that hypercholesterolemia is a risk factor for 
ICLAD (Ingall et al., 1991) and ischemic stroke (Balci et al., 2011; Cui et al., 
2012). Increasing incidence of ischemic stroke caused by both extracranial and 
intracranial large-artery atherothromboembolism, is secondary to an elevated 
prevalence of hypercholesterolemia associated with increased dietary intake of 
saturated fat, physical inactivity, obesity, and diabetes (Hankey et al., 2010).  
Increased lipoprotein is an independent biochemical risk factor for 
ICLAD development (Vrhovski-Hebrang et al., 2002), and increased serum 
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cholesterol is associated with elevated levels of oxidized LDL (Chen et al., 
2003). Oxidized LDL inhibits nitric oxide in endothelial cells to induce 
vasospasm (Giardina et al., 2001), or increases tissue factor activity in these 
cells to promote thrombosis (Weis et al., 1991). Various clinical trials have 
demonstrated the relationship of elevated LDL cholesterol levels with ischemic 
strokes related to intracranial stenosis, as well as myocardial infarction and 
vascular death (Turan et al., 2012).  
Statins are therapeutic agents for treatment of hypercholesterolemia by 
lowering serum cholesterol level through the inhibition of HMG-CoA 
reductase, the rate limiting enzyme of cholesterol biosynthesis (Honjo et al., 
2012). Reduced cholesterol level with statin treatment has been shown to delay 
the lesion progression in ICLAD patients (Mok et al., 2009). The findings of the 
Stroke Prevention Aggressive Reduction in Cholesterol Levels (SPARCL) trial 
have suggested that statin treatment should aim to achieve a LDL cholesterol 
concentration of less than 1.8 mmol/L (Amarenco et al., 2007). According to 
the trial, individuals with LDL cholesterol of this concentration was linked to a 
decrease in stroke risk by 28%, compared with those who had a concentration 
of more than 2.59 mmol/L (Amarenco et al., 2007).  
 
3.2.5.2. Hypertension  
Hypertension is characterized by persistent systolic blood pressure (BP) 
≥ 140 mm Hg and diastolic BP ≤ 90 mm Hg (Rios et al., 2014). It is a well-
known risk factor for stroke (Balci et al., 2011), coronary heart disease, and 
vascular dementia (Honjo et al., 2012). Individuals with hypertension possess 
3-4 times higher risk of stroke than those without hypertension (Pedelty and 
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Gorelick, 2007). Epidemiological studies also showed the association of 
hypertension with elevated odds for developing ICLAD (Mohammad et al., 
2010). Results from clinical trials have revealed more than 50% of patients with 
a history of ischemic stroke related to intracranial stenosis, had BP of  ≥ 140/90 
mm Hg at baseline and at 1-year follow-up (Turan et al., 2012). Besides that, 
systolic BP of ≥ 140 mm Hg has been related to a higher rate of recurrent 
ischemic stroke in patients with intracranial stenosis (Turan et al., 2012). 
The combination of hypertension with other risk factors may further 
enhance the risk (Wong et al., 2007). For example, both hypercholesterolemia 
and hypertension may result in greater damage to vessels (Xu et al., 1991; 
Alexander, 1995). Additionally, a strong association is found between 
asymptomatic ICLAD (which is presented as intracranial stenosis or 
calcification with large artery stiffness) and patients with untreated 
hypertension (Zhang et al., 2011). Arterial stiffness is a major determinant of 
increased systolic BP, and is associated with lesions in intracranial arteries 
(O'Rourke and Safar, 2005). Prolonged elevation of BP leads to reduced vessel 
cross sectional area, increased wall thickness and accelerated plaque formation 
(Xu et al., 1991; Hollander et al., 1993). Moreover, hypertension is thought to 
drive the atherosclerotic changes from larger to smaller vessels, and from 
extracranial to intracranial vessels (Mills et al., 2007; Ropper et al., 2009). 
Hence, the use of antihypertensive drugs is recommended for prevention 
of intracranial atherosclerosis and ischemic events (Furie et al., 2011). Early 
administration of antihypertensive, statins and antiplatelet drugs, have been 
shown to successfully reduce the incidence of recurrent vascular events to 7% 
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in patients with intracranial narrowing or occlusion at 1-year follow-up 
(Meseguer et al., 2010).  
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 Alzheimer’s Disease (AD) 
 AD is an age-related disorder and the most common type of dementia 
that affects approximately 36 million people worldwide (Rios et al., 2014). The 
progression rate of AD is not constant and on average, patients may survive up 
to 10 years after diagnosis (Whitehouse, 1997). An estimation of 8-10% of the 
human population above the age of 65 have AD and subsequently, the 
prevalence doubles every 5 years (Cummings, 2004; Bertram and Tanzi, 2005). 
As the global prevalence is projected to reach 110 million by 2050 (Hampel et 
al., 2011; Wimo et al., 2013), AD is marked as one of the most critical health 
problems especially in industrialized nations (Ballard et al., 2011; Mayeux and 
Stern, 2012; Wong et al., 2014).  
From a clinical perspective, AD is defined by progressive cognitive 
decline particularly in learning and memory (Castellani et al., 2010; Ballard et 
al., 2011), and is accompanied by neuropsychiatric symptoms such as affective, 
behavioral disturbances (Starkstein et al., 1997). The onset of AD can be 
categorized as either familial or sporadic. The early-onset familial AD (less than 
5% of AD cases) manifests its symptoms before the age of 65 (Janssen et al., 
2003; Raux et al., 2005). It is caused by mutations in the form of autosomal 
dominant that occur within three genes encoding amyloid precursor protein 
(APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2) (Piaceri et al., 2013). In 
contrast, the majority of the AD cases is accounted by the late-onset sporadic 
AD which occurs after the age of 65. The etiology of this AD onset is 
multifactorial and complex, encompassing an array of age-related changes in 
metabolism, repair mechanisms, immune response, oxidative stress, prior brain 
trauma, and environmental factors (e.g. life style) (Muller-Spahn and Hock, 
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1999; Chen et al., 2009). Several candidate genes have been identified by the 
genome-wide association studies (GWAS) that markedly enhance the risk of 
late-onset AD and among them, ε4 allele of the APO gene is deemed as the 
strongest risk factor (Farrer et al., 1997).  
Pathologically, AD is associated with aberrant protein processing. It is 
characterized by the presence senile plaques (extracellular aggregates of Aβ), 
neurofibrillary tangles (NFTs) (intraneuronal protein clusters of 
hyperphosphorylated tau protein) (Serrano-Pozo et al., 2011; Selkoe et al., 
2012), as well as extensive neuronal and synaptic losses (Adlard and 
Cummings, 2004). Senile plaques consist of both Aβ1-42 and Aβ1-40. Being the 
more amyloidogenic form, Aβ1-42 has higher capability in producing insoluble 
amyloid deposits, a characteristic of AD pathology (Coughlan and Breen, 
2000).  
In AD, senile plaques and NFTs are mainly observed in the cerebral 
cortex and hippocampus (Sugerman and Huether, 2011). Although both Aβ and 
phosphorylated tau are thought to be the primary factors in AD pathogenesis 
(Sun et al., 2014), studies have shown that Aβ aggregation may drive tau 
pathology (Blurton-Jones and Laferla, 2006). In AD, Aβ deposition can occur 
as parenchymal amyloid plaques and cerebral vascular deposits, called the 
cerebral amyloid angiopathy (CAA) (Xu et al., 2014). Deposition of insoluble 
fibrillar Aβ within cerebral vessels is a feature of CAA (Weller et al., 1998) and 
CAA is observed in almost all AD brains (Jellinger, 2002). Being a main cause 
of lobar intracerebral hemorrhage and cognitive deficits (Jellinger, 2002; 
Viswanathan and Greenberg, 2011), CAA may be implicated in AD  
pathogenesis (Sun et al., 2014).  
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3.3.1. Frontal Cortex (FC) 
The FC is the cortex of the anterior pole of the mammalian brain, which 
is located in front of the motor cortex on the lateral surface and the limbic cortex 
on the orbital and medial surfaces (Fuster, 2008b). Anatomically, it can be 
defined as the region of the cerebral cortex that obtains projection fibers from 
the mediodorsal nucleus of the thalamus in addition to other subcortical 
locations (Fuster, 2008b). Besides, the FC is also known as the PFC in primates 
(Fuster, 2008a). It consists of a six-layered neocortex, characterized by a well-
defined internal granular layer called layer IV (Fuster, 2008b). Other layers of 
the FC include layer I (molecular layer), layer II (external granular layer), layer 
III (external pyramidal layer), layer V (internal pyramidal layer) and layer VI 
(multiform layer).  
 Generally, the FC is deemed as the “action cortex” that executes its 
action in cooperation with other cortices, subcortical structures, and parts of the 
sensory and motor apparatus as well as the autonomic system (Fuster, 2008c). 
FC involves in executive functions, emotional behavior and temporal 
organization of action (Fuster, 2008c). Executive functions consist of high-
order functions operating in non-routine situations such as executive attention, 
planning and decision making. Various pathologies including AD and stroke 
can disrupt executive functions (Godefroy, 2003). Thus, FC is not only a critical 
cortical area in morphological aging, but it is also one of the regions most prone 
to neurodegeneration leading to dementia (Fuster, 2008b) .  
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3.3.2. Amyloid-β (Aβ) 
Aβ (38-43 amino acid peptide) is the key component of the extracellular 
senile plaque in AD (Blennow et al., 2006). The amyloid cascade hypothesis is 
the most promising hypothesis to AD. It postulates that Aβ peptide deposition 
in the brain is a central event in AD pathology, highlighting the significance of 
Aβ as a critical initiator and player in both familial and sporadic AD 
pathogenesis (Hardy, 1997; Karran et al., 2011).  
Aβ is derived from the proteolysis of APP, a type I transmembrane 
protein (Hardy and Selkoe, 2002; Tharp and Sarkar, 2013). The majority of Aβ 
is synthesized via endocytic pathway that involves endosome/lysosome and 
Golgi apparatus, while some are produced via secretory pathway, involving 
ER/Golgi apparatus (Small and Gandy, 2006; Mayeux and St George-Hyslop, 
2009). APP is sequentially processed by secretases following the non-
amyloidogenic or amyloidogenic pathway, where the latter is responsible for 
Aβ peptides production (Hardy and Selkoe, 2002). In the non-amyloidogenic 
pathway, the cleavage at the N-terminus of the Aβ domain by α-secretase 
generates soluble APP derivatives (sAPPα) and sheds membrane tethered C-
terminal fragments (CTFα). CTFα is then cleaved by γ-secretase, generating p3 
and APP intracellular domain (AICD) (Wong et al., 2014). In contrast, the 
amyloidogenic pathway involves the cleavage of APP by β-secretase, which 
produces sAPPβ and CTFβ. CTFβ is further processed by γ-secretase to release 
Aβ and AICD (Wong et al., 2014). Between these two pathways, the non-
amyloidogenic pathway is the major pathway under normal conditions. 
However, factors such as diet, hormones and genetic mutation, may perturb the 
normal function of APP, β- and γ-secretases, leading to aberrant Aβ 
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accumulation (Sun et al., 2014). The summary of APP processing is illustrated 
in Figure 1.6. 
The major β-secretase in neurons is the transmembrane aspartyl protease 
β-site APP cleaving enzyme 1 (BACE1) (Sinha et al., 1999) and it is also the 
rate-limiting enzyme in Aβ generation (Vassar et al., 1999; Yan et al., 1999). It 
is mainly located in the Golgi apparatus and endosomes (Mayeux and St 
George-Hyslop, 2009). The α-secretases come from ‘a disintegrin and 
metalloproteinase’ (ADAM) family of proteases (Lichtenthaler, 2011) and 
ADAM10 is the main enzyme that catalyzes APP in the brain (Kuhn et al., 
2010). In addition, mature γ-secretase consists of an assembly of four individual 
components that includes presenilin (PSEN), nicastrin, anterior pharynx 
defective 1 and PSEN enhancer 2 (Pen-2). Among these four, PSEN acts as the 
key catalytic unit of the complex (Wong et al., 2014). The hierarchical and site-
specific cleavage of APP by β- and γ-secretases yield different lengths of Aβ 
(Wong et al., 2014). Although Aβ1-40 is the major Aβ species, the less abundant 
Aβ1-42 is the main culprit that deposits into amyloid plaques in AD (Coughlan 
and Breen, 2000) and is more neurotoxic than Aβ1-40 (Hamley, 2012).  
Furthermore, Aβ peptides can exist in different forms. The non-toxic 
monomeric Aβ peptides are predominant in normal physiological condition 
(Haass et al., 1992; Shoji, 2002). However, Aβ monomers can be converted to 
neurotoxic aggregated forms (i.e. soluble Aβ oligomer), insoluble fibrils and 
plaques in pathological conditions. The soluble Aβ oligomer is considered as a 
critical neurotoxin in AD, making Aβ aggregation as the primary event in 
neurotoxicity (Roychaudhuri et al., 2009; Shankar and Walsh, 2009; Wong et 
al., 2014).  





















Figure 1.6. APP processing in non-amyloidogenic (A) and amyloidogenic (B) 
pathways. [Adapted from (Sun et al., 2014)]. 
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3.3.3. Cholesterol in the Pathogenesis of AD  
Increasing links between cholesterol and AD pathology have been 
unraveled. AD brains have higher cholesterol levels (Cutler et al., 2004; Xiong 
et al., 2008) with up to 34% increase in the cerebral cortex of AD cases (Lazar 
et al., 2013), and the severity of disease is correlated to elevated membrane free 
cholesterol (Cutler et al., 2004). A recent study has shown that increased 
membrane cholesterol in cultured neurons models the early phenotypes of AD, 
suggesting that age-associated elevation of membrane cholesterol may be one 
of the early events that promotes sporadic AD (Marquer et al., 2014). The 
following are some examples that illustrate the involvement of cholesterol in 
AD pathogenesis. 
 
3.3.3.1. Cholesterol Modulation of Aβ Biosynthesis 
Cholesterol are associated with Aβ production in AD. Depletion of 
cholesterol by cyclodextrin or inhibition of cholesterol biosynthesis by statins, 
reduces Aβ generation in vitro (Simons et al., 1998). In contrast, elevated levels 
of cellular cholesterol promote Aβ generation while reducing the non-
amyloidogenic processing of APP (Bodovitz and Klein, 1996; Frears et al., 
1999).  
Full-length APP, Aβ, CTFs, and PSEN1 which are associated with lipid 
rafts (Lee et al., 1998; Simons et al., 2001), are affected by altered cholesterol 
levels (Wong et al., 2014). BACE1 and γ-secretase are localized within lipid 
rafts (Wahrle et al., 2002; Kalvodova et al., 2005) whereas ADAM10 is mainly 
distributed outside of these lipid domains (Kojro et al., 2001). APP is located 
within and outside of the lipid rafts (Ehehalt et al., 2003). Accumulating 
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evidences have shown that APP within the lipid rafts involves in Aβ production 
whereas non-amyloidogenic pathway occurs in the non-rafts regions (Ehehalt 
et al., 2003). Amyloidogenic processing may be enhanced by the direct 
interaction of cholesterol to APP through the binding of cholesterol to APP at 
the transmembrane C-terminal region between amino acids 672 and 770 (or 
CTFβ) (Beel et al., 2010; Barrett et al., 2012). 
 Additionally, elevated levels of membrane cholesterol may upregulate 
the percentage of lipid raft, favoring interaction between APP and BACE1, and 
promoting Aβ synthesis (Wong et al., 2014). Studies have shown that 
cholesterol loading induces Aβ production by modifying the accessibility of 
BACE1 to APP in the lipid rafts (Marquer et al., 2011). Besides, high 
cholesterol level induces BACE1 transcription but reduces ADAM10 
production in vivo (Sharman et al., 2013), as well as upregulates Aβ synthesis 
but reduces α-secretase activity in vitro (Bodovitz and Klein, 1996; Fonseca et 
al., 2010). Similarly, γ-secretase activity is also dependent on cholesterol as 
reduced membrane cholesterol impairs γ-secretase-mediated cleavage (Wahrle 
et al., 2002; Urano et al., 2005). 
 
3.3.3.2. Cholesterol Modulation of Aβ Aggregation and Neurotoxicity 
Cholesterol-rich lipid rafts may participate in Aβ aggregation (Wong et 
al., 2014). In AD patients, increased aggregated Aβ is associated with increased 
cholesterol levels (Schneider et al., 2006). Cholesterol potentiates Aβ 
cytotoxicity, possibly through the involvement of oxidative stress (Schneider et 
al., 2006; Ferrera et al., 2008; Qiu et al., 2009; Abramov et al., 2011). In 
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contrast, reduction of cholesterol decreases cytotoxicity by inhibiting Aβ-
induced calcium signaling (Abramov et al., 2011). 
 
3.3.3.3. Cholesterol Modulation of Aβ Elimination 
There are several enzymes in the CNS that participate in the degradation 
of Aβ, including insulin-degrading enzyme (IDE), neprilysin (NEP), and 
plasmin (Miners et al., 2008). Cholesterol is also involved in Aβ clearance 
through the regulation of Aβ-degrading enzymes. IDE is a Zn2+ metalloprotease 
that degrades insulin and Aβ. Reduced cholesterol content in the lipid raft 
microdomain may affect the enzymatic activity of IDE (Bulloj et al., 2008). 
NEP is a type II membrane metallopeptidase that degrades Aβ, particularly the 
oligomeric form, in the brain tissue (Kanemitsu et al., 2003). The distribution 
of mature NEP in lipid rafts are modulated by cholesterol (Sato et al., 2012). An 
in vivo study has shown that high cholesterol diet could increase Aβ 
accumulation but inhibit NEP expression and activity in the retinal pigment 
epithelial cells (Wang et al., 2012). Plasmin, a raft-resident serine protease, is 
produced from its inactive precursor, plasminogen, through tissue-plasminogen 
activator (tPA) or urokinase plasminogen activator (uPA) mediated cleavage 
(Miners et al., 2008; Stefani and Liguri, 2009). Plasmin prevents Aβ 
aggregation by cleaving Aβ at multiples sites (Miners et al., 2008). The use of 
statins could induce the activities of tPA and uPA, but suppress the activity of 
plasminogen activator inhibitor type 1 (PAI-1), an inhibitor of tPA, in both in 
vivo and in vitro studies (Essig et al., 1998). 
Besides Aβ degradation, Aβ clearance can be achieved through the 
elimination of Aβ peptides from the brain into the circulation. This process is 
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facilitated by transport proteins that are expressed on the BBB such as ABCB1 
and LDLR-related protein 1 (LRP-1) (Sun et al., 2014). ABCB1 is a member of 
the ATP-binding cassette transporter family that is highly expressed at the 
luminal side of the endothelial cells (Hermann and ElAli, 2012). A study has 
demonstrated that oxysterols may increase ABCB1 expression through LXR 
activation, and alleviate Aβ burden (Saint-Pol et al., 2013). Likewise, LRP-1, a 
member of the LDL family (May et al., 2007), is expressed in the brain capillary 
endothelium (Deane et al., 2004). Direct binding of LRP-1 to Aβ1-40 aids the 
efflux of the latter across the BBB (Deane et al., 2004). Although the exact role 
of cholesterol on the regulation of LRP-1 is still unknown, it has been proposed 
that cholesterol levels may control LRP-1 expression on the BBB (Sun et al., 
2014). 
 
3.3.4. Risk Factors of AD 
3.3.4.1. Hypercholesterolemia  
Hypercholesterolemia has been shown to be an important risk factor for 
AD in addition to its well-established etiological role in CAD (Honjo et al., 
2012). The association of hypercholesterolemia and AD has been highlighted in 
several epidemiological studies in which enhanced susceptibility to AD has 
been observed in individuals with elevated plasma or serum cholesterol levels 
(Jarvik et al., 1995; Kuo et al., 1998; Pappolla et al., 2003). Some clinical studies 
have shown that low HDL cholesterol level may be a risk factor for dementia 
and it is associated with the severity of AD (Bonarek et al., 2000; Merched et 
al., 2000; van Exel et al., 2002; McGrowder et al., 2011). In contrast, elderly 
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individuals with high HDL cholesterol level is related to a reduced risk of AD 
(Reitz et al., 2010). Various studies have reported that AD patients showed 
higher levels of total serum and LDL cholesterol (Kuo et al., 1998; Lesser et al., 
2001) with reduced levels of apolipoprotein A and HDL cholesterol in their 
plasma (Kuo et al., 1998; Fernandes et al., 1999), compared with aged-matched 
controls. Interestingly, statins may prevent the development of AD (Silva et al., 
2013) as statin therapy could reduce the risk of late-onset AD by 50% in 
Rotterdam Study (Haag et al., 2009).  
In in vivo models, hypercholesterolemic rabbits showed increased 
deposition of cerebral Aβ (Sparks et al., 1994), while hypercholesterolemia in 
an APP/PSEN1 double-transgenic mouse model accelerated the amyloid 
pathology of AD (Refolo et al., 2000). AD mice fed with a high cholesterol diet 
exhibited more severe impairment of spatial learning than those fed with normal 
diet, despite the presence of cerebral Aβ deposition in both types of mice (Li et 
al., 2003). In addition, hypercholesterolemia-induced memory impairment has 
been associated with an AD-like pathology, with features of dendritic integrity 
loss, cholinergic dysfunction, inflammation, increased cortical Aβ and 
phosphorylated tau (Granholm et al., 2008; Ullrich et al., 2010). 
A significantly lower prevalence of AD in patients who took statins than 
those without statins was observed in retrospective clinical studies (Wolozin et 
al., 2000; Rockwood et al., 2002; Wolozin et al., 2007). In an AD mouse model, 
statins were able to reverse the high cholesterol diet-induced Aβ accumulation 
and cholesterol level in plasma and CNS (Refolo et al., 2001). High doses of 
simvastatin also showed significant reduction of cerebral Aβ1-40 and Aβ1-42 
levels in the CSF and brains of guinea pigs. Likewise, attenuation of both 
Chapter I - Introduction 
 
49 
intracellular and extracellular levels of Aβ1-40 and Aβ1-42 peptides was shown in 
primary cultures of hippocampal neurons and mixed cortical neurons after statin 
treatments (Fassbender et al., 2001).  
 
3.3.4.2. Hypertension 
Hypertension which affects approximately 20% of the population 
worldwide (Rios et al., 2014), is a leading risk factor of vascular cognitive 
impairment (Gorelick et al., 2011). Epidemiological studies have suggested 
links concerning midlife hypertension with dementia and cognitive impairment, 
and demonstrated midlife hypertension as a risk factor for AD (Faraco and 
Iadecola, 2013; Iadecola, 2013). Furthermore, hypertension-induced lesions and 
AD may produce a synergistic effect that further exacerbates the severity of 
cognitive deficits, when compared with either condition alone (Iadecola, 2010). 
Hypertension may cause alteration of cerebral vessel walls, leading to 
hypoperfusion, ischemia, and hypoxia, which subsequently, initiates the 
pathogenesis of AD (Leszek et al., 2012). Besides that, this vascular risk factor 
may also promote Aβ accumulation and aggregation in the brain as increased 
amyloid plaque burden and NFTs have been observed in the brain of patients 
with hypertension (Rodrigue et al., 2013). Additionally, in murine models of 
hypertension with enhanced BBB permeability in both cortex and hippocampus, 
increased Aβ-immunoreactivity and Aβ-fragments were observed in these 
regions of the hypertensive mice (Gentile et al., 2009; Carnevale and Lembo, 
2011). 
Various potential protective effects of antihypertensive drugs against the 
development of dementia have been reported. The use of a calcium channel 
Chapter I - Introduction 
 
50 
antagonist in an uncontrolled hypertensive population reduced the number of 
dementia cases (Forette et al., 1998). In a randomized controlled trial, 
angiotensin converting enzyme inhibitors was shown to successfully alleviate 
cognitive decline in mild to moderate AD patients (Ohrui et al., 2004). 
Moreover, valsartan (an angiotensin AT1 receptor blocker) is able to prevent 
the AD pathological process in vivo and blocks oligomeric Aβ peptides 
generation in vitro (Oprisiu-Fournier et al., 2006).  
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4. Animal Models of Atherosclerosis and AD 
  Cholesterol-Fed Rabbit Model of Hypercholesterolemia 
Hypercholesterolemia is a risk factor for both atherosclerosis and AD. 
Surmounting evidences have suggested that LDL cholesterol is a major 
contributor of hypercholesterolemia whereas HDL cholesterol acts as a 
protector (Russell and Proctor, 2006). Despite the establishment of various 
animal models to elucidate the roles of dyslipidemia, metabolic syndrome and 
atherosclerosis (Russell and Proctor, 2006), none of these can exclusively 
mimic all the complexities of human atherosclerosis (Russell and Proctor, 
2006). Nevertheless, rabbit is the most widely used animal in atherosclerosis 
research, especially the cholesterol-fed rabbit model (Burkholder et al., 2012). 
It was first established by Nikolaj Anitschkow in 1913 (Finking and Hanke, 
1997) and it is the most commonly used model to evaluate pharmacological 
interventions for atherosclerosis (Bocan, 1998). 
Till date, cholesterol-fed New Zealand white (NZW) rabbit is the gold 
standard animal model in atherosclerosis studies (Yanni, 2004) and the best 
small animal model of human CAD (Sparks, 2011). Rabbits are more 
advantageous than other animals because rabbits are small and relatively 
inexpensive, but sufficiently large for physiological experiments to be 
conducted (Russell and Proctor, 2006). Although rabbits are not innately 
atherosclerosis-prone, they are more susceptible to the induction of vascular 
lesions and atherosclerosis by high cholesterol diets than rodents (Yanni, 2004; 
Russell and Proctor, 2006). Hypercholesterolemia can be easily observed in 
rabbits, reaching up to two to eight times after the administration of a high 
cholesterol (0.1-2%) diet within the first 20 days (Bocan et al., 1993). In 
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contrast, most normal rodents are resistant to the development atherosclerosis 
due to the high HDL cholesterol concentration as a result of low cholesteryl 
ester transfer protein (CETP) activity (Moghadasian et al., 2001).  
In the cholesterol-fed rabbit model, atherosclerotic lesions develop as 
fatty streaks on the aorta, followed by advanced lipid-laden intimal plaques that 
resemble early human atheromas (Yanni, 2004). The latter is the stage which is 
targeted by therapeutic intervention. The predominant location of the atheromas 
in rabbits are at the aortic arch and thoracic aorta (Yanni, 2004). Besides that, 
the morphology of atherosclerotic lesion is influenced by the percentage of 
dietary cholesterol intake and duration of the intake diet (Bocan et al., 1993). 
For example, prolonged administration of a diet with lower cholesterol 
percentage (< 2%) causes atherosclerotic lesions in VSMCs and cholesterol 
deposition in rabbits. This produces atherosclerotic lesions that are more 
comparable to those of humans (Kolodgie et al., 1996). However, long-term 
experiments with higher cholesterol percentage are not recommended due to 
high hepatotoxicity that leads to elevated mortality of the rabbits (Yanni, 2004). 
Other than atherosclerosis and CAD, the cholesterol-fed NZW rabbits 
are often being used as a non-transgenic animal model in AD studies as it 
demonstrates various pathological hallmarks of AD. These include Aβ 
immunoreactivity, extracellular Aβ plaques, meningeal Aβ immunoreactivity, 
APOE immunoreactivity, cathepsin D immunoreactivity, superoxide dismutase 
immunoreactivity, microgliosis, apoptosis, vascular activation of superoxide 
dismutase, breaches of the BBB, increased brain cholesterol and enhanced Aβ 
concentration (Sparks et al., 1994; Sparks et al., 2000; Sparks and Schreurs, 
2003; Ghribi et al., 2006b; Sparks, 2011; Deci et al., 2012). Furthermore, rabbits 
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are phylogenetically closer to humans than rodents (Graur et al., 1996). Unlike 
rodents, the Aβ sequence of rabbits is similar to that of the humans (Johnstone 
et al., 1991). Hence, cholesterol-fed rabbit model may more closely resemble 
sporadic AD (Marwarha et al., 2010).  
 
 2-Kidney, 1-Clip (2K1C) Model of Hypertension 
Hypertension has been linked to atherosclerosis and AD. Untreated 
hypertension damages vascular endothelium, resulting in a proliferative 
response, arteriosclerosis and end-organ damage (Navar et al., 1998). 
Hypertension is one of the major factors that causes the disability or death due 
to stroke, heart attack and chronic renal failure (Navar et al., 1998). While there 
are various models of hypertension which share common features with human 
hypertension, renovascular hypertension is one of the most extensively used 
animal models in hypertension studies. Renovascular hypertension is usually 
perform to mimic human renovascular disease, a progressive condition 
characterized by the narrowing or occlusion of one or both renal arteries due to 
atherosclerosis (Zhang and Eirin, 2014). Consequently, renal artery stenosis 
(RAS) initiates secondary hypertension and renal failure, elevating 
cardiovascular morbidity and mortality (Kalra et al., 2005; Zhang and Eirin, 
2014). 
 The first animal model of hypertension was established by Goldblatt and 
coworkers in 1934, which involved the constriction of one or both renal arteries 
in dogs using a small modifiable silver clamp (Goldblatt et al., 1934). Since 
then, this method has progressed from using clamps to clips, and has been 
successfully reproduced in a range of animals including rats and rabbits 
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(Pickering and Prinzmetal, 1938; Wilson and Byrom, 1939; Zhang and Eirin, 
2014). Generally, there are three forms of renovascular hypertension models: 
the 2-kidney, 1-clip hypertension (2K1C) model; the 1-kidney, 1-clip 
hypertension (1K1C) model; and the 2-kidney, 2-clip hypertension (2K2C) 
model (Zhang and Eirin, 2014). In the 2K1C model, one renal artery is 
constricted whereas the contralateral kidney upregulates the excretion of 
sodium in response to hypertension (Zhang and Eirin, 2014). In the 1K1C 
model, one renal artery is constricted while the contralateral kidney is removed 
(Zhang and Eirin, 2014). In this model, compensatory increase in sodium and 
water excretion cannot take place due to the lack of a normal contralateral 
kidney. This promotes fluid retention and BP becomes more dependent on the 
sodium-fluid volume expansion (Zhang and Eirin, 2014). Hence, the 
compensatory elevation in sodium excretion from the contralateral kidney is a 
vital feature that differentiates the mechanism of hypertension between 2K1C 
and 1K1C models (Zhang and Eirin, 2014). Unlike the two previous models, 
the aorta or both renal arteries are constricted in the 2K2C model (Zhang and 
Eirin, 2014). 
 Among these, the 2K1C model is an important method for secondary 
form of experimental hypertension (Zhang and Eirin, 2014). The roles of renin-
angiotensin system are associated with RAS. Hypertension is induced in the 
2K1C model by the increased renin release and the subsequent angiotension II 
production (Zhang and Eirin, 2014). The kidney secretes renin when the 
sympathetic activity is elevated due to decreased blood volume to the kidney. 
Angiotension II is a potent vasoconstrictor that increases BP and promotes 
aldosterone release, leading to salt and water retention, increased blood volume 
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and eventually, hypertension. Elevation of circulating plasma renin activity 
(PRA) and aldosterone levels are most evident in the initial phase of 
hypertension (Brunner et al., 1971). The BP is gradually elevated in this model 
as a chronic response until it reaches a plateau at 2 weeks after surgery (Zhang 
and Eirin, 2014).  
Different species of animals used in 2K1C demonstrate variability in the 
activation pattern of the renin-angiotensin system (Zhang and Eirin, 2014). For 
example, rodents show slower increase in systemic PRA than rabbits but the  
sustenance of PRA is longer in mice (Amiri and Garcia, 1997). In contrast, dogs 
are more suitable for short term hypertension studies as the elevation of PRA is 
much faster and dogs can rapidly generate collateral circulation (Cerqua and 
Samaan, 1939). Together, a rapid drop in renal blood flow and significant 
decreased glomerular filtration rate are the features of an affected kidney in all 
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Cholesterol is important for normal brain function. However, cholesterol 
and its derivatives, oxysterols, have been associated with various neurological 
conditions including excitotoxicity and neurodegeneration, and CNS disorders 
such as ICLAD, stroke and AD. Furthermore, oxysterols are implicated in 
neuronal cell death. Significant elevation of cholesterol and oxysterols have 
been demonstrated in an animal model of excitotoxicity as early as 1 week after 
intracerebroventricular injection of KA (Kim et al., 2010; Ong et al., 2010; Kim 
et al., 2011). In additional, hypercholesterolemia is a risk factor for ICLAD 
(Ingall et al., 1991), stroke (Balci et al., 2011) and AD (Honjo et al., 2012). 
Despite emerging associations of cholesterol and/or oxysterols in excitotoxicity, 
neurodegeneration, ICLAD and AD, little is known about the possible effects 
of cholesterol or oxysterols on gene expression in these conditions. 
The present study was therefore carried out using microarray analyses, 
(1) to elucidate global gene expression changes in the rat prefrontal cortex 
(PFC) after cholesterol or oxysterol treatment; (2) to compare gene expression 
and morphological changes in cerebral vessels, MCA, of rabbits after exposure 
to hypercholesterolemia and/or hypertension; (3) to examine the gene 
expression changes in the frontal cortex (FC) of rabbits after exposure to 
hypercholesterolemia and/or hypertension; and (4) to compare gene expression 
changes between the FC and cerebral vessels (i.e. MCA) after exposure to 
hypercholesterolemia and/or hypertension.  
The PFC or FC was chosen for this study because this region is 
important in cognitive control (Miller, 2000) and it is one of the regions most 
prone to neurodegeneration, leading to dementia (Fuster, 2008b). On the other 
hand, MCA was selected as this intracranial vessel is the most commonly 
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affected artery by ICLAD (Olsen et al., 1985; Wong, 2006; Ritman and Lerman, 
2007; Brown et al., 2010). Cholesterol-fed rabbits and Goldblatt 2K1C were 
used as models of hypercholesterolemia and hypertension, respectively, for the 
study of stroke and AD risk factors.  
The differentially expressed genes (DEGs) obtained from the gene 
expression microarray data of each experimental model were further analyzed 
by Ingenuity Pathway Analysis (IPA). Focus genes or ‘node molecules’ in IPA 
networks were selected for validation using real-time RT-PCR, Western blot, 
immunohistochemistry and/or electron microscopy. Morphological changes in 
MCA and Aβ expression in FC of rabbits that were exposed to 
hypercholesterolemia and/or hypertension were examined.  
Considering the effect of cholesterol on SREBP activation pathway, 
SREBP signaling may be affected during hypercholesterolemia. Present study 
was aimed (5) to elucidate possible regulation of selected genes of interest by 
SREBP signaling. Cultured human endothelial EA.hy926 cells and human 
neuroblastoma SH-SY5Y cells were used to model changes in brain endothelial 
and neuronal cells, in order to determine the effect of SREBP on the expression 
of genes identified by the microarray.
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The brain has the highest cholesterol concentration in the body 
(Björkhem and Meaney, 2004). High demand for brain cholesterol is supplied 
by de novo synthesis, whereas elimination of excess cholesterol from the brain 
requires its conversion to oxysterols (Björkhem and Meaney, 2004; Vejux et al., 
2008). These can be generated by enzymatic action or direct oxidation of 
cholesterol. The former generates 24S-HC, 25-HC and 27-HC, mainly through 
the action of cytochrome P450 family enzymes (Brown and Jessup, 2009). In 
contrast, the latter forms 7α-HC, 7β-HC, 7-KC, 5α,6α-epoxycholesterol, 5β,6β-
epoxycholesterol, and cholestane-3β,5β,6β-triol as a result of direct radical 
attack by ROS (Vejux et al., 2008; Brown and Jessup, 2009). 
Under normal physiological conditions, oxysterols are maintained at 
103- to 106-fold lower levels compared with cholesterol (Björkhem and 
Diczfalusy, 2002; Brown and Jessup, 2009). However, increased levels of 
oxysterols have been associated with the pathophysiology of atherosclerosis 
(Brown and Jessup, 1999), AD (Leoni, 2009; Leoni and Caccia, 2011), age-
macular degeneration (Malvitte et al., 2006), osteoporosis (Liu et al., 2005), and 
cancer (Jusakul et al., 2011). Elevated levels of 7β-HC and 7-KC have been 
observed in atherosclerotic lesions and plasma of cardiovascular patients, as 
well as subjects on a high-fat diet (Brown and Jessup, 1999; Colles et al., 2001; 
Guardiola, 2002). Furthermore, increased 7β-HC and 7-KC have also been 
reported in the rat model of KA-induced excitotoxicity and neurodegeneration 
(Kim et al., 2010; Kim et al., 2011). 
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Oxysterols have additional polar moieties that enable them to transport 
through cellular membranes more readily than cholesterol (Brown and Jessup, 
2009; Jusakul et al., 2011). Incorporation of these polar moieties into the 
hydrophobic regions of cell membrane induces local re-arrangement of acyl 
chains (Meaney et al., 2002; Jusakul et al., 2011), and oxysterols have been 
shown to enhance the fluidity of brain synaptic plasma membrane (Wood et al., 
1995). Studies have also highlighted the involvement of 7β-HC and 7-KC in 
inducing cell death and inflammation (Vejux et al., 2008). Moreover, enhanced 
exocytosis has been shown in PC12 cells after treatment with 7-KC, 24S-HC, 
or cholesterol-5,6-beta epoxide (Ma et al., 2010). These findings suggest that 
elevated levels of oxysterols could promote cellular damage in the brain, and 
may be a promoting factor in excitotoxic brain injury (Ong et al., 2010). 
Although increasing evidence are supporting the association of elevated 
oxysterols in neuronal cell death and neurodegenerative conditions, little is 
known about possible effects of oxysterols on gene expression in the brain. 
Therefore, this portion of the study was performed using microarray analysis to 
elucidate global gene expression changes in the rat PFC after oxysterol 
treatment. The PFC was selected for this study based on its role in cognitive 
control (Miller, 2000). 
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2. Material and Methods 
 Animal and Treatment 
Sixteen rats were used in this portion of the study. They were divided 
into four groups: vehicle, 7β-HC, 7-KC and cholesterol treatments (four rats per 
group). Adult male Wistar rats, weighing approximately 300 g each, were 
purchased from the Centre for Animal Resources (CARE), NUS. They were 
anesthetized with a ketamine (75 mg/kg) and xylazine (10 mg/kg) cocktail, and 
placed on a stereotaxic apparatus (Stoelting, Wood Dale, IL, USA). 7β-HC, 7-
KC, cholesterol (Steraloids, Newport, RI, USA; 0.8 nmol in 1 µl solution, 
dissolved in 5% ethanol), or vehicle (5% ethanol) were stereotaxically injected 
into the right PFC (coordinates: 4.7 mm rostral to bregma, 2.5 mm lateral to 
midline, and 1.6 mm from surface of the cortex) through a small craniotomy 
(Paxinos and Watson, 1996). The needle was withdrawn 5 min after the 
intracortical injection and the scalp was sutured. Rats were housed under 
controlled conditions (23 ± 1°C, 12:12 h light-dark cycle) and were given 
standard laboratory chow and water ad libitum. Administration of test 
compounds, 7β-HC, 7-KC, or cholesterol at same concentration in the rat PFC 
was conducted to compare the effects of the two autoxidatively generated 
oxysterols vs. cholesterol on gene expression in the brain, relative to vehicle-
injected controls. The total dose of test compounds (1 μl of 0.8 mM solution of 
test compounds) was determined based on the excess amount of oxysterol 
induced by KA excitotoxicity in the rat hippocampus (approximately 2.8 
ng/mg) (Kim et al., 2011) multiplied by the average estimated mass of the rat 
PFC (115 mg) (Loke et al., 2013). All procedures involving animals were 
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approved by the Institutional Animal Care and Use Committee (IACUC) of the 
National University of Singapore (NUS), and conducted in accordance with 
guidelines of the National Advisory Committee for Laboratory Animal 
Research (NACLAR).  
 
 RNA extraction 
The same sixteen rats used in Chapter III, Section 1:2.1, were used in 
this portion of the study. They were divided into four groups: vehicle, 7β-HC, 
7-KC, and cholesterol treatments (four rats per group). Rats were deeply 
anaesthetized by a ketamine (75 mg/kg) and xylazine (10 mg/kg) cocktail and 
sacrificed 24 h after injection with vehicle, oxysterol, or cholesterol. The right 
PFC was harvested, immersed in RNAlater® (Ambion, Austin, TX, USA), 
snap-frozen in liquid nitrogen, and stored in the -80°C freezer till analysis. Total 
RNA was extracted from the PFC using Trizol reagent (Invitrogen, Carlsbad, 
CA, USA), and purified with the RNeasy® Mini Kit (Qiagen, Valencia, CA, 
USA) following the manufacturer’s protocol. The extracted RNAs were stored 
in the -80°C freezer till they were used for microarray and real-time RT-PCR 
analyses (Loke et al., 2013).  
 
 DNA microarray analyses 
 The same sixteen rats used in Chapter III, Section 1:2.2, were used in 
this portion of the study. Gene expression profiles were elucidated using the 
Agilent SurePrint G3 Rat GE 8x60K Microarray (Agilent Technologies, Palo 
Alto, CA, USA). 5µl of total RNA of the PFC from each rat was submitted to 
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the BFIG Core Facility Lab (NUS, Department of Pediatrics). The quality of 
RNA was analyzed using the Agilent 2100 Bioanalyzer (Agilent Technologies) 
to ensure that only these with RNA integrity number (RIN) greater than 8.0 
were used for analyses. cRNA generated from each sample was labeled using 
the one-cycle target labeling method and hybridized to a single array according 
to standard Agilent protocols. Data was imported to GeneSpring GX10 (Agilent 
Technologies) software for analysis, using parametric test based on cross gene 
error model (PCGEM). DEGs were genes with altered expression induced by 
each treatment group, compared with vehicle treated rats. DEGs with greater 
than 2-fold change were identified using one-way analysis of variance 
(ANOVA) analysis. P < 0.05 was considered significant (Loke et al., 2013). 
 
 Network analyses 
The list of DEGs that showed significant changes in expression were 
uploaded to IPA software (http://www.ingenuity.com; Ingenuity Systems, 
Redwood City, CA, USA). Gene interaction networks were generated, ranked 
by score and presented as network diagrams. Each node in the network diagram 
depicted a gene and its association with other molecules was indicated by a line 
(solid and dotted lines indicate direct and indirect interactions, respectively). 
Grey nodes were DEGs detected in this study, called the ‘focus genes’ or ‘focus 
molecules’. White nodes were molecules added by IPA according to the 
Ingenuity Knowledge Base to generate a highly connected network. This 
network demonstrates the interaction between focus genes and ‘node 
molecules’ and how they work together at the molecular level. The network 
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score is the negative logarithm of P-value that reflects the likelihood of finding 
the focus genes in a particular network by random chance. A high score is an 
indication of the molecular connection with the network is more likely to be 
accurate.   
 
 Real-time RT-PCR  
The same sixteen rats used in Chapter III, Section 1:2.2, were used in 
this portion of the study. Prior to real-time RT-PCR, extracted RNA samples 
were subjected to reverse transcription using the High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Foster City, CA, USA). The conditions 
for reverse transcription reaction were 25°C for 10 min, 37°C for 120 min, and 
85°C for 5 sec. Real-time PCR was conducted using the 7500 Real-Time PCR 
system (Applied Biosystems) to verify some of the DEGs detected by 
microarray. The preparation of samples and solutions was conducted according 
to the manufacturer’s protocol using TaqMan® Universal PCR Master Mix 
(Applied Biosystems) with rat TaqMan® probes for OXTR, CCKAR, NPFFR1, 
NTSR1 and β-actin (Applied Biosystems). Each sample was prepared in 
triplicate and all replicates were used for statistical calculations. Thermal 
cycling conditions during real-time RT-PCR included two incubations each at 
50°C for 2 min and 95°C for 10 min, followed by 40 cycles of reaction in which 
each cycle consisted of two incubations at 95°C for 15 sec and 60°C for 1 min. 
The cycle threshold (CT) which correlates inversely with the target mRNA 
levels, was measured as the number of cycles at which the reported fluorescence 
emission exceeded the preset threshold level. The comparative CT method was 
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used to quantify the amplified transcripts with the formula for relative fold 
change = 2−DDCT (Livak and Schmittgen, 2001). DCT is the CT normalization 
of OXTR, CCKAR, NPFFR1, or NTSR to the endogenous reference, β-actin. 
The mean and standard error were calculated. Possible significant differences 
between the values of each treatment group were analyzed, using one-way 
ANOVA with Bonferroni’s multiple comparison post-hoc test. P < 0.05 was 
considered significant (Loke et al., 2013). 
 
 Western blot  
Eight rats were used in this portion of the study. They were divided into 
two groups: vehicle and 7β-HC treatment (four rats per group). Rats were 
deeply anaesthetized by a ketamine (75 mg/kg) and xylazine (10 mg/kg) 
cocktail and sacrificed 24 h after injection with vehicle or 7β-HC. The right PFC 
was harvested, snap-frozen in liquid nitrogen, and stored in the -80°C freezer 
till analysis. Tissue samples were weighed and homogenized in 
radioimmunoprecipitation assay (RIPA) lysis buffer system (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) according to the manufacturer’s 
protocol. Samples were centrifuged at 12,000 g and 4°C for 30 minutes to 
separate cellular protein extracts from tissue debris. The protein concentration 
of the supernatant was determined using the Bio-Rad protein assay kit (Bio-Rad 
Laboratories, Richmond, CA, USA). Homogenates (50 µg) were resolved in 
10% SDS-polyacrylamide gel under reducing conditions for approximately 2 h 
and electrotransferred to a polyvinylidene difluoride membrane (Amersham 
Pharmacia Biotech, Little Chalfont, UK) for 1 h. The membrane was incubated 
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with blocking buffer, consisting of a solution of 5% non-fat milk in Tris-
buffered saline with 0.1% Tween-20 (TBST) for 1 h. The polyvinylidene 
difluoride membrane was incubated overnight at 4°C with a rabbit polyclonal 
antibody to oxytocin receptor (OXTR; Alpha Diagnostic, San Antonio, TX, 
USA; diluted 1:500 in blocking buffer). After washing with TBST, the 
membrane was incubated with horseradish peroxidase-conjugated anti-rabbit 
immunoglobulin G (IgG; Pierce, Rockford, IL, USA; diluted 1:2000 in blocking 
buffer), and visualized using SuperSignal West Pico Chemiluminescent 
Substrate (Pierce). Loading controls were conducted by incubating the blots at 
room temperature for 15 min with stripping buffer (100 mM 2-mercaptoethanol, 
2% SDS, and 62.5 mM Tris-hydrochloride, pH 6.7), followed by reprobing with 
a mouse monoclonal antibody to β-actin (Sigma, St. Louis, MO, USA; diluted 
1:10,000 in blocking buffer). Exposed films containing blots were scanned, 
densities of OXTR bands were normalized against those of β-actin, and the 
mean and standard error were calculated. Possible significant differences 
between the values of 7β-HC and vehicle groups were analyzed using Student’s 
t-test. P < 0.05 was considered significant. Rat uterine tissue was used as a 
positive control (Loke et al., 2013). 
 
 Immunohistochemistry 
Four untreated rats were used in this portion of the study. They were 
deeply anesthetized by a ketamine (75 mg/kg) and xylazine (10 mg/kg) cocktail 
and cardiac perfusion was performed with a solution of 4% paraformaldehyde 
in 0.1 M phosphate buffer (PB) at pH 7.4. The fixed brain tissues were removed 
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and blocks containing the PFC were sectioned coronally at 100 μm using a 
vibrating microtome. Free floating sections were washed with phosphate-
buffered saline (PBS) to remove traces of fixative and incubated overnight with 
a rabbit polyclonal antibody to OXTR (diluted 1:25 in PBS). The sections were 
washed in six changes of PBS followed by incubation with a biotinylated horse 
anti-rabbit IgG (Vector Laboratories, Burlingame, CA, USA; diluted 1:200 in 
PBS) for 1 h. They were then reacted with the avidin-biotinylated horseradish 
peroxidase complex (ABC; Vector Laboratories) for 1 h and incubated with 
nickel Tris-buffered saline (NTBS). The reaction was visualized for 5 min with 
0.05% 3,3,-diaminobenzidine tetrahydrochloride (DAB) solution in NTBS 
containing 0.05% hydrogen peroxide, followed by several rinses of Tris-
buffered saline (TBS). Some sections were mounted on gelatin-coated slides, 
counterstained with methyl green, coverslipped, and viewed using a light 
microscope (IX70; Olympus, Tokyo, Japan). The remaining sections were 
processed for electron microscopy. Tissue sections incubated with PBS only 
(without primary antibody) were used as a negative control (Loke et al., 2013).  
 
 Electron microscopy 
Some of the OXTR-immunolabeled brain sections were subdissected 
into smaller portions that included the PFC. These were osmicated, dehydrated 
in an ascending series of ethanol and acetone, and embedded in Araldite. Thin 
sections were obtained from the first 5 μm of the sections, mounted on copper 
grids coated with 0.3% Formvar, stained with lead citrate, and examined using 
a Jeol 1010 electron microscope (Jeol, Tokyo, Japan) (Loke et al., 2013). 
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3. Results  
 Microarray data collection and analyses 
 DNA microarray analyses identified changes in the gene expression 
with more than 2-fold change that were both common and exclusive to 1-day 
post-7β-HC, post-7-KC, post-cholesterol, or post-vehicle intracortical 
injections. As shown in Figure 3.1, 7-KC treatment produced the highest 
number of DEGs with a total of 2024 genes. Of the DEGs regulated by 7-KC 
treatment, 1659 and 365 genes were downregulated and upregulated, 
respectively. 7β-HC treatment resulted in 1588 DEGs, of which 1186 and 402 
genes were downregulated and upregulated, respectively. Only 39 DEGs were 
detected after cholesterol treatment, of which 30 and 9 were downregulated and 













Figure 3.1. Venn diagram showing the classification of DEGs in the PFC after 1-day 
post-treatment with 7β-HC, 7-KC, or cholesterol. The numbers in parenthesis represent 
the number of genes that were both downregulated and upregulated with more than 2-
fold change and P < 0.05 compared with vehicle (n = 4 in each group). (Loke et al., 
2013). 
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 DEGs exclusive to 7β-HC treatment 
A total of 213 DEGs with more than 2-fold change which were exclusive 
to 7β-HC treatment compared with vehicle treatment (Figure 3.1). Of these, 131 
genes were downregulated and 82 were upregulated. Downregulated genes with 
the highest fold change included: VGLL1, REG3B, and LOC686013 (Appendix 
1). Upregulated genes with the highest fold change included: LOC298613, 
RGD1562534, and TAF7L (Loke et al., 2013). 
 
 DEGs exclusive to 7-KC treatment 
  A total of 649 DEGs with more than 2-fold change compared with 
vehicle which were exclusive to 7-KC treatment compared with vehicle 
treatment (Figure 3.1). Of these, 601 genes were downregulated and 48 were 
upregulated. Downregulated genes with the highest fold change included: 
RNASE1L1, RETNLG, and RGD1559489 (Appendix 2). Upregulated genes 
with the highest fold change included: PTX3, TIMD2, and WWOX (Loke et al., 
2013).  
 
 DEGs common to 7β-HC and 7-KC treatments 
Large number of DEGs was found in this category, which included 
DEGs that were altered in common after treatment with 7β-HC or 7KC. This 
category also accounted for the highest percentage of DEGs, i.e. 1365 DEGs 
out of a total of 2266 DEGs after treatment with all test compounds vs. vehicle 
controls, or 60.2% (Figure 3.1). Genes with the highest fold change of more 
than 6-fold were also found in this category (Appendix 3). Of the 1365 DEGs, 
Chapter III, Section 1 - Gene Expression Analyses of the Rat Prefrontal 
Cortex after Cholesterol or Oxysterol Treatment  
 
72 
1050 genes were downregulated and 315 were upregulated. Downregulated 
genes with the highest fold change included: LOC680012, LOC688874, and 
RGD1562492. Upregulated genes with the highest fold change included: PERC, 
LOC307263, and NUDT9 (Loke et al., 2013). 
 
 DEGs common to 7β-HC and cholesterol treatments 
There were 6 DEGs in this group (Figure 3.1). Of these, 2 were 
downregulated and 4 were upregulated by 7β-HC, whereas 5 were 
downregulated and 1 was upregulated by cholesterol. Downregulated genes by 
7β-HC treatment with highest fold change included: TNNT2, and MPZL2 
(Appendix 4). Upregulated genes by 7β-HC treatment with highest fold change 
included: LOC688828, LOC100365120, and LOC100366054 (Loke et al., 
2013).  
 
 DEGs common to 7-KC and cholesterol treatments 
There were 6 DEGs in this group (Figure 3.1). Of these, 5 genes were 
downregulated and 1 was upregulated. The downregulated genes with highest 
fold change included: GFRAL, SLC9A4, and PIGN (Appendix 5). The 
upregulated gene was TRY10 (Loke et al., 2013). 
 
 DEGs common to 7β-HC, 7-KC, and cholesterol treatments 
There were 4 genes in this group (Figure 3.1). All 4 genes were 
downregulated by cholesterol, whereas 1 of the genes was upregulated by both 
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7β-HC and 7-KC treatments. Downregulated genes included: FMO9, IGFBPL1, 
and WNT9B (Appendix 6). ANKRD57 was upregulated by 7β-HC and 7-KC, 
but downregulated by cholesterol (Loke et al., 2013).  
 
 Networks for downregulated DEGs common to 7β-HC and 7-KC 
treatments  
The largest category of DEGs that showed more than 2-fold change, and 
was found in common after either 7β-HC or 7-KC treatment were selected for 
further analysis using IPA, to identify potential functional networks. The top 
network with the highest number of downregulated DEGs was related to 
carbohydrate metabolism, cell signaling, and nucleic acid metabolism (Table 
3.1). This network had 30 focus genes: TAAR5, OXTR, AVPR1B, GPR152, 
GPR157, P2RY4, GPR112L, GPR35, GPR142, NPVF, GPR63, TAS1R3, 
CCKAR, F2RL3, LGR5, NPFFR1, GHSR, PCP2, TAS1R2, GPR44, GPR156, 
TAAR8C, UTS2R, CCRL2, SUCNR1, UTS2D, V1RL1, GPR132, S1PR4, and 
NTSR1 (Table 3.2 and Figure 3.2). Most of these genes encode G-protein 
coupled receptors (GPCRs). 
The network with the second highest number of downregulated DEGs 
had 25 focus genes, which were related to lipid metabolism, molecular 
transport, and small molecule biochemistry (Table 3.1).  
The network with the third highest number of DEGs was related to 
endocrine system development and function, small molecule biochemistry, and 
molecular transport with 25 focus genes (Table 3.1) (Loke et al., 2013).  
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Table 3.1. Top five associated network functions mapped by IPA for downregulated 
DEGs in the PFC, which were found in common to 1-day post-7β-HC and post-7-KC 
treatments. (Loke et al., 2013).  
 
Associated Network Functions Score Focus Genes 
Carbohydrate metabolism, cell signaling, nucleic acid 
metabolism 42 30 
Lipid metabolism, molecular transport, small molecule 
biochemistry 38 25 
Endocrine system development and function, small 
molecule biochemistry, molecular transport 38 25 
Cell signaling, nucleic acid metabolism, small molecule 
biochemistry 38 25 
Cellular compromise, cell-to-cell signaling and 
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Table 3.2. Downregulated DEGs in the PFC found in common to 1-day post-7β-HC 
and post-7-KC treatments. These are the 30 genes that are mapped in the top network 
pertaining to carbohydrate metabolism, cell signaling, and nucleic acid metabolism by 
IPA (Loke et al., 2013). 
 Gene  Gene Symbol 
7β-HC 7-KC 
P-value Fold Change P-value 
Fold 
Change 
Trace amine-associated receptor 5  TAAR5 0.0001 -5.35 <0.0001 -10.64 
Oxytocin receptor  OXTR 0.0001 -4.39 <0.0001 -6.91 
Arginine vasopressin receptor 1B  AVPR1B <0.0001 -4.16 <0.0001 -4.53 
Predicted: G protein-coupled receptor 152  GPR152 <0.0001 -3.32 <0.0001 -4.00 
G protein-coupled receptor 157  GPR157 0.0009 -3.32 0.0009 -3.29 
Pyrimidinergic receptor P2Y, G-protein coupled, 
4  P2RY4 0.0038 -3.26 0.0073 -2.33 
Predicted: G protein-coupled receptor 112 like  GPR112L <0.0001 -3.22 <0.0001 -5.88 
G protein-coupled receptor 35  GPR35 0.0001 -3.18 0.0001 -3.86 
Predicted: G protein-coupled receptor 142  GPR142 0.0002 -3.17 0.0002 -5.34 
Neuropeptide VF precursor  NPVF 0.0002 -3.00 0.0001 -3.18 
G protein-coupled receptor 63  GPR63 0.0056 -2.86 0.0009 -3.55 
Taste receptor, type 1, member 3  TAS1R3 0.0019 -2.78 0.0046 -3.76 
Cholecystokinin A receptor  CCKAR 0.0077 -2.75 0.0005 -2.97 
Coagulation factor II  F2RL3 0.0053 -2.69 0.0004 -3.19 
Leucine rich repeat containing G protein coupled 
receptor 5  LGR5 <0.0001 -2.62 0.0124 -2.80 
Neuropeptide FF receptor 1  NPFFR1 0.0176 -2.59 <0.0001 -3.27 
Growth hormone secretagogue receptor  GHSR 0.0024 -2.39 <0.0001 -3.49 
Purkinje cell protein 2  PCP2 <0.0001 -2.38 <0.0001 -2.74 
Taste receptor type 1 member 2 precursor TAS1R2 0.0060 -2.36 0.0163 -2.65 
G protein-coupled receptor 44  GPR44 0.0157 -2.31 0.0001 -3.73 
G protein-coupled receptor 156  GPR156 0.0004 -2.31 0.0003 -2.48 
Trace amine-associated receptor 8c  TAAR8C 0.0001 -2.29 <0.0001 -2.71 
Urotensin 2 receptor  UTS2R 0.0050 -2.27 0.0084 -2.38 
Chemokine (C-C motif) receptor-like 2 CCRL2 0.0011 -2.20 <0.0001 -2.91 
Succinate receptor 1  SUCNR1 0.0001 -2.17 0.0027 -2.79 
Urotensin 2 domain containing  UTS2D 0.0004 -2.12 0.0001 -3.58 
Vomeronasal 1 receptor, L1  V1RL1 0.0002 -2.11 0.0009 -2.16 
G protein-coupled receptor 132  GPR132 0.0001 -2.09 <0.0001 -2.93 
Sphingosine-1-phosphate receptor 4  S1PR4 0.0016 -2.07 0.0038 -2.50 
Neurotensin receptor 1  NTSR1 0.0005 -2.06 0.0001 -2.61 
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Figure 3.2. IPA network of downregulated genes found in common to 1-day post-7β-
HC and post-7-KC treatments with DEGs with more than 2-fold change. IPA identified 
these genes were involved in carbohydrate metabolism, cell signaling, and nucleic acid 
metabolism (as shown in Table 3.2) as the largest network for downregulated genes. 
Data is represented as nodes displayed using various shapes that represent the 
functional class of the gene product. DEGs in these pathways are indicated in grey 
nodes. Solid and dotted lines indicate direct and indirect interactions, respectively 
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 Networks for upregulated DEGs common to 7β-HC and 7-KC 
treatments  
The top network with the highest number of upregulated DEGs was 
related to cell death, cell morphology, cellular assembly and organization 
(Appendix 7). 26 focus genes involved were KCNH2, TXNIP, TPT1, EIF3H, 
RPS23, LAP3, TSG101, CBX3, ERC1, RNF7, CLINT1, TCC28, DOT1L, 
S100B, STMN1, HSP90AB1, EEF1A1, RPAP3, EP400, CDC25C, HIST1H4B, 
IRAK4, AP2B1, FBXO33, ADRM1, and SNAI1 (Figure 3.3 and Appendix 8). 
Upregulated genes in this network were related to NF-κB. 
The network with the second highest number of upregulated DEGs had 
21 focus genes and was related to cancer, cell-mediated immune response, and 
cellular development (Appendix 7) (Loke et al., 2013). 
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Figure 3.3. IPA network of upregulated genes found in common to 1-day post-7β-HC- 
and post-7-KC treatments with DEGs with more than 2-fold change. IPA identified 
these genes were involved in cell death, cell morphology, cellular assembly and 
organization (as shown in Appendix 1) as the largest network for upregulated genes 
(Loke et al., 2013).   
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 Real-time RT-PCR  
Real-time RT-PCR was performed to validate some selected genes from 
the largest downregulated network ‘carbohydrate metabolism, cell signaling, 
and nucleic acid metabolism’ mapped by IPA. In this study, the verified genes 
were chosen based on the availability of commercial TaqMan® probes. There 
was significant downregulation of OXTR mRNA levels following 7β-HC and 
cholesterol treatments by 58% and 55% compared with vehicle group (P = 
0.0165 and 0.0410, respectively; Figure 3.4A), respectively. CCKAR showed 
downregulation in mRNA levels after 7β-HC, 7-KC, and cholesterol treatments 
with 68%, 63%, and 61% reduction compared with vehicle treatment (P = 
0.0009, 0.0024, and 0.0036, respectively; Figure 3.4B), respectively. 7β-HC 
treatment reduced NPFFR1 mRNA levels by 55% compared with vehicle 
treatment (P = 0.0006; Figure 3.4C) and there was also significant 
downregulation of NPFFR1 mRNA levels after 7β-HC treatment compared 
with 7-KC (P = 0.0215). Treatment with cholesterol resulted in 52% lower 
mRNA levels of NTSR1 than vehicle treatment (P = 0.0087; Figure 3.4D) (Loke 
et al., 2013). 
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Figure 3.4. Real-time PCR analyses in the rat PFC. The expression changes of the four 
genes (A: OXTR; B: CCKAR; C: NPFFR1; and D: NTSR1) that were found in the 
network ‘carbohydrate metabolism, cell signaling, and nucleic acid metabolism’, were 
validated and analyzed by one-way ANOVA with Bonferroni’s multiple comparison 
post-hoc test. Data represent the mean and standard error (n = 4 per group). * indicates 
significant difference compared with vehicle group. * P < 0.05 and ** P < 0.01 (Loke 
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 Western Blot  
OXTR was chosen for further verification at the protein expression level 
in the rat PFC after 7β-HC treatment, compared with vehicle group. OXTR was 
selected based on its functional importance in the brain (i.e. cognition) and 
commercially available antibody. The OXTR antibody detected two major 
bands at approximately 35 kDa and 50 kDa in the rat uterine sample, which was 
used as a positive control (Figure 3.5A). Blots from the PFC showed a major 
band at approximately 35 kDa and a faint band at approximately 50 kDa. These 
correspond to the deglycosylated form (38 kDa) which is close to the expected 
theoretical molecular mass of receptor core and partial deglycosylated form (48 
kDa) of OXTR (Kojro et al., 1991; Breton et al., 2001), respectively. 
Densitometric analysis showed significantly reduced OXTR protein expression 
in the rat PFC after 7β-HC treatment compared with vehicle group (33%, P = 
0.0144; Figure 3.5B) (Loke et al., 2013).  
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Figure 3.5. Western blot analysis of OXTR. A: Immunoblot of OXTR. Lanes 1-4: 
vehicle control; lanes 5-8: 1-day post-7β-HC treatment and lane 9: a positive control of 
OXTR. The positive control of OXTR was performed using homogenates from the 
uterine tissue of a female rat that had just given birth. β-actin was used as loading 
control. B: Densitometric analysis of OXTR protein normalized to β-actin and analyzed 
by Student’s t-test. Data represent the mean and standard error (n = 4 per group). * 
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 Immunolocalization of OXTR in the PFC 
Dense immunoreactivity to OXTR was observed in the neuronal cell 
bodies and punctate profiles in the neuropil (Figure 3.6A-B). Negative control 
(tissue sections incubated with PBS only and without primary antibody) showed 
negative immunoreactivity (data not shown). 
Electron micrographs of OXTR-immunostained sections showed 
labeling in axon terminals (Figure 3.7A-B). The latter were identified by the 
presence of neurotransmitter containing small round vesicles, a classical feature 
of glutamatergic axon terminals (Edwards, 1995).  
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Figure 3.6. Light micrographs of OXTR-immunostained brain slices in the PFC. A: 
Light micrograph at 60X magnification. B: Light micrographs at 100X magnification. 
Dense immunoreactivity to OXTR (arrows) was observed in the neuronal cell bodies 
and punctate profiles in the neuropil. Scale = 50 (A) and 30 μm (B) (Loke et al., 2013). 
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Figure 3.7. Electron micrograph of OXTR-immunostained sections from the PFC. 
Immunoreactive products (arrows in A and B) were present in axon terminals. The 
dendrite (D) formed an asymmetrical synapse (S) with axon terminal (AT), which was 
identified by the presence of neurotransmitter containing small round vesicles in the 
axon terminals. Scale = 0.1 μm (Loke et al., 2013).  
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The present study aimed to elucidate global gene expression changes in 
the rat PFC after treatment with cholesterol or oxysterols. In general, treatment 
with these oxysterols exerted potent effects on gene expression, compared with 
their parent compound, cholesterol (Loke et al., 2013). Many DEGs with high 
fold change were found in common after 7β-HC or 7-KC treatment, whereas 
few DEGs were found after cholesterol treatment (Loke et al., 2013). This study 
focused on gene expression changes in the PFC after treatment with oxysterols 
that are generated by autoxidation of cholesterol, i.e. 7β-HC or 7-KC, while 
possible effects of oxysterols that are formed by enzymatic action such as 24S-
HC were not elucidated (Loke et al., 2013). 24S-HC is different from 7β-HC 
and 7-KC due to the side-chain hydroxylation of cholesterol (Brown and Jessup, 
2009). Although elevation of 24S-HC, 7-KC, and 7β-HC levels were observed 
at 2-weeks post-KA lesion, the levels of 24S-HC were several folds higher than 
7β-HC and 7-KC (He et al., 2006; Kim et al., 2010; Kim et al., 2011). The 
relatively higher abundance of 24S-HC makes it incompatible for direct 
comparison with 7β-HC and 7-KC in this study (Loke et al., 2013). The dose of 
oxysterols used in the present study was calculated based on the level of 7β-HC 
and 7-KC in the rat hippocampus after excitotoxic brain injury induced by the 
glutamate analog, KA (Kim et al., 2011). This dose is also similar to the 
concentration of these oxysterols discovered in the visual cortex of patients with 
PD (Cheng et al., 2011).  
Oxysterols are involved in the transcriptional control of lipid 
metabolism through the interaction with LXRs (Edwards et al., 2002) and 
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SREBP (Olsen et al., 2012). Oxysterols also exert pro-inflammatory effects at 
transcriptional level through activation of LXR (Vejux et al., 2008; Jusakul et 
al., 2011). A microarray analysis in human macrophages has identified various 
LXR targets (Pehkonen et al., 2012) and out of these, RPLP1 and RANBP1 
were detected in our microarray analysis. This suggests a possible involvement 
of LXR in oxysterol-induced gene expression changes (Loke et al., 2013). 
Oxysterols can bind to INSIG proteins and inhibit SREBP activation, resulting 
in inhibition of cholesterol synthesis (Radhakrishnan et al., 2007). Moreover, 
oxysterols participate in the transcriptional mechanisms of the JAK2/STAT3 
pathway to elevate gene expression (Romeo and Kazlauskas, 2008). Changes in 
gene expression could also be due to epigenetic effects such as histone 
modification, DNA methylation, RNA-associated silencing, and nucleosome 
positioning (Portela and Esteller, 2010). Oxysterols have been demonstrated to 
mediate gene transcription via the recruitment of epigenetic modifying proteins 
such as histone acetyltransferase, histone deacetylase (HDAC), and chromatin-
remodeling factors, together with a transcription factor to the gene promoter 
(Romeo and Kazlauskas, 2008). Effects of oxysterols in mutagenicity and 
genotoxicity have been reported (Jusakul et al., 2011). In addition, oxysterols 
can enhance the severity of mitochondrial DNA damage that results in increased 
ROS production (Gramajo et al., 2010), and this may lead to alterations in gene 
expression (Loke et al., 2013). 
The pathways that were altered in response to oxysterol treatment in the 
brain were also determined by IPA analyses. Interestingly, many of the DEGs 
in the top network of downregulated genes which pertained to carbohydrate 
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metabolism, cell signaling, and nucleic acid metabolism, were found to encode 
GPCRs (Loke et al., 2013). GPCRs are the largest family of plasma membrane 
proteins with seven membrane-spanning α-helical domains, that participate in 
various forms of information processing (Rosenbaum et al., 2009). They are 
involved in transcriptional regulation of target genes, and modulation of 
signaling proteins and enzymatic effectors (Shaywitz and Greenberg, 1999; 
Neves et al., 2002; Rosenbaum et al., 2009). Regulation of GPCR signaling is 
governed by the phosphorylation status of the receptor for rapid and precise 
temporal control, whereas long-term regulation can be attained by 
transcriptional and post-transcriptional mechanisms (Collins et al., 1991; Pierce 
et al., 2002). Transcriptional downregulation of GPCRs in the PFC has been 
observed in the aging human brain and this could be attributed to accumulative 
oxidative damage to DNA, lipids, and protein (Erraji-Benchekroun et al., 2005).  
Other downregulated genes mapped in the second largest network are 
related to lipid metabolism, molecular transport, and small molecule 
biochemistry (Loke et al., 2013). Genes that were involved in this network are 
related to NF-κB (nuclear factor κB) and retinoid X receptor (RXR). One 
possibility is that oxysterols could induce cellular oxidative stress which initiate 
NF-κB activation as well as LXR activation that usually occurs simultaneously 
with the former (Robbesyn et al., 2004). Furthermore, the largest network 
generated from the upregulated genes associated with cell death, cell 
morphology, cellular assembly and organization with 26 focus genes, also 
demonstrated relationship with NF-κB (Loke et al., 2013).  
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In view of the downregulation of DEGs as the major trend in gene 
expression induced by oxysterol treatments and the importance of GPCRs in 
key cellular functions, several genes from the largest network of downregulated 
genes were selected for further verification by real-time RT-PCR (Loke et al., 
2013). Oxysterol treatment reduced the mRNA expression of OXTR, CCKAR, 
and NPFFR1, while NTSR1 was only reduced by cholesterol treatment (Loke 
et al., 2013). CCKAR (cholecystokinin A receptor), NPFFR1 (neuropeptide FF 
receptor 1), and NTSR1 (neurotensin receptor 1) are neuropeptide receptors and 
members of GPCR (Loke et al., 2013). CCKAR is one of the receptors that 
binds cholecystokinin (Koefoed et al., 2009; Wilson et al., 2011), and the latter 
is a neuropeptide transmitter with strong associations with schizophrenia and 
bipolar affective disorder (Asherson et al., 1998; Christoforou et al., 2007). 
NPFFR1 binds to neuropeptide FF (Bonini et al., 2000; Elshourbagy et al., 
2000) and can be activated by neuropeptide VF precursor (Liu et al., 2001). 
NTSR1 is thought to play a role in the working memory of humans (Li et al., 
2011) and rodents (Tirado-Santiago et al., 2006). Reduced NTSR1 mRNA 
levels have been reported in the temporal gyrus of AD patients (Gahete et al., 
2010). 
The reduction in OXTR expression by oxysterol is a novel observation, 
and is of interest due to its emerging role in cognition (Loke et al., 2013). OXTR 
is a receptor for oxytocin which is associated with social cognition (Kirsch et 
al., 2005; Kosfeld et al., 2005; Hollander et al., 2007), autism (Hollander et al., 
2007; Kosaka et al., 2012), and anxiety (Scantamburlo et al., 2007). Reduced 
OXTR mRNA expression due to hypermethylation of the gene promoter has 
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been shown in the temporal cortex and peripheral blood lymphocytes of patients 
with autism spectrum disorders (Gregory et al., 2009). Rodents with loss of 
oxytocin or OXTR showed elevated aggressive behavior (Takayanagi et al., 
2005) and anxiety (Mantella et al., 2003), as well as declined social recognition 
(Takayanagi et al., 2005; Lee et al., 2008b) and reciprocal social interactions 
(Pobbe et al., 2012). Consistent with the gene expression, the deglycosylated 
form of OXTR protein was significantly reduced in the PFC after 7β-HC 
treatment (Loke et al., 2013). It has been demonstrated that the glycosylation 
status at the N-terminal of OXTR has no effect on the activity and characteristics 
of the protein (Kimura et al., 1997). Immunohistochemical analysis also showed 
that OXTR was localized to neurons in the PFC, consistent with the results of a 
previous study (Adan et al., 1995), and electron microscopy demonstrated 
OXTR immunoreactivity in axon terminals (Loke et al., 2013). A probable 
explanation of the present findings is that increased oxysterols during neuronal 
injury could result in downregulation of OXTR at nerve terminals, thus 
affecting neuronal plasticity (Loke et al., 2013). Although the exact mechanism 
for downregulation of OXTR upon oxysterol treatment is yet to be elucidated, 
decreased OXTR expression could be due to long term exposure of OXTR to 
its agonist. It has been shown that oxysterols can bind to certain class-A GPCRs, 
other than their canonical receptors, LXRs (Sensi et al., 2014). Since OXTR 
belongs to a subfamily in Class-A GPCR, oxysterol may be a potential agonist 
of OXTR. Thus, long term activation of OXTR by oxysterol may lead to 
reduced receptor synthesis through inhibition of gene transcription.
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ICLAD is a major cause of stroke particularly among Asians, Hispanics 
and Africans (Wong, 2006), and is possibly the most common vascular lesion 
in the world (Gorelick et al., 2008). It carries poor prognosis in subsequent 
vascular event and death and there is 25-30% incidence of recurrence in the first 
2 years after stroke (Wong and Li, 2003; Mazighi et al., 2006). It is also 
prevalent among 53% of vascular dementia and 18% of AD patients of Asian 
ethnicity (Wong, 2006; De Silva et al., 2009; Ong et al., 2013). 
The risk factors for ICLAD include hypercholesterolemia, hypertension, 
diabetes and cigarette smoking (Ingall et al., 1991). Increasing incidence of 
ischemic stroke caused by both extracranial and intracranial large-artery 
atherothromboembolism is secondary to an elevated prevalence of 
hypercholesterolemia which is associated with increased dietary intake of 
saturated fat, physical inactivity, obesity, and diabetes (Hankey et al., 2010). 
Increased serum cholesterol is linked to elevated levels of oxidized LDL (Chen 
et al., 2003). The latter suppresses nitric oxide in endothelial cells to induce 
vasospasm (Giardina et al., 2001), or enhances tissue factor activity in these 
cells to support thrombosis (Weis et al., 1991). Furthermore, statin treatment 
that reduces cholesterol levels, can delay the progression of lesions in patients 
with ICLAD (Mok et al., 2009; Ong et al., 2013).  
Besides that, a strong association is demonstrated between 
asymptomatic ICLAD which is presented as intracranial stenosis or 
calcification with large artery stiffness, and patients with untreated hypertension 
(Zhang et al., 2011). Prolonged elevation of BP results in decreased vessel cross 
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sectional area, increased wall thickness and accelerated plaque formation (Xu 
et al., 1991; Hollander et al., 1993). Moreover, hypertension is believed to be a 
driving force that promotes the atherosclerotic changes from larger to smaller 
vessels, and from extracranial to intracranial vessels (Mills et al., 2007; Ropper 
et al., 2009). In addition, a combination of hypercholesterolemia and 
hypertension may further exacerbate the damage to vessels (Xu et al., 1991; 
Alexander, 1995; Ong et al., 2013). 
Epidemiological studies revealed an augmented risk of a second stroke 
especially in the first 1 or 2 years of post-stroke event (Wong and Li, 2003; 
Mazighi et al., 2006). Although the reasons for this are not well-understood, 
almost certainly that it involves gene expression changes at the vascular level 
that drives the atherothrombotic process (Ong et al., 2013). To date, however, 
there have been no studies to elucidate global gene expression or gene network 
profiles in large intracerebral arteries at risk of atherothrombosis (Ong et al., 
2013). 
This portion of the study was conducted to compare gene expression and 
morphological changes in intracranial vessels of rabbits, after exposure to 
hypercholesterolemia and/or hypertension (Ong et al., 2013). These conditions 
were induced by mostly non-genetically based methods to minimize possible 
confounding effects during microarray analyses (Ong et al., 2013). The MCA 
was chosen for this study as this vessel is often implicated in ICLAD (Olsen et 
al., 1985; Wong, 2006; Ritman and Lerman, 2007; Brown et al., 2010). 
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2. Material and Methods 
 Animals 
Male NZW rabbits were used as it is the gold standard in atherosclerosis 
studies (Yanni, 2004). Although it is possible to produce hypertension in 
rodents (Doggrell and Brown, 1998), it is difficult to produce 
hypercholesterolemia in these animals (Moghadasian et al., 2001; Russell and 
Proctor, 2006). The very small size of the MCA in rodents also hinders gene 
expression analyses of these vessels (Ong et al., 2013).  
Thirty rabbits were used in this portion of the study. They were divided 
into five groups: untreated control on normal diet, sham operated control on 
normal diet, ‘hypertension on normal diet’, ‘hypercholesterolemia plus sham’, 
and ‘hypercholesterolemia plus hypertension’ (six rabbits per group). Rabbits 
were approximately 8 weeks old (young adults) and weighed 2.0-2.5 kg each at 
the start of the experiments. Two sets of experiments were carried out: i) to 
determine gene expression changes in the MCA after ‘hypertension on a normal 
diet’, and ii) to determine gene expression changes in the MCA after 
‘hypercholesterolemia plus sham operation’ and ‘hypercholesterolemia plus 
hypertension’. The first set of experiments were carried on six rabbits with the 
Goldblatt 2K1C method used to induce hypertension and fed with normal diet 
vs. six sham operated controls on a normal diet. The second set of experiments 
were carried out on six rabbits on a high cholesterol diet with sham operation, 
six rabbits on a high cholesterol diet plus 2K1C to induce hypertension, and six 
rabbits on a normal diet (Ong et al., 2013). 
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The 2K1C procedure to induce hypertension was performed as 
previously described (Akabane et al., 1985). In brief, animals were anesthetized 
with ketamine (75 mg/kg)/xylazine (10 mg/kg) cocktail followed by isoflurane 
maintenance, and the left renal artery was exposed. The artery was partially 
occluded by the attachment of a U-shaped silver ‘clip’ with a 0.6 mm slot 
(Figure 3.8). The clip was in left in situ until the animals were sacrificed. Sham 
operated animals received the same surgical procedures as the 2K1C group, 
except that the renal artery was not partially occluded after its exposure (Ong et 
al., 2013). Animals in the ‘hypercholesterolemia plus sham/hypertension’ 
groups were allowed to recover for 1 week from surgery before proceeding with 
the high cholesterol dietary treatment. The diet for these groups of rabbit was 
Guinea Pig and Rabbit (GPR) diet + 1% cholesterol (Glen Forrest Stockfeeders, 
Glen Forrest, Australia). Sham operated control rabbits were fed with GPR diet 
without cholesterol (Ong et al., 2013). All procedures including animals were 
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Figure 3.8. The 2K1C model of hypertension. 
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 Measurement of body weight, mean arterial pressure (MAP) and 
serum total cholesterol 
The same thirty rabbits used in Chapter III, Section 2:2.1, were used in 
this portion of the study. They were divided into five groups: untreated control 
on normal diet, sham operated control on normal diet, ‘hypertension on normal 
diet’, ‘hypercholesterolemia plus sham’, and ‘hypercholesterolemia plus 
hypertension’ (six rabbits per group). Rabbits were anaesthetized by 
intramuscular injection of ketamine/xylazine cocktail, followed by MAP 
measurements, and collection of blood. MAP was recorded from the ‘middle’ 
ear artery (Powerlab 4/30; AD Instruments, Colorado Springs, CO, USA), and 
blood samples obtained for cholesterol analysis at 0, 4, 10 and 12 weeks. 
Approximately 3 mL of blood was withdrawn from the artery and collected in 
BD Vacutainer® Serum Tubes with Clot activator and silicone-coated interior 
(Becton Dickinson, Franklin Lakes, NJ, USA). Whole blood was centrifuged at 
1,000 g for 15 min, and the serum transferred to new vials and kept frozen at -
80°C till analysis. Serum total cholesterol levels were measured by a 
fluorometric assay (Ex/Em 535/587 nm; BioVision Inc., Mountain View, CA, 
USA). Samples were analyzed in triplicates and read with a microplate reader 
(Infinite® i-control; Tecan Trading AG, Maennedorf, Switzerland) (Ong et al., 
2013). 
 
 Tissue harvesting and RNA extraction 
The same thirty rabbits used in Chapter III, Section 2:2.1, were used in 
this portion of the study. They were divided into five groups: untreated control 
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on normal diet, sham operated control on normal diet, ‘hypertension on normal 
diet’, ‘hypercholesterolemia plus sham’, and ‘hypercholesterolemia plus 
hypertension’ (six rabbits per group). The sham operated control rabbits on 
normal diet, ‘hypertension only’ rabbits on normal diet, ‘hypercholesterolemia 
plus sham’ rabbits, and ‘hypercholesterolemia plus hypertension’ rabbits were 
sacrificed 12 weeks after surgery. Sham operated control rabbits or untreated 
controls on a normal diet were sacrificed after a similar time. Animals were 
deeply anaesthetized by ketamine/xylazine cocktail and euthanized by 
intravenous injection of pentobarbital (250 mg/kg). The brains were removed 
and hemisected. The left half of the brain was immersed in 4% 
paraformaldehyde in 0.1M PB in preparation for histology or electron 
microscopy (see below). The right MCA was stripped off the surface of the 
brain without any underlying cortical tissue, immersed in RNAlater®, snap-
frozen in liquid nitrogen and stored in -80°C till further analysis. Total RNA 
was extracted from the MCA using TRIzol reagent and was purified using the 
RNeasy® Micro Kit (Qiagen) according to the manufacturer's protocol. The FC, 
hippocampus, liver, kidney, aorta and other organs were also harvested and 
snap-frozen, or stored in paraformaldehyde for future analysis (Ong et al., 
2013). 
 
 DNA microarray analyses 
Sixteen rabbits were used in this portion of the study and these samples 
were obtained from Chapter III, Section 2:2.3. They were divided into four 
groups: sham operated control on normal diet, ‘hypertension on normal diet’, 
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‘hypercholesterolemia plus sham’, and ‘hypercholesterolemia plus 
hypertension’ (four rabbits per group). Ten μL of total RNA from the MCA of 
each rabbit group were submitted to Genomax Technologies, Singapore. RNA 
quality was confirmed using an Agilent 2100 Bioanalyzer. cRNA was then 
generated and labeled using the one-cycle target labeling method, and 
hybridized to the 1-colour Agilent Rabbit Microarray (G2519F-020908; Agilent 
Technologies), according to the manufacturer’s protocol. Data was imported 
into GeneSpring v11 software (Agilent Technologies) for analysis using 
PCGEM. DEGs were genes with altered expression induced by each rabbit 
treatment group compared with sham operated control group. They were 
identified using one-way ANOVA with Tukey HSD post-hoc test, and corrected 
for multiple comparisons using Benjamini Hochberg FDR. P < 0.05 was 
considered significant. In this study, to reduce false positives, only DEGs with 
greater than 4-fold change (or in the case of common genes between two data 
sets, greater than 4-fold change in at least one data set) and P < 0.01 were 
presented and used in IPA network analyses (Ong et al., 2013). 
 
 Network analyses 
The list of DEGs with more than 4-fold change and P < 0.01 was 
uploaded to IPA software. The procedures were conducted as previously 
described (see Chapter III, Section 1:2.4). 
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 Electron microscopy 
Sixteen rabbits were used in this portion of the study and these rabbits 
were the same animals used in Chapter III, Section 2:2.1. They were divided 
into four groups: sham operated control on normal diet, ‘hypertension on normal 
diet’, ‘hypercholesterolemia plus sham’, and ‘hypercholesterolemia plus 
hypertension’ (four rabbits per group). The left half of the brain was dissected 
out, fixed in 4% paraformaldehyde and 0.1M PB, and kept at 4°C. Blocks 
containing the MCA were osmicated, dehydrated in an ascending series of 
ethanol and acetone and embedded in Araldite. Thin sections were cut, mounted 
on Formvar coated copper grids and stained with lead citrate. They were viewed 
using a Jeol 1010 electron microscope (Ong et al., 2013).  
 
 Real-time RT-PCR  
Twelve rabbits were used in this portion of the study and these samples 
were obtained from Chapter III, Section 2:2.3. They were divided into three 
groups: untreated control on normal diet, ‘hypercholesterolemia plus sham’, and 
‘hypercholesterolemia plus hypertension’ (four rabbits per group). The mRNA 
expression HNF4A, one of the ‘node molecules’ identified by IPA, was further 
verified in the aorta by real-time RT-PCR. This was needed as only a small 
amount of RNA could be extracted from the rabbit MCA (Ong et al., 2013). 
Purified RNA from the descending aorta of ‘hypercholesterolemia plus sham’, 
‘hypercholesterolemia plus hypertension’ and untreated control rabbits were 
reverse-transcribed with the High-Capacity cDNA Reverse Transcription Kit. 
Real-time PCR was conducted using the 7500 Real-Time PCR system with 
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TaqMan® Universal PCR Master Mix and rabbit TaqMan® probes for HNF4A 
and β-actin (Applied Biosystems). All procedures were conducted as previously 
described (see Chapter III, Section 1:2.5). The comparative CT method was 
used to quantify the amplified transcripts with the formula for relative fold 
change = 2−DDCT (Livak and Schmittgen, 2001). DCT is the CT normalization 
of HNF4A to the endogenous reference, β-actin. The mean and standard error 
were calculated. Possible significant differences between the values of each 
treatment group were analyzed, using one-way ANOVA with Bonferroni’s 
multiple comparison post-hoc test. P < 0.05 was considered significant (Ong et 
al., 2013). 
 
 Western blot  
Nine rabbits were used in this portion of the study and these rabbits were 
the same animals used in Chapter III, Section 2:2.1. They were divided into 
three groups: untreated control on normal diet, ‘hypercholesterolemia plus 
sham’, and ‘hypercholesterolemia plus hypertension’ (three rabbits per group). 
Aorta samples were homogenized in 10 volumes of ice-cold lysis buffer 
(150 mM sodium chloride, 50 mM Tris–hydrochloride, 0.25 mM EDTA, 1% 
Triton X-100, 0.1% sodium orthovanadate, and 0.1% protease inhibitor 
cocktail, pH 7.4), followed by centrifugation at 10,000 g for 10 min at 4°C. The 
supernatant was then collected, and protein concentrations measured using the 
Bio-Rad protein assay kit. The homogenates (20 µg) were resolved in 10% 
SDS-polyacrylamide gels under reducing conditions. The subsequent 
procedures were conducted as previously described (see Chapter III, Section 
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1:2.6), with a mouse monoclonal antibody to HNF4A (K9218; Abcam, 
Cambridge, UK; diluted 1:500 in blocking buffer) and a horseradish peroxidase-
conjugated secondary anti-mouse IgG (Pierce). The densities of HNF4A bands 
were normalized against those of β-actin, and the mean and standard error 
calculated. Possible significant differences between the values of each treatment 
group were analyzed, using one-way ANOVA with Bonferroni’s multiple 
comparison post-hoc test. P < 0.05 was considered significant (Ong et al., 
2013). 
 
 Histochemistry and immunohistochemistry 
Twelve rabbits were used in this portion of the study and these rabbits 
were the same animals used in Chapter III, Section 2:2.1. They were divided 
into three groups: untreated control on normal diet, ‘hypercholesterolemia plus 
sham’, and ‘hypercholesterolemia plus hypertension’ (four rabbits per group). 
Aorta samples were sectioned at 40 µm using a freezing microtome. Sections 
were processed for histochemistry using Masson’s Trichrome histochemical 
stain, or immunoperoxidase staining. The latter sections were incubated in a 
blocking solution composed of 5% donkey serum (Vector Laboratories) and 
0.1% Triton X-100 for 1 h, followed by incubation with a mouse monoclonal 
antibody to HNF4A (diluted 1:100 in PBS) overnight. The sections were then 
washed three times with PBS and incubated with a biotinylated anti-mouse 
secondary antibody. Immunoreaction product was visualized using an ABC kit 
and DAB solution as previously described (see Chapter III, Section 1:2.7). 
Histochemically or immunohistochemically stained sections were mounted on 
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gelatin-coated slides and viewed using a light microscope (IX70) (Ong et al., 
2013). 
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 Body weight, mean arterial pressure (MAP) and serum total 
cholesterol levels 
The average body weight was not significantly different between the 
2K1C and sham operated groups (data not shown), but MAP of 2K1C group 
was markedly higher than that of sham group at 4, 10, 12 weeks after the surgery 
(Figure 3.9A). The serum total cholesterol level remained at a low level 
(<100mg/dl) for both groups throughout the experiment, and no difference was 
found between the groups, except for a slightly lower value in the 2K1C group 
on week 4 (Figure 3.9B). The average body weight among all groups was not 
significantly different (data not shown). 
Increased MAP was found in the cholesterol-fed plus 2K1C rabbits 
(Figure 3.10A), and markedly elevated serum total cholesterol levels 
(>200mg/dl) were found in both the ‘hypercholesterolemia plus sham’ and 
‘hypercholesterolemia plus 2K1C’ groups at 4, 10 and 12 weeks, compared with 
control rabbits on a normal diet (Figure 3.10B) (Ong et al., 2013). 
 
Chapter III, Section 2 - Gene Expression Analyses of the Rabbit Cerebral 







































Figure 3.9. MAP (A) and serum cholesterol levels (B) in ‘hypertension only’ rabbits. 
HT: ‘Hypertension only’ group. Data represent the mean and standard error, analyzed 
by Student’s t-test (n = 6 per group). *indicates significant difference compared with 
control. *P < 0.05 (Ong et al., 2013). 
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Figure 3.10. MAP (A) and serum cholesterol levels (B) in ‘hypercholesterolemia plus 
sham’ and ‘hypercholesterolemia plus hypertension’ rabbits. HC: 
‘Hypercholesterolemia plus sham’ group. HCHT: ‘Hypercholesterolemia plus 
hypertension’ group. Data represent the mean and standard error, analyzed by one-way 
ANOVA with Tukey multiple comparison post-hoc test (n = 6 per group). * indicates 
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 Microarray analyses in the MCA 
3.2.1. Microarray analyses of the ‘hypertension only’ group 
The gene expression profile in the MCA of the ‘hypertension only’ 
group was compared with that of sham operated controls on a normal diet. After 
unknown genes and repeated probes of the same genes were omitted, a total of 
148 DEGs with 51 upregulated and 97 downregulated genes (greater than 4-fold 
change) was found in the MCA (Figure 3.11). Among the highly upregulated 
genes in the MCA of the ‘hypertension only’ group compared with sham 
operated controls were FAM167A, CERS3 and FAM53C (Appendix 9). Among 
the highly downregulated genes were FOXN1, NSRP1 and THUMPD3 
(Appendix 10). The panel of genes was imported into IPA to analyze network 
interactions (Ong et al., 2013).  
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Figure 3.11. Venn diagram of DEGs in the MCA of ‘hypertension only’ rabbits, 
‘hypercholesterolemia plus sham’ rabbits, and ‘hypercholesterolemia plus 
hypertension’ rabbits; each group vs. sham operated control rabbits. (n = 4 in each 
group).A: total number of genes, B: upregulated genes C: downregulated genes (One 
gene found common between the ‘hypertension only’ and ‘hypercholesterolemia plus 
hypertension’ group was both upregulated and downregulated, and it was omitted) 
(Ong et al., 2013).The IPA network with the ‘largest number of upregulated focus 
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genes’, contained 16 focus genes with functions in Cancer, Connective Tissue 
Disorders, Skeletal and Muscular Disorders. Focus genes in this network were 
ASB4, C1orf50, CCDC89, CSDE1, DIS3L2, EHBP1, FAM167A, GIT1, 
KIAA0232, NAA25, NAE1, PHRF1, SIPA1L3, TAF15, TESK2 and TTLL5 
(Figure 3.12, Appendix 9). They were related to the ‘node molecule’, UBC. The 
network with the second largest number of upregulated focus genes had 12 
focus genes, with functions in Cell-mediated Immune Response, Cellular 
Development, Cellular Function and Maintenance. Focus genes were CCL1, 
CD46, CYP1A2, FANCC, MEP1B, MFI2, MMP1, PDCD11, RNASE1, 
SERPINB2, SPAG6 and ZDHHC23 (Figure 3.13, Appendix 9). They were 
related to P38 MAPK, ERK, NFĸB, SERPINB2, MMP1 and APP (Ong et al., 
2013). 
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Figure 3.12. IPA network showing the network with the largest number of upregulated 
focus genes in the MCA of the ‘hypertension only’ group, compared with sham 
operated control group. Nodes are represented using various shapes that represent 
functional classes of gene products (Ong et al., 2013).  
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Figure 3.13. IPA network showing the network with the second largest number of 
upregulated focus genes in the MCA of the ‘hypertension only’ group, compared with 
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The network with the largest number of downregulated focus genes 
contained 23 focus genes with functions in Cardiovascular System 
Development and Function, Organismal Development, Cell Morphology. Focus 
genes in this network were ANK2, BTG1, CCNH, EPAS1, GNMT, HPGD, 
ITK, KDM4A, LIMD1, MS4A1, NDUFB6, NPM1, OGN, PAK4, PAPOLA, 
PARK7, PSMD4, PURA, RPL26, SFRP4, SPARC, TNFAIP8 and TRPV5 
(Figure 3.14, Appendix 10). They were related to MAPK, ERK1/2, Akt, 26s 
proteasome and histone H3. The network with the second largest number of 
downregulated focus genes had 16 focus genes with functions in Cell Death and 
Survival, Embryonic Development, Cellular Development. Focus genes were 
ARMCX3, BUD31, DPY19L1, FAM177A1, FAM210B, GALK2, ITM2C, 
LSG1, LYRM7, MRPL15, NDUFAF5, SEC24A, TBC1D8B, THUMPD3, 
TIMMDC1 and TOMM5 (Figure 3.15, Appendix 10). They were related to 
UBC (Ong et al., 2013). 
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Figure 3.14. IPA network showing the network with the largest number of 
downregulated focus genes in the MCA of the ‘hypertension only’ group, compared 
with sham operated control group (Ong et al., 2013). 
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Figure 3.15. IPA network showing the network with the second largest number of 
downregulated focus genes in the MCA of the ‘hypertension only’ group, compared 
with sham operated control group (Ong et al., 2013). 
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3.2.2. Microarray analyses of the ‘hypercholesterolemia plus sham’ group 
The gene expression profile in the MCA of the ‘hypercholesterolemia 
plus sham’ group was compared with that of sham operated controls on a normal 
diet. After unknown and repeated genes were omitted, a total of 458 DEGs with 
107 upregulated and 351 downregulated genes (greater than 4-fold change) was 
found (Figure 3.11). Among the highly upregulated genes in the MCA of the 
‘hypercholesterolemia plus sham’ group compared with sham operated controls 
were SLFN14, CA1, and LOC100357902 (Appendix 11). Among the highly 
downregulated genes were LOC100125984, PFDN5 and CUL3 (Appendix 12). 
The IPA network with the largest number of upregulated focus genes, 
contained 21 focus genes with functions in Cell Death and Survival, Lipid 
Metabolism, Small Molecule Biochemistry. Focus genes in this network were 
ATP7A, C11orf71, C1orf51, CA1, CA2, CCNB3, CMTM2, CORIN, DTX3, 
EPHA1, FAM19A4, GTF2E2, MEP1B, NAA25, PALM2, RNASE1, SOAT2, 
SP110, TENM4, TSPAN33 and UHRF1BP1 (Figure 3.16, Appendix 11). They 
were related to the ‘node molecules’, APP and tretinoin. The next network of 
upregulated focus genes had 18 focus genes, with functions in Organ 
Morphology, Reproductive System Development and Function, Developmental 
Disorder. Focus genes were APBB3, AQP1, CD2, FANCC, FCRL3, FSHR, 
IAPP, IKBKE, MAP3K4, NR1D1, OGT, PSMC3IP, SERPINB2, SP100, SYK, 
TAF15, TMEM173 and TRAF3IP1 (Figure 3.17, Appendix 11). They were 
related to P38 MAPK, ERK1/2, NFĸB, SERPINB2, Akt, interferon alpha and 
VEGF (Ong et al., 2013). 
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Figure 3.16. IPA network showing the network with the largest number of upregulated 
focus genes in the MCA of the ‘hypercholesterolemia plus sham’ group, compared with 
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Figure 3.17. IPA network showing the network with the second largest number of 
upregulated focus genes in the MCA of the ‘hypercholesterolemia plus sham’ group, 
compared with sham operated control group (Ong et al., 2013). 
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The network with the largest number of downregulated focus genes 
contained 26 focus genes with functions in Tissue Development, Connective 
Tissue Disorders, and Developmental Disorder. Focus genes in this network 
were ARNT, BMF, CADM1, CDC37L1, DNAJB4, DNAJC6, ELOVL5, 
GPBP1, GTF2F2, INSIG1, INSIG2, KDM4A, KIF20A, NUMB, PHIP, PKN2, 
PSMC6, PSMD4, PVRL3, RNF168, RPN1, SNAP25, SNTA1, SPRR3, STX2 
and TOP2B (Figure 3.18, Appendix 12). They were related to Ubiquitin, 26s 
Proteasome, and Akt. The next network of downregulated focus genes had 25 
focus genes with functions in Organ Morphology, Visual System Development 
and Function, Lipid Metabolism. Focus genes were ABLIM1, ACTA1, 
ATAD2, CDC73, CRYAA, CYP7A1, DHX9, HNRNPC, ME1, MLL3, 
MYBBP1A, PABPC4, POU2F3, SHROOM3, SMARCA5, SMARCAD1, 
SYT12, TIAL1, TMPO, TRPM7, USP3, WDR61, XRN1, YWHAQ and 
ZBTB44 (Figure 3.19, Appendix 12). They were related to histone H3 and F 
Actin (Ong et al., 2013). 
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Figure 3.18. IPA network showing the network with the largest number of 
downregulated focus genes in the MCA of the ‘hypercholesterolemia plus sham’ group, 
compared with sham operated control group (Ong et al., 2013). 
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Figure 3.19. IPA network showing the network with the second largest number of 
downregulated focus genes in the MCA of the ‘hypercholesterolemia plus sham’ group, 
compared with sham operated control group (Ong et al., 2013). 
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3.2.3. Microarray analyses of the ‘hypercholesterolemia plus 
hypertension’ group 
The gene expression profile in the MCA of the ‘hypercholesterolemia 
plus hypertension’ group was compared with that of sham operated controls on 
a normal diet. After unknown and repeated genes were omitted, a total of 355 
DEGs with 222 upregulated and 133 downregulated genes (greater than 4-fold 
change) was found (Figure 3.11). Among the highly upregulated genes in the 
MCA of the ‘hypercholesterolemia plus hypertension’ group compared with 
sham operated controls were EPHA1, SP110, SLFN14 (Appendix 13). Among 
the highly downregulated genes were FOXN1, TNFRSF11B and GAPDHS 
(Appendix 14). 
The IPA network with the largest number of upregulated focus genes, 
contained 22 focus genes with functions in Tissue Development, Connective 
Tissue Disorders, and Developmental Disorder. Focus genes in this network 
were ALAS2, CCL19, CD2, CD4, CD244, CLEC1B, CNP, DHRS9, FKBP1B, 
IAPP, KLF13, LTN1, MS4A2, RASGRP4, RNASEL, SLC5A1, SPTA1, SYK, 
TMEM173, TRAF3IP1, TYMP and UBASH3B (Figure 3.20, Appendix 13). 
They were related to ERK1/2, Interferon alpha, IL12 complex and SYK 
(complex), CD2, CD4 and CD244. The next network of upregulated focus genes 
had 18 focus genes, with functions in Organ Morphology, Visual System 
Development and Function, Lipid Metabolism. Focus genes were CA2, 
CDH17, COL17A1, ELOVL3, FANCC, FCRLA, FLT3, HRH1, MAP3K4, 
MEP1B, MMP1, NFĸBID, NR1D1, PIGR, RET, SERPINB2, SPINK1 and 
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TINF2 (Appendix 13 and15). They were related to P38 MAPK, NFĸB, 




Figure 3.20. IPA network showing the network with the largest number of upregulated 
focus genes in the MCA of the ‘hypercholesterolemia plus hypertension’ group, 
compared with sham operated control group (Ong et al., 2013). 
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The network with the largest number of downregulated focus genes 
contained 21 focus genes with functions in Cardiovascular Disease, Cellular 
Assembly and Organization, Post-Translational Modification. Focus genes in 
this network were ARNT, CCT2, ELAVL4, HNRNPC, KIF20A, ME1, 
NCALD, NRGN, PDK4, PFDN5, PLN, PPP1R8, PPYR1, SHROOM3, 
SNAP25, SNTA1, SSB, STMN2, SYT12, TTN and WAC (Figure 3.21, 
(Appendix 14). They were related to ERK, Akt, PKC, Vegf, actin and insulin. 
The next network of downregulated focus genes had 20 focus genes with 
functions in Endocrine System Disorders, Gastrointestinal Disease, and 
Hereditary Disorder. Focus genes were BMF, CDX1, CKM, CRYAA, 
DNAJB4, DNAJC6, GTF2E2, IFIH1, IFRD1, INSIG2, PAX4, PLP1, POU2F3, 
PSMD4, RPN1, SAP30, SMARCA5, TANK, TIAL1 and WDR61 (Appendix 
14 and 16). They were related to P38 MAPK, NFĸB, 26S proteasome, histone 
H3, interferon alpha and IL12 (Ong et al., 2013). 
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Figure 3.21. IPA network showing the network with the largest number of 
downregulated focus genes in the MCA of the ‘hypercholesterolemia plus 
hypertension’ group, compared with sham operated control group (Ong et al., 2013). 
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3.2.4. Microarray analyses of the ‘common area’ between 
‘hypercholesterolemia plus sham’ and ‘hypertension only’ groups  
The gene expression profile in the ‘common area’ between the 
‘hypercholesterolemia plus sham’ and ‘hypertension only’ groups, was also 
compared with that of sham operated controls on a normal diet (Figure 3.11). 
After unknown and repeated genes were omitted, a total of 31 DEGs with 18 
upregulated and 13 downregulated genes (greater than 4-fold change) was 
found. Among the highly upregulated common genes of both groups in the 
MCA were LOC100352398, TAF15 and ANKAR (Table 3.3). Among the 
highly downregulated common genes of both groups in the MCA were FOXN1, 
LOC100354966 and ADAMTS17 (Table 3.4) (Ong et al., 2013).  
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Table 3.3. Upregulated genes in the MCA found in common between 
‘hypercholesterolemia plus sham’ and ‘hypertension only’ rabbits (each group vs. sham 
operated control group) with greater than 4-fold change (Ong et al., 2013). 
















Nibrin-like LOC100352398 0.00171 4.71 7.92 3.74 
TAF15 RNA polymerase II, TATA box 
binding protein (TBP)-associated factor, 
68kDa 
TAF15 0.00004 4.71 7.45 4.65 
Ankyrin and armadillo repeat containing ANKAR 0.00006 7.99 7.05 5.23 
N(alpha)-acetyltransferase 25, NatB 
auxiliary subunit NAA25 <0.00001 8.91 6.43 18.66 
Fanconi anemia, complementation group 
C FANCC <0.00001 4.25 6.10 6.39 
Serine proteinase inhibitor, clade B, 
member 2 (Predicted) SERPINB2 0.00005 6.99 5.63 9.10 
IDI1 protein-like LOC100346274 0.00042 4.87 5.51 6.67 
Meprin A, beta MEP1B 0.00291 5.12 5.37 5.85 
Fibroblast growth factor binding protein 
1-like LOC100353835 0.00122 4.01 5.01 4.63 
Ankyrin repeat and SOCS box-
containing 4 ASB4 0.00027 4.06 4.98 3.51 
Ankyrin repeat-containing protein 
C20orf12 DZANK1 <0.00001 5.04 4.87 7.37 
Signal-induced proliferation-associated 1 
like 3 SIPA1L3 0.00001 8.45 4.80 6.50 
Relaxin/insulin-like family peptide 
receptor 2 RXFP2 0.00029 5.62 4.79 6.96 
Guanylate cyclase 2D, membrane 
(retina-specific) GUCY2D 0.00008 4.11 4.64 8.34 
Testis-specific kinase 2 TESK2 0.00571 5.11 4.50 2.41 
Ribonuclease, RNase A family, 1 
(pancreatic) RNASE1 <0.00001 5.62 4.17 4.82 
DIS3 mitotic control homolog (S. 
cerevisiae)-like 2 DIS3L2 0.00024 4.32 4.17 3.96 
Glucose-fructose oxidoreductase domain 
containing 2-like LOC100351150 0.00001 6.34 4.01 12.42 
HC: ‘Hypercholesterolemia plus sham’ rabbits. HT: ‘Hypertension only’ rabbits. HCHT: ‘Hypercholesterolemia plus 
hypertension’ rabbits.   
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Table 3.4. Downregulated genes in the MCA found in common between 
‘hypercholesterolemia plus sham’ and ‘hypertension only’ rabbits (each group vs. sham 
operated control group) with greater than 4-fold change (Ong et al., 2013). 



















Forkhead box N1  FOXN1 0.00048 -56.89 -26.20 -45.12 
Ribosomal protein S3a-like LOC100354966 <0.00001 -5.74 -16.54 -1.83 
ADAM metallopeptidase with 
thrombospondin type 1 motif, 17 ADAMTS17 0.00001 -7.25 -15.85 -3.06 
peptidylprolyl isomerase G (cyclophilin 
G)  PPIG <0.00001 -6.20 -12.61 -1.81 
Hematopoietic prostaglandin D synthase  HPGDS 0.00043 -21.44 -12.38 -13.63 
Large subunit GTPase 1 homolog (S. 
cerevisiae)  LSG1 <0.00001 -20.38 -7.69 -1.93 
Mitochondrial ribosomal protein L15  MRPL15 <0.00001 -23.01 -6.97 -9.57 
Translocase of outer mitochondrial 
membrane 5 homolog (yeast) TOMM5 0.00014 -4.05 -5.67 -1.60 
Ribosomal protein L26  RPL26 0.00016 -14.60 -5.27 -2.81 
Family with sequence similarity 177, 
member A1  FAM177A1 0.00016 -10.75 -4.41 -1.95 
Proteasome (prosome, macropain) 26s 
subunit, non-ATPase, 4 PSMD4 0.00005 -17.67 -4.34 -11.67 
Aggrecanase-2  ADAMTS-11 0.00005 -9.31 -4.26 -6.51 
BRCA2 and CDKN1A interacting 
protein BCCIP <0.00001 -14.00 -4.06 -2.58 
HC: ‘Hypercholesterolemia plus sham’ rabbits. HT: ‘Hypertension only’ rabbits. HCHT: ‘Hypercholesterolemia plus 
hypertension’ rabbits.   
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A single network of upregulated focus genes was found, which 
contained 13 focus genes with functions in Drug Metabolism, Endocrine 
System Development and Function, Lipid Metabolism. Focus genes in this 
network were ASB4, DIS3L2, DZANK1, FANCC, GUCY2D, MEP1B, 
NAA25, RNASE1, RXFP2, SERPINB2, SIPA1L3, TAF15 and TESK2 (Figure 
3.22, Table 3.3). They were related to UBC, APP, SERPINB2, TNF and 
HNF4A (Ong et al., 2013). 
 
Figure 3.22. IPA network showing the network with the largest number of upregulated 
focus genes in the MCA between the ‘hypercholesterolemia plus sham’ and 
‘hypertension only’ group (‘common area’), compared with sham operated control 
group (Ong et al., 2013). 
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A single network of downregulated focus genes was found, which 
contained 11 focus genes with functions in Cell Morphology, Embryonic 
Development, and Cellular Compromise. Focus genes were ADAMTS17, 
BCCIP, FAM177A1, FOXN1, HPGDS, LSG1, MRPL15, PPIG, PSMD4, 
RPL26 and TOMM5 (Figure 3.23, Table 3.4). They were related to UBC (Ong 
et al., 2013). 
 
Figure 3.23. IPA network showing the network with the largest number of 
downregulated focus genes in the MCA between the ‘hypercholesterolemia plus sham’ 
and ‘hypertension only’ group (‘common area’), compared with sham operated control 
group(Ong et al., 2013). 
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3.2.5. Microarray analyses of the ‘exclusive area’ in the 
‘hypercholesterolemia plus hypertension’ group 
The gene expression profile in the ‘exclusive area’ of the 
‘hypercholesterolemia plus hypertension’ group was compared with that of 
sham operated controls on a normal diet. After unknown and repeated genes 
were omitted, a total of 154 DEGs with 132 upregulated and 22 downregulated 
genes (greater than 4-fold change) was found (Figure 3.11). Among the highly 
upregulated genes in the MCA that are exclusive to the ‘hypercholesterolemia 
plus hypertension’ compared with sham operated controls were SLFN14, 
MRS2, and LOC100357872 (Appendix 17). Among the highly downregulated 
exclusive genes were SST, ADAM6, and PRLR (Appendix 18). The panel of 
genes was analyzed by IPA. 
The IPA network with the largest number of upregulated focus genes 
contained 20 focus genes with functions in Cell Death and Survival, Cellular 
Compromise, Inflammatory Response. Focus genes in this network were 
CCL19, CD2, CD4, CD244, CDH17, CGN, CNP, COL17A1, DHRS9, FLT3, 
IQUB, KLF13, LTN1, MS4A2, PIGR, RASGRP4, RET, RNASEL, TYMP and 
UBASH3B (Figure 3.24, Appendix 17). They were related to P38 MAPK, ERK 
1/2, interferon alpha and CD2, CD4 and CD244. The next network of 
upregulated focus genes had 14 focus genes with functions in Cell Cycle, 
Nervous System Development and Function, Cell Death and Survival. Focus 
genes were C5orf28, CDK15, FAM71C, GBA3, GLB1L3, IRX2, LRRTM4, 
NAA25, NAV2, PRPF18, PSRC1, PTCH2, SLC13A1 and STAMBPL1 (Figure 
3.25, Appendix 17). They were related to UBC and APP (Ong et al., 2013).  
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Figure 3.24. IPA network showing the network with the largest number of upregulated 
focus genes in the MCA of the ‘hypercholesterolemia plus hypertension’ group 
(‘exclusive area’), compared with sham operated control group(Ong et al., 2013). 
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Figure 3.25. IPA network showing the network with the second largest number of 
upregulated focus genes in the MCA of the ‘hypercholesterolemia plus hypertension’ 
group (‘exclusive area’), compared with sham operated control group(Ong et al., 2013). 
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The network with the largest number of downregulated focus genes 
contained 10 focus genes with functions in Digestive System Development and 
Function, Hepatic System Development and Function, Organ Morphology. 
Focus genes in this network were ELAVL4, GFRA4, KCNK18, PAX4, PDK4, 
POU3F4, PRLR, SPHKAP, SST and STMN2 (Figure 3.26, Appendix 18). They 
were related to MAPK, ERK and insulin. The next network of downregulated 
focus genes also had 10 focus genes with functions in Metabolic Disease, Gene 
Expression, and Cellular Compromise. Focus genes were INHBE, KIAA1549, 
MARCH6, MOBP, NRGN, OLFM3, PLP1, SEMA4D, SULT4A1 and 
ZC3H7B (Figure 3.27, Appendix 18). They were related to UBC and APP (Ong 
et al., 2013). 
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Figure 3.26. IPA network showing the network with the largest number of 
downregulated focus genes in the MCA of the ‘hypercholesterolemia plus 
hypertension’ group (‘exclusive area’), compared with sham operated control group 
(Ong et al., 2013). 
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Figure 3.27. IPA network showing the network with the second largest number of 
downregulated focus genes in the MCA of the ‘hypercholesterolemia plus 
hypertension’ group (‘exclusive area’), compared with sham group (Ong et al., 2013). 
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 Electron microscopy of the MCA 
The MCA of sham operated rabbits on a normal diet showed continuous 
healthy appearing endothelial cells (Figure 3.28A). In comparison, the MCA of 
‘hypertension only’ rabbits contained pyknotic endothelial cells (Figure 3.28B), 
while that of ‘hypercholesterolemia plus sham’ rabbits showed large 
intracellular vacuoles in endothelial cells (Figure 3.28C). The above changes 
were exacerbated in the ‘hypercholesterolemia plus hypertension’ rabbits, and 
pyknotic endothelial cells, breaks in the basement membrane, and large 
extracellular spaces were present between the basement membrane and 
underlying smooth muscle cells (Figure 3.28D-E). In addition, subendothelial 
foam cells were observed (Figure 3.28E-F) consistent with early atherosclerotic 
changes. The tunica media and tunica adventitia had a normal appearance (Ong 
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Figure 3.28. Electron micrographs of the MCA. A: Sham operated rabbit on a normal 
diet showing continuous endothelial cells (EC). B: ‘Hypertension only’ rabbit, showing 
a pyknotic cell (arrow) in the endothelial layer (EC). C: ‘Hypercholesterolemia plus 
sham’ rabbit, showing large intracellular vacuoles (V) in endothelial cells (EC). D: 
‘Hypercholesterolemia plus hypertension’ rabbit, showing breaks in the basement 
membrane (BR), and a large extracellular space (S) between the basement membrane 
and the underlying smooth muscle cells. E: ‘Hypercholesterolemia plus hypertension’ 
rabbit, showing a pyknotic cell among the endothelial layer (arrow), and presence of 
extracellular spaces (S) and subendothelial foam cells (FC). F: Higher magnification 
of a foam cell in E, showing intracellular vacuoles (V), and extracellular spaces (S) 
containing collagen fibrils. Scale: A = 1 µm, B-D = 0.5 µm, E = 2 µm, F = 0.2 µm 
(Ong et al., 2013). 
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 Vascular changes in the aorta 
3.4.1. Real-time RT-PCR  
HNF4A mRNA expression was increased in the aorta of the 
‘hypercholesterolemia plus sham/hypertension’ rabbits to 3.64 and 2.25-fold 
change, respectively, compared with controls on a normal diet (P = 0.0012 and 






















Figure 3.29. Real-time RT-PCR analysis of HNF4A in the aorta of control, 
‘hypercholesterolemia plus sham’ and ‘hypercholesterolemia plus hypertension’ 
rabbits. Analyzed by one-way ANOVA with Bonferroni’s multiple comparison post-
hoc test. Data represent the mean and standard error (n = 4 per group). * indicates 
significant difference compared with control. * P < 0.05 and ** P < 0.01. HC: 
‘Hypercholesterolemia plus sham’ group. HCHT: ‘Hypercholesterolemia plus 
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3.4.2. Western blot  
The antibody to HNF4A detected a 53 kDa band in homogenates of the 
aorta consistent with the expected molecular weight of the protein (Figure 
3.30A). Increased density of the HNF4A band relative to β-actin was found in 
homogenates from ‘hypercholesterolemia plus sham/hypertension’ groups 
compared with controls (P < 0.001 for both groups; Figure 3.30B), indicating 
upregulation of HNF4A protein expression after exposure to 





























Figure 3.30. Western blot analysis of HNF4A in the aorta of control, 
‘hypercholesterolemia plus sham’ and ‘hypercholesterolemia plus hypertension’ 
rabbits. A: Immunoblot of HNFA. Lanes 1-3 control rabbits; lanes 4-6: 
‘hypercholesterolemia plus sham’ rabbits; and lanes 7-9: ‘hypercholesterolemia plus 
hypertension’ rabbits. β-actin was used as loading control. B: Densitometric analysis 
of HNF4A protein, normalized to β-actin and analyzed by one-way ANOVA with 
Bonferroni’s multiple comparison post-hoc test. Data represent the mean and standard 
error (n = 3 per group). * indicates significant difference compared with control. *** P 
< 0.001. Abbreviations as in Figure 3.29 (Ong et al., 2013). 
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3.4.3. Histochemistry and immunohistochemistry 
The general structure of the aorta was examined by Masson’s Trichrome 
staining (Figure 3.31A-C). ‘Hypercholesterolemia plus sham’ and 
‘hypercholesterolemia plus hypertension’ rabbits showed neointimal formation 
along part of the circumference of the vessel. This was associated with 
migration of red-staining, smooth muscle cells from the tunica media into the 
neointima (Figure 3.31C). The changes were more prominent in the 
‘hypercholesterolemia plus hypertension’ than the ‘hypercholesterolemia plus 
sham’ rabbits. The tunica media and tunica adventitia had a normal appearance. 
Immunostaining of the aorta with HNF4A antibody showed that the 
endothelial layer of ‘hypercholesterolemia plus sham/hypertension’ groups 
were densely stained for HNF4A compared with controls (Figure 3.31D-I). 
Immunolabel was observed in the nucleus and cytoplasm of endothelial cells 
and other cells near the endothelial layer. No staining was observed in the tunica 
media or adventitia (Figure 3.31D-I). These results indicate that elevated 
HNF4A gene expression in the aorta occurred predominantly in endothelial 
cells (Ong et al., 2013). 
Chapter III, Section 2 - Gene Expression Analyses of the Rabbit Cerebral 











Figure 3.31. Histochemical and immunohistochemical staining of the aorta from rabbits 
exposed to stroke risk factors.A, D, G: Rabbits on normal diet. B, E, H: 
‘Hypercholesterolemia plus sham’ group. C, F, I: ‘Hypercholesterolemia plus 
hypertension’ group. A-C: Aorta of rabbits stained by Masson’s Trichrome. Increased 
thickness of the neointima (NI) is seen in the ‘hypercholesterolemia plus sham’ group 
(B). The changes are exacerbated in the ‘hypercholesterolemia plus hypertension’ 
group (C). SM denotes smooth muscle cells in the neointima. D, E, F: Aorta of rabbits 
immunostained with a mouse monoclonal antibody to HNF4A. Very little or no 
labeling is present in normal rabbits, but dense staining is observed in endothelial cells 
in the ‘hypercholesterolemia plus sham’, and ‘hypercholesterolemia plus hypertension’ 
rabbits (arrows). G, H, I: Higher magnification of the aorta of rabbits immunostained 
with mouse monoclonal antibody to HNF4A, showing dense staining in endothelial 
cells of ‘hypercholesterolemia plus sham’, and ‘hypercholesterolemia plus 
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The present study was performed to elucidate differential gene 
expression changes in the MCA of rabbits exposed to two stroke risk factors, 
i.e. hypertension and/or hypercholesterolemia. Of the DEGs in the MCA that 
were altered by a single risk factor, hypertension alone vs. sham operated 
controls on a normal diet, FAM167A had the highest fold change, followed by 
CERS3 and FAM53C (Ong et al., 2013). FAM167A (family with sequence 
similarity 167, member A) encodes a ubiquitously expressed gene, but the 
function remains unknown. CERS3 (ceramide synthase 3) aids in the formation 
of ceramide (Merrill and Jones, 1990). Among the downregulated DEGs in the 
MCA of the ‘hypertension only’ group were FOXN1, NSRP1 and THUMPD3. 
FOXN1 (forkhead box N1) is a forkhead transcription factor that is essential for 
thymus development (Nowell et al., 2011) and keratinocyte differentiation 
(Phillips et al., 2013).  
Of the DEGs in the MCA that were upregulated in the 
‘hypercholesterolemia plus sham’ group vs. sham operated controls on a 
normal diet, SLFN14 had the largest fold change, followed by CA1 and 
LOC100357902 (Ong et al., 2013). SLFN14 is a member of the Schlafen family 
of proteins with growth regulatory properties (Schwarz et al., 1998). CA1 
(carbonic anhydrase I) belongs to the carbonic anhydrase family and 
polymorphism of this gene is associated with rheumatoid arthritis (Chang et al., 
2012). Among the DEGs that were downregulated in the ‘hypercholesterolemia 
plus sham’ group vs. sham operated controls were LOC100125984, PFDN5 and 
CUL3. CUL3 (cullin 3) is a member of the cullin protein family that involves 
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in ubiquitination (Petroski and Deshaies, 2005), and gene polymorphism is 
associated with hypertension (Boyden et al., 2012). 
Of the DEGs in the MCA that were upregulated in the 
‘hypercholesterolemia plus hypertension’ group vs. sham operated controls on 
a normal diet, EPHA1 had the largest fold change, followed by SP110, and 
SLFN14. EPHA1 (EPH receptor A1) is identified as one of the risk genes for 
late onset AD (Hollingworth et al., 2011; Naj et al., 2011) and the polymorphism 
of SP110 (SP110 nuclear body protein) is associated with tuberculosis (Fox et 
al., 2014). SLFN14 has been mentioned in the ‘hypercholesterolemia plus 
sham’ group. Among the DEGs that were downregulated in the 
‘hypercholesterolemia plus hypertension’ group were FOXN1, TNFRSF11B, 
and GAPDHS. FOXN1 has been mentioned in the ‘hypertension only’ group. 
TNFRSF11B (tumor necrosis factor receptor superfamily, member 11b) is the 
gene encoding osteoprotegerin and is involved in vascular diseases (Ueland et 
al., 2005).Gene polymorphism of TNFRSF11B is a risk factor for ischemic 
stroke (Biscetti et al., 2013).  
Of the DEGs in the MCA that were upregulated in common between the 
‘hypertension only’ and ‘hypercholesterolemia plus sham’ groups (each group 
vs. sham operated control group), LOC100352398 showed the largest fold 
change, followed by TAF15, and ANKAR (Ong et al., 2013). Not much 
information can be found for LOC100352398 (nibrin-like). TAF15 (TAF15 
RNA polymerase II, TATA box binding protein (TBP)-associated factor, 
68kDa) is a member of the FET family of RNA-binding proteins (Kovar, 2011). 
ANKAR (ankyrin and armadillo repeat containing) is associated with aortic 
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dilatation/dissection (Meienberg et al., 2010). Among the DEGs that were 
downregulated in common, between the ‘hypertension only’ and 
‘hypercholesterolemia plus sham’ groups (each group vs. sham operated control 
group) were FOXN1, LOC100354966 and ADAMTS17. FOXN1 has been 
mentioned earlier and there is not much obtainable information about 
LOC100354966 (Ribosomal protein S3a-like). ADAMTS17 (ADAM 
metallopeptidase with thrombospondin type 1 motif, 17) comes from the 
ADAMTS family of genes that is related to cancer, arthritis and coagulation (Le 
Goff and Cormier-Daire, 2011), and variants of ADAMTS17 are associated 
with pediatric stroke (Arning et al., 2012).  
The network in the MCA with largest number of upregulated focus genes 
affected by hypertension showed many focus genes related to the ‘node 
molecule’, ubiquitin (Ong et al., 2013), a regulatory protein that directs other 
proteins to the proteasome (Meller, 2009). Apart from chronic 
neurodegenerative diseases, the ubiquitin-proteasome system (UPS) is 
implicated in brain ischemia through induction of cell damage or leukocyte 
infiltration into the brain (Meller, 2009).  
The network in the MCA with the second largest number of upregulated 
molecules was related to P38 MAPK, ERK, NF-κB, SERPINB2, MMP1 and 
APP (Ong et al., 2013). P38 MAPK (mitogen-activated protein kinase) is a 
member of the MAPK family that involves in stress-related signal transductions 
(Barone et al., 2001a), and sustained activation can cause apoptosis (Frasch et 
al., 1998; Aoshiba et al., 1999). Suppression of P38 activity is reported to reduce 
infarct volume and neurological deficits (Barone et al., 2001b). ERK1/2 
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(extracellular signal-regulated kinase 1/2) is a well-characterized member of the 
MAPK family that is activated by mitogens or stressors, and plays an important 
role in cell differentiation and proliferation (Roux and Blenis, 2004; Sawe et al., 
2008). Phosphorylated ERK1/2 is increased after cerebral ischemia/reperfusion, 
and the ERK pathway is involved in both neuroprotection and cell death (Sawe 
et al., 2008). NF-κB is a central regulator of inflammation and apoptosis 
(Hoffmann and Baltimore, 2006) and is active in many chronic inflammatory 
diseases including atherosclerosis (Monaco and Paleolog, 2004). It could have 
damaging effects in cerebral ischemia (Schneider et al., 1999), and inhibition of 
NF-κB decreases neointimal formation (Yoshimura et al., 2001; Breuss et al., 
2002), infarct volume and neurological deficits after stroke (Xu et al., 2002). 
However, NF-κB activation could also be neuroprotective (Blondeau et al., 
2001) as it participates in cell death/survival pathways through regulation of 
pro- and anti-apoptotic genes (Barkett and Gilmore, 1999; Dutta et al., 2006). 
SERPINB2 (serpin peptidase inhibitor, clade B, member 2) is also called 
plasminogen activator inhibitor type 2 (PAI-2) and is an inhibitor of both uPA 
(Kawano et al., 1970) and tPA (Thorsen et al., 1988). Increased SERPINB2 
expression has been observed in the AD brain (Akiyama et al., 1993) and after 
ischemic or traumatic conditions, particularly in the basement membrane and 
endothelial cells of vessels adjacent to the lesion (Dietzmann et al., 2000). 
MMP1 (matrix metallopeptidase 1) belongs to a family of protein-digesting 
enzymes that degrades the extracellular matrix in both physiological and 
pathological conditions including stroke (Horstmann et al., 2003). MMP1 is 
increased in atherosclerotic plaques (Morgan et al., 2004) and gene 
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polymorphism is associated with CAD risk (Ye et al., 2003). The amyloidogenic 
processing of APP is vital in the formation of Aβ. Aβ and various vascular risk 
factors (Meyer et al., 2000; Skoog and Gustafson, 2002) contribute to the 
pathogenesis of AD (Altman and Rutledge, 2010; Zlokovic, 2011). Endothelial 
dysfunction in APP-overexpressing mice increases the susceptibility of the 
brain to AD pathology (Iadecola et al., 1999) and cerebral ischemia (Zhang et 
al., 1997).  
The network in the MCA with the largest number of downregulated 
focus genes affected by hypertension was related to MAPK, ERK 1/2, Akt, 26s 
proteasome and histone, while the network with the second largest number of 
downregulated focus genes was related to UBC (ubiquitin C) (Ong et al., 2013). 
Akt is a serine/threonine kinase that is activated by phosphatidylinositol-3-
kinase (PI3K) in various growth factors-mediated signaling cascades (Dudek et 
al., 1997). The PI3K/Akt signaling pathway is important in mediating cell 
survival (Brunet et al., 2001) and Akt activity confers neuroprotection after 
ischemic brain injury (Wu et al., 2013). 26s Proteasome and ubiquitin are 
essential components of the UPS that functions to degrade cellular proteins 
(Wojcik and Di Napoli, 2004). The exact role of the UPS in cerebral ischemia 
is at present unclear, and deleterious effects of proteasome malfunction, as well 
as beneficial effects of proteasome inhibition on cerebral ischemia have been 
reported (Wojcik and Di Napoli, 2004; Meller, 2009). Histones affect gene 
transcription by binding to DNA; hence changes in histone H3 may affect the 
expression of downstream molecules in vessels during hypercholesterolemia. 
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Interestingly, promising outcomes from the use of HDAC inhibitors have been 
reported in preclinical stroke models (Langley et al., 2009).  
Gene network analysis of the MCA after hypercholesterolemia (plus 
sham operation), surprisingly, showed very similar networks as that the 
‘hypertension only’ group (Ong et al., 2013). This was despite a relatively low 
percentage of genes in the ‘common area’ between these two conditions (21% 
of hypertension genes and 7% of hypercholesterolemia genes were in the 
‘common area’, respectively) (Ong et al., 2013). The results suggest recruitment 
of different focus genes that are related to similar ‘node molecules’, as in the 
following example: the network in the MCA with largest number of upregulated 
focus genes affected by hypercholesterolemia showed many molecules related 
to APP. This is similar to ‘hypertension only’ rabbits, and could be an indication 
of synergy between the two risk factors in affecting the expression of molecules 
related to APP. Other focus genes were related to tretinoin, a molecule known 
to modulate Aβ associated memory deficits and neuropathological alterations in 
animal models of AD (Ding et al., 2008; Sodhi and Singh, 2013). The network 
with the second largest number of upregulated focus genes also had many 
similarities with the ‘hypertension only’ group, with P38 MAPK, ERK 1/2, 
NFĸB and Akt being central players. 
The network in the MCA with largest number of downregulated focus 
genes affected by hypercholesterolemia is related to ubiquitin, 26s proteasome 
and Akt, and the network with the second largest number of downregulated 
focus genes is related to histone H3 and actin. These changes in ubiquitin, 
proteasome, and histone H3 are very similar to that of ‘hypertension only’ 
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animals (Ong et al., 2013). Downregulation of genes related to actin may affect 
process outgrowth or motility of vascular cells, and actin cytoskeleton signaling 
is one of the functional pathways that are related to male-specific ischemic 
stroke genes (Tian et al., 2012). 
The network in the MCA with largest number of upregulated focus genes 
affected by ‘hypercholesterolemia plus hypertension’ showed many molecules 
related to ERK 1/2, interferon alpha, IL12, SYK, CD2, CD4, and CD244. 
Interferon alpha is a member of a family of nonspecific antiviral agents with 
immunomodulatory and cytostatic properties (Young et al., 2002). Although 
interferon beta and gamma are linked to atherosclerosis (Young et al., 2002), 
possible role of interferon alpha is still unknown. IL12 (interleukin 12) is a 
proinflammatory and immunomodulatory cytokine (Trinchieri, 1998) released 
in response to tissue injury (DeGraba, 1998). Elevated serum levels of IL12 are 
observed in patients with ischemic stroke (Zaremba and Losy, 2006) and IL12 
signaling is related to female-specific ischemic stroke genes (Tian et al., 2012). 
SYK (spleen tyrosine kinase) is a non-receptor tyrosine kinase (Sada et al., 
2001) involved in signaling cascades in platelets (Speich et al., 2008). The use 
of inhibitors of SYK is a potential treatment for occlusive vascular disease, due 
to its effect in modulating platelet aggregation and thrombus formation (Speich 
et al., 2008). CD2 molecule is a member of the immunoglobulin superfamily 
and mediates the activation of T and natural killer cells (Crawford et al., 2003). 
CD4 molecule is expressed on the surface of T cells (Hedrick, 2002) and 
deficiency in CD4+ T cells is associated with decreased lesion size after stroke 
(Gu et al., 2012). CD244 (CD244 molecule, natural killer cell receptor 2B4) is 
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part of the ‘signaling lymphocyte activation molecule’ family of receptors 
(Veillette and Latour, 2003) and it may be involved in a pathway that promotes 
inflammatory neurological disease (Enose-Akahata et al., 2009). The network 
with the second largest number of upregulated focus genes was related to P38 
MAPK, NFĸB, SERPINB2, MMP1 and Tnf (family). TNF (tumor necrosis 
factor) plays a key role in increasing the expression of inflammation-related 
genes in atherosclerosis (McKellar et al., 2009), and expression is increased in 
brain during ischemia (Perez-de-Puig et al., 2013) or in patients who suffer 
intracerebral hemorrhage (Fang et al., 2007). Antagonism of the TNF-α receptor 
alleviates neurovascular injury and neurobehavioral outcomes after 
intracerebral hemorrhage in mice (King et al., 2013). 
The network in the MCA with largest number of downregulated focus 
genes affected by ‘hypercholesterolemia plus hypertension’ showed many 
molecules related to ERK, Akt, PKC, Vegf, actin, and insulin. Several isozymes 
of PKC (protein kinase C) are associated with cerebral ischemic and reperfusion 
injury (Bright and Mochly-Rosen, 2005). Diabetes mellitus and insulin 
resistance increase the risk of ICLAD and stroke (Park and Kwon, 2008). 
Moreover, patients with diabetes show poorer post-stroke functional outcomes 
in terms of mortality (Tuomilehto et al., 1996; Prosser et al., 2007) and cognition 
(Luchsinger et al., 2001). These may be due to the effect of insulin on NFĸB 
activation and generation of pro-inflammatory factors involved in atherogenesis 
(Bienek et al., 2012). The network with the second largest number of 
downregulated focus genes was related to P38 MAPK, NFĸB, 26s proteasome, 
histone H3, interferon alpha and IL12.  
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The ‘common area’ between the ‘hypertension only’ and 
‘hypercholesterolemia plus sham’ groups showed upregulated focus genes 
related to UBC, APP, SERPINB2, TNF and HNF4A, and downregulated focus 
genes related to UBC. HNF4A (hepatocyte nuclear factor 4 alpha) is a 
constitutively active ligand-activated nuclear receptor (Gonzalez, 2006) that 
regulates the expression of various genes related to the synthesis or metabolism 
of fatty acid, cholesterol, glucose, and urea (Gonzalez, 2008). It is associated 
with lipid transport, hypoxia response, cell cycle, immunity, apoptosis, stress 
response and cancer (Bolotin et al., 2010; Xu et al., 2011a). Increased 
expression of HNF4A was shown by RT-PCR and Western blot, and the protein 
immunolocalized to endothelial cells in the aorta (Ong et al., 2013). Since 
HNF4A suppresses hepatocyte proliferation in adult mice (Bonzo et al., 2012), 
increased expression may likewise affect the turnover of endothelial cells. The 
effect of this on atherosclerosis is unclear, although excess proliferation of 
smooth muscle cells is known to have an atherogenic effect (Rivard and Andres, 
2000).  
The ‘hypercholesterolemia plus hypertension’ ‘exclusive’ area showed 
upregulated and downregulated pathways, related to many of the ‘node 
molecules’ mentioned above. This area is tentatively interpreted as containing 
genes that are exacerbated by two risk factors, and the effects tends towards 
recruitment of additional molecules into existing networks rather than initiation 
of new networks (Ong et al., 2013). Nevertheless, upregulation of molecules 
related to TNF and downregulation of those related to insulin in this area could 
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signal the particular effects of two risk factors on increasing inflammation and 
insulin resistance (Ong et al., 2013). 
An ischemic cerebrovascular event or TIA is a risk factor for a 
subsequent event (Burn et al., 1994; Bergman, 2011). The causes for this are 
multifactorial (Hillen et al., 2003) and may be partially attributed to the presence 
of existing atherosclerotic lesions. The present findings extend these concepts 
to the gene network level, and defines pathways related to NF-κB and TNF that 
have implications in inflammation and atherosclerosis (Monaco and Paleolog, 
2004; Csiszar et al., 2008), as well as focus genes related to ubiquitin, 
proteasome, histone, HNF4A, insulin and APP (Ong et al., 2013). It is hoped 
that these could provide a basis for better understanding of pathophysiological 
mechanisms, and development of new therapies for ICLAD (Ong et al., 2013). 
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Metabolic syndrome (MS) is a multifactorial disorder demonstrated by 
the presence of several vascular conditions which are related to central obesity 
such as dyslipidemia, hypertension and aberrant glucose metabolism (Panza et 
al., 2008). With a growing worldwide prevalence, MS is associated with 
increased risk of developing type 2 diabetes mellitus, coronary artery disease 
(Panza et al., 2008), age-related cognitive deficits (Ho et al., 2008), and 
dementia including vascular dementia (Solfrizzi et al., 2010) and AD (Watts et 
al., 2013; Rios et al., 2014). 
The association of hypercholesterolemia and AD has been highlighted 
in several epidemiological studies. Enhanced susceptibility to AD has been 
observed in individuals with elevated plasma or serum cholesterol levels; thus, 
suggesting a possible contribution of high levels of cholesterol in AD (Jarvik et 
al., 1995; Kuo et al., 1998; Pappolla et al., 2003). Furthermore, AD patients 
have shown higher levels of total serum and LDL cholesterol (Kuo et al., 1998; 
Lesser et al., 2001) with reduced levels of apolipoprotein A and HDL 
cholesterol in their plasma (Kuo et al., 1998; Fernandes et al., 1999), compared 
with aged-matched controls. Interestingly, statins may be preventive in the 
development of AD (Silva et al., 2013) given that statin therapy could reduce 
the risk of late-onset AD by 50% in Rotterdam Study (Haag et al., 2009). In in 
vivo models, hypercholesterolemic rabbits showed increased deposition of 
cerebral Aβ (Sparks et al., 1994), while hypercholesterolemia in an APP/PSEN1 
double-transgenic mouse model accelerated the amyloid pathology of AD 
(Refolo et al., 2000). Similarly, statins were able to reverse the high cholesterol 
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diet-induced Aβ accumulation and cholesterol level in plasma and CNS in AD 
mice (Refolo et al., 2001).  
Hypertension is a leading risk factor of vascular cognitive impairment 
(Gorelick et al., 2011) and midlife hypertension is a risk factor for AD (Faraco 
and Iadecola, 2013; Iadecola, 2013). AD and hypertension-induced lesions have 
been suggested to work in synergy in increasing the severity of cognitive 
deficits (Iadecola, 2010). In addition, hypertension may promote Aβ 
accumulation and aggregation in the brain as increased amyloid plaque burden 
and NFTs have been observed in the brain of patients with hypertension 
(Rodrigue et al., 2013). Besides that, in murine models of hypertension with 
enhanced BBB permeability in both cortex and hippocampus, increased Aβ-
immunoreactivity and Aβ-fragments were observed in these regions of the 
hypertensive mice (Gentile et al., 2009; Carnevale and Lembo, 2011). 
Despite the emerging association of serum cholesterol and hypertension 
with AD, relatively little is known about the possible effects of serum 
cholesterol or hypertension in gene expression changes in the brain. Hence, this 
portion of the study was carried out to elucidate the gene expression changes in 
the FC of rabbits, after exposure to hypercholesterolemia and/or hypertension. 
It is hoped that the results may contribute to the elucidation of potential 
susceptibility genes and gene networks in AD. 
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2. Material and Methods 
 Animals  
The same thirty rabbits used in Chapter III, Section 2:2.1, were used in 
this portion of the study. They were divided into five groups: untreated control 
on normal diet, sham operated control on normal diet, ‘hypercholesterolemia 
plus sham’, ‘hypercholesterolemia plus hypertension’, and ‘hypertension on 
normal diet’ (six rabbits per group). Male NZW rabbits were approximately 8 
weeks old (young adults) and weighed 2.0-2.5 kg each at the start of the 
experiments. Three sets of experiments were carried out to determine gene 
expression changes in the FC after i) ‘hypercholesterolemia plus sham 
operation’, ii) ‘hypercholesterolemia plus hypertension’, and iii) ‘hypertension 
on a normal diet’. Goldblatt 2K1C method was used to induce hypertension. 
The first and second set of experiments were carried out on six rabbits on a high 
cholesterol diet plus sham operation, six rabbits on a high cholesterol diet plus 
the 2K1C method to induce hypertension, and six rabbits on a normal diet. The 
third set of experiment was carried on six rabbits with 2K1C-induced 
hypertension and fed with normal diet, vs. six sham operated controls on a 
normal diet. The subsequent procedures were conducted as previously described 
(see Chapter III, Section 2:2.1). All procedures including animals were 
approved by the IACUC of the NUS, and conducted in accordance with 
guidelines of NACLAR. This portion of the study was assisted by Ms. Ng Pei 
Ern Mary. 
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 Measurement of body weight, mean arterial pressure (MAP) and 
serum total cholesterol 
The same thirty rabbits used in Chapter III, Section 2:2.1 and Section 
2:2.2, were used in this portion of the study. They were divided into five groups: 
untreated control on normal diet, sham operated control on normal diet, 
‘hypercholesterolemia plus sham’, ‘hypercholesterolemia plus hypertension’, 
and ‘hypertension on normal diet’ (six rabbits per group). Rabbits were 
anaesthetized by ketamine/xylazine cocktail and the procedures for MAP 
measurements and blood collection were conducted as previously described 
(see Chapter III, Section 2:2.2). 
 
 Tissue harvesting and RNA extraction 
The same thirty rabbits used in Chapter III, Section 2:2.3, were used in 
this portion of the study. They were divided into five groups: untreated control 
on normal diet, sham operated control on normal diet, ‘hypercholesterolemia 
plus sham’, ‘hypercholesterolemia plus hypertension’, and ‘hypertension on 
normal diet’ (six rabbits per group). All procedures for tissue harvesting of the 
FC and RNA extraction were conducted as previously described (see Chapter 
III, Section 2:2.3). Total RNA was extracted from the FC using TRIzol reagent 
and was purified using the RNeasy® Mini Kit (Qiagen) according to the 
manufacturer's protocol. The hippocampus, liver, kidney, aorta and other organs 
were also harvested and snap-frozen, or stored in paraformaldehyde for future 
analysis. 
Chapter III, Section 3 - Gene Expression Analyses of the Rabbit Frontal 
Cortex after Hypercholesterolemia and/or Hypertension 
 
157 
 DNA microarray analyses 
The same sixteen rabbits used in Chapter III, Section 2:2.4, were used 
in this portion of the study. They were divided into four groups: sham operated 
control on normal diet, ‘hypercholesterolemia plus sham’, 
‘hypercholesterolemia plus hypertension’, and ‘hypertension on normal diet’ 
(four rabbits per group). Ten μL of total RNA from the FC of each rabbit group 
were submitted to Genomax Technologies, Singapore. The procedures were 
conducted as previously described (see Chapter III, Section 2:2.4). DEGs were 
genes with altered expression induced by each rabbit treatment group compared 
with sham operated control group. They were identified using one-way 
ANOVA with Tukey HSD post-hoc test and corrected for multiple comparisons 
using Benjamini Hochberg FDR. P < 0.05 was considered significant. In this 
study, to reduce false positives, only DEGs with greater than 4-fold change and 
P < 0.01 were presented and used in IPA network analysis. 
 
 Network analyses 
The list of DEGs with more than 4-fold change and P < 0.01 was 
uploaded to IPA software. The procedures were conducted as previously 
described (see Chapter III, Section 1:2.4). 
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 Body weight, mean arterial pressure (MAP) and serum total 
cholesterol levels 
The average body weight, MAP and serum total cholesterol levels have 
been previously shown using the same rabbits for the corresponding treatment 
groups (see Chapter III, Section 2:3.1) (Ong et al., 2013).  
 
 Microarray analyses in the FC 
3.2.1. Microarray analyses of the ‘hypercholesterolemia plus sham’ group 
Gene expression profile in the FC of the ‘hypercholesterolemia plus 
sham’ group was compared with sham operated controls on a normal diet. After 
unknown and repeated genes were omitted, a total of 858 DEGs with 575 
upregulated and 283 downregulated genes (greater than 4-fold change) was 
observed in the FC (Figure 3.32). Among the highly upregulated genes in the 
FC of the ‘hypercholesterolemia plus sham’ group compared with sham 
operated control group were CIDEC, ODF2, RNASEL, FSHR, CES3, and 
MAB21L3 (Table 3.5). Among the highly downregulated genes were 
FAM184B, CUL3, LOC100351029, TMEM109, LOC100357097, and PFDN5 
(Table 3.6). The panel of genes was imported into IPA to analyze network 
interactions. 
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Hypertension Only vs. Sham Controls  
(5 DEGs)
Hypercholesterolemia plus Hypertension 
vs. Sham Controls (971 DEGs)
Hypercholesterolemia plus Sham 
vs. Sham Controls (858 DEGs)
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Hypertension Only vs. Sham Controls 
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vs. Sham Controls (870 DEGs)
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vs. Sham Controls (575 DEGs)
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Hypercholesterolemia plus Hypertension 
vs. Sham Controls (101 DEGs)
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Figure 3.32. Venn diagram of DEGs in the FC of the ‘hypercholesterolemia plus sham’ 
rabbits; ‘hypercholesterolemia plus hypertension’ rabbits; and ‘hypertension only’ 
rabbits; each group vs. sham operated control rabbits.(n = 4 in each group). A: total 
number of genes; B: upregulated genes; and C: downregulated genes.  
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Table 3.5. Upregulated genes in the FC of the ‘hypercholesterolemia plus sham’ rabbits 
vs. sham operated control rabbits with greater than 10-fold change. For the purpose of 
brevity, the table only includes genes with more than 10-fold change. 
Gene  Gene Symbol Corrected P-value 







Cell death-inducing DFFA-like effector c CIDEC < 0.00001 62.26 78.38 2.71 
Outer dense fiber of sperm tails 2  ODF2 < 0.00001 29.07 21.24 1.27 
Ribonuclease L (2',5'-oligoisoadenylate 
synthetase-dependent)  RNASEL 0.00177 28.98 19.09 -1.63 
Follicle stimulating hormone receptor  FSHR < 0.00001 28.24 48.62 -1.44 
Carboxylesterase 3  CES3 < 0.00001 27.26 15.59 -1.14 
Protein mab-21-like 3 MAB21L3 < 0.00001 25.83 18.73 1.29 
Fc receptor-like 3  FCRL3 < 0.00001 21.65 8.63 1.27 
Gonadotropin-releasing hormone 
receptor  GnRHR < 0.00001 18.76 32.62 -1.09 
TAF15 RNA polymerase II, TATA box 
binding protein (TBP)-associated factor, 
68kDa  
TAF15 < 0.00001 18.25 16.57 1.56 
Fibroblast growth factor binding protein 
2  FGFBP2 < 0.00001 17.99 39.21 -1.11 
Tetraspanin 12  TSPAN12 < 0.00001 17.91 10.83 1.11 
Solute carrier family 35, member D2  SLC35D2 < 0.00001 17.77 16.43 -1.06 
Leucine rich repeat containing 15  LRRC15 < 0.00001 17.58 13.90 1.70 
Homeobox A2 (Predicted)  HOXA2 < 0.00001 15.21 28.54 1.18 
Protease, serine, 38  PRSS38 < 0.00001 14.94 18.71 1.42 
Cytochrome P450 1A2 (EC 
1.14.14.1)(CYPIA2)(Cytochrome P450 
isozyme 4)(Cytochrome P450 
LM4)(Cytochrome P450-PM4)  
CYP1A2 0.00016 14.88 12.53 -1.27 
Myosin, heavy chain 6, cardiac muscle, 
alpha MYH6 < 0.00001 14.58 13.18 -1.31 
Galactosidase, beta 1-like 3  GLB1L3 < 0.00001 13.91 25.21 1.17 
Paired box 1  PAX1 < 0.00001 13.89 15.76 2.87 
Uncharacterized protein C2orf71  C2orf71 < 0.00001 13.74 21.24 1.38 
NPC1 (Niemann-Pick disease, type C1, 
gene)-like 1  NPC1L1 0.00007 13.61 20.95 2.11 
Peptide YY (PYY)(PYY-I)(Peptide 
tyrosine tyrosine)  PYY < 0.00001 13.58 11.35 -1.27 
Leucine-rich repeat-containing G 
protein-coupled receptor 5  LGR5 < 0.00001 13.08 19.35 -1.01 
Beta-carotene 15,15'-monooxygenase 1  BCMO1 < 0.00001 13.07 12.88 1.14 
V-set and transmembrane domain 
containing 1  VSTM1 < 0.00001 13.03 16.10 -1.19 
Collagen, type II, alpha 1 COL2A1 < 0.00001 12.63 18.14 2.70 
Serine proteinase inhibitor, clade B, 
member 2 (Predicted)  SERPINB2 < 0.00001 12.41 13.04 -1.54 
Collagen, type VIII, alpha 2  COL8A2 < 0.00001 12.39 16.64 -1.47 
Prominin 2  PROM2 < 0.00001 12.26 10.58 1.12 
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G protein-coupled receptor 182  GPR182 < 0.00001 12.02 13.61 1.43 
Cytochrome P450 2G1 (EC 
1.14.14.1)(CYPIIG1)(Cytochrome P450-
NMB)(Cytochrome P450 olfactive)  
CYP2G1 0.00001 12.02 10.58 1.37 
Claudin 16  CLDN16 0.00001 11.99 13.94 1.44 
Kinesin family member 13B  KIF13B < 0.00001 11.98 24.14 1.24 
ZW10 interactor  ZWINT < 0.00001 11.97 12.62 1.12 
TRNA splicing endonuclease 54 
homolog (S. cerevisiae)  TSEN54 < 0.00001 11.80 15.23 -1.16 
G protein-coupled receptor 156  GPR156 < 0.00001 11.56 8.90 1.07 
RAS guanyl releasing protein 4  RASGRP4 0.00001 11.47 17.78 1.81 
Keratin 84  KRT84 < 0.00001 11.36 17.46 -1.15 
Phospholipase A2 Precursor (EC 
3.1.1.4)(Phosphatidylcholine 2-
acylhydrolase)(Group IB phospholipase 
A2)  
PLA2G1B < 0.00001 11.30 15.54 1.26 
Teneurin transmembrane protein 4 TENM4 0.00010 11.25 3.71 -1.00 
Retinitis pigmentosa GTPase regulator 
interacting protein 1  RPGRIP1 < 0.00001 11.12 9.10 1.64 
Iroquois homeobox 2  IRX2 < 0.00001 11.09 16.95 1.14 
Cartilage intermediate layer protein, 
nucleotide pyrophosphohydrolase  CILP < 0.00001 11.02 13.91 -1.02 
Protease, serine, 16 (thymus)  PRSS16 < 0.00001 10.91 8.96 1.18 
Proteoglycan 3  PRG3 0.00001 10.89 14.11 -1.15 
Olfactory receptor, family 2, subfamily 
B, member 11  OR2B11 < 0.00001 10.85 9.64 1.25 
5-hydroxytryptamine (serotonin) 
receptor 4  HTR4 < 0.00001 10.69 14.80 -1.01 
Cytochrome P450 2C4-like LOC100347004 0.00002 10.53 20.63 -1.19 
Pregnancy-zone protein PZP < 0.00001 10.47 14.40 -1.22 
Homeobox D11  HOXD11 < 0.00001 10.46 10.70 1.08 
Caspase 14 LOC100101622 < 0.00001 10.46 7.01 1.42 
Tetratricopeptide repeat domain 28  TTC28 < 0.00001 10.42 13.15 1.33 
G protein-coupled receptor 52  GPR52 0.00002 10.41 11.89 1.32 
CYP4A5 cytochrome P450, family 4, 
subfamily A, polypeptide 5 CYP4A5 < 0.00001 10.37 14.46 1.01 
UTP14, U3 small nucleolar 
ribonucleoprotein, homolog A (yeast) UTP14A < 0.00001 10.31 17.21 1.62 
Double homeobox A  DUXA < 0.00001 10.17 8.57 -1.41 
CD38 molecule CD38 < 0.00001 10.15 15.64 1.78 
Rac GTPase activating protein 1 
pseudogene  RACGAP1P < 0.00001 10.09 12.13 1.01 
Tyrosine hydroxylase TH 0.00002 10.04 14.41 1.54 
Maestro heat-like repeat-containing 
protein family member 6 MROH6 < 0.00001 10.01 10.05 -1.20 
Abbreviations as in Table 3.3. 
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Table 3.6. Downregulated genes in the FC of the ‘hypercholesterolemia plus sham’ 
rabbits vs. sham operated control rabbits with greater than 10-fold change. 
Gene  Gene Symbol Corrected P-value 







Family with sequence similarity 184, 
member B  FAM184B <0.00001 -116.47 -33.99 1.04 
Cullin 3  CUL3 <0.00001 -80.07 -5.26 -1.14 
Glutamate dehydrogenase 1-like LOC100351029 <0.00001 -79.97 -3.09 1.44 
Transmembrane protein 109  TMEM109 <0.00001 -68.30 -5.54 1.06 
Progesterone receptor membrane 
component 1 LOC100357097 <0.00001 -64.16 -29.78 1.12 
Prefoldin subunit 5  PFDN5 <0.00001 -63.30 -5.59 -1.27 
3'(2'), 5'-bisphosphate nucleotidase 1  BPNT1 <0.00001 -59.24 -12.82 -1.28 
Heterogeneous nuclear ribonucleoprotein 
C (hnRNP C)  HNRNPC <0.00001 -52.05 -20.30 -1.01 
Transmembrane protein 38B  TMEM38B <0.00001 -47.36 -20.84 -1.02 
Androgen-induced 1  AIG1 <0.00001 -43.77 -19.47 1.25 
Interferon-related developmental 
regulator 1  IFRD1 <0.00001 -38.79 -3.43 1.10 
Ribophorin I  RPN1 <0.00001 -36.98 -11.77 -1.03 
Glyceraldehyde-3-phosphate 
dehydrogenase, spermatogenic  GAPDHS <0.00001 -35.05 -52.83 -1.39 
Periphilin 1  PPHLN1 <0.00001 -33.60 -4.43 -1.05 
Crystallin, alpha A  CRYAA <0.00001 -33.04 -6.22 -1.06 
Fibroblast growth factor 16  FGF16 <0.00001 -31.13 -8.93 -1.07 
Zinc finger protein 642  ZNF642 0.00145 -29.17 -13.49 -2.41 
GC-rich promoter binding protein 1  GPBP1 <0.00001 -28.51 -1.92 -1.15 
Tyrosine 3-monooxygenase/tryptophan 
5-monooxygenase activation protein, 
beta polypeptide-like 
LOC100358299 <0.00001 -28.25 -3.83 -1.02 
IQ motif and Sec7 domain 3  IQSEC3 <0.00001 -27.98 -11.84 -1.18 
Proteasome (prosome, macropain) 26S 
subunit, ATPase, 6  PSMC6 0.00035 -26.83 -11.24 -1.14 
UDP-glucuronosyltransferase 2B13 UGT2B13 <0.00001 -26.47 -28.50 -1.38 
Nucleolar protein 10  NOL10 <0.00001 -25.56 -3.97 -1.08 
Obg-like ATPase 1  OLA1 <0.00001 -23.46 -2.30 -1.02 
Solute carrier family 35, member B3  SLC35B3 <0.00001 -22.89 -2.16 -1.08 
Zinc finger protein 638  ZNF638 <0.00001 -22.50 -1.40 -1.32 
WW domain containing adaptor with 
coiled-coil  WAC <0.00001 -21.29 -19.01 1.09 
Uncharacterized LOC100347346 LOC100347346 <0.00001 -21.18 -1.41 -1.02 
Microtubule associated tumor suppressor 
1  MTUS1 <0.00001 -21.06 -3.97 1.24 
Rhophilin associated tail protein 1-like ROPN1L <0.00001 -20.85 -5.05 -1.06 
Myosin IE  MYO1E <0.00001 -20.09 -3.76 -1.01 
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Protein kinase C, beta PRKCB <0.00001 -19.92 -5.39 1.11 
Guanylate cyclase 1, soluble, beta 3  GUCY1B3 <0.00001 -19.50 -4.48 -1.38 
Manganese superoxide dismutase SOD-2 <0.00001 -18.33 -5.65 -1.04 
OTU deubiquitinase 6A  OTUD6A <0.00001 -17.62 -4.45 -27.65 
Gamma-aminobutyric acid (GABA) A 
receptor, alpha 6  GABRA6 <0.00001 -17.62 -2.53 -1.16 
ALX homeobox 1  ALX1 <0.00001 -17.40 -10.42 -1.34 
Upregulated during skeletal muscle 
growth 5 homolog (mouse)  USMG5 <0.00001 -16.81 -2.04 1.11 
Eukaryotic translation initiation factor 3, 
subunit M  EIF3M <0.00001 -16.15 -2.56 -1.06 
Matrix metallopeptidase 9 (gelatinase B, 
92kDa gelatinase, 92kDa type IV 
collagenase) 
MMP9 <0.00001 -16.10 -6.89 -1.44 
Secretion regulating guanine nucleotide 
exchange factor  SERGEF 0.00002 -15.87 -2.76 -1.16 
Elongation of very long chain fatty acids 
(FEN1/Elo2, SUR4/Elo3, yeast)-like 2  ELOVL2 <0.00001 -15.72 -4.26 1.26 
Tubulin, beta 1  TUBB1 <0.00001 -15.57 -14.84 -1.10 
RAB3A interacting protein (rabin3)  RAB3IP <0.00001 -15.36 -17.70 -1.02 
V-Ki-ras2 Kirsten rat sarcoma viral 
oncogene homolog  KRAS <0.00001 -15.13 -12.86 -1.01 
Chaperonin containing TCP1, subunit 2 
(beta) CCT2 <0.00001 -14.88 -21.14 1.34 
Nuclear transport factor 2-like export 
factor 2  NXT2 <0.00001 -14.82 -5.18 -1.17 
Mitochondrial ribosomal protein L1  MRPL1 <0.00001 -14.79 -7.10 1.05 
BRCA2 and CDKN1A interacting 
protein  BCCIP <0.00001 -14.65 -2.72 -1.10 
Tripartite motif-containing 37  TRIM37 0.00003 -13.86 -1.95 -1.11 
SWI/SNF related, matrix associated, 
actin dependent regulator of chromatin, 
subfamily a, member 5  
SMARCA5 <0.00001 -13.77 -6.46 -1.10 
SWI/SNF related, matrix associated, 
actin dependent regulator of chromatin, 
subfamily d, member 3  
SMARCD3 <0.00001 -13.66 -3.00 1.03 
Cytochrome P450, family 7, subfamily 
A, polypeptide 1 CYP7A1 <0.00001 -13.41 -5.34 1.14 
Poly(rC) binding protein 3  PCBP3 <0.00001 -13.35 -6.37 -1.14 
Tyrosine 3-monooxygenase/tryptophan 
5-monooxygenase activation protein, 
theta polypeptide 
YWHAQ <0.00001 -13.24 -2.15 -1.05 
Insulin-like 6  INSL6  <0.00001 -13.21 -14.96 -1.82 
Sin3A-associated protein, 30kDa  SAP30 <0.00001 -13.11 -14.83 1.13 
Zinc finger protein 326  ZNF326 0.00006 -12.97 -6.01 -1.25 
Transthyretin (Prealbumin)  TTR 0.00047 -12.96 -34.41 1.27 
RWD domain containing 3  RWDD3 <0.00001 -12.93 -2.36 1.08 
SERTA domain containing 4  SERTAD4 <0.00001 -12.85 -4.52 -1.07 
Destrin LOC100358081 <0.00001 -12.68 -3.25 -1.01 
Chapter III, Section 3 - Gene Expression Analyses of the Rabbit Frontal 
Cortex after Hypercholesterolemia and/or Hypertension 
 
164 
Gene  Gene Symbol Corrected P-value 







Mitochondrial ribosomal protein L15  MRPL15 <0.00001 -12.53 -5.43 1.32 
Aryl hydrocarbon receptor nuclear 
translocator (ARNT protein)(Dioxin 
receptor, nuclear translocator)(Hypoxia-
inducible factor 1 beta)(HIF-1 beta)  
ARNT <0.00001 -12.52 -4.53 1.21 
Zinc finger protein 330  ZNF330 0.00004 -12.39 -9.67 -1.03 
Lupus La protein homolog Fragment (La 
ribonucleoprotein)(La autoantigen 
homolog)  
SSB <0.00001 -12.31 -3.80 -1.22 
Uncharacterized protein C20orf160  CCM2L <0.00001 -12.18 -9.10 -1.44 
Eukaryotic translation initiation factor 2 
subunit 1 EIF2S1 <0.00001 -12.06 -15.20 -1.02 
FtsJ homolog 3 (E. coli)  FTSJ3 <0.00001 -12.05 -12.38 -1.17 
N-myristoyltransferase 2  NMT2 <0.00001 -11.89 -3.02 -1.03 
KIAA0305-like LOC100358165 <0.00001 -11.86 -1.75 1.01 
TSR1, 20S rRNA accumulation, 
homolog (S. cerevisiae)  TSR1 <0.00001 -11.63 -12.87 -1.18 
KIAA0513  KIAA0513 0.00003 -11.59 -2.21 1.07 
Asparagine-linked glycosylation 9, 
alpha-1,2-mannosyltransferase homolog 
(S. cerevisiae)  
ALG9 <0.00001 -11.38 -3.04 -1.05 
Alpha-tubulin N-acetyltransferase 1 ATAT1 <0.00001 -11.32 -1.16 2.00 
Tumor protein, translationally-controlled 
1  TPT1 0.00193 -11.32 1.57 1.04 
DENN/MADD domain containing 1B  DENND1B 0.00002 -11.09 -2.21 1.21 
Proline, glutamate and leucine rich 
protein 1  PELP1 <0.00001 -10.97 -7.51 1.19 
Proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 4 PSMD4 <0.00001 -10.69 -8.77 -1.33 
WD repeat domain 43  WDR43 <0.00001 -10.68 -13.37 -1.20 
Methyltransferase like 10  METTL10 <0.00001 -10.49 -1.99 -1.32 
Heterogeneous nuclear ribonucleoprotein 
A1 LOC100343627 <0.00001 -10.11 -3.62 1.35 
Adaptor-related protein complex 4, 
sigma 1 subunit  AP4S1 <0.00001 -10.08 -3.14 -1.05 
Cell shaded in peach denotes DEG which is in common between the FC and MCA (more than 10-fold change in both 
regions). HC: ‘Hypercholesterolemia plus sham’ rabbits. HT: ‘Hypertension only’ rabbits. HCHT: 
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The IPA network with the ‘largest number of upregulated focus genes’, 
contained 22 focus genes with functions in Lipid Metabolism, Molecular 
Transport, and Small Molecule Biochemistry. Focus genes in this network were 
AOC1, CD244, CP, DEPTOR, ELK3, ELOVL3, FBP1, FGF19, GPRIN2, 
IL20RA, KLB, KLF13, MLXIP, OVGP1, PKMYT1, PLA2G1B, RASGRP4, 
RPTOR, SH2D1A, SULT2A1, SYNPO2, and TPH2 (Figure 3.33). They were 
related to the ‘node molecule’ ERK1/2. The second network of upregulated 
focus genes had 22 focus genes, with functions in Humoral Immune Response, 
Protein Synthesis, and Endocrine System Disorders. Focus genes in this 
network were CARD11, CHFR, CORIN, DUOX2, EPHB3, FCRLA, IL25, 
IL2RB, INO80D, LAX1, MS4A2, NFRKB, PAX9, PIGR, PLD1, PROK1, 
PROKR2, SP4, TBX18, TBX21, TCL1A, and TPO (Figure 3.34). They were 
associated with Akt, BCR (complex), Ige, IgG1, and Igm.  
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Figure 3.33. IPA network showing the network with the largest number of upregulated 
focus genes in the FC of the ‘hypercholesterolemia plus sham’ group, compared with 
sham operated control group.  
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Figure 3.34. IPA network showing the network with the second largest number of 
upregulated focus genes in the FC of the ‘hypercholesterolemia plus sham’ group, 
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The network with the largest number of downregulated focus genes 
contained 24 focus genes with functions in Cancer, Cell Cycle, Cellular 
Assembly and Organization. Focus genes in this network were ASF1A, ECT2, 
ELOVL5, FAM188A, IFRD1, INPP4A, INSIG2, KLF1, MCM4, MYBBP1A, 
NCKAP1, NGB, PARD6B, PELP1, PSMC6, PSMD4, RPN1, SAP30, 
SMARCA5, SMARCD1, SMARCD3, SPRR3, SUCLG1, and TYMS (Figure 
3.35). They were related to Akt, Cyclin A, Cyclin E, E2f, Hdac, and Histone h4. 
The second network of downregulated focus genes had 23 focus genes which 
were related to Protein Synthesis, Infectious Disease, Cell Death and Survival. 
Focus genes in this network include ATP2A3, CCNH, CCT2, DDX58, EIF2S1, 
EIF3B, EIF3M, ENAH, FGL2, GAPDH, IRAK1BP1, MYO1E, NCBP1, 
NCK1, PFDN5, PGK2, TBK1, TPT1, TRIM37, TSPAN6, TUBB1, USP3, and 
VBP1 (Figure 3.36). These genes were related to Alpha tubulin, BCR 
(complex), Beta Tubulin, Ifn, IFN Beta, IFN type 1, Ikb, NF-κB (complex), Pro-
inflammatory Cytokine, and Sos.  
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Figure 3.35. IPA network showing the network with the largest number of 
downregulated focus genes in the FC of the ‘hypercholesterolemia plus sham’ group, 
compared with sham operated control group. 
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Figure 3.36. IPA network showing the network with the second largest number of 
downregulated focus genes in the FC of the ‘hypercholesterolemia plus sham’ group, 
compared with sham operated control group. 
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3.2.2.  Microarray analyses of the ‘hypercholesterolemia plus 
hypertension’ group 
Gene expression profile in the FC of the ‘hypercholesterolemia plus 
hypertension’ group was compared with sham operated controls on a normal 
diet. After unknown and repeated genes were omitted, a total of 971 DEGs with 
870 upregulated and 101 downregulated genes (greater than 4-fold change) was 
observed in the FC (Figure 3.32). Among the highly upregulated genes in the 
FC of the ‘hypercholesterolemia plus hypertension’ group compared with sham 
operated control group were CIDEC, FSHR and FGFBP2 (Table 3.7). Among 
the highly downregulated genes were GAPDHS, FAM184B and TTR (Table 
3.8). 
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Table 3.7. Upregulated genes in the FC of the ‘hypercholesterolemia plus hypertension’ 
rabbits vs. sham operated control rabbits with greater than 10-fold change. 
Gene  Gene Symbol Corrected P-value 







Cell death-inducing DFFA-like effector c  CIDEC <0.00001 78.38 62.26 2.71 
Follicle stimulating hormone receptor  FSHR <0.00001 48.62 28.24 -1.44 
Fibroblast growth factor binding protein 2  FGFBP2 <0.00001 39.21 17.99 -1.11 
Secretoglobin, family 3A, member 1  SCGB3A1 <0.00001 36.99 20.36 1.37 
Gonadotropin-releasing hormone receptor  GnRHR <0.00001 32.62 18.76 -1.09 
Homeobox A2 (Predicted)  HOXA2 <0.00001 28.54 15.21 1.18 
Galactosidase, beta 1-like 3  GLB1L3 <0.00001 25.21 13.91 1.17 
Kinesin family member 13B  KIF13B <0.00001 24.14 11.98 1.24 
Uncharacterized protein C2orf71  C2orf71 <0.00001 21.24 13.74 1.38 
Outer dense fiber of sperm tails 2  ODF2 <0.00001 21.24 29.07 1.27 
NPC1 (Niemann-Pick disease, type C1, 
gene)-like 1  NPC1L1 0.00007 20.95 13.61 2.11 
Cytochrome P450 2C4-like LOC100347004 0.00002 20.63 10.53 -1.19 
Interstitial collagenase Precursor (EC 
3.4.24.7)(Matrix metalloproteinase-1) MMP1 <0.00001 20.41 3.39 1.26 
Secretagogin, EF-hand calcium binding 
protein  SCGN 0.00480 19.47 5.04 -1.85 
Tolloid-like 1  TLL1 0.00014 19.18 8.61 1.96 
Uncharacterized protein C1orf161  MAB21L3 <0.00001 18.73 25.83 1.29 
Protease, serine, 38  PRSS38 <0.00001 18.71 14.94 1.42 
Collagen, type II, alpha 1 COL2A1 <0.00001 18.14 12.63 2.70 
Transcription factor CP2-like 1  TFCP2L1 0.00056 18.06 8.16 -1.15 
RAS guanyl releasing protein 4  RASGRP4 <0.00001 17.78 11.47 1.81 
CCR4 carbon catabolite repression 4-like 
(S. cerevisiae)  CCRN4L <0.00001 17.76 4.43 -1.70 
Keratin 84  KRT84 <0.00001 17.46 11.36 -1.15 
UTP14, U3 small nucleolar 
ribonucleoprotein, homolog A (yeast) UTP14A <0.00001 17.21 10.31 1.62 
Iroquois homeobox 2  IRX2 <0.00001 16.95 11.09 1.14 
Collagen, type VIII, alpha 2  COL8A2 <0.00001 16.64 12.39 -1.47 
TAF15 RNA polymerase II, TATA box 
binding protein (TBP)-associated factor, 
68kDa  
TAF15 <0.00001 16.57 18.25 1.56 
Solute carrier family 35, member D2  SLC35D2 <0.00001 16.43 17.77 -1.06 
Sulfotransferase family, cytosolic, 2A, 
dehydroepiandrosterone (DHEA)-
preferring, member 1 
SULT2A1 <0.00001 16.32 9.61 -1.14 
Pleckstrin homology domain containing, 
family G (with RhoGef domain) member 6  PLEKHG6 <0.00001 16.22 7.80 1.23 
Interleukin 20 receptor, alpha  IL20RA <0.00001 16.14 8.23 -1.17 
V-set and transmembrane domain 
containing 1  VSTM1 <0.00001 16.10 13.03 -1.19 
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Transmembrane protein 201  TMEM201 <0.00001 16.02 6.58 1.02 
Glucose-fructose oxidoreductase domain 
containing 2-like LOC100351150 <0.00001 15.95 8.05 1.16 
Paired box 1  PAX1 <0.00001 15.76 13.89 2.87 
CD38 molecule CD38 <0.00001 15.64 10.15 1.78 
Carboxylesterase 3  CES3 <0.00001 15.59 27.26 -1.14 
Phospholipase A2 Precursor (EC 
3.1.1.4)(Phosphatidylcholine 2-
acylhydrolase)(Group IB phospholipase 
A2)  
PLA2G1B <0.00001 15.54 11.30 1.26 
TRNA splicing endonuclease 54 homolog 
(S. cerevisiae)  TSEN54 <0.00001 15.23 11.80 -1.16 
Minor cytochrome P450 CYP2C14 0.00122 15.13 6.69 -1.12 
ELOVL fatty acid elongase 3 ELOVL3 <0.00001 14.86 8.18 1.07 
5-hydroxytryptamine (serotonin) receptor 4 HTR4 <0.00001 14.80 10.69 -1.01 
Family with sequence similarity 71, 
member F2  FAM71F2 <0.00001 14.65 8.38 -1.18 
Tyrosine hydroxylase  TH 0.00002 14.41 10.04 1.54 
DEAQ box RNA-dependent ATPase 1  DQX1 0.00002 14.30 9.48 1.19 
Flavin containing monooxygenase 4  FMO4 <0.00001 14.29 9.23 -1.47 
Interleukin 8 IL8 0.00003 14.16 7.48 1.06 
Granulate-macrophage stimulating factor 
(Predicted)  GMCSF <0.00001 14.12 8.32 -1.01 
Solute carrier family 14 (urea transporter), 
member 1 (Kidd blood group)  SLC14A1 <0.00001 14.09 8.58 -1.09 
Claudin 16  CLDN16 <0.00001 13.94 11.99 1.44 
Cartilage intermediate layer protein, 
nucleotide pyrophosphohydrolase  CILP <0.00001 13.91 11.02 -1.02 
Leucine rich repeat containing 15  LRRC15 <0.00001 13.90 17.58 1.70 
N-deacetylase/N-sulfotransferase (heparan 
glucosaminyl) 4  NDST4 0.00042 13.82 7.19 -1.21 
G protein-coupled receptor 182  GPR182 <0.00001 13.61 12.02 1.43 
Relaxin/insulin-like family peptide 
receptor 2  RXFP2 0.00058 13.47 6.67 1.14 
Radial spoke head 4 homolog A 
(Chlamydomonas)  RSPH4A <0.00001 13.41 7.60 1.16 
CDC14 cell division cycle 14 homolog A 
(S. cerevisiae)  CDC14A <0.00001 13.35 9.29 1.32 
Myosin, heavy chain 6, cardiac muscle, 
alpha MYH6 <0.00001 13.18 14.58 -1.31 
Tetratricopeptide repeat domain 28  TTC28 <0.00001 13.15 10.42 1.33 
Trans-2,3-enoyl-CoA reductase-like  TECRL <0.00001 13.04 8.20 -1.00 
Serine proteinase inhibitor, clade B, 
member 2 (Predicted)  SERPINB2 <0.00001 13.04 12.41 -1.54 
Beta-carotene 15,15'-monooxygenase 1  BCMO1 <0.00001 12.88 13.07 1.14 
Bardet-Biedl syndrome 5 LOC100342443 <0.00001 12.86 8.32 -1.01 
Exocyst complex component 3-like  EXOC3L <0.00001 12.79 9.32 1.07 
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Eukaryotic translation initiation factor 2-
alpha kinase 2 EIF2AK2 <0.00001 12.73 8.22 -1.25 
Na+-dependent purine-selective nucleoside 
transporter SPNT1 0.00002 12.67 7.45 -1.17 
TNF receptor-associated factor 3 
interacting protein 1  TRAF3IP1 <0.00001 12.66 8.07 1.45 
ZW10 interactor  ZWINT <0.00001 12.62 11.97 1.12 
Cytochrome P450 1A2 (EC 
1.14.14.1)(CYPIA2)(Cytochrome P450 
isozyme 4)(Cytochrome P450 
LM4)(Cytochrome P450-PM4)  
CYP1A2 0.00016 12.53 14.88 -1.27 
Interleukin 22 receptor, alpha 1  IL22RA1 0.00002 12.52 8.42 1.30 
Haptoglobin HP <0.00001 12.39 4.75 -1.26 
Receptor (chemosensory) transporter 
protein 1  RTP1 0.00003 12.38 9.47 1.29 
Taste receptor, type 2, member 3  TAS2R3 <0.00001 12.31 7.03 -1.38 
Mast cell-expressed membrane protein 1  MCEMP1 <0.00001 12.17 6.29 -1.25 
Filamin A, alpha isoform 2 (Predicted)  FLNA <0.00001 12.17 8.94 1.70 
Rac GTPase activating protein 1 
pseudogene  RACGAP1P <0.00001 12.13 10.09 1.01 
RNA binding motif protein 12B  RBM12B <0.00001 12.08 9.17 2.00 
Paired box 2  PAX2 <0.00001 12.03 9.02 -1.04 
AP2 associated kinase 1  AAK1 <0.00001 12.01 6.21 1.07 
G protein-coupled receptor 52  GPR52 0.00002 11.89 10.41 1.32 
Fibrinogen beta chain FGB <0.00001 11.88 9.55 1.34 
TAF7-like RNA polymerase II, TATA box 
binding protein (TBP)-associated factor, 
50kDa  
TAF7L <0.00001 11.68 7.58 1.30 
FCH and double SH3 domains 1  FCHSD1 <0.00001 11.63 7.89 1.02 
Solute carrier family 18 (vesicular 
monoamine), member 1  SLC18A1 0.00006 11.43 6.48 -1.73 
Transmembrane 4 L six family member 20  TM4SF20 <0.00001 11.41 6.47 -1.17 
Growth factor receptor bound protein 2-
associated protein 3 (Predicted)  GAB3 <0.00001 11.37 4.43 -1.03 
Peptide YY (PYY)(PYY-I)(Peptide 
tyrosine tyrosine)  PYY <0.00001 11.35 13.58 -1.27 
Homeobox A4 (Predicted)  HOXA4 <0.00001 11.31 9.15 1.20 
Sarcospan (Kras oncogene-associated 
gene) SSPN 0.00001 11.27 5.57 -1.08 
Thyroid peroxidase  TPO 0.00057 11.25 6.57 -1.06 
Proteoglycan 3  PRG3 0.00110 11.22 6.69 -1.15 
CD244 molecule, natural killer cell 
receptor 2B4  CD244 <0.00001 11.17 7.90 1.22 
Ceruloplasmin (ferroxidase) CP 0.00001 11.16 6.97 1.07 
Phospholipase C, zeta 1  PLCZ1 <0.00001 11.13 8.25 -1.09 
Sex comb on midleg-like 4 (Drosophila)  SCML4 0.00011 11.11 7.55 -1.14 
Myosin heavy chain PBV1SPCR2 <0.00001 11.10 7.04 1.25 
Chapter III, Section 3 - Gene Expression Analyses of the Rabbit Frontal 
Cortex after Hypercholesterolemia and/or Hypertension 
 
175 
Gene  Gene Symbol Corrected P-value 







Chymotrypsin-like elastase family, 
member 1  CELA1 0.00014 11.08 6.44 1.32 
Uncharacterized LOC100350105 LOC100350105 <0.00001 11.00 9.64 -1.20 
Dehydrogenase/reductase (SDR family) 
member 9  DHRS9 0.00031 10.95 6.67 -1.54 
Transmembrane protein C5orf28  C5orf28 0.00001 10.93 6.67 2.01 
CD4 molecule  CD4 <0.00001 10.86 7.58 -1.17 
T-box 21  TBX21 <0.00001 10.85 7.26 -1.20 
Leucine zipper, putative tumor suppressor 
1  LZTS1 <0.00001 10.85 7.91 1.17 
Tetraspanin 12  TSPAN12 <0.00001 10.83 17.91 1.11 
Arylsulfatase family, member J  ARSJ <0.00001 10.80 9.55 1.23 
Cholinergic receptor, nicotinic, alpha 10  CHRNA10 <0.00001 10.71 8.72 1.08 
Homeobox D11  HOXD11 <0.00001 10.70 10.46 1.08 
Keratin 7  KRT7 0.00002 10.60 6.25 1.21 
Cation channel, sperm associated 1  CATSPER1 <0.00001 10.58 5.65 1.06 
Prominin 2  PROM2 <0.00001 10.58 12.26 1.12 
Cytochrome P450 2G1 (EC 
1.14.14.1)(CYPIIG1)(Cytochrome P450-
NMB)(Cytochrome P450 olfactive)  
CYP2G1 0.00001 10.58 12.02 1.37 
Carbonic anhydrase I  CA1 0.00283 10.57 5.15 -1.32 
Lymphocyte antigen 6 complex locus 
protein G5c LY6G5C <0.00001 10.54 4.57 1.32 
Dynein, axonemal heavy chain 11 
Fragment  dnahc11 <0.00001 10.51 7.41 1.17 
N(alpha)-acetyltransferase 25, NatB 
auxiliary subunit  NAA25 <0.00001 10.47 5.32 1.30 
Nicotinamide nucleotide 
adenylyltransferase 3  NMNAT3 <0.00001 10.47 7.76 1.09 
Gap junction alpha-3 protein-like LOC100357902 0.00068 10.43 4.86 1.57 
Calcitonin gene-related peptide LOC100008771 <0.00001 10.43 5.64 -1.00 
DnaJ (Hsp40) homolog, subfamily C, 
member 5 beta  DNAJC5B <0.00001 10.41 6.36 -1.32 
Otopetrin 2  OTOP2 <0.00001 10.41 5.90 1.03 
Leptin  LEP <0.00001 10.38 6.98 1.27 
CAMP responsive element binding protein 
3-like 2  CREB3L2 <0.00001 10.32 6.34 -1.07 
Solute carrier family 17 (sodium 
phosphate), member 4  SLC17A4 <0.00001 10.31 7.08 1.04 
Uncharacterized protein C11orf42  C11orf42 <0.00001 10.31 4.89 -1.46 
Serine proteinase inhibitor, clade B, 
member 13 (Predicted)  SERPINB13 <0.00001 10.22 6.52 -1.14 
CUB domain containing protein 2  CDCP2 <0.00001 10.22 6.92 1.73 
T-cell leukemia/lymphoma 1A  TCL1A <0.00001 10.21 7.63 1.04 
Serpin peptidase inhibitor, clade A (alpha-
1 antiproteinase, antitrypsin), member 4  SERPINA4 <0.00001 10.19 8.17 1.17 
Arylformamidase  AFMID 0.00009 10.17 6.95 1.84 
Chapter III, Section 3 - Gene Expression Analyses of the Rabbit Frontal 
Cortex after Hypercholesterolemia and/or Hypertension 
 
176 
Gene  Gene Symbol Corrected P-value 







Amiloride binding protein 1 (amine 
oxidase (copper-containing))  ABP1 <0.00001 10.16 9.00 1.08 
Secretoglobin, family 1C, member 1  SCGB1C1 <0.00001 10.15 6.54 1.23 
Selectin E  SELE <0.00001 10.08 9.60 1.11 
Guanylate cyclase 2D, membrane (retina-
specific)  GUCY2D 0.00004 10.05 9.86 1.25 
Myogenin myog <0.00001 10.05 6.21 1.09 
Putative uncharacterized protein C8orf73  MROH6 <0.00001 10.05 10.01 -1.20 
Cell shaded in peach denotes DEG which is in common between the FC and MCA (more than 10-fold change in both 
regions). HC: ‘Hypercholesterolemia plus sham’ rabbits. HT: ‘Hypertension only’ rabbits. HCHT: 
‘Hypercholesterolemia plus hypertension’ rabbits. 
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Table 3.8. Downregulated genes in the FC of the ‘hypercholesterolemia plus 
hypertension’ rabbits vs. sham operated control rabbits with greater than 10-fold 
change. 
Gene  Gene Symbol Corrected P-value 








dehydrogenase, spermatogenic  GAPDHS <0.00001 -52.83 -35.05 -1.39 
Family with sequence similarity 184, 
member B  FAM184B <0.00001 -33.99 -116.47 1.04 
Transthyretin (Prealbumin)  TTR 0.00069 -33.37 -12.38 1.26 
UDP-glucuronosyltransferase 2B13 UGT2B13 <0.00001 -28.50 -26.47 -1.38 
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 58 DDX58 <0.00001 -21.25 -20.90 -1.27 
Transmembrane protein 38B  TMEM38B <0.00001 -20.84 -47.36 -1.02 
Heterogeneous nuclear ribonucleoprotein C 
(hnRNP C)  HNRNPC <0.00001 -20.30 -52.05 -1.01 
Androgen-induced 1  AIG1 <0.00001 -19.47 -43.77 1.25 
WW domain containing adaptor with 
coiled-coil  WAC <0.00001 -19.01 -21.29 1.09 
RAB3A interacting protein (rabin3)  RAB3IP <0.00001 -17.70 -15.36 -1.02 
Eukaryotic translation initiation factor 2 
subunit 1 EIF2S1 <0.00001 -15.20 -12.06 -1.02 
Insulin-like 6  INSL6 <0.00001 -14.96 -13.21 -1.82 
Tubulin, beta 1  TUBB1 <0.00001 -14.84 -15.57 -1.10 
Zinc finger protein 642  ZFP69 0.00145 -13.49 -29.17 -2.41 
WD repeat domain 43  WDR43 <0.00001 -13.37 -10.68 -1.20 
TSR1, 20S rRNA accumulation, homolog 
(S. cerevisiae)  TSR1 <0.00001 -12.87 -11.63 -1.18 
V-Ki-ras2 Kirsten rat sarcoma viral 
oncogene homolog  KRAS <0.00001 -12.86 -15.13 -1.01 
3'(2'), 5'-bisphosphate nucleotidase 1  BPNT1 <0.00001 -12.82 -59.24 -1.28 
FtsJ homolog 3 (E. coli)  FTSJ3 <0.00001 -12.38 -12.05 -1.17 
IQ motif and Sec7 domain 3  IQSEC3 <0.00001 -11.84 -27.98 -1.18 
Ribophorin I  RPN1 <0.00001 -11.77 -36.98 -1.03 
Proteasome (prosome, macropain) 26S 
subunit, ATPase, 6  PSMC6 0.00035 -11.24 -26.83 -1.14 
Leucine-rich, glioma inactivated 1  LGI1 <0.00001 -11.12 -8.68 -1.21 
ALX homeobox 1  ALX1 <0.00001 -10.42 -17.40 -1.34 
Solute carrier family 25, member 46  SLC25A46 <0.00001 -10.13 -8.44 1.05 
Cell shaded in peach denotes DEG which is in common between the FC and MCA (more than 10-fold change in both 
regions). HC: ‘Hypercholesterolemia plus sham’ rabbits. HT: ‘Hypertension only’ rabbits. HCHT: 
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The IPA network with the ‘largest number of upregulated focus genes’, 
contained 26 focus genes with functions in Cell Signaling, Cell-To-Cell 
Signaling and Interaction, and Nucleic Acid Metabolism. Focus genes in this 
network were ADRA1A, AVPR1B, BDKRB1, CALCRL, CCR10, CHRM2, 
FZD4, GHRHR, GPR18, GPR52, GPR115, GPR119, GPR156, GPR174, 
GPR182, HRH1, HTR4, LGR5, NMBR, NPFFR1, P2RY10, PTGER3, RXFP1, 
RXFP2, TACR2, and VIPR2 (Figure 3.37). They were related to GPCR. 
 
Figure 3.37. IPA network showing the network with the largest number of upregulated 
focus genes in the FC of the ‘hypercholesterolemia plus hypertension’ group, compared 
with sham operated control group. 
Chapter III, Section 3 - Gene Expression Analyses of the Rabbit Frontal 
Cortex after Hypercholesterolemia and/or Hypertension 
 
179 
The IPA network with the ‘largest number of downregulated focus 
genes’, contained 20 focus genes with functions in Cellular Movement, 
Infectious Disease, Cell Death and Survival. Focus genes in this network were 
CCT2, CRYAA/LOC102724652, EIF2S1, ELOVL2, FABP7, FGF16, 
GUCY1B3, INSL6, KRAS, LGI1, MMP9, ORMDL3, PFDN5, PRKCB, 
PSMC6, SLC2A3, TMEM109, TNFRSF11B, TUBB1, and UTS2. They were 
related to Beta tubulin, Cyclin E, ERK1/2, growth hormone, Insulin, LDL, 
MAP2K1/2, Mek, STAT5a/b and Tgf beta (Figure 3.38).  
 
Figure 3.38. IPA network showing the network with the largest number of 
downregulated focus genes in the FC of the ‘hypercholesterolemia plus hypertension’ 
group, compared with sham operated control group. 
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3.2.3.  Microarray analyses of the ‘hypertension only’ group 
Gene expression profile in the FC of the ‘hypertension only’ group was 
compared with sham operated controls on a normal diet. After unknown genes 
and repeated probes of the same genes were omitted, a total of 5 DEGs with 1 
upregulated and 4 downregulated genes (greater than 4-fold change) was 
observed in the FC (Figure 3.32). CCNB1IP1 was the only upregulated gene in 
the FC of the ‘hypertension only’ group compared with sham operated control 
group (Table 3.9). Among the highly downregulated genes were OTUD6A, 
GNMT and C1QTNF1 (Table 3.10). 
 
Table 3.9. Upregulated genes in the FC of the ‘hypertension only’ rabbits vs. sham 
operated control rabbits with greater than 4-fold change. 
Gene  Gene Symbol Corrected P-value 







Cyclin B1 interacting protein 1, E3 
ubiquitin protein ligase  CCNB1IP1 0.00568 5.04 3.47 2.68 






Table 3.10. Downregulated genes in the FC of ‘hypertension only’ rabbits vs. sham 
operated control rabbits with greater than 10-fold change. 
Gene  Gene Symbol Corrected P-value 







OTU deubiquitinase 6A  OTUD6A <0.00001 -27.65 -17.62 -4.45 
Glycine N-methyltransferase GNMT <0.00001 -13.46 -1.77 1.19 
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Only one IPA network with the only one upregulated focus gene, 
CCNB1IP1, was detected and it had functions in Cell Cycle, Dermatological 
Diseases and Conditions, Reproductive System Development and Function 




Figure 3.39. IPA network showing the network with the only upregulated focus gene 
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The network with the largest number of downregulated focus genes 
contained only 2 focus genes with functions in Lipid Metabolism, Molecular 
Transport, and Small Molecule Biochemistry. Focus genes in this network were 
C1QTNF1 and GNMT; they were related to NR3C1 (Figure 3.40).  
 
Figure 3.40. IPA network showing the network with the largest number of 
downregulated focus genes in the FC of the ‘hypertension only’ group, compared with 
sham operated control group. 
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The present study was the first to elucidate differential gene expression 
changes in the FC of rabbits exposed to two neurodegeneration risk factors, i.e. 
hypercholesterolemia and/or hypertension. Hypercholesterolemia and 
hypertension are risk factors of Alzheimer’s disease (Kivipelto et al., 2002; 
Pappolla et al., 2003; Iadecola, 2010; Faraco and Iadecola, 2013) and the 
determination of DEGs by microarray analyses may be useful in facilitating the 
identification of candidate genes that associate these risk factors with the 
neuropathology of dementia such as AD.  
The overall results indicate that hypercholesterolemia with/without 
hypertension induced more severe effects on gene expression, compared with 
hypertension alone. Of the DEGs in the FC that were upregulated by a single 
risk factor, ‘hypercholesterolemia plus sham’ vs. sham operated controls on a 
normal diet, CIDEC had the highest fold change, followed by ODF2, RNASEL, 
FSHR, and CES3. CIDEC (cell death-inducing DFFA-like effector c) belongs 
to the family of cell death-inducing DNA fragmentation factor 45-like effector 
(CIDE) with crucial roles in apoptosis, energy metabolism (Yonezawa et al., 
2011), lipid metabolism (Xu et al., 2012) and the development of metabolic 
disorders (Gong et al., 2009). Overexpression of CIDEC isoforms induces DNA 
fragmentation and apoptosis in mammalian cells (Liang et al., 2003). Increased 
expression of CIDEC has been shown in humans with hepatic steatosis (Zhou 
et al., 2012), and in the livers of obese and high-fat diet-induced mice (Matsusue 
et al., 2008). In addition, it may be involved in foam cells formation and 
atherosclerosis as elevated levels of CIDEC have been noted in macrophages in 
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the presence of oxidized LDL (Li et al., 2010). ODF2 (outer dense fiber of 
sperm tails 2) is a cancer or testis gene and a de novo transcriptional target of 
hypoxia (Baghbani et al., 2013). It is also an important component of the 
cytoskeleton of the sperm tail (Baghbani et al., 2013). Its interaction with other 
proteins helps in spindle formation and aids in mitosis (Donkor et al., 2004). 
RNASEL (ribonuclease L (2',5'-oligoisoadenylate synthetase-dependent)) is 
involved in the function of interferon and plays an important role in antiviral, 
anticellular proliferation, apoptosis, autophagy and the regulation of gene 
expression (Liang et al., 2006; Chakrabarti et al., 2012). Recently, the role of 
RNASEL in macrophage functions including endocytosis, migration and 
cytokine production have been discovered, and macrophage migration is one of 
the features of macrophage functions in neurodegenerative disorders and 
chronic inflammation (Yi et al., 2013). FSHR (follicle stimulating hormone 
receptor) is the receptor of follicle stimulating hormone, a hormone that is 
involved in human reproduction (Corbo et al., 2011). A study has suggested that 
a certain FSHR genotype protects against AD susceptibility in a gender-specific 
manner (Corbo et al., 2011). CES3 (carboxylesterase 3) is important in basal 
lipolysis (Wei et al., 2007) and it has been recently discovered as a main 
molecular target of bioactive compounds that helps in lipid storage in 
adipocytes (Dominguez et al., 2014). Furthermore, CES3 inhibition was able to 
attenuate several characteristics of metabolic syndrome in mouse models of 
obesity-diabetes (Dominguez et al., 2014).  
Among the DEGs that were downregulated in the FC of the 
‘hypercholesterolemia plus sham’ vs. sham operated controls on a normal diet 
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were FAM184B with the highest fold change, followed by CUL3, 
LOC100351029, TMEM109, and LOC100357097. FAM184B (family with 
sequence similarity 184, member B) has limited information regarding its 
function till date. CUL3 belongs to the cullin family that participates in post-
translational modification of proteins such as ubiquitination (Anderica-Romero 
et al., 2013). With its associations in cell cycle regulation of redox homeostasis, 
CUL3 has been implicated in the etiopathology of oxidative stress associated 
chronic degenerative diseases (Anderica-Romero et al., 2013). No information 
regarding the functions of LOC100351029 (glutamate dehydrogenase 1-like), 
TMEM109 (transmembrane protein 109) and LOC100357097 (progesterone 
receptor membrane component 1) could be found to date.  
Of the DEGs in the FC that were upregulated in the 
‘hypercholesterolemia plus hypertension’ group vs. sham operated controls on 
a normal diet, CIDEC had the largest fold change, followed by FSHR, and 
FGFBP2. CIDEC and FSHR were also among the upregulated DEGs with high 
fold change in the ‘hypercholesterolemia plus sham’ group. FGFBP2 (fibroblast 
growth factor binding protein 2) which is expressed in cytotoxic T lymphocytes 
and natural killer cells (Ogawa et al., 2001), has been proposed as a potential 
prognostic biomarker for ovarian carcinomas (Elgaaen et al., 2010).  
Among the DEGs that were downregulated in the 
‘hypercholesterolemia plus hypertension’ group were GAPDHS, FAM184B, 
and TTR. GAPDHS (glyceraldehyde-3-phosphate dehydrogenase, 
spermatogenic), a paralog of glyceraldehyde-3-phosphate dehydrogenase 
(GAPD), is mainly expressed in the testis but lower expression is found in the 
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brain (Li et al., 2004). The effect of this paralog is associated in AD patients 
with onset before 75 years of age (Li et al., 2004) and has been suggested as a 
potential AD susceptibility gene (Bertram et al., 2007). FAM184B has been 
mentioned previously as the largest downregulated DEG in 
‘hypercholesterolemia plus sham’ group. TTR (transthyretin) is a conserved 
serum and cerebrospinal fluid protein that transports thyroid hormone and holo-
retinol-binding protein (Buxbaum and Reixach, 2009). TTR is suggested to 
reduce the formation or toxicity of Aβ oligomers (Buxbaum and Reixach, 
2009), as well as to prevent Aβ deposition and formation of senile plaques 
(Schwarzman et al., 1994). Cerebrospinal fluid and plasma TTR have been 
suggested as a marker for AD as lower TTR levels were observed in these 
components in AD subjects (Perrin et al., 2011; Velayudhan et al., 2012). 
There was only one DEG in the FC that was upregulated in the 
‘hypertension only’ group vs. sham operated controls on a normal diet: 
CCNB1IP1. CCNB1IP1 (cyclin B1 interacting protein 1, E3 ubiquitin protein 
ligase) is regarded as a potential tumor suppressor in breast and lung cancer, 
and its downregulation is linked to poor prognosis in these neoplasias 
(Confalonieri et al., 2009). Furthermore, a recent study has shown that the 
expression of CCNB1IP1 changes following stress exposure (Nayak et al., 
2014).  
Among the DEGs that were downregulated in the ‘hypertension only’ 
group vs. sham operated control group were OTUD6A, GNMT and C1QTNF1. 
Limited information is available for OTUD6A (OTU deubiquitinase 6A) till 
date. GNMT (glycine N-methyltransferase) is known as a susceptibility gene 
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for hepatocellular carcinoma (Tseng et al., 2003) and the gene expression is also 
suggested to be a favorable prognosis predictor for cholangiocarcinoma (Huang 
et al., 2008). C1QTNF1 (C1q and tumor necrosis factor related protein 1) 
regulates glucose metabolism and BP, and has antithrombotic effects (Schaffler 
and Buechler, 2012).  
The DEGs that were found in the FC in rabbits after respective 
treatments were associated with ‘node molecules’ based on IPA analyses. The 
network in the FC with largest number of upregulated focus genes affected by 
hypercholesterolemia (plus sham operation) showed many focus genes related 
to the ‘node molecule' ERK1/2. The network in the FC with the largest number 
of downregulated focus genes affected by hypercholesterolemia was related to 
Akt, Cyclin A, Cyclin E, E2f, Hdac, and Histone h4. 
The network in the FC with largest number of upregulated focus genes 
affected by ‘hypercholesterolemia plus hypertension’ showed many molecules 
related to GPCR. In contrast, the network in the FC with largest number of 
downregulated focus genes affected by ‘hypercholesterolemia plus 
hypertension’ were related to Beta tubulin, Cyclin E, ERK1/2, growth hormone, 
Insulin, LDL, MAP2K1/2, Mek, STAT5a/b and Tgf beta. 
Gene network analysis of the FC after hypertension showed the lowest 
number of generated networks corresponding to a relatively small number of 
DEGs. There was no ‘node molecule’ observed in the network of the 
upregulated genes, whereas the network with the largest number of 
downregulated molecules showed association with NR3C1. 
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Hypercholesterolemia and hypertension are risk factors for the 
pathogenesis of AD. However, more genes were altered after exposure to 
hypercholesterolemia than hypertension in the FC, thus, implying that 
hypercholesterolemia exerted a more crucial role in gene expression changes in 
the FC. The novel findings of gene expression changes in the FC of the 
hypercholesterolemic and/or hypertensive rabbits in the present study may shed 
new light on the identification of potential susceptibility genes in humans with 
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Neurodegenerative and cerebrovascular disorders are the leading causes 
of cognitive decline in aging population (Chui et al., 2012). AD is the classical 
neurodegenerative disorder and it is the most common form of dementia, 
comprising of 50-70% of all dementia cases (Leszek et al., 2012). On the other 
hand, atherosclerosis leading to stroke is the exemplary cerebrovascular disease 
(Chui et al., 2012). Generally, dementia and stroke are considered as different 
forms of brain injury as the former being a progressive degenerative disease 
whereas the latter is an acute vascular damage (Cumming and Brodtmann, 
2011). Despite the differences, these disorders are the two major contributors to 
the global disease burden and various studies have demonstrated the 
relationship between them, including the dementia of the AD’s type (Cumming 
and Brodtmann, 2011). People who have had a stroke show increased likelihood 
of developing dementia than those who are stroke-free (Leys et al., 2005), and 
enhanced AD prevalence by 2-fold has been observed among elderly patients 
with a history of stroke (Sun et al., 2006). Presence of pathological precursors 
of AD has also been observed in stroke-lesioned regions and inflammation is 
associated with neurodegenerative features of both conditions (Leszek et al., 
2012). Besides that, significantly increased atherosclerotic stenosis of the 
intracranial arteries have been reported in postmortem AD patients (Beach et 
al., 2007), and intracranial atherosclerosis is suggested as a contributing factor 
to AD’s dementia (Roher et al., 2011). Although dementia and stroke have been 
viewed as separate entities that develop independently of each other, both 
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disorders can overlap and accelerate signs of dementia (Engelberg, 2004; 
Cumming and Brodtmann, 2011). 
Over the years, accumulating evidence from epidemiological and 
clinical studies supports the concept that links vascular risk factors in the 
pathogenesis of AD in addition to stroke (Leszek et al., 2012). Based on the 
two-hit vascular hypothesis of AD, vascular risk factors (hit one) promote BBB 
dysfunction and decrease cerebral blood flow, and these induce a series of 
events (Aβ accumulation and tau pathology in hit two) that precedes dementia 
(Zlokovic, 2011). These vascular risk factors which are related to higher risk of 
AD include hypercholesterolemia, hypertension, diabetes and smoking (Meng 
et al., 2014). Associations of increased midlife cholesterol levels and BP with 
augmented AD risk have long been reported (Kivipelto et al., 2001). 
Furthermore, AD patients exhibit higher cholesterol levels than non-demented 
individuals (Kuo et al., 1998), whereas AD patients with hypertension have 
lower cerebral blood flow than normotensive patients (den Heijer et al., 2005). 
Although various evidences are supporting the role of vascular risk 
factors in AD, relatively little is known about the similarities in the alteration of 
gene expression between the brain and cerebral vessels. Hence, this portion of 
the study was conducted to compare the gene expression changes in the FC and 
MCA of rabbits after exposure to hypercholesterolemia and/or hypertension. 
The identification of common genes affected by these risk factors may provide 
a better understanding of the physiopathology of both AD and stroke.  
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2. Material and Methods 
 DNA microarray analyses 
The same eight rabbits used in Chapter III, Section 2:2.4 and Section 
3:2.4, were used in this portion of the study. The rabbits are divided into two 
groups: sham operated control on normal diet and ‘hypercholesterolemia plus 
sham’ (four rabbits per group). For each group, samples were derived from FC 
and MCA. The DNA microarray data for FC and MCA were obtained from 
previous studies (Chapter III, Section 2 and 3), imported into GeneSpring v11 
software (Agilent Technologies) for analysis using PCGEM. DEGs from the 
analysis of ‘hypercholesterolemia plus sham’ group vs. sham operated control 
group were compared between the FC and MCA, using unpaired T-test and 
Benjamini Hochberg FDR. P < 0.05 was considered significant. In this study, 
to reduce false positives, only DEGs with greater than 4-fold change and P < 
0.01 were presented and used in IPA network analysis. 
 
 Network analyses 
The list of DEGs with more than 4-fold change and P < 0.01 was 
uploaded to IPA software. The procedures were conducted as previously 
described (see Chapter III, Section 1:2.4). 
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Sixteen rabbits were used in this portion of the study and these rabbits 
were the same animals used in Chapter III, Section 2:2.4 and Section 3:2.4. They 
were divided into four groups: sham operated control on normal diet, 
‘hypercholesterolemia plus sham’, ‘hypercholesterolemia plus hypertension’, 
and ‘hypertension on normal diet’ (four rabbits per group). FC tissues were 
dehydrated in graded ethanol and set in paraffin. The paraffin-embedded tissues 
were sectioned at 5 µm, mounted on gelatin-coated slides, deparaffinized with 
xylene, and rehydrated through graded concentrations of ethanol. Sections were 
processed for immunoperoxidase staining. The procedures were conducted as 
previously described (see Chapter III, Section 2:2.9) using a mouse monoclonal 
antibody to Aβ (clone 4G8, SIG-39220; Signet/Covance, Dedham, MA, USA; 
diluted 1:500 in PBS) and a biotinylated anti-mouse secondary antibody. 
Immunohistochemically stained sections were mounted on gelatin-coated slides 
and viewed using a light microscope (IX70). Cells that were labeled for Aβ in 
layer III and V of the FC were counted on three sections per animal for all rabbit 
groups using ImageJ. The mean and standard deviation were calculated, and 
possible significant differences between the values of each rabbit group were 
analyzed using one-way ANOVA with Bonferroni’s multiple comparison post-
hoc test. P < 0.05 was considered significant. Tissue sections incubated with 
PBS only (without primary antibody) were used as a negative control. 
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 Microarray analyses of the ‘hypercholesterolemia plus sham’ group 
in the FC and MCA 
3.1.1. Microarray analyses of the ‘exclusive area’ in the FC 
The gene expression profile in the ‘exclusive area’ of FC was compared 
between the ‘hypercholesterolemia plus sham’ group vs. sham operated controls 
on a normal diet. After unknown and repeated genes were omitted, a total of 
516 DEGs that were exclusive to the FC was observed and it comprised of 411 
upregulated and 105 downregulated genes (greater than 4-fold change) (Figure 
3.41). Among the highly upregulated genes in the FC of the 
‘hypercholesterolemia plus sham’ group compared with sham operated control 
group were CIDEC, TFCP2L1 and ODF2 (Appendix 19). Among the highly 
downregulated genes in the FC were UGT2B13, ROPN1L and KIAA0513 
(Appendix 20).  
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Hypercholesterolemia plus Sham 
vs. Sham Controls
FC (450 DEGs)
411 39 41 Upregulated Genes
C
MCA (340 DEGs)
Hypercholesterolemia plus Sham 
vs. Sham Controls
FC (270 DEGs)
105 165 175 Downregulated Genes
 
Figure 3.41. Venn diagram of DEGs in the FC and MCA of the ‘hypercholesterolemia 
plus sham’ rabbits vs. sham operated control rabbits. (n = 4 in each group). A: total 
number of genes; B: upregulated genes; and C: downregulated genes. 
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3.1.2. Microarray analyses of the ‘exclusive area’ in the MCA 
The gene expression profile in the ‘exclusive area’ of MCA was 
compared between the ‘hypercholesterolemia plus sham’ group vs. sham 
operated controls on a normal diet. After unknown and repeated genes were 
omitted, a total of 216 DEGs that were exclusive to the FC was observed and it 
comprised of 41 upregulated and 175 downregulated genes (greater than 4-fold 
change) (Figure 3.41). Among the highly upregulated genes in the MCA of the 
‘hypercholesterolemia plus sham’ group compared with sham operated control 
group were FAM46C, SIPA1L3 and C11orf71 (Appendix 21). Among the 
highly downregulated genes in the MCA were FOXN1, UQCRFS1P1 and 
SLC9A2 (Appendix 22).  
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3.1.3. Microarray analyses of the ‘common area’ between the FC and 
MCA 
The gene expression profile in the ‘common area’ of FC and MCA was 
compared between the ‘hypercholesterolemia plus sham’ group vs. sham 
operated controls on a normal diet. After unknown and repeated genes were 
omitted, a total of 204 DEGs that were in common between the FC and MCA 
was observed and it comprised of 39 upregulated and 165 downregulated genes 
(greater than 4-fold change) (Figure 3.41). Among the highly upregulated 
common genes in FC and MCA of the ‘hypercholesterolemia plus sham’ group 
compared with sham operated control group were FCRL3, GnRHR and TAF15 
(Appendix 23). Among the highly downregulated common genes in FC and 
MCA were FAM184B, CUL3 and LOC100351029 (Appendix 24).  
The IPA network with the largest number of upregulated focus genes 
contained 15 focus genes with functions in Lipid Metabolism, Small Molecule 
Biochemistry, Vitamin and Mineral Metabolism. Focus genes in this network 
were AKNA, CACNG1, CORIN, EPHA1, GUCY2D, KIF13B, MLXIP, 
NAA25, PZP, RBM6, SLC9A8, SP110, TENM4, TMCO4, and TMPRSS11E 
(Figure 3.42). They were related to HNF4A, MAPK1, NPPA, and UBC. 
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Figure 3.42. IPA network showing the network with the largest number of upregulated 
focus genes in the ‘common area’ of the FC and MCA (‘hypercholesterolemia plus 
sham’ group vs. sham operated control group). 
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The network with the largest number of downregulated focus genes 
contained 22 focus genes with functions in Gene Expression, Cancer, and 
Cellular Development. Focus genes in this network were ASB10, ECT2, 
HIF1A, IFRD1, KDM4A, KLF1, MYBBP1A, NCKAP1, NUMB, PFDN5, 
PSMC6, PSMD4, RPN1, RUFY1, SAP30, SMARCA5, SMARCD3, SPRR3, 
SSB, SUCLG1, TXNIP, and VBP1 (Figure 3.43). They were related to 26s 
Proteasome, Ubiquitin, Akt, Hdac, and Hsp70. 
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Figure 3.43. IPA network showing the network with the largest number of 
downregulated focus genes in the ‘common area’ of the FC and MCA 
(‘hypercholesterolemia plus sham’ group vs. sham operated control group). 
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 Comparison of the DEGs from the hypercholesterolemia and/or 
hypertension groups in the FC and MCA 
The DEGs of the ‘hypercholesterolemia plus sham’, 
‘hypercholesterolemia plus hypertension’, and ‘hypertension only’ groups vs. 
sham operated control group, were compared between the FC and MCA for the 
determination of common genes (Tables 3.5-3.10). DEGs with at least 10-fold 
change from the FC and MCA were used for comparison. The cells highlighted 
in peach found in Tables 3.6, 3.7 and 3.8 represent common genes in FC and 
MCA. The results are tabulated in Table 3.11. In the ‘hypercholesterolemia plus 
sham’ group, there was no common gene detected among the upregulated DEGs 
(Tables 3.5 and 3.11) whereas 57% (47) of the 83 downregulated DEGs in the 
FC were shown to be common genes in MCA (Tables 3.6 and 3.11). In the FC 
of the ‘hypercholesterolemia plus hypertension’ group, about 2% (3) and 16% 
(4) of the 134 upregulated and 25 downregulated DEGs, respectively, were 
found in MCA (Tables 3.7, 3.8 and 3.11). In contrast, no common genes were 
detected among the DEGs in the ‘hypertension only’ group (Tables 3.9, 3.10 
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Table 3.11. Comparison of the DEGs between the FC and MCA of 
‘hypercholesterolemia plus sham’, ‘hypercholesterolemia plus hypertension’, and 
‘hypertension only’ rabbits (each group vs. sham operated control group). 
Rabbit Treatment 






Total No. of 
DEG in the FC 
(> 10-Fold 
Change) 
The DEG in the FC (> 10-Fold 
Change) that is in Common with 








Up 60 0 0 
Down 83 47 57 
HCHT 
Up 134 3 2 
Down 25 4 16 
HT 
Up 0 0 0 
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In the FC of the sham operated control group, immunostaining with Aβ 
antibody showed lightly stained neurons in layers III (Figure 3.44A) and V 
(Figure 3.44B). In contrast, dense Aβ immunostaining in neurons were observed 
in layers III and V of the ‘hypercholesterolemia plus sham’ (Figure 3.44C-D), 
‘hypercholesterolemia plus hypertension’ (Figure 3.44E-F), and ‘hypertension 
only’ (Figure 3.44G-H) groups. The number of neurons stained were 
significantly increased in layer III of the ‘hypercholesterolemia plus sham’ and 
‘hypercholesterolemia plus hypertension’ groups compared with sham operated 
control group (P = 0.0025 and P = 0.0028, respectively; Figure 3.45A). 
Moreover, the number of immunostained neurons were also significantly higher 
in layer V of the ‘hypercholesterolemia plus sham/hypertension’ groups 
compared with sham operated control (P = 0.0014 and P = 0.0002, respectively; 
Figure 3.45B) and ‘hypertension only’ groups (P = 0.0144 and P = 0.0018, 
respectively; Figure 3.45B). Negative control (tissue sections incubated with 
PBS only and without primary antibody) showed negative immunoreactivity 
(data not shown). 
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Figure 3.44. Immunohistochemical staining of Aβ in the FC of rabbit exposed to AD 
risk factors. Layer III (A, C, E, and G) and layer V (B, D, F, and H) of the FC were 
immunostained. Dense Aβ immunostaining in neurons (arrows) were observed in 
‘hypercholesterolemia plus sham’ (C-D), ‘hypercholesterolemia plus hypertension’ (E-
F), and ‘hypertension only’ rabbits (G-H). A-B: Sham operated control; C-D: 
‘Hypercholesterolemia plus sham’ group; E-F: ‘Hypercholesterolemia plus 
hypertension’ group; and G-H: ‘Hypertension only’ group. Scale: A-H = 50 µm. 
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Figure 3.45. Number of Aβ-immunostained neurons in the FC of rabbits exposed to 
AD risk factors. Aβ-immunostained neurons in layer III (A) and layer V (B) were 
calculated. Significant differences were analyzed by one-way ANOVA with 
Bonferroni’s multiple comparison post-hoc test. Each bar in the diagram indicates 
mean + standard error (n = 4 in each group). * indicates significant difference compared 
with control. ** P < 0.01 and *** P < 0.001. # indicates significant difference compared 
with HT. # P < 0.05 and ## P < 0.01. HC: ‘Hypercholesterolemia plus sham’ rabbits. 
HT: ‘Hypertension only’ rabbits. HCHT: ‘Hypercholesterolemia plus hypertension’ 
rabbits. 
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The previous study (from Section 2) has profiled the gene expression in 
the MCA of rabbits after hypercholesterolemia and/or hypertension (Ong et al., 
2013) and these rabbits were the same as those in the present study. A 
comparison of the DEGs in the ‘hypercholesterolemia plus sham’ group vs. 
sham operated controls on a normal diet between those in the FC and MCA 
were performed.  
Of the upregulated DEGs which were exclusive to the FC, CIDEC 
showed the largest fold change, followed by TFCP2L1, and ODF2. CIDEC and 
ODF2 have been mentioned in the ‘hypercholesterolemia plus 
sham/hypertension’ groups (see Chapter III, Section 3:3.2.1 and Section 3:3.2.2, 
respectively) and CIDEC was the gene with the highest fold change in the FC 
of both groups. TFCP2L1 (transcription factor CP2-like 1) has been recently 
described to be a transcriptional factor core of naïve pluripotency that controls 
the capability to produce, derive and propagate naïve pluripotent stem cells 
(Martello et al., 2013). Among the downregulated DEGs which were exclusive 
to the FC were UGT2B13, ROPN1L and KIAA0513. UGT2B13 (UDP-
glucuronosyltransferase 2B13) is one of the UDP-glucuronosyltransferases 
(UGTs) found in the rabbit liver. UGT is vital in the glucuronidation of both 
endogenous and exogenous compounds, facilitating their excretion process and 
cell detoxicification (Tukey et al., 1993; Nguyen and Tukey, 1997). ROPN1L 
(rhophilin associated tail protein 1-like) and rhophilin associated tail protein 1 
(ROPN1) are important for normal male fertility (Fiedler et al., 2013). 
KIAA0513, a highly expressed gene in the human brain, has been suggested as 
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a prospective candidate in schizophrenia and the protein may be associated with 
neuroplasticity, cytoskeletal regulation and apoptosis (Lauriat et al., 2006). The 
upregulated DEGs which were exclusive to the MCA were FAM46C, SIPA1L3 
and C11orf71. Among the downregulated DEGs which were exclusive to the 
MCA were FOXN1, UQCRFS1P1, and SLC9A2.  
Of the upregulated DEGs which were in common between the FC and 
MCA of the hypercholesterolemic (plus sham operated) rabbits, FCRL3 showed 
the largest fold change, followed by GnRHR and TAF15. FCRL3 (Fc receptor-
like 3) is mainly found in mature B cells in secondary lymphoid organs and it 
modulates the later stages of B cell maturation (Davis et al., 2001). 
Polymorphisms of this gene are associated with autoimmune diseases including 
Graves’ disease, rheumatoid arthritis and type-1 diabetes (Yang et al., 2013). 
GnRHR (gonadotropin-releasing hormone receptor) is a GPCR that interacts 
with gonadotropin-releasing hormone (GnRH) and regulates nervous system 
control of reproduction (Pazaitou-Panayiotou et al., 2013). The expression of 
GnRH and GnRHR is correlated to poor prognosis in human breast cancer 
(Pazaitou-Panayiotou et al., 2013). TAF15 (TAF15 RNA polymerase II, TATA 
box binding protein (TBP)-associated factor, 68kDa) encodes for RNA-binding 
protein that is associated with neurodegeneration (Mackenzie and Neumann, 
2012). Among the downregulated DEGs which were in common between the 
FC and MCA of the hypercholesterolemic rabbits were FAM184B, CUL3 and 
LOC100351029. FAM184B, CUL3 and LOC100351029 were the higher 
downregulated DEGs in the FC of the ‘hypercholesterolemia plus sham’ group 
and have been mentioned earlier (see Chapter III, Section 3.2.1). Since 
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endothelial cells are found in common between the brain tissue and vessel, it is 
possible that these genes: FCRL3, GnRHR, TAF15, FAM184B, CUL3 and 
LOC100351029 could be altered in endothelial cells. 
An interesting observation from the above analyses is that more than 
half of the downregulated DEGs in the FC were found in the MCA of the same 
hypercholesterolemic (plus sham operated) rabbits. These DEGs showed 
relatively high fold change (i.e. at least 10-fold change) in both regions. 
Similarly, common DEGs with more than 10-fold change were also observed in 
the upregulated and downregulated genes of the ‘hypercholesterolemia plus 
hypertension’ rabbits. In contrast, no common gene was found in the 
‘hypertension only’ rabbits. The observations suggest that downregulated genes 
in the brain parenchyma and vessels were severely implicated by 
hypercholesterolemia. This may also imply that hypercholesterolemia as a more 
important risk factor than hypertension in inducing gene expression changes in 
both of these tissues.  
The upregulated DEGs that were in common between FC and MCA 
after hypercholesterolemia (plus sham operation) were analyzed and the DEGs 
were related to ‘node molecules’ such as HNF4A, MAPK1, NPPA, and UBC. 
HNF4A has been described earlier in Chapter III, Section 2:4. MAPK1 
(mitogen-activated protein kinase 1) signaling cascades are stimulated by 
oxidative stress which may possibly lead to cell survival or death (Schroeter et 
al., 2002). MAPK1 is thought to play a role in hyperphosphorylation of tau and 
altered expression of MAPK1 is suggested to be an early event in the 
pathogenesis of AD following a region-specific manner (Gerschutz et al., 2014). 
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NPPA (natriuretic peptide A) encodes for the atrial natriuretic peptide (ANP) 
from the nautriuretic peptides family that consists of important cardio-renal 
hormones which regulate electrolytes, water balance homeostasis and BP 
(Volpe et al., 2014). ANP is a major contributor to endothelial cell function in 
the general population (Rubattu et al., 2008). The vascular health in both the 
endothelial and vascular smooth muscle cells are maintained by natriuretic 
peptides through the disruption of critical mechanisms of atherosclerosis which 
include proliferation, angiogenesis, apoptosis and inflammation (Rubattu et al., 
2008). Furthermore, alteration of natriuretic peptide levels by common genetic 
variants of NPPA could influence hypertension risk (Volpe et al., 2014). UBC 
encodes for a polyubiquitin precursor that mediates the polyubiquitination of 
proteins for degradation by proteasome (Manavalan et al., 2013). Recently, a 
proteomic study with IPA network analysis revealed strong interactions 
between UBC signaling and various AD-associated proteins in the 
hippocampus, parietal cortex and cerebellum of the post-mortem AD brains, 
implicating a pivotal role of ubiquitin in AD (Manavalan et al., 2013). 
Increasing evidence has implicated the deregulation of UPS in aging-related 
dementia (Oddo, 2008; Riederer et al., 2011) and proposed that declined UPS 
as one of the causative factors of AD (Manavalan et al., 2013). 
On the contrary, downregulated DEGs that were in common between 
FC and MCA after exposure to hypercholesterolemia (plus sham operation) 
were related to 26s Proteasome, Ubiquitin, Akt, Hdac, and Hsp70. These 
molecules are connected to AD in various ways. 26s proteasome and ubiquitin 
are part of the UPS in which the dysfunction in this system has been 
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demonstrated in AD (Keller et al., 2000). Decreased trypsin-like proteolytic 
activity of 26s proteasome has been reported in the cerebral cortex from post-
mortem human AD brains (Lopez Salon et al., 2000) and proteasome inhibition 
is regarded as one of the mediators that promotes Aβ neurotoxicity through the 
accumulation of cellular proteins (Hegde and Upadhya, 2011; Shim et al., 
2011). Akt (protein kinase B) regulates PI3K survival signaling for insulin-like 
growth factor I and other trophic factors (Russell et al., 1998). Glycogen 
synthase kinase-3β (GSK-3β), a target of Akt, is associated with 
phosphorylation of tau and interaction with APP, Aβ, and PSEN1 (Grimes and 
Jope, 2001; Bhat and Budd, 2002). Histone acetylation is aberrant in the 
pathology of AD and the potential use of HDAC inhibitors to improve cognitive 
impairment in AD patients has been extensively studied (Xu et al., 2011b). 
HDAC inhibitors could influence the activity of essential proteins in AD such 
as Aβ, GSK-3β and tau protein (Xu et al., 2011b). Hsp70 (heat shock protein 
70) belongs to the heat shock proteins (HSPs) which are important regulators of 
neurodegeneration associated with misfolding of proteins in various 
neurodegenerative diseases (Muchowski and Wacker, 2005; Lo Bianco et al., 
2008). Increased expression of HSPs including HSP70 has been observed in 
human AD brains (Perez et al., 1991; Muchowski and Wacker, 2005). Besides 
that, the potential therapeutic use of Hsp70 has also been demonstrated in mice 
models of AD where the overexpression or treatment of exogenous Hsp70 was 
able to mitigate the pathological and functional phenotypes of AD including Aβ 
plaque burden and cognitive functions (Hoshino et al., 2011; Bobkova et al., 
2014). Since endothelial cells are found in common between the brain tissue 
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and MCA, it is possible that altered ‘node molecules’ in both the upregulated 
and downregulated networks could be localized in endothelial cells. 
Alternatively, it is possible that the same factors such as cholesterol oxidation 
products that cause changes in vessels could also affect the brain parenchyma, 
beyond the endothelial layer. 
Remarkably, some of the ‘node molecules’ including 26s proteasome, 
Akt, ERK1/2, Histone h3, IL12, Insulin, Interferon alpha, and NF-κB which 
were affected by hypercholesterolemia and/or hypertension in both FC and 
MCA, are associated in complex feedback pathways involving APP and its 
proteolytic fragments (Hunter and Brayne, 2012). The involvement and 
perturbation of 26s proteasome as a part of the UPS in association with Aβ and 
AD has been discussed earlier. Akt phosphorylation is regulated by Aβ42 in a 
complex manner. Induction of Akt phosphorylation via alpha7 nicotinic and 
NMDA receptors occurs following acute exposure of Aβ42 whereas chronic 
exposure downregulates Akt phosphorylation, which is in line with the altered 
excitatory neurotransmission in APP transgenic mice (Abbott et al., 2008). 
ERK1/2 phosphorylation or activity is increased in AD brains (Russo et al., 
2002). Besides that, ERK1/2 is also activated by Aβ in vitro and is involved in 
the processing of APP and phosphorylation of Tau (Guise et al., 2001). It has 
been suggested that when the activation of intracellular signaling by APP and 
PSEN1 is dysfunctional in neurons especially the ERK1/2-induced activation 
of cell cycle-machinery, activation of neurodegeneration may take place 
(Nizzari et al., 2012). Altered histone acetylation homeostasis is often 
implicated in cognitive deficits observed in AD (Peleg et al., 2010; Graff et al., 
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2012). Histone h3 is particularly important for learning and memory (Levenson 
et al., 2004; Chwang et al., 2006; Day and Sweatt, 2011) and soluble Aβ may 
indirectly modulate gene transcriptional activity by regulating histone h3 
acetylation and methylation (Lithner et al., 2013). Recently, hyperacetylation of 
histone h3 by histone acetyltransferase p300 has also been reported in the 
promoter of AD-related genes such as PSEN1 and BACE1 in cellular models 
of AD, implicating a critical role of p300 in controlling the expression of these 
genes (Lu et al., 2014). IL12 is a cytokine synthesized by antigen-presenting 
cells such as monocytes or macrophages, in response to immune signal (Ma and 
Trinchieri, 2001). Treatment of Aβ in human microglia has led to an increase in 
IL12 mRNA levels along with cytokines and chemokines (Lee et al., 2002). 
Besides that, the suppression of IL12 and interleukin 23 (IL23) expressions and 
signaling was able to decrease Aβ plaque burden and reverse cognitive 
impairments in a mouse model of AD (Vom Berg et al., 2012). Elevated levels 
of insulin in the brain are involved in cognition, synaptic plasticity, and learning 
and memory (Zhao and Alkon, 2001). Insulin has been implicated in Aβ 
accumulation through the dysfunction of insulin/ insulin receptor, or the 
competition with Aβ for IDE that subsequently prevents Aβ degradation and 
promotes senile plaques formation (Sebastiao et al., 2014). Interferon alpha is a 
part of the type-1 interferons with important anti-viral and inflammatory roles 
(Taylor et al., 2014). Increased interferon alpha has been identified in the PFC 
from AD patients and the brains from AD mice (Taylor et al., 2014). 
Furthermore, in vitro ablation of interferon alpha receptor 1 expression could 
prevent Aβ-induced toxicity (Taylor et al., 2014). The NF-κB family consists 
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of transcription factors that is crucial in inflammation, immunity, cell 
proliferation, differentiation and survival (Oeckinghaus and Ghosh, 2009). It 
has been shown that NF-κB may decrease the expression of BACE1 (Rossner 
et al., 2006).  
Considering the close relationship between many of the above ‘node 
molecules’ with APP and its fragments, immunostaining for Aβ was carried out 
on brain tissue from rabbits exposed to hypercholesterolemia and/or 
hypertension. The presence of Aβ, the product of β-cleavage of APP, was 
determined in the FC from all rabbit groups by immunohistochemistry using a 
widely-used, classical monoclonal Aβ (4G8) antibody (Ramakrishnan et al., 
2009; Chen et al., 2010; Ly et al., 2011). Immunohistochemical analysis showed 
densely stained neurons in the FC with higher number of immunolabeled 
neurons in the hypercholesterolemic and/or hypertensive rabbits. The 
significant increase in the number of Aβ-immunostained neurons after exposure 
to hypercholesterolemia (plus sham/hypertension) as shown in the present study 
is consistent with a previous immunohistochemical observation that 
demonstrated increased intracellular Aβ accumulation in the brains of rabbits 
which were fed with high cholesterol diets (Sparks et al., 1994). 
The exact mechanism on how serum or plasma circulating cholesterol 
affects the brain cholesterol is not known. However, previous studies have 
shown that cholesterol-enriched diet could alter brain cholesterol homeostasis, 
increase brain cholesterol levels and enhance cellular cholesterol concentration 
in neurons (Ghribi et al., 2006a; Sparks, 2008). Although the BBB is not 
permeable to the transport of serum cholesterol into the brain under normal 
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conditions, studies have shown disruption of BBB integrity in the cholesterol-
fed rabbits (Sparks et al., 2000; Chen et al., 2008a). Additionally, several 
findings have demonstrated small amounts of cholesterol from the plasma that 
may enter the CNS. Transgenic mice with hypercholesterolemia showed 
increased plasma, CNS and brain total cholesterol levels (Howland et al., 1998; 
Refolo et al., 2000). Besides that, serum cholesterol may affect the brain through 
its conversion to oxysterols such as 27-HC. 27-HC is predominantly originated 
from the periphery (Farooqui, 2011) and has the ability to transport in and out 
of the brain through the BBB (Heverin et al., 2005). Marked increased levels of 
27-HC has been shown in various brain regions of AD patients (Heverin et al., 
2004; Shafaati et al., 2011). It has been suggested that hypercholesterolemia 
induced by cholesterol-enriched diets, may enhance the conversion of 
cholesterol to 27-HC, leading to their increased levels in the circulation and 
possible in the brain (Ghribi, 2008). Thus, dysregulation of oxysterol levels may 
represent a potential link between high circulating cholesterol levels and AD 
pathology in the brain (Ghribi, 2008). 
It is known that hypercholesterolemia and hypertension are risk factors 
for the pathogenesis of AD and stroke. However, higher number of common 
DEGs, particularly the downregulated genes, were reported in both the brain 
and cerebral vessels after exposure to hypercholesterolemia, implying an 
important role of cholesterol in governing gene expression changes in both 
tissues. The novel findings of the comparison between gene expression in the 
FC and brain vessels in the present study may shed new light on the 
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identification of potential susceptibility genes in humans with these risk factors 
that may lead to the development of AD and stroke. 
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AD is characterized by the presence of extracellular senile plaques with 
Aβ aggregates, and intracellular NFTs with hyperphosphorylated tau, that lead 
to widespread neurodegeneration (Selkoe, 2001; Hardy and Selkoe, 2002). The 
generation of Aβ from APP is the key event in pathogenesis of AD (Masters et 
al., 1985), and Aβ deposition can occur as parenchymal amyloid plaques and 
cerebral vascular deposits called CAA (Xu et al., 2014). Intraneuronal 
accumulation of Aβ is an important event that precedes Aβ plaque deposition 
and NFTs formation (D'Andrea et al., 2001; Wirths et al., 2002). Furthermore, 
Aβ accumulation has been implicated in cell death (Tomiyama et al., 2010), 
synaptic dysfunction (Oddo et al., 2003), and cognitive deficits (Billings et al., 
2005).  
Over the recent years, an intriguing relationship between cholesterol, 
APP, Aβ, and AD has been documented in various epidemiological and 
biochemical studies (Marx, 2001; Wolozin, 2001). High cholesterol levels favor 
Aβ production through modification of the activities of secretases (Ehehalt et 
al., 2003; Grimm et al., 2008) and the use of cholesterol-lowering drugs is 
associated with decreased prevalence or risk for AD in some studies (Hoglund 
and Blennow, 2007; Sparks et al., 2008; Haag et al., 2009). Despite the link 
between cholesterol in AD, relatively little is known about possible mechanism 
by which cholesterol affects APP expression.  
As mentioned earlier, high cholesterol level is known to inhibit SREBP 
maturation. In cells with low cholesterol, SREBP forms a complex with SCAP 
and is transported from the ER to the Golgi for sequential proteolytic cleavage 
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by S1P and S2P. This releases mSREBP from the membrane into the nucleus 
for the transcription of genes which are important for the maintenance of sterol 
levels (Brown and Goldstein, 1999; Osborne and Espenshade, 2009). In 
contrast, excess ER cholesterol inhibits the translocation of SREBP-SCAP 
complex through the interaction involving cholesterol, oxysterols, SCAP, and 
INSIG (Osborne and Espenshade, 2009).  
Based on the previous studies on the NZW rabbit models, global gene 
expression changes were observed in both FC and cerebral vessels after 
exposure to hypercholesterolemia and/or hypertension (Ong et al., 2013). An 
interesting finding of several genes related to the ‘node molecule’, APP, in IPA 
networks was noted. Among the genes that are closely related to APP were 
SERPINB2, N(alpha)-acetyltransferase 25, NatB auxiliary subunit (NAA25), 
family with sequence similarity 19 (chemokine (C-C motif)-like), member A4 
(FAM19A4) and proline/serine-rich coiled-coil 1 (PSRC1) (Ong et al., 2013).  
In view of the influence of cholesterol on SREBP pathway, this portion 
of the study was carried out to determine whether any of the above genes could 
be regulated by SREBP signaling, which may be affected during 
hypercholesterolemia (Shimomura et al., 1997; Korn et al., 1998; Mosig et al., 
2008). Cultured human endothelial EA.hy926 cells and human neuroblastoma 
SH-SY5Y cells were used to model changes in brain endothelial cells and 
neurons, respectively, to determine the effect of SREBP inhibition on APP-
related genes identified by microarray. It is hoped that results of this study could 
shed light on a possible link between serum cholesterol and AD. 
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2. Material and Methods 
 Treatment with SREBP inhibitors 
Human endothelial cell line EA.hy926 and human neuroblastoma cell 
line SH-SY5Y (America Type Culture Collection, Manassas, VA, USA). 
EA.hy926 and SH-SY5Y cells were cultured in Dulbecco’s modified Eagle’s 
medium supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin (Gibco-Invitrogen, Carlsbad, CA, USA). Cells were 
plated in 100 mm2 petri dishes and maintained in an incubator at 37oC, 100% 
humidity with 95% air and 5% CO2. They were treated with vehicle (dimethyl 
sulfoxide (DMSO)), betulin, fatostatin, PF429242, and 1,10-phenanthroline at 
10 µM and in a dose-dependent manner for 1,10-phenanthroline. Six biological 
replicates were used for each treatment group. All chemicals were purchased 
from Sigma except PF429242 and 1,10-phenanthroline, which were purchased 
from Tocris Bioscience (Ellisville, MO, USA). Stock solutions were prepared 
in DMSO and were further diluted in cell culture medium. Cells were harvested 
24 h after treatment, and analyzed by real-time RT-PCR and 
immunofluorescence (see below). The dose 10 µM is the dose that causes 
complete inhibition of SREBP activation by PF-429242 (Hay et al., 2007; 
Hawkins et al., 2008). It was selected because 10 µM is the smallest effective 
dose that could be used by other SREBP inhibitors for standardization purposes. 
 
 Real-time RT-PCR 
Total RNA was extracted from each sample with the RNeasy® Mini Kit, 
reverse-transcribed with the High-Capacity cDNA Reverse Transcription Kit, 
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and subjected to real-time RT-PCR using a 7500 Real-Time PCR system with 
TaqMan® Universal PCR Master Mix and human TaqMan® probes for 
SERPINB2, APP, and β-actin (Applied Biosystems). All procedures were 
conducted as previously described (see Chapter III, Section 1:2.5). Six 
biological replicates were used for each treatment group. The comparative CT 
method was used to quantify the amplified transcripts with the formula for 
relative fold change = 2-DDCT (Livak and Schmittgen, 2001). The mean and 
standard error were calculated. Possible significant differences between the 
values of each treatment group were analyzed, using one-way ANOVA with 




Cells were subcultured with 0.5 x 105 cells on coverslips that had been 
coated with fibronectin (Sigma) for EA.hy926 cells and poly-L-lysine solution 
(Sigma) for SH-SY5Y cells in a 24-well plate. Cells were treated with vehicle 
or 10 μM 1,10-phenanthroline for 24 h prior to immunofluorescence staining. 
Cells were washed twice with PBS and fixed in 2% paraformaldehyde in 0.1M 
PB for 20 min at room temperature, rinsed with PBS, treated with 70% formic 
acid for 30 min, permeabilized with 0.1% Triton-X in PBS for 15 min, and 
blocked with 1% BSA in PBS (blocking buffer) for 1 h. Cells were then 
incubated overnight with primary antibodies for SERPINB2 (ab47742; Abcam; 
diluted 1:250 in blocking buffer) or Aβ (diluted 1:50 in blocking buffer) at 4°C. 
This was followed by rinsing with PBS and 1 h incubation with secondary 
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antibodies (Alexa Fluor; Molecular Probes, Eugene, OR, USA; diluted 1:200 in 
blocking buffer) at room temperature. After washing with PBS, coverslips were 
mounted on glass slides using ProLong® Gold Antifade Mountant with DAPI 
(Molecular Probes) and viewed using an inverted confocal laser scanning 
microscope (LSM 510 META; Zeiss, Oberkochen, Germany) with a 405 nm 
argon laser and a 543 nm helium-neon laser. Confocal microscopy images were 
taken from four biological samples for each treatment group and three images 
were taken from each biological sample. Cell fluorescence was measured using 
ImageJ and corrected total cell fluorescence (CTCF) was calculated with the 
formula: integrated density – (area of selected cell X mean fluorescence of 
background readings). The mean and standard error were calculated, and 
possible differences between the values of 1,10-phenanthroline and vehicle 
treatment groups were analyzed using Student’s t-test. P < 0.05 was considered 
significant. 
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 Human endothelial EA.hy926 cells  
3.1.1. Real-time RT-PCR analysis of APP expression after treatment with 
SREBP inhibitors  
Treatment with various SREBP inhibitors at 10 μM for 24 h showed that 
APP mRNA expression levels were not significantly altered by betulin or 
fatostatin (Figure 3.46). In contrast, APP mRNA expression was significantly 
upregulated by PF429242 and 1,10-phenanthroline treatments to 1.45- and 1.80-
fold compared with vehicle group, respectively (P < 0.001 for both). Expression 
levels of APP after treatment with PF429242 or 1,10-phenanthroline were 
markedly elevated compared with betulin and fatostatin (P < 0.001 for all). 
Additionally, significant higher expression of APP mRNA was observed after 
1,10-phenanthroline treatment compared with PF429242 (P < 0.05). 
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Figure 3.46. Real-time RT-PCR analysis of APP mRNA expression levels in human 
endothelial EA.hy926 cells after treatment with various SREBP inhibitors at 10 µM for 
24 h.  The values were normalized to the value of vehicle group as control. Analyzed 
by one-way ANOVA with Bonferroni’s multiple comparison post-hoc test. Data 
represent the mean and standard error (n = 6 per group). * indicates significant 
difference compared with vehicle treatment. *** P < 0.001. # indicates significant 
difference compared with 10 µM betulin treatment. ### P < 0.001. ^  indicates significant 
difference compared with 10 µM fatostatin treatment. ^^^ P < 0.001. @ indicates 
significant difference compared with 10 µM PF429242 treatment. @ P < 0.05. 
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Treatment with 1,10-phenanthroline in a dose-dependent manner for 24 
h showed that the doses at 5 μM and 10 μM upregulated APP mRNA expression 
levels to 1.53- and 1.34-fold that of vehicle group, respectively (P < 0.001 and 
P = 0.002, respectively; Figure 3.47). Upregulation induced by both of these 
treatments were significant compared with 20 μM 1,10-phenanthroline 
treatment group (P < 0.001 and P = 0.002, respectively). However, treatment 
with 20 μM 1,10-phenanthroline did not significantly alter the APP mRNA 
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Figure 3.47. Real-time RT-PCR analysis of APP mRNA expression levels in human 
endothelial EA.hy926 cells after treatment with 1,10-phenanthroline in a dose-
dependent manner for 24 h.  The values were normalized to the value of vehicle group 
as control. Analyzed by one-way ANOVA with Bonferroni’s multiple comparison 
post-hoc test. Data represent the mean and standard error (n = 6 per group). * indicates 
significant difference compared with vehicle treatment. ** P < 0.01 and *** P < 0.001. 
# indicates significant difference compared with 5 µM 1,10-phenanthroline treatment. 
### P < 0.001. ^ indicates significant difference compared with the 10 µM 1,10-
phenanthroline treatment. ^^ P < 0.01.   
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3.1.2. Real-time RT-PCRT analysis of SERPINB2 expression after 
treatment with SREBP inhibitors  
All treatments with SREBP inhibitor at 10 μM for 24 h, except fatostatin, 
significantly increased mRNA expression levels of SERPINB2 compared with 
the vehicle group (Figure 3.48). Treatment with 10 μM betulin and PF429242 
increased SERPINB2 expression to 2.68- and 2.58-fold compared with vehicle 
group, respectively (P < 0.001 for both). The highest fold change of SERPINB2 
mRNA expression levels at 11.53-fold (P < 0.001) was induced by 1,10-
phenanthroline treatment. In contrast, fatostatin treatment caused a 
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Figure 3.48. Real-time RT-PCR analysis of SERPINB2 mRNA expression levels in 
human endothelial EA.hy926 cells after treatment with various SREBP inhibitors at 10 
µM for 24 h.  The values were normalized to the value of vehicle group as control. 
Analyzed by one-way ANOVA with Bonferroni’s multiple comparison post-hoc test. 
Data represent the mean and standard error (n = 6 per group). * indicates significant 
difference compared with vehicle treatment. *** P < 0.001. # indicates significant 
difference compared with 10 µM betulin treatment. ### P < 0.001. ^  indicates significant 
difference compared with 10 µM fatostatin treatment. ^^^ P < 0.001. @ indicates 
significant difference compared with 10 µM PF429242 treatment. @@@ P < 0.001. 
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The mRNA expression of SERPINB2 was significantly increased in a 
dose-dependent manner after treatment with various doses of 1,10-
phenanthroline for 24 h compared with vehicle group (P < 0.001 for all groups; 
Figure 3.49). Significant increase to 3.21-fold that of vehicle treatment was 
observed after treatment with 1,10-phenanthroline at a dose as low as 5 μM (P 
< 0.001). Treatment with 10 μM 1,10-phenanthroline treatment caused a 
significant increase to 5.36-fold that of vehicle treatment (P < 0.001) and it is 
also significantly increased compared with 5 μM 1,10-phenanthroline treatment 
group. The highest fold-change up to 6.08-fold was observed after 20 μM 1,10-
phenanthroline treatment (P < 0.001) and it also showed significant difference 
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Figure 3.49. Real-time RT-PCR analysis of SERPINB2 mRNA expression levels in 
human endothelial EA.hy926 cells after treatment with 1,10-phenanthroline in a dose-
dependent manner for 24 h. The values were normalized to the value of vehicle group 
as control. Analyzed by one-way ANOVA with Bonferroni’s multiple comparison 
post-hoc test. Data represent the mean and standard error (n = 6 per group). * indicates 
significant difference compared with vehicle treatment. *** P < 0.001. # indicates 
significant difference compared with 5 µM 1,10-phenanthroline treatment. ### P < 
0.001. 
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3.1.3. Immunofluorescence analysis of Aβ after treatment with 10 μM 
1,10-phenanthroline 
Aβ immunofluorescence staining was mainly observed in the cytoplasm 
with lighter staining in the nucleus of the human endothelial EA.hy926 cells 
after a 24 h treatment with vehicle (Figure 3.50A) or 10 μM 1,10-phenanthroline 
(Figure 3.50B). Increased cytoplasmic staining along with significant elevated 
average CTCF value to 1.47-fold that of vehicle group was observed after 1,10-
phenanthroline treatment (P = 0.037; Figure 3.50B-C). The actual size of these 
cells in both groups were similar when viewed under microscope. However, in 
Figures 3.50A-B, cells in 1,10-phenanthroline group might look larger than 
those in vehicle group because the Aβ immunofluorescence staining in the latter 
was very weak. As a result, the weak signal was not well captured by the 
confocal microscope and this made the cells in vehicle group appeared smaller 
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Figure 3.50. Immunofluorescence labeling of Aβ in human endothelial EA.hy926 cells 
after treatment with vehicle or 10 µM 1,10-phenanthroline for 24 h. Vehicle (A) and 
10 µM 1,10-phenanthroline (B) treatments in cells were labeled with DAPI (blue) and 
Aβ antibody (green). Increased immunofluorescence staining especially in the 
cytoplasm (arrows), was observed in cells after 1,10-phenanthroline treatment. Scale 
bar = 50 μm. (C) Fluorescence intensity of Aβ in EA.hy926 cells after treatment with 
10 µM 1,10-phenanthroline. Data represent the mean and standard error of (n = 4 per 
group). * indicates significant difference compared with vehicle treatment, by 
Student’s t-test. * P < 0.05. 
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3.1.4. Immunofluorescence analysis of SERPINB2 after treatment with 10 
μM 1,10-phenanthroline 
SERPINB2 immunofluorescence staining was observed in both 
cytoplasm and nucleus of the human endothelial EA.hy926 cells after a 24 h 
treatment with vehicle (Figure 3.51A) or 10 μM 1,10-phenanthroline (Figure 
3.51B). Denser nuclear staining was observed in the both groups. Treatment 
with 1,10-phenanthroline upregulated the immunofluorescence staining of 
SERPINB2, particularly in the nucleus (Figure 3.51B), with a significant 
elevation in the average CTCF value to 2.43-fold compared with vehicle group 
(P = 0.019; Figure 3.51C). 
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Figure 3.51. Immunofluorescence labeling of SERPINB2 in human endothelial 
EA.hy926 cells after treatment with vehicle or 10 µM 1,10-phenanthroline for 24 h.  
Vehicle (A) and 10 µM 1,10-phenanthroline (B) treatments in cells were labeled with 
DAPI (blue) and SERPINB2 antibody (green). Increased immunofluorescence staining 
especially in the nucleus (arrows), was observed in cells after 1,10-phenanthroline 
treatment. Scale bar = 50 μm. (C) Fluorescence intensity of SERPINB2 in EA.hy926 
cells after treatment with 10 µM 1,10-phenanthroline. Data represent the mean and 
standard error (n = 4 per group).* indicates significant difference compared with 
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 Human neuroblastoma SH-SY5Y cells  
3.2.1. Real-time RT-PCR analysis of APP expression after treatment with 
SREBP inhibitors  
Treatments with various SREBP inhibitors at 10 μM for 24 h showed 
that APP mRNA expression levels were not significantly upregulated compared 
with vehicle group (Figure 3.52). However, mRNA levels of APP after 
treatments with 10 μM fatostatin and 1,10-phenanthroline were shown to be 
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Figure 3.52. Real-time RT-PCR analysis of APP mRNA expression levels in human 
neuroblastoma SH-SY5Y cells after treatment with various SREBP inhibitors at 10 µM 
for 24 h. The values were normalized to the value of vehicle group as control. Analyzed 
by one-way ANOVA with Bonferroni’s multiple comparison post-hoc test. Data 
represent the mean and standard error of (n = 6 per group). * indicates significant 
difference compared with 10 µM PF429242 treatment. * P < 0.05 and ** P < 0.01. 
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3.2.2. Real-time RT-PCR analysis of SERPINB2 expression after 
treatment with SREBP inhibitors  
Treatment with various SREBP inhibitors at 10 μM for 24 h showed that 
SERPINB2 mRNA expression levels were only significantly upregulated by 10 
μM 1,10-phenanthroline to 36.26-fold (P < 0.001; Figure 3.53) that of vehicle 
group. Significant increased mRNA levels was observed after 1,10-
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Figure 3.53. Real-time RT-PCR analysis of SERPINB2 mRNA expression levels in 
human neuroblastoma SH-SY5Y cells after treatment with various SREBP inhibitors 
at 10 µM for 24 h. The values were normalized to the value of vehicle group as control. 
Analyzed by one-way ANOVA with Bonferroni’s multiple comparison post-hoc test. 
Data represent the mean and standard error of (n = 6 per group). * indicates significant 
difference compared with vehicle treatment. *** P < 0.001. # indicates significant 
difference compared with 10 µM betulin treatment. ### P < 0.001. 
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3.2.3. Immunofluorescence analysis of Aβ after treatment with 10 μM 
1,10-phenanthroline 
Similar to EA.hy926 cells, immunofluorescence staining of Aβ was 
mainly observed in the cytoplasm with lighter staining in the nucleus of the 
human neuroblastoma SH-SY5Y cells after a 24 h treatment with vehicle 
(Figure 3.54A) or 10 μM 1,10-phenanthroline (Figure 3.54B). The staining in 
the cytoplasm was enhanced in the 1,10-phenanthroline treatment group (Figure 
3.54B). A significant increase in the average CTCF value to 2.42 fold- that of 
vehicle group was observed after treatment with 1,10-phenanthroline (P = 
0.008, Figure 3.54C). 
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Figure 3.54. Immunofluorescence labeling of Aβ in human neuroblastoma SH-SY5Y 
cells after treatment with vehicle or 10 µM 1,10-phenanthroline for 24 h. Vehicle (A) 
and 10 µM 1,10-phenanthroline (B) treatments in cells were labeled with DAPI (blue) 
and Aβ antibody (green). Increased immunofluorescence staining especially in the 
cytoplasm (arrows), was observed in cells after 1,10-phenanthroline treatment. Scale 
bar = 50 μm. (C) Fluorescence intensity of Aβ in SH-SY5Y cells after treatment with 
10 µM 1,10-phenanthroline. Data represent the mean and standard error (n = 4 per 
group).* indicates significant difference compared with vehicle treatment, by Student’s 
t-test. ** P < 0.01. 
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3.2.4. Immunofluorescence analysis of SERPINB2 after treatment with 10 
μM 1,10-phenanthroline 
Similar to EA.hy926 cells, SERPINB2 immunofluorescence staining 
was observed in both cytoplasm and nucleus of the human neuroblastoma SY-
SY5Y cells after a 24 h treatment with vehicle (Figure 3.55A) or 10 μM 1,10-
phenanthroline (Figure 3.55B). Denser staining was also observed in the 
nucleus in both groups. Enhanced SERPINB2 immunofluorescence staining 
especially in the nucleus, was demonstrated in the 1,10-phenanthroline 
treatment group (Figure 3.55B). This was consistent with the significant 
upregulation in the average CTCF value to 2.56-fold that of vehicle group (P = 
0.004; Figure 3.55C). 
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Figure 3.55. Immunofluorescence labeling of SERPINB2 in human neuroblastoma SH-
SY5Y cells after treatment with vehicle or 10 µM 1,10-phenanthroline for 24 h.  
Vehicle (A) and 10 µM 1,10-phenanthroline (B) treatments in cells were labeled with 
DAPI (blue) and SERPINB2 antibody (green). Increased immunofluorescence staining 
especially in the nucleus (arrows), was observed in cells after 1,10-phenanthroline 
treatment. Scale bar = 50 μm. (C) Fluorescence intensity of SERPINB2 in SH-SY5Y 
cells after treatment with 10 µM 1,10-phenanthroline. Data represent the mean and 
standard error (n = 4 per group).* indicates significant difference compared with 
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The previous microarray studies on FC and cerebral vessels in rabbits 
exposed to hypercholesterolemia and/or hypertension revealed various DEGs 
including APP-related genes such as SERPINB2, NAA25, FAM19A4 and 
PSRC1 (Ong et al., 2013). The present study elucidated the possible regulatory 
role of SREBP in expression of APP and related genes in cultured human 
endothelial EA.hy926 cells and human neuroblastoma SH-SY5Y cells. In 
endothelial cells, betulin or fatostatin treatment that inhibits SREBP 
translocation from ER to Golgi, did not affect APP gene expression. In contrast, 
PF429242 (S1P inhibitor) or 1,10-phenanthroline (S2P inhibitor) treatment, 
significantly increased APP gene expression. The SERPINB2 mRNA levels 
were upregulated by all SREBP inhibitors (except fatostatin), with the highest 
upregulation exceeding 10-fold change by 1,10-phenanthroline. Dose-
dependent treatment with 1,10-phenanthroline in endothelial cells increased 
mRNA expression of APP and SERPINB2. Unlike endothelial cells, 
neuroblastoma cells APP mRNA levels remained relatively unchanged after 
SREBP inhibition. Interestingly, SERPINB2 mRNA level was only upregulated 
by 1,10-phenanthroline treatment in neuroblastoma cells. 
Although SREBP maturation was inhibited at various stages, the 
expression of these genes varied with different inhibitor treatments. Expression 
of the above genes were more affected by the later steps in the SREBP activation 
pathway, i.e. 1,10-phenanthroline that acts on a later stage was more effective 
than betulin and fatostatin that work at an earlier stage in the abovementioned 
pathway. The reason is unknown, but possibly due to compensatory or residual 
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activity even after inhibition of the earlier steps in the pathway. Alternatively, 
SREBP may be regulated independently from the classical ER-to-Golgi 
transport manner by controlling the localization of both S1P and S2P (Walker 
et al., 2011). Upon depletion of phosphatidylcholine, S1P and S2P can be 
translocated from Golgi to ER, stimulating proteolytic activation of SREBP-1 
(Walker et al., 2011). Thus, this proposes that inhibition of S1P- and S2P-
mediated proteolytic cleavage is more critical in suppressing SREBP 
maturation. This two-step cleavage can be blocked by sterols through 
suppression of these proteases (Brown and Goldstein, 1999).  
Based on present results, APP gene expression may be influenced by 
SREBP through S1P and S2P activities in endothelial cells but not in 
neuroblastoma cells, suggesting APP gene expression regulation by SREBP in 
a cell-specific manner. Consistent with significant elevated SERPINB2 mRNA 
levels induced by hypercholesterolemia and/or hypertension in both cerebral 
vessels and FC shown in previous studies (Ong et al., 2013), increased 
SERPINB2 expression following SREBP inhibition was also observed in 
endothelial and neuroblastoma cells. Moreover, consistent elevation of 
SERPINB2 mRNA levels induced by S2P inhibition in both cell types shows 
the potential of S2P in mediating this gene expression. Similarly, a study has 
shown the combined ablation of SREBP1 and SREBP2 by siRNA-mediated 
gene silencing, upregulated SERPINE1 (serpin peptidase inhibitor, clade E 
(nexin, PAI-1), member 1; another member of serpin) gene expression (Griffiths 
et al., 2013). These findings may propose that S2P inhibition influences the gene 
expression of APP and SERPINB2. 
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Considering S2P may be important in regulating the expression of APP 
and SERPINB2, expression of APP/Aβ and SERPINB2 were further 
investigated by immunofluorescence. Immunofluorescence staining using a 
widely-used, classical monoclonal Aβ (4G8) (Ramakrishnan et al., 2009; Chen 
et al., 2010; Ly et al., 2011) showed Aβ staining primarily in cytoplasm and 
expression was significantly increased after S2P inhibition in both cell types. 
Despite the lack of increase in APP mRNA levels in neuroblastoma cells, 
enhanced Aβ immunofluorescence staining may suggest a more prominent 
effect of 1,10-phenanthroline on Aβ generation. Furthermore, SERPINB2 
immunofluorescence staining using a reliable antibody (Peng et al., 2012; 
Suarez et al., 2014) demonstrated SERPINB2 expression in cytoplasm and 
nucleus in both cell types which concurs with another previous observation 
(Boncela et al., 2013). Moreover, this expression was markedly elevated, 
particularly in nucleus after S2P inhibition.  
Various studies highlighted association between Aβ and SREBP. 
Observations regarding high cholesterol level induces Aβ production (Shie et 
al., 2002; Sparks, 2008) and Aβ reduces SREBP activation (Pierrot et al., 2013) 
have been reported. Downregulation of mSREBP by Aβ through disruption of 
SREBP proteolytic mechanism is observed in SH-SY5Y cells (Kelicen et al., 
2009). In addition, an inverse correlation of APP and SREBP expressions has 
been demonstrated in neurons, and in brain samples of transgenic AD mice and 
AD patients (Pierrot et al., 2013). APP-SREBP interaction in Golgi has been 
shown to inhibit the S2P-mediated SREBP processing, thus preventing 
mSREBP nuclear translocation without affecting the activating transcription 
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factor 6 (ATF6) (another substrate of S2P) (Pierrot et al., 2013). Interestingly, 
in this study, we found that SREBP inhibition can in turn, increase APP and/or 
Aβ levels, thus potentially completing a ‘feedback loop’ (Figure 3.56). This 
SREBP inhibition may be caused not only by high Aβ levels, but also 
potentially, high serum cholesterol levels, and could be a mechanistic 
explanation for the increased Aβ reported in AD patients’ brains (Kivipelto et 
al., 2001) and animal models of hypercholesterolemia (Refolo et al., 2000; Shie 
et al., 2002; Umeda et al., 2012). 
SERPINB2 (PAI-2) is a member of the ovalbumin-serpin subfamily 
(SERPIN clade B) (Ye et al., 1989). It is expressed in various cell types: 
monocytes, macrophages (Ritchie et al., 1997), eosinophils (Swartz et al., 
2004), microglia (Akiyama et al., 1993), keratinocytes (Robinson et al., 1997), 
endothelial and epithelial cells (Kruithof et al., 1987). SERPINB2 is an inhibitor 
of uPA (Kawano et al., 1970) and tPA (Thorsen et al., 1988). It is highly 
upregulated in pregnancy, inflammation, infection and other pathophysiological 
conditions. Additionally, SERPINB2 secretion by endothelial cells is 
discovered to occur via an ER-Golgi-dependent mechanism (Boncela et al., 
2013).  
In AD, the observation of increased immunoreactivity to SERPINB2 in 
microglia has proposed a possible involvement of SERPINB2 in the regulation 
of plasminogen activator/plasmin system in lesions of AD brain (Akiyama et 
al., 1993). Due to significantly low plasmin levels detected in AD brains 
(Ledesma et al., 2000), decreased plasmin activity may contribute to AD 
pathogenesis (Eckman and Eckman, 2005; Wang et al., 2006). Plasmin is 
Chapter III, Section 5 - Gene Expression Regulation By Sterol Regulatory 
Element Binding Protein 
 
241 
activated from plasminogen by tPA and uPA. These activators are regulated by 
inhibitors including SERPINE1 (PAI-1) and neuroserpin (Barker et al., 2012). 
Apart from being an Aβ-catabolizing protease, plasmin increases APP α-
cleavage, implying a preventive role of brain plasmin in APP amyloidogenesis 
(Ledesma et al., 2000). However, tPA/plasmin cascade may be suppressed in 
AD (Dotti et al., 2004) and SERPINE1 is elevated in AD patients’ brains. 
Remarkably, SERPINE1 inhibition increases tPA and plasmin activity in vitro, 
reduces plasma and brain Aβ in vivo, and reverses long-term potentiation and 
cognitive impairments in transgenic AD mice (Jacobsen et al., 2008). Hence, 
we hypothesize that increased SERPINB2 may inhibit tPA, leading to decreased 
plasmin, reduced Aβ clearance, and enhanced Aβ accumulation. Further work 
is necessary to elucidate the cellular mechanism underlying SREBP inhibition 
in SERPINB2 expression.  
In conclusion, present study to report the role of SREBP in the regulation 
of APP/Aβ and SERPINB2 expression is unprecedented. These novel findings 
may provide a possible feedback mechanism that links cholesterol, SREBP, 
APP, Aβ and other APP-related genes (Figure 3.56). Although the role of 
SERPINB2 in Aβ clearance is not fully understood, the findings of present study 
may unravel possible SREBP regulatory function on SERPINB2 and 
potentially, on other serpin family members linked to AD.  
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Figure 3.56. The association between cholesterol, SREBP, APP, Aβ and APP-related 
genes. Solid line denotes relationship documented in literature whereas dotted line 
denotes association postulated by present study. Present findings propose that SREBP 
inhibition can in turn, increase APP and/or Aβ levels, thus potentially completing a 
‘feedback loop’. SREBP signaling may mediate the expression of SERPINB2 and 
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Cholesterol is a vital component of the cell membrane and crucial for 
CNS function. As the brain cholesterol metabolism is tightly regulated, any 
metabolic changes may perturb normal brain physiological functions. Aberrant 
levels of cholesterol and its derivatives such as oxysterols, have been implicated 
in neurological pathologies such as AD and stroke. However, little is known 
regarding the potential regulatory roles of cholesterol and oxysterols in gene 
expression when they exist in excessive levels in such pathologies. Using 
microarray-based approaches, this study was aimed to elucidate the effects of 
cholesterol or oxysterols on gene expression changes in the brain and cerebral 
vessels, which may contribute to the CNS disorders mentioned above.  
Intracranial injection of low concentration of cholesterol and oxysterols 
(i.e. 7β-HC and 7-KC) in the PFC was performed to elucidate their effects on 
gene expression changes. The injected concentration corresponded to the excess 
oxysterols levels that were observed previously in a rat model of KA-induced 
excitotoxicity. Microarray analysis demonstrated that both 7β-HC and 7-KC 
exert more potent effects on gene expression changes at 1-day post-injection 
compared with their parent compound, cholesterol. Many DEGs with high fold 
change were found in common after 7β-HC or 7-KC treatment and among these, 
downregulated genes outnumbered the upregulated genes. IPA analysis 
revealed that downregulated genes had a significant role in carbohydrate 
metabolism, cell signaling, and nucleic acid metabolism, and the majority of 
these genes were GPCRs. Altered expression of selected genes from this 
pathway was validated by quantitative real-time PCR. Western blot data 
confirmed downregulation of OXTR after 1-day post-7β-HC treatment. 
Immunohistochemical analysis showed the localization of OXTR in neurons in 
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the rat PFC. Furthermore, electron microscopy identified the presence of 
OXTR-immunoreactivity in axon terminals. These findings provide insights 
into the molecular mechanisms by which oxysterols exert their 
pathophysiological effects and suggest that increased oxysterols may affect 
synaptic function through transcriptional repression of GPCRs. 
Besides that, comprehensive gene expression profiles in the MCA of 
NZW rabbits exposed to two stroke risk factors (i.e. hypercholesterolemia 
and/or hypertension), by dietary supplementation with cholesterol and/or the 
2K1C method, were also investigated. Microarray and IPA analyses of the 
MCA of the hypertensive rabbits showed upregulated genes in networks 
containing the ‘node molecules’: UBC, P38 MAPK, ERK, NFĸB, SERPINB2, 
MMP1 and APP; and downregulated genes related to MAPK, ERK 1/2, Akt, 
26s proteasome, histone H3 and UBC. The MCA of hypercholesterolemic 
rabbits showed DEGs that are remarkably, linked to almost the same ‘node 
molecules’ as the hypertensive rabbits despite a relatively low percentage of 
‘common genes’ (21% and 7%) between the two conditions. Upregulated 
common genes were related to: UBC, SERPINB2, TNF, HNF4A and APP, 
while downregulated genes related to UBC. Increased HNF4A mRNA and 
protein expression were also verified in the aorta. Together, similar ‘node 
molecules’ and gene pathways found in cerebral vessels affected by 
hypercholesterolemia or hypertension could be a basis for synergistic action of 
risk factors in the pathogenesis of ICLAD. 
In addition, hypercholesterolemia and hypertension are also risk factors 
of AD. The cerebral Aβ accumulation in sporadic AD may be multifactorial, 
but relatively little is known about gene expression changes in the FC at risk. 
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Using the same animal models of hypercholesterolemia and hypertension, gene 
expression alterations were also profiled in the FC. The present findings showed 
more genes were altered in the FC after hypercholesterolemia than 
hypertension. IPA analysis of the FC from the hypercholesterolemic and/or 
hypertensive rabbits showed the mapping of upregulated and downregulated 
genes in networks and their relationship with various ‘node molecules’. 
The comparison between gene expression profiles of the FC and cerebral 
vessels i.e. MCA, surprisingly revealed a majority of the downregulated DEGs 
in the FC were common genes in the MCA from the same hypercholesterolemic 
rabbits. Besides that, common ‘node molecules’ were also noted in these tissues 
after exposure to hypercholesterolemia. Interestingly, ‘node molecules’ that 
were affected by hypercholesterolemia and/or hypertension in both FC and 
MCA such as 26s proteasome, Akt, ERK1/2, Histone h3, IL12, Insulin, 
Interferon alpha, and NFκB, are associated with pathways involving APP and 
its proteolytic fragments. Immunohistochemical analysis demonstrated 
significantly increased Aβ-immunolabeled neurons in the FC of the 
‘hypercholesterolemia plus sham/ hypertension’ rabbits. The present results 
may open new research avenue for the elucidation of potential pathological 
mechanisms of AD and may identify common genes that are associated to both 
AD and stroke. 
In view of the association of APP and its related genes with 
hypercholesterolemia, possible regulation of these genes by SREBP signaling, 
which may be affected during hypercholesterolemia, was also examined. 
SREBP inhibition caused significant increase in APP and SERPINB2 mRNA 
levels in human endothelial cells. In human neuroblastoma cells, SERPINB2 
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gene expression was only elevated by the S2P inhibitor whereas SREBP 
inhibition had no effect on APP mRNA levels. Immunofluorescence study 
showed significantly increased Aβ and SERPINB2 expression induced by S2P 
inhibition in both endothelial and neuroblastoma cells. It is postulated that 
increased SERPINB2 may inhibit tPA, leading to decreased plasmin and 
enhanced Aβ accumulation. Novel results of this study could add on to the 
current understanding regarding the link between serum cholesterol and AD. 
In conclusion, the present findings have demonstrated the role of 
cholesterol in inducing gene expression changes in the brain and cerebral 
vessels, depending on the dose used and the condition of treatment. Acute 
intracortical administration of oxysterols at low concentration were capable of 
inducing more severe gene expression changes compared with its parent 
compound, cholesterol. This offers an insight into possible molecular 
mechanisms through which increased level of autoxidatively formed oxysterols 
could exert a pathophysiological effect in the brain. In contrast, consumption of 
a high cholesterol diet for an extended period chronically induced massive gene 
expression changes in the brain and cerebral vessels, possibly through the 
mediation of SREBP signaling. In comparison with hypertension, 
hypercholesterolemia exerted a more crucial role in the induction of gene 
expression changes, affecting common genes and similar pathways in both FC 
and MCA. Together, this study suggests that alteration of gene expression by 
cholesterol may be a common mechanism underlying the pathology of AD and 
stroke, hence, shedding new light on the identification of potential susceptibility 
genes in humans with this risk factor. It is hoped that these discoveries may 
establish a better understanding of the pathophysiological mechanism and 
development of new interventions for both AD and stroke.  
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Appendix 1. DEGs in the PFC exclusive to 1-day post-7β-HC injections. These are 
DEGs that show downregulation or upregulation compared with vehicle treated rats. 
For the purpose of brevity, the table only includes genes with more than 3-fold change 
(Loke et al., 2013).  
Gene  Gene Symbol 
7β-HC 
P-value Fold Change 
Vestigial like 1 homolog (Drosophila) VGLL1 0.0001 -4.51 
Regenerating islet-derived 3 beta  REG3B 0.0004 -4.18 
Predicted: hypothetical protein LOC686013  LOC686013 0.0017 -4.18 
Procollagen, type VI, alpha 3  COL6A3 0.0044 -3.62 
B-cell translocation gene 4  BTG4 0.0018 -3.34 
Predicted: lin-9 homolog  LIN9 0.0003 -3.25 
TBC1 domain family, member 2  TBC1D2 0.0003 -3.18 
Predicted: deleted in lung and esophageal cancer 1 isoform 
DLEC1-N1  DLEC1 0.0002 -3.17 
Gamma-aminobutyric acid  GABRR3 0.0001 -3.17 
Predicted: mCG1050586-like  LOC100359793 0.0013 -3.02 
RT1 class Ib, locus M4  RT1-M4 0.0003 -3.02 
Predicted: similar to preferentially expressed antigen in 
melanoma like 4  LOC298613 <0.0001 8.61 
Predicted: similar to insulin-like growth factor binding protein 4 
precursor  RGD1562534 0.0047 4.56 
TAF7-like RNA polymerase II, TATA box binding protein 
(TBP)-associated factor  TAF7L 0.0012 4.46 
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Appendix 2. DEGs in the PFC exclusive to 1-day post-7-KC injections. These are 
DEGs that show downregulation or upregulation compared with vehicle treated rats 






P-value Fold Change 
Ribonuclease, RNase A family, 1-like 1  RNASE1L1 <0.0001 -4.50 
Resistin-like gamma  RETNLG 0.0482 -4.34 
Predicted: similar to sentrin 15  RGD1559489 <0.0001 -4.26 
Predicted: solute carrier family 38, member 11, transcript variant 1 SLC38A11 <0.0001 -4.25 
Predicted: retinol dehydrogenase 5  RDH5 0.0001 -4.18 
Predicted: rCG64258-like  LOC502821 0.0001 -4.11 
Interleukin 20 receptor beta  IL20RB <0.0001 -4.10 
Histone cluster 1, H2aa  HIST1H2AA 0.0037 -4.09 
Olfactory receptor 1087  OLR1087 0.0003 -3.97 
Actin, beta-like 2  ACTBL2 0.0001 -3.91 
Similar to RIKEN cDNA 5031410I06 LOC689091 0.0385 -3.86 
Predicted: keratin associated protein 14 like  KRTAP14L 0.0001 -3.79 
Similar to NHP2-like protein 1  LOC298245 0.0006 -3.76 
Actin-like 7a  ACTL7A 0.0036 -3.72 
Similar to putative protein, with at least 6 transmembrane 
domains, of ancient origin  AGMO 0.0009 
-3.72 
Ig gamma chain segment LOC679045 0.0279 -3.70 
Similar to melanoma antigen family B, 4  RGD1563904 0.0002 -3.70 
Rho guanine nucleotide exchange factor (GEF) 5 ARHGEF5 0.0016 -3.67 
Similar to RIKEN cDNA 2210409E12 RGD1565915 0.0001 -3.63 
Predicted: similar to olfactory receptor Olr1374  LOC690140 0.0001 -3.62 
Carboxypeptidase A3, mast cell  CPA3 0.0001 -3.58 
Lymphocyte-activation gene 3  LAG3 0.0001 -3.57 
G protein-coupled receptor 101  GPR101 0.0121 -3.56 
Transmembrane 4 L six family member 20  TM4SF20 0.0014 -3.52 
Olfactory receptor 124  OLR124 0.0002 -3.49 
Integrin, alpha 10  ITGA10 0.0010 -3.48 
Follicle stimulating hormone, beta polypeptide  FSHB 0.0014 -3.46 
Solute carrier family 6 (neurotransmitter transporter), member 20B SLC6A20B 0.0029 -3.46 
Espin  ESPN 0.0002 -3.46 
Myotubularin related protein 14  MTMR14 0.0002 -3.45 
Predicted: similar to corneodesmosin, transcript variant 1  LOC682408 0.0006 -3.42 
Potassium voltage-gated channel, Isk-related subfamily, member 1  KCNE1 <0.0001 -3.41 
Similar to secretory protein precursor  CHI3L4 0.0004 -3.41 
Predicted: similar to DNA helicase HEL308  LOC289471 0.0002 -3.37 
Predicted:similar to neuron navigator 3  LOC685727 0.0002 -3.36 
Leucine rich repeat containing 63  LRRC63 0.0010 -3.35 
Predicted: similar to S100 calcium-binding protein, ventral 
prostate  LOC685685 0.0044 
-3.34 
Castor homolog 1, zinc finger (Drosophila) CASZ1 0.0001 -3.33 
Predicted: desmoglein 3  DSG3 0.0004 -3.32 








P-value Fold Change 
Glyceraldehyde-3-phosphate dehydrogenase, spermatogenic  GAPDHS 0.0004 -3.30 
LOC362633  RGD1561426 0.0007 -3.28 
Olfactory receptor 1117  OLR1117 0.0438 -3.28 
Predicted: hypothetical LOC301882  LOC301882  0.0024 -3.26 
Cytochrome P450, family 11, subfamily b, polypeptide 3  CYP11B3 0.0004 -3.26 
Protease, serine, 7  PRSS7 <0.0001 -3.23 
Hypothetical protein LOC499530  LOC499530 0.0038 -3.23 
Predicted: galactosidase, beta 1-like 2  GLB1L2 0.0004 -3.22 
Myogenin  MYOG <0.0001 -3.18 
Gasdermin domain containing protein RGD1359449  RGD1359449 <0.0001 -3.17 
Histocompatibility 2, M region locus 9  H2-M9 0.0206 -3.14 
Laminin, gamma 2  LAMC2 0.0046 -3.13 
LRRGT00018-like  LOC100363129 0.0014 -3.13 
Fanconi anemia, complementation group I FANCI 0.0013 -3.12 
Olfactory receptor 704  OLR704 0.0005 -3.12 
Predicted: Cd300 molecule-like family member G, transcript 
variant 1  CD300LG <0.0001 
-3.12 
Matrilin 1, cartilage matrix protein  MATN1 0.0005 -3.11 
Similar to spindlin-like protein 2  LOC301839 0.0011 -3.11 
Similar to Ras-related protein Rab-15  RAB44 0.0003 -3.10 
Predicted: similar to forkhead box R2  FOXR2 0.0006 -3.09 
Olfactory receptor 1646  OLR1646 0.0001 -3.07 
Protease, serine, 32  PRSS32 0.0003 -3.07 
Wingless-type MMTV integration site family, member 8A  WNT8A 0.0046 -3.05 
Predicted: hypothetical protein LOC680077  LOC680077 0.0017 -3.05 
Dopamine receptor D3  DRD3 0.0004 -3.04 
Predicted: similar to ring finger and KH domain containing 2  RGD1564904 <0.0001 -3.04 
Predicted: similar to spindlin-like protein 2  GM16388 0.0091 -3.03 
Olfactory receptor 1280  OLR1280 0.0007 -3.03 
Predicted: rCG43168-like  LOC100359653 <0.0001 -3.02 
Predicted: zinc finger protein 160-like  ZNF665 0.0004 -3.01 
Pentraxin related gene  PTX3 0.0465 3.76 
T-cell immunoglobulin and mucin domain containing 2  TIMD2 0.0007 3.68 
WW domain-containing oxidoreductase  WWOX 0.0136 3.07 
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Appendix 3. DEGs in the PFC common to 1-day post-7β-HC and post-7-KC injections. 
These are DEGs that show downregulation or upregulation compared with vehicle 
treated rats with more than 6-fold change from either one of the treatment groups (Loke 






P-value Fold Change P-value 
Fold 
Change 
Predicted: similar to tolloid-like 2  LOC680012 <0.0001 -8.24 <0.0001 -13.04 
Predicted: similar to NEDD4-binding 
protein 1  LOC688874 <0.0001 -7.33 <0.0001 -11.27 
Similar to orphan sodium- and chloride-
dependent neurotransmitter transporter 
NTT5  
RGD1562492 0.0005 -6.45 0.0011 -4.68 
Olfactory receptor 560  OLR560 <0.0001 -6.40 <0.0001 -9.69 
CDNA sequence BC053393 BC053393 0.0002 -6.33 0.0001 -5.33 
DNA-directed RNA polymerase I 
subunit RPA1 POLR1A 0.0002 -6.25 <0.0001 -9.23 
Predicted: rCG41835-like  LOC100361577 0.0054 -5.50 <0.0001 -18.06 
Predicted: similar to GPI-anchored 
membrane protein 1  LOC678703 0.0036 -5.37 <0.0001 -10.94 
Predicted: trace amine-associated 
receptor 5  TAAR5 0.0001 -5.35 <0.0001 -10.64 
Predicted: similar to DNA segment, Chr 
5, ERATO Doi 577, expressed  RGD1559654 <0.0001 -5.39 <0.0001 -8.36 
Vomeronasal 1 receptor, 78  VOM1R78 0.0003 -3.66 0.0001 -8.25 
Similar to enoyl coenzyme A hydratase 
domain containing 2 LOC686940 0.0062 -4.28 <0.0001 -8.23 
Serine peptidase inhibitor, Kazal type 5  SPINK5 0.0059 -2.91 <0.0001 -7.92 
Insulin-like growth factor 2 mRNA 
binding protein 2 IGF2BP2 0.0002 -4.18 <0.0001 -7.83 
Olfactory receptor 157  OLR157 <0.0001 -5.96 <0.0001 -7.70 
Predicted: TD and POZ domain 
containing 1  TDPOZ1 <0.0001 -4.32 <0.0001 -7.24 
Predicted: transglutaminase 6  TGM6 0.0038 -3.19 <0.0001 -7.20 
Predicted: similar to TDPOZ2  RGD1562545 0.0009 -4.63 <0.0001 -7.16 
Titin TTN 0.0005 -3.41 0.0004 -7.13 
Similar to hypothetical protein 
F830045P16  RGD1566226 0.0023 -5.28 0.0014 -7.11 
Dynein, axonemal, heavy chain 17  DNAH17 0.0001 -3.33 0.0002 -7.03 
AE binding protein 2  AEBP2 <0.0001 -4.24 <0.0001 -7.01 
Predicted: type II keratin Kb40  KRT78 0.0001 -5.14 <0.0001 -6.92 
Transmembrane 4 L six family member 
20  TM4SF20 <0.0001 -4.14 <0.0001 -6.92 
Oxytocin receptor  OXTR 0.0001 -4.39 <0.0001 -6.91 
Olfactory receptor 1455  OLR1455 <0.0001 -4.07 <0.0001 -6.84 
Predicted: similar to chromosome X 
open reading frame 2  LOC681457 0.0025 -4.19 <0.0001 -6.76 
Calcium-activated potassium channel 
beta subunit  LOC60591 0.0003 -5.07 <0.0001 -6.75 
Transmembrane protease, serine 6  TMPRSS6 <0.0001 -4.52 <0.0001 -6.71 
Olfactory receptor 162  OLR162 0.0001 -4.58 0.0001 -6.70 
Olfactory receptor 921  OLR921 0.0002 -3.42 <0.0001 -6.65 
Similar to hypothetical protein FLJ21963 ACSS3 0.0007 -4.82 <0.0001 -6.61 
Predicted: hypothetical protein 
LOC678966  LOC678966 0.0002 -4.14 <0.0001 -6.60 
Runt related transcription factor 2  RUNX2 0.0002 -4.04 0.0003 -6.57 








P-value Fold Change P-value 
Fold 
Change 
UDP-glucuronosyltransferase 2 family, 
member 37 UGT2B37 <0.0001 -3.58 <0.0001 -6.57 
Predicted: similar to spindlin-like protein 
2  LOC302228 0.0004 -3.26 0.0001 -6.56 
Predicted: similar to chain A, solution 
structure of a bola-like protein from Mus 
Musculus  
RGD1562977 0.0106 -3.16 <0.0001 -6.54 
Predicted: OTU domain containing 6A  OTUD6A <0.0001 -4.41 0.0019 -6.52 
Predicted: similar to mast cell protease 
1-like 3 precursor  RGD1562035 <0.0001 -3.20 <0.0001 -6.52 
Phosphatidylinositol glycan, class Z-like 
1 PIGZL1 0.0004 -3.70 <0.0001 -6.49 
Trace amine-associated receptor 7b  TAAR7B 0.0001 -4.60 0.0001 -6.47 
Cd79a molecule, immunoglobulin-
associated alpha LOC687079 0.0001 -5.08 <0.0001 -6.45 
Melanocortin 5 receptor  MC5R <0.0001 -3.48 <0.0001 -6.45 
Keratin associated protein 1-3-like LOC100361571 0.0001 -4.09 <0.0001 -6.42 
Predicted: homeobox A9-like  HOXA9L <0.0001 -4.46 <0.0001 -6.34 
Predicted: similar to ribosomal protein 
S12  LOC689821 0.0008 -4.40 0.0001 -6.32 
Predicted: similar to spetex-2C protein  LOC685994 0.0005 -3.24 0.0001 -6.29 
Predicted: dynein, axonemal, heavy 
polypeptide 9  DNAH9 0.0005 -5.20 0.0003 -6.27 
Similar to 40S ribosomal protein S7  LOC500148 0.0007 -4.06 <0.0001 -6.23 
Mast cell protease 1-like 2 precursor MCPT1L2 <0.0001 -4.23 <0.0001 -6.14 
Predicted: similar to hypothetical protein 
4930474N05  RGD1562641 0.0223 -3.09 <0.0001 -6.14 
Coiled-coil domain containing 69  CCDC69 <0.0001 -4.37 <0.0001 -6.11 
Predicted: cell surface receptor 
FDFACT-like  LOC100360108 0.0026 -3.21 0.0005 -6.10 
Hypothetical protein LOC686031  LOC686031 0.0003 -3.35 0.0006 -6.10 
Epithelial splicing regulatory protein 2  ESRP2 0.0002 -3.41 <0.0001 -6.08 
Hypothetical protein LOC688459  LOC688459 0.0002 -2.76 0.0012 -6.00 
Predicted: similar to similar to 60S 
ribosomal protein L12  LOC688511 0.0001 -3.13 0.0002 -6.00 
Peroxisomal trans-2-enoyl-CoA 
reductase  PECR <0.0001 11.83 <0.0001 8.42 
Predicted: similar to glyceraldehyde-3-
phosphate dehydrogenase  LOC307263 <0.0001 11.81 <0.0001 10.10 
Nudix (nucleoside diphosphate linked 
moiety X)-type motif 9 NUDT9 <0.0001 11.37 <0.0001 10.17 
Predicted: similar to heat shock protein 8  LOC310891 <0.0001 10.87 <0.0001 9.33 
Predicted: coiled-coil domain containing 
64  CCDC64 <0.0001 9.96 <0.0001 9.28 
Predicted: Ts translation elongation 
factor, mitochondrial, transcript variant 1 TSFM <0.0001 9.85 <0.0001 9.25 
Proprotein convertase subtilisin/kexin 
type 7  PCSK7 <0.0001 9.40 <0.0001 8.96 
Praja 2, RING-H2 motif containing  PJA2 <0.0001 9.36 <0.0001 8.88 
Potassium voltage-gated channel, 
subfamily H (eag-related), member 2 KCNH2 <0.0001 9.27 <0.0001 7.91 
ADAM metallopeptidase domain 7  ADAM7 0.0040 9.18 0.0047 7.36 
Reticulon 4 receptor-like 1  RTN4RL1 <0.0001 8.98 <0.0001 8.60 
Vitamin K epoxide reductase complex, 
subunit 1-like 1  VKORC1L1 <0.0001 8.86 <0.0001 7.97 
Nuclear receptor subfamily 3, group C, 
member 1  NR3C1 <0.0001 8.45 0.0002 7.54 
Histone cluster 1, H2bh  HIST1H2BH <0.0001 8.40 0.0004 6.32 








P-value Fold Change P-value 
Fold 
Change 
Predicted: NADH dehydrogenase 
(ubiquinone) 1 beta subcomplex, 4-like 1 NDUFB4L1 <0.0001 8.34 <0.0001 6.58 
Predicted: similar to BRCA1-associated 
protein  LOC687346 <0.0001 8.24 <0.0001 7.16 
Predicted: similar to glyceraldehyde-3-
phosphate dehydrogenase  RGD1561881 <0.0001 8.24 <0.0001 8.38 
Predicted: similar to ribosomal protein 
S24  RGD1562937 <0.0001 8.12 <0.0001 6.92 
Predicted: similar to 60S ribosomal 
protein L26  LOC688981 <0.0001 8.03 <0.0001 6.83 
Predicted: similar to peptidyl-prolyl cis-
trans isomerase NIMA-interacting 4  LOC684441 <0.0001 7.98 <0.0001 8.33 
Ash1 (absent, small, or homeotic)-like 
(Drosophila) ASH1L <0.0001 7.64 <0.0001 8.77 
Predicted: similar to heat shock protein 
HSP 90-beta  LOC302786 <0.0001 7.64 <0.0001 6.56 
Splicing factor, arginine/serine-rich 8  SFRS8 <0.0001 7.30 <0.0001 7.40 
Predicted: similar to RIKEN cDNA 
1200011M11  SMG8 <0.0001 7.18 <0.0001 5.87 
Small nuclear RNA activating complex, 
polypeptide 1  SNAPC1 0.0001 7.06 0.0001 6.08 
Predicted: similar to dynein, axonemal, 
light chain 4  RGD1559781 <0.0001 7.02 <0.0001 6.44 
Sorting nexin 24  SNX24 <0.0001 6.97 <0.0001 6.55 
Similar to RIKEN cDNA 2210409M21  LOC290453 0.0002 6.83 <0.0001 6.62 
Thioredoxin interacting protein  TXNIP <0.0001 6.81 <0.0001 5.79 
Lactamase, beta  LACTB <0.0001 6.78 <0.0001 6.99 
Similar to 60S ribosomal protein L3  LOC302564 <0.0001 6.73 <0.0001 5.34 
Mitochondrial ribosomal protein L17  MRPL17 <0.0001 6.71 <0.0001 6.32 
Predicted: similar to ATPase inhibitory 
factor 1  RGD1559545 <0.0001 6.55 <0.0001 5.51 
Tumor protein, translationally-controlled 
1  TPT1 <0.0001 6.39 <0.0001 5.51 
Predicted: similar to open reading frame 
A  RGD1565030 <0.0001 6.38 <0.0001 6.25 
Myocyte enhancer factor 2a  MEF2A 0.0057 6.29 0.0008 4.02 
Ribosomal protein L31 RPL31 <0.0001 6.27 <0.0001 4.84 
Intraflagellar transport 20 homolog  IFT20 <0.0001 6.25 <0.0001 6.52 
RAB11 family interacting protein 3 
(class II) RAB11FIP3 <0.0001 6.13 <0.0001 5.42 
Predicted: similar to high mobility group 
protein 17  LOC688424 <0.0001 6.13 0.0001 5.70 
Similar to RIKEN cDNA 3110001N18  RGD1566002 <0.0001 6.11 <0.0001 4.71 
Similar to 60S ribosomal protein L23a  LOC292743 <0.0001 6.06 <0.0001 5.39 
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Appendix 4. DEGs in the PFC found in common to 1-day post-7β-HC and post-
cholesterol injections. These are DEGs that show downregulation or upregulation 
compared with vehicle treated rats with more than 2-fold change (Loke et al., 2013). 
Gene   Gene symbol 
7β-HC Cholesterol 
P-value Fold Change P-value 
Fold 
Change 
Troponin T, cardiac muscle TNNT2 0.0242 -2.97 0.0220 -2.44 
Myelin protein zero-like 2  MPZL2 0.0214 -2.60 0.0314 -2.27 
Similar to nucleoside diphosphate-
linked moiety X motif 16 (nudix motif 
16) 
LOC688828 0.0135 3.76 0.0447 2.88 
Predicted: hypothetical protein 
LOC100365120  LOC100365120 0.0291 2.46 0.0295 -2.24 
Da1-10-like  LOC100366054 0.0308 2.41 0.0286 -2.13 
Predicted: hypothetical protein 
LOC100366147  LOC100366147 0.0434 2.40 0.0379 -2.18 
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Appendix 5. DEGs in the PFC found in common to 1-day post-7-KC and post-
cholesterol injections. These are DEGs that show downregulation or upregulation 
compared with vehicle treated rats with more than 2-fold change (Loke et al., 2013). 
Gene Gene Symbol 
7-KC Cholesterol 
P-value Fold Change P-value 
Fold 
Change 
GDNF family receptor alpha like GFRAL 0.0021 -3.31 0.0205 -2.68 
Solute carrier family 9 (sodium/hydrogen 
exchanger), member 4 SLC9A4 0.0010 -2.67 0.0008 -2.86 
Phosphatidylinositol glycan, class N  PIGN 0.0033 -2.57 0.0130 -2.21 
Nuclear autoantigenic sperm protein (histone 
binding)  NASP 0.0305 -2.11 0.0072 -2.54 
Predicted: membrane-spanning 4-domains, 
subfamily A, member 4A  MS4A4A 0.0071 -2.09 0.0055 -2.06 
Trypsin 10  TRY10 0.0024 2.03 0.0481 2.07 
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Appendix 6. DEGs in the PFC found in common to 1-day post-7β-HC, post-7-KC, and 
post-cholesterol injections. These are DEGs that show downregulation or upregulation 
compared with vehicle treated rats with more than 2-fold change (Loke et al., 2013).  
Gene Gene Symbol 
7β-HC 7-KC Cholesterol 
P- value Fold Change P- value 
Fold 




monooxygenase 9  FMO9 <0.0001 -3.98 0.0004 -4.03 0.0001 -2.43 
Insulin-like growth 
factor binding 
protein-like 1  
IGFBPL1 0.0334 -3.30 0.0395 -3.06 0.0130 -4.65 
Wingless-type 
MMTV integration 
site family, member 
9B  
WNT9B 0.0487 -2.09 0.0184 -2.35 0.0378 -2.17 
Ankyrin repeat 
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Appendix 7. Upregulated DEGs in the PFC found in common to 1-day post-7β-HC and 
post-7-KC treatments. These are the top five associated network functions mapped by 
IPA (Loke et al., 2013).  
Associated Network Functions Score Focus Genes 
Cell death, cell morphology, cellular assembly and 
organization 54 26 
Cancer, cell-mediated immune response, cellular 
development 41 21 
Reproductive system development and function, tissue 
morphology, cellular development 29 16 
Cellular assembly and organization, cell death, DNA 
replication, recombination, and repair 29 16 
Cell death, cellular development, hematological system 
development and function 24 14 
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Appendix 8. Upregulated DEGs in the PFC found in common to 1-day post-7β-HC and 
post-7-KC treatments. These are the 26 genes that are mapped in the top network 
pertaining to cell death, cell morphology, cellular assembly and organization (Loke et 
al., 2013). 
 
 Gene  Gene symbol 
7β-HC 7-KC 
P-value Fold Change P-value 
Fold 
Change 
Potassium voltage-gated channel, subfamily 
H (eag-related), member 2  KCNH2 <0.0001 9.27 <0.0001 7.91 
Thioredoxin interacting protein  TXNIP <0.0001 6.81 <0.0001 5.79 
Tumor protein, translationally-controlled 1  TPT1 <0.0001 6.39 <0.0001 5.51 
Eukaryotic translation initiation factor 3, 
subunit H  EIF3H <0.0001 5.91 <0.0001 5.08 
Ribosomal protein S23  RPS23 <0.0001 5.76 <0.0001 4.67 
Leucine aminopeptidase 3  LAP3 <0.0001 5.70 0.0001 5.40 
Tumor susceptibility gene 101  TSG101 <0.0001 5.65 <0.0001 4.82 
Chromobox homolog 3 (HP1 gamma 
homolog, Drosophila) CBX3 <0.0001 5.40 <0.0001 4.64 
ELKS/RAB6-interacting/CAST family 
member 1  ERC1 <0.0001 4.97 0.0002 5.09 
Ring finger protein 7  RNF7 <0.0001 4.68 <0.0001 4.02 
(HP1 gamma homolog, Drosophila) CLINT1 <0.0001 4.39 <0.0001 3.56 
Predicted: similar to TPR repeat-containing 
protein KIAA1043  TCC28 0.0006 4.06 <0.0001 4.52 
DOT1-like, histone H3 methyltransferase 
(S. cerevisiae) DOT1L 0.0003 3.97 0.0008 3.74 
S100 calcium binding protein B  S100B <0.0001 3.71 <0.0001 3.18 
Stathmin 1  STMN1 <0.0001 3.63 <0.0001 3.18 
Heat shock protein HSP 90-beta (Heat 
shock 84 kDa) HSP90AB1 <0.0001 3.12 <0.0001 2.72 
Eukaryotic translation elongation factor 1 
alpha 1  EEF1A1 <0.0001 3.04 <0.0001 2.65 
RNA polymerase II associated protein 3  RPAP3 <0.0001 3.01 <0.0001 3.25 
E1A binding protein p400  EP400 <0.0001 2.89 <0.0001 2.69 
Cell division cycle 25 homolog C (S. 
pombe) CDC25C 0.0002 2.88 0.0002 2.53 
Histone cluster 1, H4b  HIST1H4B 0.0001 2.83 0.0021 2.87 
Interleukin-1 receptor-associated kinase 4  IRAK4 0.0023 2.69 0.0067 2.03 
Adaptor-related protein complex 2, beta 1 
subunit  AP2B1 <0.0001 2.41 0.0001 2.29 
F-box protein 33  FBXO33 0.0001 2.31 <0.0001 2.62 
Adhesion regulating molecule 1  ADRM1 0.0002 2.22 0.0004 2.29 
Snail homolog 1 (Drosophila) SNAI1 0.0011 2.17 <0.0001 2.19 
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Appendix 9. Upregulated genes in the MCA of ‘hypertension only’ rabbits vs. sham 
operated control rabbits with greater than 4-fold change. (Ong et al., 2013) 
Gene  Gene Symbol 
Corrected 
P-value 







Family with sequence similarity 167, 
member A  FAM167A 0.00017 14.04 2.44 5.11 
Ceramide synthase 3 CERS3 0.00486 11.44 -1.50 3.68 
Family with sequence similarity 53, 
member C  FAM53C <0.00001 9.87 2.48 4.03 
Tubulin tyrosine ligase-like family, 
member 5 TTLL5 0.00005 8.16 -1.18 1.86 
Olfactory receptor, family 1, 
subfamily J, member 1 OR1J1 0.00002 8.14 3.83 -1.85 
Interstitial collagenase Precursor (EC 
3.4.24.7)(Matrix metalloproteinase-
1)(MMP-1) MMP1 0.00149 8.12 2.20 6.33 
Nibrin-like LOC100352
398 ^ 0.00171 7.92 4.71 3.74 
TAF15 RNA polymerase II, TATA 
box binding protein (TBP)-associated 
factor, 68kDa TAF15 ^, + 0.00004 7.45 4.71 4.65 
Zinc finger, DHHC-type containing 
23 ZDHHC23 0.00001 7.18 3.22 5.64 
Ankyrin and armadillo repeat 
containing  ANKAR ^, + 0.00006 7.05 7.99 5.23 
N(alpha)-acetyltransferase 25, NatB 
auxiliary subunit  NAA25 ^, + <0.00001 6.43 8.91 18.66 
Corticotropin releasing hormone 
binding protein  CRHBP 0.00005 6.38 2.23 4.02 
Cytochrome P450 1A2 (EC 
1.14.14.1)(CYPIA2)(Cytochrome 
P450 isozyme 4)(Cytochrome P450 
LM4)(Cytochrome P450-PM4) CYP1A2 0.00004 6.15 1.73 -1.90 
KIAA0232  KIAA0232 0.00002 6.13 1.77 1.44 
Fanconi anemia, complementation 
group C  FANCC ^, + <0.00001 6.10 4.25 6.39 
NEDD8 activating enzyme E1 subunit 
1 NAE1 0.00009 6.10 3.26 -2.34 
Zinc finger protein 638 LOC100345
662 0.00005 6.01 1.02 -2.87 
Uncharacterized protein C1orf50  C1orf50 0.00006 5.81 3.80 8.01 
Mix paired-like homeobox MIXL1 0.00093 5.80 3.54 4.64 
Serine proteinase inhibitor, clade B, 
member 2 (Predicted)  
SERPINB2 
^, + 0.00005 5.63 6.99 9.10 
IDI1 protein-like LOC10034627
4 ^, + 0.00042 5.51 4.87 6.67 
B-cell receptor-associated protein 31 LOC100356
247 0.00464 5.45 2.83 1.09 
Sperm associated antigen 6 SPAG6 0.00139 5.39 1.31 2.69 
Meprin A, beta  MEP1B ^, + 0.00291 5.37 5.12 5.85 
G protein-coupled receptor kinase 
interacting ArfGAP 1 GIT1 <0.00001 5.22 2.76 3.91 
Ciliary rootlet coiled-coil, rootletin  CROCC 0.00003 5.08 2.33 2.79 
SRY (sex determining region Y)-box 
2-like 
LOC100341
629 0.00001 5.05 1.43 -7.56 
Fibroblast growth factor binding 
protein 1-like 
LOC10035383
5 ^, + 0.00122 5.01 4.01 4.63 
Ankyrin repeat and SOCS box-
containing 4  ASB4 ^ 0.00027 4.98 4.06 3.51 
Double zinc ribbon and ankyrin 
repeat-containing protein 1 
DZANK1 ^, 
+ <0.00001 4.87 5.04 7.37 
CD46 molecule, complement 
regulatory protein CD46 0.00230 4.85 3.14 -1.11 
Programmed cell death 11 PDCD11 0.00003 4.85 -1.62 -1.11 
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Gene  Gene Symbol 
Corrected 
P-value 








associated 1 like 3  SIPA1L3 ^, + 0.00001 4.80 8.45 6.50 
Relaxin/insulin-like family peptide 
receptor 2  RXFP2 ^, + 0.00029 4.79 5.62 6.96 
PHD and ring finger domains 1  PHRF1 0.00002 4.69 1.13 1.17 
Guanylate cyclase 2D, membrane 
(retina-specific)  
GUCY2D ^, 
+ 0.00008 4.64 4.11 8.34 
EH domain binding protein 1 EHBP1 0.00171 4.60 2.08 -1.19 
Testis-specific kinase 2 TESK2 ^ 0.00571 4.50 5.11 2.41 
Golgin subfamily B member 1 LOC100340
420 0.00001 4.32 -2.30 -1.39 
Coiled-coil domain containing 54  CCDC54 0.00669 4.25 2.96 4.62 
Solute carrier family 39 (zinc 
transporter), member 12  SLC39A12 0.00006 4.23 2.48 4.96 
L(3)mbt-like (Drosophila)  L3MBTL1 0.00011 4.21 1.80 1.38 
Chemokine (C-C motif) ligand 1 CCL1 <0.00001 4.18 1.13 1.37 
Ribonuclease, RNase A family, 1 
(pancreatic)  RNASE1 ^, + <0.00001 4.17 5.62 4.82 
DIS3 mitotic control homolog (S. 
cerevisiae)-like 2 DIS3L2 ^ 0.00024 4.17 4.32 3.96 
Cold shock domain containing E1, 
RNA-binding CSDE1 0.00002 4.16 1.89 2.99 
Antigen p97 (melanoma associated) 
identified by monoclonal antibodies 
133.2 and 96.5 (MFI2) MFI2 0.00386 4.04 2.47 1.09 
Glucose-fructose oxidoreductase 
domain containing 2-like 
LOC10035115
0 ^, + 0.00001 4.01 6.34 12.42 
Coiled-coil domain containing 89  CCDC89 0.00238 4.01 1.64 3.00 
^ DEGs that are common between ‘hypertension only’ and ‘hypercholesterolemia plus sham’ rabbits (each group vs. 
sham operated control group). + DEGs that are common among ‘hypertension only’, ‘hypercholesterolemia plus sham’, 
and ‘hypercholesterolemia plus hypertension’ rabbits (each group vs. sham operated control group). HT: ‘Hypertension 
only’ rabbits. HC: ‘Hypercholesterolemia plus sham’ rabbits. HCHT: ‘Hypercholesterolemia plus hypertension’ 
rabbits. 
  




Appendix 10. Downregulated genes in the MCA of ‘hypertension only’ rabbits vs. 
sham operated control rabbits with greater than 4-fold change. (Ong et al., 2013) 
 
Gene  Gene Symbol 
Corrected 
P-value 







Forkhead box N1  FOXN1 ^, + 0.00048 -26.20 -56.89 -45.12 
Nuclear speckle splicing regulatory 
protein 1 NSRP1 <0.00001 -24.13 -1.56 -1.23 
THUMP domain containing 3  THUMPD3 <0.00001 -17.18 1.04 1.31 
AT rich interactive domain 2 (ARID, 
RFX-like) ARID2 <0.00001 -16.92 -2.86 -2.29 
Ribosomal protein S3a-like LOC100354966 ^ <0.00001 -16.54 -5.74 -1.83 
NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex assembly factor 5 NDUFAF5 0.00007 -15.92 -2.60 -1.44 
ADAM metallopeptidase with 
thrombospondin type 1 motif, 17 
ADAMTS17 
^ 0.00001 -15.85 -7.25 -3.06 
Peptidylprolyl isomerase G 
(cyclophilin G)  PPIG ^ <0.00001 -12.61 -6.20 -1.81 
Hematopoietic prostaglandin D 
synthase HPGDS ^, + 0.00043 -12.38 -21.44 -13.63 
Cyclin H  CCNH <0.00001 -10.89 -3.52 -1.34 
LYR motif containing 7 LYRM7 0.00001 -10.41 -1.63 -1.65 
Male-specific lethal 2 homolog 
(Drosophila)  MSL2 0.00022 -9.72 -2.22 -2.10 
Secreted frizzled-related protein 4 SFRP4 <0.00001 -9.32 -1.07 -1.11 
Ankyrin 2, neuronal  ANK2 0.00002 -9.32 -1.39 -1.31 
Ras-related protein Rab-7a  RAB7A 0.00001 -9.20 -1.18 -1.35 
NLR family, pyrin domain containing 
5  NLRP5 <0.00001 -8.60 1.51 2.02 
Integrin-linked kinase-associated 
serine/threonine phosphatase ILKAP 0.00001 -8.57 1.49 1.39 
Histone H3.3B-like LOC100341225 0.00209 -8.43 -1.36 -2.17 
Membrane-spanning 4-domains, 
subfamily A, member 1  MS4A1 0.00073 -7.86 -3.98 -2.53 
Sorting nexin 9 SNX9 0.00016 -7.82 -1.54 -1.78 
Protein tyrosine phosphatase, non-
receptor type 23 PTPN23 0.00003 -7.80 1.69 1.30 
Large subunit GTPase 1 homolog (S. 
cerevisiae)  LSG1 ^ <0.00001 -7.69 -20.38 -1.93 
Coiled-coil domain containing 59 CCDC59 <0.00001 -7.66 -2.29 -1.40 
Protein SLX4IP SLX4IP 0.00008 -7.64 -1.90 -1.79 
Ribosomal protein S12 RPS12 0.00079 -7.57 -1.56 -1.28 
Breast carcinoma amplified sequence 
2  BCAS2 0.00001 -7.39 -1.24 -1.18 
Secreted protein, acidic, cysteine-rich 
(osteonectin) SPARC 0.00030 -7.26 -2.00 -1.62 
Mitochondrial ribosomal protein L15  MRPL15 ^, + <0.00001 -6.97 -23.01 -9.57 
Translocase of inner mitochondrial 
membrane domain-containing protein 
1 
TIMMDC1 0.00021 -6.72 1.06 -1.07 
Olfactory receptor, family 4, 
subfamily D, member 2  OR4D2 0.00009 -6.61 -1.25 1.18 
Tumor necrosis factor, alpha-induced 
protein 8 TNFAIP8 0.00148 -6.59 -2.12 -2.30 
LIM domains containing 1 LIMD1 0.00007 -6.10 -2.35 -1.61 
Neurolysin, mitochondrial Precursor  NLN 0.00072 -6.05 -1.23 -1.39 
Osteoglycin OGN 0.00004 -5.96 -1.58 -1.49 
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Ribosomal protein L35-like LOC100339185 0.00176 -5.85 -3.09 -1.69 
Transient receptor potential cation 
channel, subfamily V, member 5 
(TRPV5) 
TRPV5 0.00002 -5.80 -1.90 -1.49 
Glycine cleavage system protein H 
(aminomethyl carrier) GCSH <0.00001 -5.68 -1.84 -1.61 
Translocase of outer mitochondrial 
membrane 5 homolog (yeast) TOMM5 ^ 0.00014 -5.67 -4.05 -1.60 
SEC24 family, member A (S. 
cerevisiae)  SEC24A 0.00205 -5.62 -2.86 -2.06 
Matrilin 2  MATN2 <0.00001 -5.55 1.73 1.69 
Ubiquitin specific peptidase 46 USP46 0.00039 -5.54 -2.52 -1.45 
Purine-rich element binding protein A  PURA 0.00034 -5.54 1.21 1.12 
Hydroxyprostaglandin dehydrogenase 
15-(NAD) HPGD 0.00366 -5.51 -2.30 -2.60 
Parkinson protein 7 PARK7 <0.00001 -5.44 1.27 1.07 
IL2-inducible T-cell kinase ITK 0.00003 -5.37 1.07 1.25 
Ribosomal protein L26  RPL26 ^ 0.00016 -5.27 -14.60 -2.81 
Endothelial PAS domain protein 1  EPAS1 0.00279 -5.24 -2.30 -1.70 
ATP-sensitive inward rectifier 
potassium channel Kir6.2 (KIR62) KIR62 0.00032 -5.21 -1.25 1.08 
Kruppel-like factor 12  KLF12 0.00008 -5.14 -1.25 -1.15 
TBC1 domain family, member 8B 
(with GRAM domain) TBC1D8B 0.00101 -5.13 -1.47 -1.01 
Nucleophosmin 1 isoform 1 
(Predicted) NPM1 0.00001 -5.12 -1.40 -1.40 
BUD31 homolog (S. cerevisiae) BUD31 0.00343 -5.08 -1.20 -1.30 
Poly(A) polymerase alpha PAPOLA <0.00001 -5.03 -2.29 -1.26 
Ribosomal protein L37a RPL37A <0.00001 -4.98 1.23 1.10 
Splicing factor 3a, subunit 3, 60kDa SF3A3 0.00003 -4.91 -1.55 -1.36 
C1q and tumor necrosis factor related 
protein 1  C1QTNF1 0.00019 -4.90 -3.22 -1.22 
Family with sequence similarity 107, 
member B FAM107B 0.00140 -4.88 -3.41 -2.58 
Integral membrane protein 2C  ITM2C 0.00015 -4.87 1.64 1.30 
Alpha-1-B glycoprotein  A1BG 0.00121 -4.87 2.01 1.19 
Histone deacetylase complex subunit 
SAP18-like 
LOC100356
364 0.00003 -4.86 -1.85 -1.65 
Phosphorylase kinase, beta (PHKB PHKB 0.00033 -4.83 -1.23 -1.12 
Vacuolar protein sorting-associated 
protein 51 homolog VPS51 0.00004 -4.74 2.15 1.65 
Uncharacterized protein C11orf57  C11orf57 0.00365 -4.65 -1.71 -1.25 
Exostoses (multiple)-like 3  EXTL3 0.00001 -4.65 -3.53 -4.65 
Ferritin heavy chain Fragment 
(Ferritin H subunit) FTH1 0.00003 -4.64 1.06 -1.09 
Uncharacterized protein C15orf62, 
mitochondrial Precursor  C15orf62 0.00018 -4.58 1.21 1.48 
Lysine (K)-specific demethylase 4A KDM4A <0.00001 -4.57 2.48 2.70 
NADH dehydrogenase (ubiquinone) 1 
beta subcomplex, 6, 17kDa  NDUFB6 0.00116 -4.56 -1.76 -1.55 
P21 protein (Cdc42/Rac)-activated 
kinase 4 PAK4 0.00002 -4.56 -1.16 -1.05 
Armadillo repeat containing, X-linked 
3 ARMCX3 0.00161 -4.49 -1.40 -1.37 
Transmembrane tyrosine kinase 
receptor c-kit 0.00981 -4.48 -2.92 -2.29 
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Leucine rich repeat (in FLII) 
interacting protein 2 LRRFIP2 0.00001 -4.47 1.23 1.14 
Cardiac calcium channel beta-subunit 
(CAB2) CAB2 0.00008 -4.46 1.34 1.20 
HERPUD family member 2 LOC100350332 0.00003 -4.42 -1.71 -1.80 
Family with sequence similarity 177, 
member A1  
FAM177A1 
^ 0.00016 -4.41 -10.75 -1.95 
Acyl-CoA synthetase long-chain 
family member 4 ACSL4 0.00397 -4.40 -2.03 -1.94 
Interleukin-1 receptor-associated 
kinase 1 binding protein 1 IRAK1BP1 0.00001 -4.38 -2.94 -1.75 
Polyamine modulated factor 1 binding 
protein 1 PMFBP1 <0.00001 -4.34 2.06 2.81 
Proteasome (prosome, macropain) 26s 
subunit, non-ATPase, 4 PSMD4 ^, + 0.00005 -4.34 -17.67 -11.67 
Dpy-19-like 1 (C. elegans)  DPY19L1 <0.00001 -4.32 1.14 1.10 
Mastermind-like 2 (Drosophila) MAML2 0.00134 -4.29 -1.57 1.05 
Choline phosphotransferase 1  CHPT1 0.00014 -4.26 -1.63 -1.47 
Aggrecanase-2  ADAMTS-11 ^, + 0.00005 -4.26 -9.31 -6.51 
Nuclear protein localization 4 
homolog (S. cerevisiae)  NPLOC4 0.00342 -4.25 -2.86 -1.62 
B-cell translocation gene 1, anti-
proliferative BTG1 0.00030 -4.24 -1.80 -1.81 
Galactokinase 2  GALK2 0.00002 -4.22 1.67 1.54 
N(alpha)-acetyltransferase 50, NatE 
catalytic subunit NAA50 0.00132 -4.21 -1.38 -1.99 
Tubulin polyglutamylase complex 
subunit 2-like 
LOC100353
679 0.00044 -4.19 1.09 -1.02 
Glycine N-methyltransferase 
Fragment (EC 2.1.1.20) GNMT 0.00006 -4.17 -2.35 -1.18 
Protein FAM210B FAM210B 0.00130 -4.16 1.36 1.38 
RNA pseudouridylate synthase 
domain containing 4 [ RPUSD4 0.00011 -4.11 1.05 1.04 
Nucleotide-binding oligomerization 
domain containing 2  NOD2 0.00111 -4.09 -1.39 -1.44 
Cysteine conjugate-beta lyase 2  CCBL2 0.00688 -4.07 -1.10 -1.03 
BRCA2 and CDKN1A interacting 
protein  BCCIP ^ <0.00001 -4.06 -14.00 -2.58 
Major facilitator superfamily domain 
containing 9 MFSD9 0.00383 -4.04 -1.26 -1.52 
Olfactory receptor 572 (Predicted)  OLFR572 0.00007 -4.03 1.30 2.27 
Neuroplastin NPTN 0.00010 -4.02 -1.19 -1.19 
^ DEGs that are common between ‘hypertension only’ and ‘hypercholesterolemia plus sham’ rabbits (each group vs. 
sham operated control group). + DEGs that are common among ‘hypertension only’, ‘hypercholesterolemia plus sham’, 
and ‘hypercholesterolemia plus hypertension’ rabbits (each group vs. sham operated control group). HT: ‘Hypertension 
only’ rabbits. HC: ‘Hypercholesterolemia plus sham’ rabbits. HCHT: ‘Hypercholesterolemia plus hypertension’ 
rabbits. 
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rabbits vs. sham operated control rabbits with greater than 4-fold change. (Ong et al., 
2013) 
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Schlafen family member 14  SLFN14 0.00565 14.04 16.33 2.01 
Carbonic anhydrase I  CA1 0.00531 10.02 10.07 2.38 
Gap junction alpha-3 protein-like LOC100357902 0.00689 9.62 9.96 2.92 
EPH receptor A1 EPHA1 0.00008 8.98 20.31 3.03 
N(alpha)-acetyltransferase 25, NatB 
auxiliary subunit NAA25 ^, + <0.00001 8.91 18.66 6.43 
Transmembrane protein 212  TMEM212 0.00039 8.84 7.93 3.48 
Family with sequence similarity 46, 
member C FAM46C 0.00016 8.51 6.92 1.72 
Signal-induced proliferation-associated 1 
like 3 SIPA1L3 ^, + 0.00001 8.45 6.50 4.80 
SP110 nuclear body protein  SP110 <0.00001 8.42 15.47 2.06 
Uncharacterized protein C11orf71  C11orf71 0.00446 8.33 9.22 2.97 
Ankyrin and armadillo repeat containing  ANKAR ^, + 0.00006 7.99 5.23 7.05 
Teneurin transmembrane protein 4 TENM4 0.00004 7.56 3.55 3.08 
Sterol O-acyltransferase 2 SOAT2 0.00003 7.18 5.94 3.01 
Serine proteinase inhibitor, clade B, 
member 2 (Predicted)  SERPINB2 ^, + 0.00005 6.99 9.10 5.63 
Fc receptor-like A FCRLA 0.00083 6.76 5.14 1.94 
Tetraspanin 33 TSPAN33 0.00078 6.37 5.53 3.97 
Glucose-fructose oxidoreductase domain 
containing 2-like 
LOC100351150 
^, + 0.00001 6.34 12.42 4.01 
CKLF-like MARVEL transmembrane 
domain containing 2  CMTM2 0.00071 6.28 7.79 2.38 
Solute carrier family 9 (sodium/hydrogen 
exchanger), member 8 SLC9A8 0.00175 6.14 10.32 3.55 
Spectrin, alpha, erythrocytic 1 
(elliptocytosis 2)  SPTA1 0.00375 6.03 8.20 2.75 
Kinesin family member 13B  KIF13B 0.00002 6.02 9.02 2.35 
Aminolevulinate, delta-, synthase 2  ALAS2 0.00072 5.86 5.93 1.97 
Protease, serine, 38 PRSS38 0.00058 5.74 6.51 1.95 
UHRF1 binding protein 1 UHRF1BP1 0.00074 5.70 4.69 2.63 
Bardet-Biedl syndrome 5 LOC100342443 0.00004 5.62 8.15 2.76 
Relaxin/insulin-like family peptide receptor 
2 RXFP2 ^, + 0.00029 5.62 6.96 4.79 
V-set and immunoglobulin domain 
containing 2  VSIG2 0.00168 5.53 4.60 3.51 
REC8 homolog (yeast)  REC8 <0.00001 5.52 4.31 1.93 
Gonadotropin-releasing hormone receptor  GnRHR 0.00008 5.47 10.39 3.11 
Transmembrane and coiled-coil domains 4  TMCO4 0.00007 5.42 4.28 2.43 
Serine incorporator 1 LOC100357075 0.00015 5.37 4.74 2.50 
Transmembrane protein 173  TMEM173 0.00141 5.36 4.70 2.88 
Solute carrier family 9 (sodium/hydrogen 
exchanger), member 5  SLC9A5 0.00057 5.36 4.19 2.33 
MLX interacting protein  MLXIP 0.00069 5.36 4.09 3.02 
BCL2-like 10 (apoptosis facilitator)  BCL2L10 0.00018 5.34 4.64 1.67 
Follicle stimulating hormone receptor  FSHR 0.00023 5.31 8.27 1.24 
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Zinc finger, CW type with PWWP domain 
2 ZCWPW2 0.00011 5.29 5.21 2.31 
Mitogen-activated protein kinase 4 MAP3K4 0.00196 5.19 4.93 3.17 
PSMC3 interacting protein PSMC3IP 0.00003 5.12 3.23 1.49 
Meprin A, beta MEP1B ^, + 0.00291 5.12 5.85 5.37 
Testis-specific kinase 2  TESK2 ^ 0.00571 5.11 2.41 4.50 
Double zinc ribbon and ankyrin repeat-
containing protein 1 DZANK1 ^, + <0.00001 5.04 7.37 4.87 
Nuclear receptor subfamily 1, group D, 
member 1 NR1D1 0.00562 4.98 6.11 2.35 
Corin, serine peptidase CORIN 0.00006 4.93 4.63 3.59 
Deltex homolog 3 (Drosophila) DTX3 0.00013 4.92 4.56 3.47 
IDI1 protein-like LOC100346274 ^, + 0.00042 4.87 6.67 5.51 
RNA binding motif protein 6 RBM6 0.00003 4.85 6.15 1.73 
TNF receptor-associated factor 3 interacting 
protein 1  TRAF3IP1 0.00043 4.80 5.56 1.29 
TAF15 RNA polymerase II, TATA box 
binding protein (TBP)-associated factor, 
68kDa 
TAF15 ^, + 0.00004 4.71 4.65 7.45 
Nibrin-like LOC100352398 ^ 0.00171 4.71 3.74 7.92 
LY6/PLAUR domain containing 5 LYPD5 0.00004 4.70 7.31 2.68 
Aquaporin 1 (Colton blood group) AQP1 0.00372 4.69 2.33 1.44 
4-hydroxyphenylpyruvate dioxygenase-like  HPDL 0.00008 4.68 8.45 2.22 
Mast cell-expressed membrane protein 1  MCEMP1 0.00003 4.67 8.27 1.74 
Amyloid beta (A4) precursor protein-
binding, family B, member 3 APBB3 <0.00001 4.66 3.33 1.82 
Chymase like protein LOC100008644 0.00009 4.58 8.36 1.84 
Transmembrane protease, serine 11E  TMPRSS11E <0.00001 4.57 6.76 1.26 
Carboxypeptidase A5 CPA5 0.00007 4.56 9.11 3.29 
Fc receptor-like 3  FCRL3 0.00022 4.52 -1.16 3.78 
Carbonic anhydrase 2 (EC 4.2.1.1) CA2 0.00964 4.51 4.68 1.67 
Pleckstrin homology domain containing, 
family G (with RhoGef domain) member 6 
[ 
PLEKHG6 0.00011 4.47 9.24 3.23 
BMS1-like, ribosome assembly protein LOC100339194 0.00003 4.46 3.99 3.51 
Potassium channel tetramerisation domain 
containing 19  KCTD19 0.00004 4.40 6.56 1.51 
G protein-coupled receptor 52  GPR52 0.00010 4.40 5.75 2.26 
Cyclin B3 CCNB3 0.00012 4.39 6.05 1.68 
Cytochrome P450, family 4, subfamily A, 
polypeptide 5 CYP4A5 0.00044 4.39 6.74 3.27 
Kelch-like 17 (Drosophila)  KLHL17 <0.00001 4.38 3.65 2.72 
WD repeat domain 13  WDR13 0.00063 4.37 3.14 2.31 
O-sialoglycoprotein endopeptidase-like LOC100348675 0.00039 4.36 3.71 3.87 
Dmx-like 2 DMXL2 0.00657 4.36 3.79 1.23 
CD2 molecule CD2 0.00002 4.35 8.04 1.47 
NADH dehydrogenase (ubiquinone) Fe-S 
protein 1, 75kDa 
LOC10034194
1 0.00022 4.34 5.46 2.69 
DIS3 mitotic control homolog (S. 
cerevisiae)-like 2  DIS3L2 ^ 0.00024 4.32 3.96 4.17 
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General transcription factor IIE, 
polypeptide 2, beta 34kDa  GTF2E2 0.00360 4.29 3.63 2.33 
Doublesex and mab-3 related transcription 
factor 2 DMRT2 0.00002 4.28 7.32 1.81 
Ribonuclease, RNase A family, 1 
(pancreatic)  RNASE1 ^, + 0.00010 4.26 3.15 3.23 
Paralemmin 2 PALM2 0.00116 4.26 3.57 2.43 
Fanconi anemia, complementation group C  FANCC ^, + <0.00001 4.25 6.39 6.10 
Collagen, type VII, alpha 1 COL7A1 0.00600 4.25 2.98 2.00 
Serine/threonine kinase 23, muscle-specific 
serine kinase 1 70 (Predicted)  SRPK3 0.00027 4.23 8.51 1.35 




OGT <0.00001 4.20 3.65 1.98 
SP100 nuclear antigen SP100 0.00039 4.19 3.25 3.36 
Uncharacterized protein C1orf51  C1orf51 0.00039 4.19 3.10 2.02 
Islet amyloid polypeptide Precursor; 
Fragment (Amylin)  IAPP 0.00004 4.17 5.78 1.40 
Family with sequence similarity 19 
(chemokine (C-C motif)-like), member A4 FAM19A4 0.00024 4.17 5.97 1.65 
MORN repeat containing 4 MORN4 <0.00001 4.14 4.53 1.45 
Leucine-rich repeat-containing G protein-
coupled receptor 5 LGR5 0.00019 4.14 5.36 3.32 
Spleen tyrosine kinase SYK 0.00072 4.13 4.88 1.52 
Guanylate cyclase 2D, membrane (retina-
specific)  GUCY2D ^, + 0.00008 4.11 8.34 4.64 
Pregnancy-zone protein PZP 0.00099 4.11 4.60 1.20 
Methyl-CpG binding domain protein 6  MBD6 <0.00001 4.11 3.11 2.26 
TERF1 (TRF1)-interacting nuclear factor 2  TINF2 0.00011 4.10 6.41 3.47 
Ankyrin repeat and SOCS box-containing 4 ASB4 ^ 0.00027 4.06 3.51 4.98 
Tripartite motif-containing 65  TRIM65 0.00079 4.05 4.87 2.63 
Inhibitor of kappa light polypeptide gene 
enhancer in B-cells, kinase epsilon IKBKE 0.00003 4.04 3.39 1.93 
Coiled-coil domain containing 54  CCDC54 0.00196 4.04 4.57 3.11 




2 0.00403 4.02 3.56 2.74 
Fibroblast growth factor binding protein 1-
like 
LOC100353835 
^, + 0.00122 4.01 4.63 5.01 
ATPase, Cu++ transporting, alpha 
polypeptide  ATP7A 0.00404 4.01 2.58 1.59 
2,3-bisphosphoglycerate mutase (BPGM) BPGM 0.00098 4.00 4.18 1.21 
 
^ DEGs that are common between ‘hypertension only’ and ‘hypercholesterolemia plus sham’ rabbits (each group vs. 
sham operated control group). + DEGs that are common among ‘hypertension only’, ‘hypercholesterolemia plus sham’, 
and ‘hypercholesterolemia plus hypertension’ rabbits (each group vs. sham operated control group). HT: ‘Hypertension 
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rabbits vs. sham operated control rabbits with greater than 10-fold change. For the 
purpose of brevity, the table only includes genes with more than 10-fold change. (Ong 
et al., 2013) 
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Beta tropomyosin (LOC100125984) LOC100125984 <0.00001 -97.92 -17.13 -2.30 
Prefoldin subunit 5  PFDN5 <0.00001 -84.52 -6.79 -1.78 
Cullin 3 CUL3 <0.00001 -73.37 -6.10 1.05 
Family with sequence similarity 184, 
member B FAM184B <0.00001 -68.05 -25.72 -1.32 
Crystallin, alpha A (CRYAA) CRYAA <0.00001 -60.93 -10.81 -1.50 
Forkhead box N1 FOXN1 ^, + 0.00048 -56.89 -45.12 -26.20 
Tumor necrosis factor receptor superfamily, 
member 11b TNFRSF11B <0.00001 -55.91 -33.58 1.69 
Glutamate dehydrogenase 1-like LOC100351029 <0.00001 -55.82 -3.96 1.18 
3'(2'), 5'-bisphosphate nucleotidase 1  BPNT1 <0.00001 -52.27 -25.01 1.05 
Interferon-related developmental regulator 
1 IFRD1 <0.00001 -51.14 -4.37 1.33 
Manganese superoxide dismutase  SOD-2 <0.00001 -46.42 -14.80 -1.23 
GC-rich promoter binding protein 1  GPBP1 <0.00001 -42.73 -3.71 -2.55 
Microtubule associated tumor suppressor 1 MTUS1 <0.00001 -41.71 -20.40 -1.88 
Ubiquinol-cytochrome c reductase, Rieske 
iron-sulfur polypeptide-like 1  UQCRFS1P1 <0.00001 -40.99 -23.74 1.08 
Lupus La protein SSB <0.00001 -40.45 -10.68 -1.63 
Transmembrane protein 109 (TMEM109) TMEM109 <0.00001 -39.14 -4.26 -1.07 
Progesterone receptor membrane 
component 1 
LOC1003570
97 <0.00001 -38.66 -21.91 1.04 
Solute carrier family 9, subfamily A 
(NHE2, cation proton antiporter 2), member 
2 
SLC9A2 0.00007 -36.54 -7.21 -2.62 
Obg-like ATPase 1  OLA1 <0.00001 -35.58 -2.87 1.04 
Chaperonin containing TCP1, subunit 2 
(beta) CCT2 <0.00001 -35.56 -30.96 -1.91 
Androgen-induced 1  AIG1 0.00002 -35.48 -14.63 -3.30 
Endoplasmic reticulum lectin 1 ERLEC1 <0.00001 -34.54 -2.93 1.35 
Glyceraldehyde-3-phosphate 
dehydrogenase, spermatogenic GAPDHS <0.00001 -33.66 -32.91 1.01 
Transmembrane protein 38B  TMEM38B <0.00001 -31.53 -18.80 1.05 
Alpha-tubulin N-acetyltransferase ATAT1 <0.00001 -29.43 -2.20 1.37 
OTU domain containing 6A  OTUD6A 0.00011 -28.99 -5.70 -3.59 
Chaperonin containing TCP1, subunit 2 
(beta) (CCT2) CCT2 <0.00001 -28.67 -4.57 -1.23 
Lysosomal-associated membrane protein 2-
like 
LOC1003509
46 <0.00001 -26.85 -15.88 -1.78 
Tumor protein, translationally-controlled 1 
(TPT1) TPT1 0.00008 -26.77 -1.80 -1.45 
Tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, beta 
polypeptide-like 
LOC1003582
99 <0.00001 -26.07 -3.37 -1.13 
AHA1, activator of heat shock 90kDa 
protein ATPase homolog 2 (yeast)  AHSA2 0.00081 -23.77 -5.22 -3.66 
Mitochondrial ribosomal protein L15 MRPL15 ^, + <0.00001 -23.01 -9.57 -6.97 
Zinc finger protein 638 ZNF638 <0.00001 -22.80 -2.82 -1.10 
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Proteasome (prosome, macropain) 26s 
subunit, ATPase, 6 PSMC6 <0.00001 -22.71 -3.80 -1.36 
V-Ki-ras2 Kirsten rat sarcoma viral 
oncogene homolog  KRAS <0.00001 -22.11 -15.47 -1.18 
Myosin IE MYO1E <0.00001 -21.50 -2.84 1.35 
Hematopoietic prostaglandin D synthase HPGDS ^, + 0.00043 -21.44 -13.63 -12.38 
Insulin induced gene 2  INSIG2 <0.00001 -21.07 -4.71 -3.78 
Putative homeodomain transcription factor 
2 PHTF2 <0.00001 -20.84 -3.07 -1.69 
Cytoplasmic beta-actin LOC100009506 <0.00001 -20.51 -7.80 -1.19 
TRAF family member-associated NFKB 
activator TANK 0.00001 -20.39 -5.66 -1.28 
Zinc finger protein 642 ZFP69 0.00058 -20.24 -12.02 -1.58 
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, 
subfamily a, member 5  
SMARCA5 <0.00001 -19.50 -8.08 1.08 
Transmembrane protein 14C-like LOC100357487 0.00875 -18.42 -1.74 1.43 
Zinc finger protein 326 ZNF326 <0.00001 -18.36 -6.29 1.09 
DCN1, defective in cullin neddylation 1, 
domain containing 4 (S. cerevisiae) DCUN1D4 <0.00001 -18.27 -15.90 -1.65 
PHD finger protein 6 PHF6 0.00001 -17.91 -3.80 -1.84 
CD302 molecule  CD302 <0.00001 -17.51 -4.14 -1.14 
ORM1-like 3 (S. cerevisiae)  ORMDL3 <0.00001 -17.49 -16.75 -1.24 
Large subunit GTPase 1 homolog (S. 
cerevisiae)  LSG1 ^ 0.00001 -17.14 -2.15 1.16 
FGGY carbohydrate kinase domain 
containing FGGY 0.00007 -16.26 -3.77 -2.04 
Eukaryotic translation initiation factor 2 
subunit 1 EIF2S1 0.00001 -16.08 -14.40 -2.04 
Ribophorin I  RPN1 0.00002 -15.81 -4.51 -1.30 
Periphilin 1  PPHLN1 <0.00001 -15.71 -2.19 1.14 
Mitochondrial ribosomal protein L1  MRPL1 <0.00001 -15.71 -12.00 -1.06 
Tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, theta 
polypeptide (YWHAQ) 
YWHAQ <0.00001 -15.13 -2.31 -1.44 
Sin3A-associated protein, 30kDa SAP30 <0.00001 -14.99 -16.96 -1.09 
Ribosomal protein L26  RPL26 ^ 0.00016 -14.60 -2.81 -5.27 
Amyloid beta precursor protein 
(cytoplasmic tail) binding protein 2 APPBP2 <0.00001 -14.30 -2.02 -1.11 
Nucleolar protein 10  NOL10 <0.00001 -14.02 -5.15 1.08 
TIA1 cytotoxic granule-associated RNA 
binding protein-like 1  TIAL1 0.00001 -13.80 -4.88 2.34 
Titin TTN 0.00001 -13.60 -6.90 -2.26 
Asparagine-linked glycosylation 9, alpha-
1,2-mannosyltransferase homolog (S. 
cerevisiae)  
ALG9 <0.00001 -13.51 -2.12 -1.33 
Aryl hydrocarbon receptor nuclear 
translocator (ARNT protein)(Dioxin 
receptor, nuclear translocator)(Hypoxia-
inducible factor 1 beta)(HIF-1 beta) 
ARNT <0.00001 -13.43 -5.12 1.04 
BRCA2 and CDKN1A interacting protein  BCCIP ^ <0.00001 -13.26 -2.51 -1.00 
WW domain containing adaptor with 
coiled-coil  WAC 0.00001 -13.20 -11.91 -3.12 
Uncharacterized LOC100347346 LOC100347346 0.00002 -13.05 -2.30 1.33 
Tweety homolog 1 (Drosophila) TTYH1 0.00108 -12.82 -27.02 -5.16 
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Ubiquitin specific peptidase 16 USP16 <0.00001 -12.55 -1.82 1.16 
UDP-glucuronosyltransferase UGT2C1 <0.00001 -12.36 -2.07 2.01 
Heterogeneous nuclear ribonucleoprotein C 
(hnRNP C)  HNRNPC <0.00001 -12.22 -7.49 -1.33 
Nucleolar protein 11 NOL11 0.00032 -11.98 -13.01 2.09 
Guanylate cyclase 1, soluble, beta 3  GUCY1B3 0.00010 -11.97 -6.79 -2.52 
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, 
subfamily d, member 3  
SMARCD3 <0.00001 -11.91 -2.86 -1.18 
Upregulated during skeletal muscle growth 
5 homolog (mouse)  USMG5 <0.00001 -11.86 -2.36 -1.47 
Endothelial differentiation gene 7 protein LOC100009484 0.00562 -11.73 -7.39 -1.86 
Cysteine-rich protein 3 CRIP3 <0.00001 -10.99 -4.26 1.45 
Interferon induced with helicase C domain 
1 IFIH1 0.00001 -10.96 -5.60 1.21 
Solute carrier family 2, facilitated glucose 
transporter member 3 Fragment (Glucose 
transporter type 3, brain)(GLUT-3)  
SLC2A3 0.00019 -10.95 -11.60 -1.81 
Eukaryotic translation initiation factor 3, 
subunit M EIF3M <0.00001 -10.81 -2.09 -1.38 
PDLIM1 interacting kinase 1 like PDIK1L 0.00010 -10.76 -2.61 -2.49 
F-box and WD repeat domain containing 7  FBXW7 <0.00001 -10.71 -2.36 1.36 
IQ motif containing GTPase activating 
protein 3  IQGAP3 0.00007 -10.54 -9.37 1.25 
Caudal type homeobox 1 CDX1 0.00001 -10.42 -6.08 -1.18 
RUN and FYVE domain containing 1  RUFY1 0.00004 -10.38 -2.46 -1.02 
Lysine (K)-specific demethylase 4A KDM4A <0.00001 -10.29 -3.47 -2.03 
RWD domain containing 3 RWDD3 <0.00001 -10.16 -2.04 1.03 
 
^ DEGs that are common between ‘hypertension only’ and ‘hypercholesterolemia plus sham’ rabbits (each group vs. 
sham operated control group). + DEGs that are common among ‘hypertension only’, ‘hypercholesterolemia plus sham’, 
and ‘hypercholesterolemia plus hypertension’ rabbits (each group vs. sham operated control group). HT: ‘Hypertension 
only’ rabbits. HC: ‘Hypercholesterolemia plus sham’ rabbits. HCHT: ‘Hypercholesterolemia plus hypertension’ 
rabbits. 
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EPH receptor A1 EPHA1 0.00008 20.31 8.98 3.03 
SP110 nuclear body protein  SP110 <0.00001 15.47 8.42 2.06 
Schlafen family member 14 SLFN14 0.00614 13.64 10.65 1.33 
Glucose-fructose oxidoreductase domain 
containing 2-like 
LOC10035115
0 ^, + 0.00001 12.42 6.34 4.01 
Gonadotropin-releasing hormone receptor GnRHR 0.00008 10.39 5.47 3.11 
Solute carrier family 9, subfamily A (NHE8, 
cation proton antiporter 8), member 8 SLC9A8 0.00175 10.32 6.14 3.55 
Carbonic anhydrase I  CA1 0.00531 10.07 10.02 2.38 
Gap junction alpha-3 protein-like LOC100357902 0.00689 9.96 9.62 2.92 
Pleckstrin homology domain containing, 
family G (with RhoGef domain) member 6  PLEKHG6 0.00011 9.24 4.47 3.23 
Uncharacterized protein C11orf71  C11orf71 0.00446 9.22 8.33 2.97 
Carboxypeptidase A5  CPA5 0.00007 9.11 4.56 3.29 
Serine proteinase inhibitor, clade B, member 
2 (Predicted)  
SERPINB2 
^, + 0.00005 9.10 6.99 5.63 
Kinesin family member 13B KIF13B 0.00002 9.02 6.02 2.35 
MRS2 magnesium homeostasis factor 
homolog (S. cerevisiae) MRS2 <0.00001 8.85 3.90 2.38 
Serine/threonine kinase 23, muscle-specific 
serine kinase 1 70 (Predicted) SRPK3 0.00027 8.51 4.23 1.35 
4-hydroxyphenylpyruvate dioxygenase-like HPDL 0.00008 8.45 4.68 2.22 
HEAT repeat containing 3 LOC100357872 0.00100 8.34 3.77 2.38 
Guanylate cyclase 2D, membrane (retina-
specific)  
GUCY2D ^, 
+ 0.00008 8.34 4.11 4.64 
Membrane-spanning 4-domains, subfamily 
A, member 2  MS4A2 0.00891 8.29 3.81 2.43 
Mast cell-expressed membrane protein 1  MCEMP1 0.00003 8.27 4.67 1.74 
Follicle stimulating hormone receptor  FSHR 0.00023 8.27 5.31 1.24 
Spectrin, alpha, erythrocytic 1 (elliptocytosis 
2)  SPTA1 0.00375 8.20 6.03 2.75 
Bardet-Biedl syndrome 5 LOC100342443 0.00004 8.15 5.62 2.76 
Uncharacterized protein C1orf50  C1orf50 0.00006 8.01 3.80 5.81 
Transmembrane protein 212  TMEM212 0.00039 7.93 8.84 3.48 
CKLF-like MARVEL transmembrane 
domain containing 2 CMTM2 0.00071 7.79 6.28 2.38 
Double zinc ribbon and ankyrin repeat-
containing protein 1 DZANK1 ^, + <0.00001 7.37 5.04 4.87 
Doublesex and mab-3 related transcription 
factor 2 DMRT2 0.00002 7.32 4.28 1.81 
LY6/PLAUR domain containing 5  LYPD5 0.00004 7.31 4.70 2.68 
Kinesin family member 21A  KIF21A 0.00003 7.31 2.93 2.10 
N(alpha)-acetyltransferase 25, NatB auxiliary 
subunit  NAA25 ^, + 0.00099 7.23 3.68 1.04 
General transcription factor IIB LOC100359058 0.00015 7.00 3.67 2.64 
Relaxin/insulin-like family peptide receptor 2 RXFP2 ^, + 0.00029 6.96 5.62 4.79 
Interleukin 20 receptor, alpha  IL20RA <0.00001 6.96 3.79 2.30 
Family with sequence similarity 46, member 
C FAM46C 0.00016 6.92 8.51 1.72 
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Fructose-1,6-bisphosphatase 1 FBP1 0.00008 6.82 2.85 1.96 
Transmembrane protease, serine 11E TMPRSS11E <0.00001 6.76 4.57 1.26 
IDI1 protein-like LOC100346274 ^, + 0.00042 6.67 4.87 5.51 
Solute carrier family 18 (vesicular 
monoamine), member 1 SLC18A1 0.00074 6.64 3.45 1.42 
IQ motif and ubiquitin domain containing  IQUB 0.00104 6.64 2.98 1.90 
Family with sequence similarity 71, member 
C FAM71C 0.00026 6.63 3.24 2.04 
Protease, serine, 38 PRSS38 0.00058 6.51 5.74 1.95 
Signal-induced proliferation-associated 1 like 
3 SIPA1L3 ^, + 0.00001 6.50 8.45 4.80 
Secretoglobin, family 3A, member 1  SCGB3A1 0.00010 6.42 3.56 -1.18 
STAM binding protein-like 1  STAMBPL1 0.00286 6.39 2.37 1.40 
Fanconi anemia, complementation group C  FANCC ^, + <0.00001 6.39 4.25 6.10 
Tripartite motif-containing 67 TRIM67 0.00175 6.39 3.25 2.15 
Serum response factor binding protein 1-like LOC100349313 0.00139 6.34 3.53 2.18 
Interstitial collagenase Precursor (EC 
3.4.24.7)(Matrix metalloproteinase-1)(MMP-
1) 
MMP1 0.00149 6.33 2.20 8.12 
G protein-coupled receptor 119 GPR119 0.00058 6.30 2.00 2.41 
RNA binding motif protein 6 RBM6 0.00003 6.15 4.85 1.73 
2',3'-cyclic nucleotide 3' phosphodiesterase CNP <0.00001 6.14 3.45 1.42 
Nuclear receptor subfamily 1, group D, 
member 1  NR1D1 0.00562 6.11 4.98 2.35 
Cyclin B3 CCNB3 0.00012 6.05 4.39 1.68 
Steroidogenic acute regulatory protein STAR 0.00007 6.05 3.31 3.36 
CD4 molecule (CD4) CD4 0.00004 6.02 2.77 1.17 
DOMON domain-containing protein 
FRRS1L FRRS1L 0.00003 5.99 3.57 1.37 
Tubulin tyrosine ligase-like family, member 
5 
LOC100359
240 0.00019 5.99 2.92 1.63 
Family with sequence similarity 19 
(chemokine (C-C motif)-like), member A4 FAM19A4 0.00024 5.97 4.17 1.65 
Sterol O-acyltransferase 2 SOAT2 0.00003 5.94 7.18 3.01 
Aminolevulinate, delta-, synthase 2  ALAS2 0.00072 5.93 5.86 1.97 
Thymidine phosphorylase  TYMP 0.00005 5.87 3.87 1.17 
Dynein heavy chain domain 1  DNHD1 0.00134 5.87 3.49 2.10 
Insulin-like 5 (INSL5), INSL5 0.00018 5.85 3.03 1.39 
Meprin A, beta MEP1B ^, + 0.00291 5.85 5.12 5.37 
Arylformamidase  AFMID 0.00100 5.81 4.03 1.65 
Islet amyloid polypeptide IAPP 0.00004 5.78 4.17 1.40 
Transcription elongation factor A (SII)-like 
2-like 
LOC100340
955 0.00015 5.75 3.22 3.13 
G protein-coupled receptor 52  GPR52 0.00010 5.75 4.40 2.26 
Solute carrier family 5 (sodium/glucose 
cotransporter), member 9 (SLC5A9) SLC5A9 0.00002 5.73 3.28 3.82 
Kruppel-like factor 13 KLF13 0.00007 5.69 3.32 1.11 
Granulate-macrophage stimulating factor 
(Predicted)  GMCSF 0.00004 5.68 3.39 2.22 
Listerin E3 ubiquitin protein ligase 1 LTN1 0.00009 5.66 2.75 3.05 
Zinc finger, DHHC-type containing 23  ZDHHC23 0.00001 5.64 3.22 7.18 
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Carboxylesterase 8 (putative) CES4A 0.00023 5.63 3.83 1.47 
C-type lectin domain family 1, member B CLEC1B 0.00584 5.60 3.65 1.50 
TNF receptor-associated factor 3 interacting 
protein 1  TRAF3IP1 0.00043 5.56 4.80 1.29 
Solute carrier family 15, member 5  SLC15A5 0.00075 5.55 2.70 1.80 
Glucosidase, beta, acid 3 (cytosolic)  GBA3 0.00012 5.55 2.77 2.27 
Tetraspanin 33  TSPAN33 0.00078 5.53 6.37 3.97 
Proline-rich protein 3 PRR3 0.00129 5.50 3.46 1.24 
Chemokine (C-C motif) ligand 19 CCL19 0.00055 5.50 2.39 2.16 
NADH dehydrogenase (ubiquinone) Fe-S 
protein 1, 75kDa 
LOC100341
941 0.00022 5.46 4.34 2.69 
AchR epsilon subunit Fragment CHRNE 0.00010 5.43 3.22 1.33 
Transmembrane protein C5orf28  C5orf28 0.00319 5.38 2.49 2.31 
Dehydrogenase/reductase (SDR family) 
member 9  DHRS9 0.00168 5.37 3.41 3.41 
FCH and double SH3 domains 1 FCHSD1 0.00015 5.37 3.24 2.85 
Leucine-rich repeat-containing G protein-
coupled receptor 5 LGR5 * 0.00019 5.36 4.14 3.32 
Uncharacterized protein C7orf72  C7orf72 0.00114 5.35 2.68 -1.29 
Family with sequence similarity 71, member 
F2 FAM71F2 0.00643 5.34 2.13 1.21 
Otopetrin 2  OTOP2 0.00006 5.31 3.23 3.74 
ELOVL fatty acid elongase 3 ELOVL3 0.00012 5.30 3.05 1.83 
Solute carrier family 7 (anionic amino acid 
transporter), member 13 SLC7A13 0.00134 5.30 2.81 1.82 
Uncharacterized protein C2orf71  C2orf71 0.00177 5.30 3.60 1.36 
Ankyrin and armadillo repeat containing ANKAR ^, + 0.00006 5.23 7.99 7.05 
Solute carrier family 14 (urea transporter), 
member 1 (Kidd blood group) SLC14A1 0.00027 5.21 3.38 1.61 
Zinc finger, CW type with PWWP domain 2  ZCWPW2 0.00011 5.21 5.29 2.31 
Fc receptor-like A  FCRLA 0.00083 5.14 6.76 1.94 
RAS guanyl releasing protein 4 RASGRP4 0.00058 5.11 3.68 2.61 
Family with sequence similarity 167, 
member A FAM167A 0.00017 5.11 2.44 14.04 
ATPase, aminophospholipid transporter, 
class I, type 8B, member 2 ATP8B2 0.00360 5.07 3.14 3.16 
Cytochrome P450, family 4, subfamily A, 
polypeptide 5 CYP4A5 0.00061 5.05 3.12 1.03 
ATPase, H+/K+ exchanging, alpha 
polypeptide (ATP4A) ATP4A <0.00001 5.02 3.53 1.47 




882 0.00001 4.99 2.64 2.48 
Ankyrin repeat and SOCS box-containing 4 ASB4 ^ <0.00001 4.97 3.70 6.36 
Phosphatidylcholine transfer protein PCTP 0.00001 4.96 3.26 2.13 
Solute carrier family 39 (zinc transporter), 
member 12  SLC39A12 0.00006 4.96 2.48 4.23 
Transmembrane emp24 protein transport 
domain containing 6  TMED6 0.00040 4.96 3.19 2.10 
Actin-related protein T1  ACTRT1 0.00005 4.94 3.11 2.95 
Wings apart-like homolog LOC100348678 0.00041 4.94 2.92 2.27 
Fructose-1,6-bisphosphatase 1 FBP1 0.00050 4.88 2.15 1.51 
Spleen tyrosine kinase  SYK 0.00072 4.88 4.13 1.52 
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Tripartite motif-containing 65 TRIM65 0.00079 4.87 4.05 2.63 
Neuron navigator 2 NAV2 0.00080 4.87 2.69 1.80 
Potassium channel tetramerisation domain 
containing 19 KCTD19 0.00123 4.87 3.10 1.42 
Spermatogenesis associated, serine-rich 1  SPATS1 0.00201 4.83 2.57 2.77 
Solute carrier family 5 (sodium/glucose 
cotransporter), member 1 SLC5A1 0.00001 4.80 2.95 2.26 
Tripartite motif-containing 35  TRIM35 0.00084 4.80 3.16 1.38 
Cytochrome P450, family 26, subfamily C, 
polypeptide 1 CYP26C1 0.00224 4.79 2.30 -1.58 
Polymeric immunoglobulin receptor PIGR 0.00025 4.75 2.82 1.40 
Serine incorporator 1 LOC100357075 0.00015 4.74 5.37 2.50 
Ras and Rab interactor-like RINL 0.00135 4.71 3.40 1.67 
Ubiquitin associated and SH3 domain 





GALNT13 <0.00001 4.70 1.93 2.52 
Transmembrane protein 173  TMEM173 0.00141 4.70 5.36 2.88 
UHRF1 binding protein 1 UHRF1BP1 0.00074 4.69 5.70 2.63 
PRP18 pre-mRNA processing factor 18 
homolog (S. cerevisiae) PRPF18 0.00144 4.68 2.28 1.10 
Carbonic anhydrase 2 (EC 4.2.1.1)(Carbonic 
anhydrase II)(CA-II)(Carbonate dehydratase 
II)  
CA2 0.00964 4.68 4.51 1.67 
Spinster homolog 3 (Drosophila) SPNS3 0.00049 4.68 3.63 2.40 
Galactosidase, beta 1-like 3  GLB1L3 0.00003 4.67 3.03 1.24 
Iroquois homeobox 2 IRX2 0.00052 4.66 3.40 -1.04 
Collagen, type XVII, alpha 1  COL17A1 0.00028 4.65 2.60 1.07 
Patched homolog 2 (Drosophila) PTCH2 0.00005 4.65 3.84 2.55 
TAF15 RNA polymerase II, TATA box 
binding protein (TBP)-associated factor, 
68kDa 
TAF15 ^, + 0.00004 4.65 4.71 7.45 
BCL2-like 10 (apoptosis facilitator) BCL2L10 0.00018 4.64 5.34 1.67 
Mix1 homeobox-like 1 (Xenopus laevis)  MIXL1 0.00093 4.64 3.54 5.80 
Fibroblast growth factor binding protein 1-
like 
LOC10035383
5 ^, + 0.00122 4.63 4.01 5.01 
Corin, serine peptidase  CORIN 0.00006 4.63 4.93 3.59 
V-set and immunoglobulin domain 
containing 2  VSIG2 0.00168 4.60 5.53 3.51 
Pregnancy-zone protein PZP 0.00099 4.60 4.11 1.20 
DEAQ box RNA-dependent ATPase 1  DQX1 0.00520 4.60 2.94 1.85 
Potassium channel, subfamily K, member 1 KCNK1 0.00217 4.58 1.68 3.22 
Purinergic receptor P2Y, G-protein coupled, 
10 P2RY10 0.00197 4.57 2.24 1.99 
Coiled-coil domain containing 54 CCDC54 0.00196 4.57 4.04 3.11 
Somatostatin receptor 2  SSTR2  0.00077 4.56 2.44 2.78 
Deltex homolog 3 (Drosophila) DTX3 0.00013 4.56 4.92 3.47 
Zinc finger, DHHC-type containing 19  ZDHHC19 0.00241 4.55 3.32 1.65 
Ret proto-oncogene RET 0.00036 4.55 2.71 1.88 
MORN repeat containing 4 MORN4 <0.00001 4.53 4.14 1.45 
Oxytocin receptor OTXR 0.00517 4.52 2.58 1.10 
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Serine peptidase inhibitor, Kazal type 1 SPINK1 0.00055 4.50 2.53 1.60 
Membrane protein, palmitoylated 2 
(MAGUK p55 subfamily member 2) MPP2 0.00409 4.50 2.89 2.36 
Solute carrier family 13 (sodium/sulfate 
symporters), member 1  SLC13A1 0.00325 4.49 1.58 1.59 
Follistatin-like 5  FSTL5 0.00071 4.49 2.31 3.17 
Mitochondrial ribosomal protein S15-like LOC100345026 0.00064 4.49 2.65 2.82 
TERF1 (TRF1)-interacting nuclear factor 2  TINF2 0.00325 4.49 3.29 2.19 
Keratin associated protein 19-4 KRTAP19-4 0.00044 4.48 2.78 1.36 
XK, Kell blood group complex subunit-
related, X-linked  XKRX 0.00051 4.47 2.54 2.36 
Chloride intracellular channel 2 (Predicted) CLIC2 0.00279 4.46 5.43 1.60 
FK506 binding protein 1B, 12.6 kDa FKBP1B 0.00274 4.46 2.32 -1.46 
Phospholipase C, zeta 1 PLCZ1 0.00002 4.45 2.92 1.01 
CD244 molecule, natural killer cell receptor 
2B4  CD244 0.00003 4.44 2.90 -1.55 
Carboxyl ester lipase (bile salt-stimulated 
lipase) (CEL) CEL 0.00016 4.44 2.68 1.98 
ADAM metallopeptidase with 
thrombospondin type 1 motif, 18  ADAMTS18 0.00213 4.43 2.90 1.94 
UDP-glucuronosyltransferase UGT2C1 0.00035 4.42 2.75 3.99 
Fms-related tyrosine kinase 3 FLT3 0.00270 4.41 3.63 1.80 
Mitogen-activated protein kinase binding 
protein 1  MAPKBP1 0.00003 4.41 2.68 3.08 
Ammonium transporter Rh type C (Rhesus 
blood group family type C glycoprotein)(Rh 
family type C glycoprotein)(Rh type C 
glycoprotein) 
RHCG 0.00032 4.41 3.29 2.20 
Kelch-like 1 (Drosophila) KLHL1 0.00003 4.35 2.80 -1.02 
Leucine rich repeat transmembrane neuronal 
4  LRRTM4 0.00002 4.34 2.67 3.58 
Proteoglycan 3  PRG3 0.00254 4.33 3.79 1.60 
Ligand of numb-protein X 1-like LOC100343259 0.00568 4.33 2.97 1.19 
Chymase like protein LOC100008644 0.00060 4.32 2.21 -1.31 
Sex comb on midleg-like 4 (Drosophila) SCML4 0.00854 4.32 2.94 1.40 
BMS1-like, ribosome assembly protein LOC100339194 0.00017 4.31 3.44 2.21 
Uncharacterized protein C2orf61  C2orf61 0.00893 4.31 3.04 3.08 
REC8 homolog (yeast) REC8 <0.00001 4.31 5.52 1.93 
Protein FAM55A FAM55A 0.00326 4.30 1.70 1.16 
Cyclin-dependent kinase 15  CDK15 0.00129 4.28 3.69 1.93 
Transmembrane and coiled-coil domains 4  TMCO4 0.00007 4.28 5.42 2.43 
Rac GTPase activating protein 1 pseudogene  RACGAP1P 0.00023 4.27 2.33 1.43 
Family with sequence similarity 170, 
member A  FAM170A 0.00008 4.23 2.99 2.43 
Mitogen-activated protein kinase 4 MAP3K4 0.00788 4.22 3.16 2.40 
ATPase, H+ transporting, lysosomal 70kDa, 
V1 subunit A ATP6V1A 0.00397 4.19 1.78 1.38 
Solute carrier family 9, subfamily A (NHE5, 
cation proton antiporter 5), member 5 SLC9A5 0.00057 4.19 5.36 2.33 
2,3-bisphosphoglycerate mutase (BPGM) BPGM 0.00098 4.18 4.00 1.21 
FRY-like FRYL 0.00291 4.18 2.56 1.46 
Clusterin-like 1 (retinal) CLUL1 0.00072 4.17 2.68 2.09 
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Superiorcervical ganglia, neural specific 10 LOC100344464 0.00228 4.14 1.59 1.78 
Histamine receptor H1 HRH1 0.00001 4.13 2.38 1.92 
Cingulin (Predicted)  CGN  0.00236 4.12 3.44 1.43 
Nuclear factor of kappa light polypeptide 
gene enhancer in B-cells inhibitor, delta NFKBID 0.00103 4.12 3.05 1.13 
Ribonuclease, RNase A family, 1 
(pancreatic)] RNASE1 ^, + 0.00043 4.11 3.92 2.83 
MLX interacting protein  MLXIP 0.00069 4.09 5.36 3.02 
Nuclear prelamin A recognition factor LOC100344024 0.00002 4.09 2.46 2.47 
Actin, beta-like 2  ACTBL2 0.00023 4.09 2.55 1.32 
Ghrelin receptor (LOC100101582) LOC100101582 0.00062 4.08 2.17 1.40 
Olfactomedin 2  OLFM2 0.00385 4.07 2.50 3.66 
Cytochrome c oxidase assembly homolog 10 
(yeast) COX10 0.00160 4.07 3.97 2.06 
Ribonuclease L (2',5'-oligoisoadenylate 
synthetase-dependent) RNASEL 0.00028 4.06 1.98 -1.16 
Keratin associated protein 11-1 KRTAP11-1 0.00013 4.04 2.57 2.16 
Family with sequence similarity 53, member 
C FAM53C <0.00001 4.03 2.48 9.87 
DnaJ (Hsp40) homolog, subfamily C, 
member 5 beta DNAJC5B 0.00016 4.03 2.35 -1.01 
Receptor (chemosensory) transporter protein 
1 RTP1 0.00012 4.03 1.76 -1.25 
Protocadherin 8  PCDH8 0.00005 4.02 3.09 3.20 
Ubiquitin specific protease 39 LOC100344046 0.00343 4.02 2.75 2.49 
Corticotropin releasing hormone binding 
protein CRHBP 0.00005 4.02 2.23 6.38 
Proline/serine-rich coiled-coil 1  PSRC1 0.00571 4.01 2.68 1.63 
Cadherin 17, LI cadherin (liver-intestine)  CDH17 0.00459 4.00 2.72 1.59 
 
^ DEGs that are common between ‘hypertension only’ and ‘hypercholesterolemia plus sham’ rabbits (each group vs. 
sham operated control group). + DEGs that are common among ‘hypertension only’, ‘hypercholesterolemia plus sham’, 
and ‘hypercholesterolemia plus hypertension’ rabbits (each group vs. sham operated control group). HT: ‘Hypertension 
only’ rabbits. HC: ‘Hypercholesterolemia plus sham’ rabbits. HCHT: ‘Hypercholesterolemia plus hypertension’ 
rabbits. 
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Appendix 14. Downregulated genes in the MCA of ‘hypercholesterolemia plus 
hypertension’ rabbits vs. sham operated control rabbits with greater than 4-fold change. 
(Ong et al., 2013) 
  
Description Gene Symbol Corrected P-value 







Forkhead box N1 FOXN1 ^, + 0.00048 -45.12 -56.89 -26.20 
Tumor necrosis factor receptor 
superfamily, member 11b TNFRSF11B <0.00001 -33.58 -55.91 1.69 
Glyceraldehyde-3-phosphate 
dehydrogenase, spermatogenic GAPDHS <0.00001 -32.91 -33.66 1.01 
Chaperonin containing TCP1, subunit 2 
(beta) CCT2 <0.00001 -30.96 -35.56 -1.91 
Tweety homolog 1 (Drosophila) TTYH1 0.00108 -27.02 -12.82 -5.16 
Family with sequence similarity 184, 
member B  FAM184B <0.00001 -25.72 -68.05 -1.32 
3'(2'), 5'-bisphosphate nucleotidase 1 BPNT1 <0.00001 -25.01 -52.27 1.05 
Ubiquinol-cytochrome c reductase, Rieske 
iron-sulfur polypeptide 1 pseudogene 1 UQCRFS1P1 <0.00001 -23.74 -40.99 1.08 
Progesterone receptor membrane 
component 1 
LOC1003570
97 <0.00001 -21.91 -38.66 1.04 
Microtubule associated tumor suppressor 
1 MTUS1 <0.00001 -20.40 -41.71 -1.88 
Transmembrane protein 38B  TMEM38B <0.00001 -18.80 -31.53 1.05 
Beta tropomyosin (LOC100125984) LOC100125984 <0.00001 -17.13 -97.92 -2.30 
ORM1-like 3 (S. cerevisiae) ORMDL3 <0.00001 -16.75 -17.49 -1.24 
DCN1, defective in cullin neddylation 1, 
domain containing 4 (S. cerevisiae)  DCUN1D4 <0.00001 -15.90 -18.27 -1.65 
Lysosomal-associated membrane protein 
2-like 
LOC1003509
46 <0.00001 -15.88 -26.85 -1.78 
V-Ki-ras2 Kirsten rat sarcoma viral 
oncogene homolog  KRAS <0.00001 -15.47 -22.11 -1.18 
Androgen-induced 1 AIG1 0.00002 -14.63 -35.48 -3.30 
Eukaryotic translation initiation factor 2 
subunit 1 EIF2S1 0.00001 -14.40 -16.08 -2.04 
Hematopoietic prostaglandin D synthase  HPGDS ^, + 0.00043 -13.63 -21.44 -12.38 
Nucleolar protein 11 NOL11 0.00032 -13.01 -11.98 2.09 
Zinc finger protein 642  ZFP69 0.00058 -12.02 -20.24 -1.58 
Mitochondrial ribosomal protein L1 MRPL1 <0.00001 -12.00 -15.71 -1.06 
WW domain containing adaptor with 
coiled-coil  WAC 0.00001 -11.91 -13.20 -3.12 
Solute carrier family 2, facilitated glucose 
transporter member 3 SLC2A3 0.00019 -11.60 -10.95 -1.81 
Crystallin, alpha A (CRYAA) CRYAA <0.00001 -10.81 -60.93 -1.50 
Lupus La protein SSB <0.00001 -10.68 -40.45 -1.63 
Somatostatin SST 0.00169 -10.49 -4.19 1.22 
Manganese superoxide dismutase SOD-2 <0.00001 -9.93 -51.78 -1.46 
Mitochondrial ribosomal protein L15  MRPL15 ^, + <0.00001 -9.57 -23.01 -6.97 
Proteasome (prosome, macropain) 26s 
subunit, non-ATPase, 4 PSMD4 ^, + <0.00001 -9.55 -12.56 -1.65 
IQ motif containing GTPase activating 
protein 3 IQGAP3 0.00007 -9.37 -10.54 1.25 
Cellular disintegrin ADAM 6d (ADAM6) ADAM6 0.00009 -9.13 -3.07 -1.03 
MRNA for prolactin receptor PRLR 0.00001 -8.55 -1.32 1.23 
Zinc finger protein 330 ZNF330 0.00012 -8.54 -7.41 -1.48 
ELAV (embryonic lethal, abnormal 
vision, Drosophila)-like 4 (Hu antigen D)  ELAVL4 0.00033 -8.49 -3.26 1.79 
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Intraflagellar transport 140-like LOC100355837 <0.00001 -8.45 -5.61 3.58 
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, 
subfamily a, member 5  
SMARCA5 <0.00001 -8.08 -19.50 1.08 
NADH dehydrogenase-like LOC100347823 <0.00001 -7.93 -7.55 2.02 
Zinc finger RNA binding protein ZFR <0.00001 -7.90 -64.53 -1.47 
Cytoplasmic beta-actin LOC100009506 <0.00001 -7.80 -20.51 -1.19 
Stathmin-like 2  STMN2 0.00129 -7.60 -4.10 1.78 
SRY (sex determining region Y)-box 2-
like 
LOC1003416
29 0.00001 -7.56 1.43 5.05 
Synaptosomal-associated protein, 25kDa  SNAP25 0.00087 -7.28 -4.33 1.08 
General transcription factor IIE, 
polypeptide 2, beta 34kDa  GTF2E2 <0.00001 -7.27 -7.79 1.06 
Solute carrier family 9, subfamily A 
(NHE2, cation proton antiporter 2), 
member 2 
SLC9A2 0.00007 -7.21 -36.54 -2.62 
Olfactomedin 3 OLFM3 0.00005 -6.99 -3.51 -1.25 
Pyruvate dehydrogenase kinase, isozyme 
4 PDK4 0.00711 -6.98 -3.47 -2.51 
Myelin-associated oligodendrocyte basic 
protein  MOBP 0.00776 -6.94 -3.86 -1.01 
Synaptotagmin XII SYT12 0.00001 -6.91 -5.36 1.14 
Titin TTN 0.00001 -6.90 -13.60 -2.26 
BPI fold containing family B, member 6 BPIFB6 0.00001 -6.83 -5.92 -1.79 
Guanylate cyclase 1, soluble, beta 3 GUCY1B3 0.00010 -6.79 -11.97 -2.52 
Prefoldin subunit 5 PFDN5 <0.00001 -6.79 -84.52 -1.78 
Proteolipid protein 1 (PLP1) PLP1 0.00339 -6.50 -6.44 -1.79 
Sodium channel, voltage-gated, type VII, 
alpha  SCN7A 0.00021 -6.43 -12.29 -1.77 
TBC1 domain family, member 15 TBC1D15 0.00297 -6.40 -4.23 -1.87 
DnaJ (Hsp40) homolog, subfamily C, 
member 6 DNAJC6 0.00001 -6.36 -9.39 -1.48 
Zinc finger protein 326  ZNF326 <0.00001 -6.29 -18.36 1.09 
Neurocalcin delta NCALD 0.00037 -6.13 -9.22 -1.93 
Cullin 3 CUL3 <0.00001 -6.10 -73.37 1.05 
Caudal type homeobox 1 CDX1 0.00001 -6.08 -10.42 -1.18 
Ring finger protein 222  RNF222 0.00001 -6.02 -8.36 -1.78 
Syntrophin, alpha 1 SNTA1 <0.00001 -5.98 -9.97 -1.04 
Creatine kinase, muscle CKM 0.00005 -5.96 -1.29 2.01 
Sin3A-associated protein, 30kDa  SAP30 <0.00001 -5.90 -43.67 1.30 
Signal recognition particle 54kDa  SRP54 <0.00001 -5.72 -16.53 1.62 
OTU domain containing 6A  OTUD6A 0.00011 -5.70 -28.99 -3.59 
Complement component 1, q 
subcomponent-like 3  C1QL3 0.00232 -5.67 -9.59 -2.89 
TRAF family member-associated NFKB 
activator  TANK 0.00001 -5.66 -20.39 -1.28 
Interferon induced with helicase C domain 
1  IFIH1 0.00001 -5.60 -10.96 1.21 
Paired box protein Pax-4 (Predicted) PAX4 0.00001 -5.45 -2.45 2.04 
IQ motif containing E  IQCE <0.00001 -5.18 -7.52 1.75 
Kinesin family member 20A  KIF20A 0.00003 -5.16 -6.68 -2.21 
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Nucleolar protein 10  NOL10 <0.00001 -5.15 -14.02 1.08 
Aryl hydrocarbon receptor nuclear 
translocator (ARNT protein)(Dioxin 
receptor, nuclear translocator)(Hypoxia-
inducible factor 1 beta)(HIF-1 beta)  
ARNT <0.00001 -5.12 -13.43 1.04 
Ribosomal protein L7-like LOC100339887 0.00001 -5.10 -6.70 -1.23 
Serine threonine kinase 39 STK39 0.00026 -5.10 -4.41 -2.06 
SPHK1 interactor, AKAP domain 
containing  SPHKAP 0.00629 -4.99 -3.70 -2.87 
NADP-dependent oxidoreductase domain-
containing protein 1 EC=1.-.-.- NOXRED1 0.00004 -4.98 -11.39 -1.28 
Neurogranin (protein kinase C substrate, 
RC3)  NRGN 0.00291 -4.98 -2.47 -1.08 
Acidic ribosomal phosphoprotein P0 36B4 0.00003 -4.94 -6.27 1.43 
Ring finger protein 38  RNF38 0.00023 -4.93 -9.14 -3.33 
TIA1 cytotoxic granule-associated RNA 
binding protein-like 1  TIAL1 0.00001 -4.88 -13.80 2.34 
GDNF family receptor alpha 4  GFRA4 0.00025 -4.88 -2.93 1.29 
Inositol polyphosphate phosphatase-like 1  INPPL1 0.00005 -4.87 -5.96 -1.14 
POU class 2 homeobox 3  POU2F3 <0.00001 -4.78 -7.48 1.89 
DnaJ (Hsp40) homolog, subfamily B, 
member 4  DNAJB4 <0.00001 -4.76 -9.11 -1.86 
Sulfotransferase family 4A, member 1 
(SULT4A1) SULT4A1 0.00285 -4.75 -3.88 -1.75 
Poly(rC) binding protein 3 PCBP3 <0.00001 -4.72 -8.33 1.19 
Insulin induced gene 2  INSIG2 <0.00001 -4.71 -21.07 -3.78 
Guanine nucleotide binding protein (G 
protein), alpha inhibiting activity 
polypeptide 1  
GNAI1 0.00012 -4.70 -4.15 -1.79 
KIAA1549  KIAA1549 0.00019 -4.67 -2.55 -1.05 
Myosin, light chain 6B, alkali, smooth 
muscle and non-muscle MYL6B 0.00002 -4.66 -7.23 -1.58 
Exostoses (multiple)-like 3  EXTL3 0.00001 -4.65 -3.53 -4.65 
Heterogeneous nuclear ribonucleoprotein 
C (hnRNP C)  HNRNPC <0.00001 -4.61 -35.05 -3.29 
Shroom family member 3 SHROOM3 <0.00001 -4.60 -7.95 -3.82 
Chaperonin containing TCP1, subunit 2 
(beta) (CCT2) CCT2 <0.00001 -4.57 -28.67 -1.23 
Enabled homolog (Drosophila) ENAH 0.00002 -4.57 -16.36 -1.23 
Bcl2 modifying factor  BMF <0.00001 -4.55 -9.18 -1.04 
Ribophorin I RPN1 0.00002 -4.51 -15.81 -1.30 
Zinc finger CCCH-type containing 7B ZC3H7B 0.00176 -4.48 -3.09 -3.56 
Inhibin, beta E INHBE 0.00005 -4.42 -1.73 1.58 
Sialic acid binding Ig-like lectin 14 SIGLEC14 <0.00001 -4.41 -6.80 1.14 
Gap junction protein, delta 3, 31.9kDa  GJD3 <0.00001 -4.40 -7.33 1.35 
Interferon-related developmental regulator 
1 IFRD1 <0.00001 -4.37 -51.14 1.33 
TPA-induced transmembrane protein  TTMP 0.00014 -4.35 -10.35 -1.23 
POU class 3 homeobox 4  POU3F4 0.00030 -4.33 -3.55 1.01 
Microtubule associated monoxygenase, 
calponin and LIM domain containing 1 MICAL1 0.00010 -4.30 -4.81 -1.87 
Ribosomal protein L36a-like LOC100358069 0.00001 -4.28 -4.82 -1.04 
Cysteine-rich protein 3  CRIP3 <0.00001 -4.26 -10.99 1.45 
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Transmembrane protein 109 (TMEM109) TMEM109 <0.00001 -4.26 -39.14 -1.07 
Phospholamban PLN 0.00002 -4.25 -7.94 -2.00 
ISL LIM homeobox 2  ISL2 0.00007 -4.24 -5.75 -1.36 
Protein phosphatase 1, regulatory 
(inhibitor) subunit 8  PPP1R8 <0.00001 -4.24 -7.27 1.09 
Dehydrogenase/reductase (SDR family) 
member 13  DHRS13 <0.00001 -4.23 -9.82 1.02 
Sarcolemmal associated protein-3 
(LOC100009199) SLAP <0.00001 -4.19 -9.38 -1.47 
Ribosomal protein S7-like LOC100345715 0.00012 -4.17 -4.96 -1.91 
Eukaryotic translation initiation factor 1 LOC100345195 0.00004 -4.16 -5.61 -1.06 
Sema domain, immunoglobulin domain 
(Ig), transmembrane domain (TM) and 
short cytoplasmic domain, (semaphorin) 
4D 
SEMA4D <0.00001 -4.16 -3.24 1.19 
Malic enzyme 1, NADP(+)-dependent, 
cytosolic  ME1 0.00007 -4.16 -4.11 -1.52 
Poly(A) binding protein, cytoplasmic 4 
(inducible form) PABPC4 0.00009 -4.16 -5.67 1.10 
WD repeat domain 61  WDR61 <0.00001 -4.14 -30.33 1.14 
Guanine nucleotide binding protein (G 
protein), gamma 3  GNG3 <0.00001 -4.14 -5.64 1.07 
CD302 molecule CD302 <0.00001 -4.14 -17.51 -1.14 
Fibroblast growth factor 13 FGF13 0.00088 -4.12 -4.00 -2.20 
Pancreatic polypeptide receptor 1 
(PPYR1) PPYR1 0.00003 -4.12 -7.22 -1.10 
Membrane-associated ring finger 
(C3HC4) 6, E3 ubiquitin protein ligase  MARCH6 0.00091 -4.11 -3.82 -3.08 
ADP-ribosylation factor 4-like LOC100341862 0.00015 -4.11 -2.92 -1.20 
Bone morphogenetic protein 7 BMP7 0.00001 -4.08 -11.02 -1.21 
Potassium channel, subfamily K, member 
18 KCNK18 0.00022 -4.05 -2.91 1.14 
Aggrecanase-2 ADAMTS-11 ^, + 0.00387 -4.02 -4.44 -1.79 
 
^ DEGs that are common between ‘hypertension only’ and ‘hypercholesterolemia plus sham’ rabbits (each group vs. 
sham operated control group). + DEGs that are common among ‘hypertension only’, ‘hypercholesterolemia plus sham’, 
and ‘hypercholesterolemia plus hypertension’ rabbits (each group vs. sham operated control group). HT: ‘Hypertension 
only’ rabbits. HC: ‘Hypercholesterolemia plus sham’ rabbits. HCHT: ‘Hypercholesterolemia plus hypertension’ 
rabbits. 
  





Appendix 15. IPA network showing the network with the second largest number of 
upregulated focus genes in the ‘hypercholesterolemia plus hypertension’ group, 
compared with sham operated control group. (Ong et al., 2013)




Appendix 16. IPA network showing the network with the second largest number of 
downregulated focus genes in the ‘hypercholesterolemia plus hypertension’ group, 
compared with sham operated control group.(Ong et al., 2013) 
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Appendix 17. Upregulated genes in the MCA that are exclusive to 
‘hypercholesterolemia plus hypertension’ rabbits vs. sham operated control rabbits 
with greater than 4-fold change. (Ong et al., 2013)  
 






Schlafen family member 14 SLFN14  0.00614 13.64 
MRS2 magnesium homeostasis factor homolog (S. cerevisiae)  MRS2 0.00000 8.85 
HEAT repeat containing 3 LOC100357872 0.00100 8.34 
Membrane-spanning 4-domains, subfamily A, member 2 MS4A2 0.00891 8.29 
Kinesin family member 21A  KIF21A 0.00003 7.31 
N(alpha)-acetyltransferase 25, NatB auxiliary subunit NAA25 0.00099 7.23 
General transcription factor IIB LOC100359058 0.00015 7.00 
Interleukin 20 receptor, alpha IL20RA 0.00000 6.96 
Solute carrier family 18 (vesicular monoamine), member 1  SLC18A1 0.00074 6.64 
IQ motif and ubiquitin domain containing  IQUB 0.00104 6.64 
Family with sequence similarity 71, member C  FAM71C 0.00026 6.63 
Secretoglobin, family 3A, member 1 SCGB3A1 0.00010 6.42 
STAM binding protein-like 1  STAMBPL1 0.00286 6.39 
Tripartite motif-containing 67 TRIM67 0.00175 6.39 
Serum response factor binding protein 1-like LOC100349313 0.00139 6.34 
G protein-coupled receptor 119  GPR119 0.00058 6.30 
2',3'-cyclic nucleotide 3' phosphodiesterase  CNP 0.00000 6.14 
Steroidogenic acute regulatory protein  STAR 0.00007 6.05 
CD4 molecule (CD4) CD4 0.00004 6.02 
DOMON domain-containing protein FRRS1L FRRS1L 0.00003 5.99 
Tubulin tyrosine ligase-like family, member 5 LOC100359240 0.00019 5.99 
Thymidine phosphorylase  TYMP 0.00005 5.87 
Dynein heavy chain domain 1  DNHD1 0.00134 5.87 
Insulin-like 5 INSL5 0.00018 5.85 
Transcription elongation factor A (SII)-like 2-like LOC100340955 0.00015 5.75 
Solute carrier family 5 (sodium/glucose cotransporter), member 9 SLC5A9 0.00002 5.73 
Kruppel-like factor 13  KLF13 0.00007 5.69 
Granulate-macrophage stimulating factor (Predicted)  GMCSF 0.00004 5.68 
Listerin E3 ubiquitin protein ligase 1 LTN1 0.00009 5.66 
Carboxylesterase 8 (putative) CES4A 0.00023 5.63 
C-type lectin domain family 1, member B  CLEC1B 0.00584 5.60 
Solute carrier family 15, member 5  SLC15A5 0.00075 5.55 
Glucosidase, beta, acid 3 (cytosolic)  GBA3 0.00012 5.55 
Proline-rich protein 3 (MHC class I region proline-rich protein 
CAT56)  PRR3 0.00129 5.50 
Chemokine (C-C motif) ligand 19 CCL19 0.00055 5.50 
AchR epsilon subunit CHRNE 0.00010 5.43 
Transmembrane protein C5orf28  C5orf28 0.00319 5.38 
Dehydrogenase/reductase (SDR family) member 9  DHRS9 0.00168 5.37 
FCH and double SH3 domains 1  FCHSD1 0.00015 5.37 
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Uncharacterized protein C7orf72  C2orf72 0.00114 5.35 
Family with sequence similarity 71, member F2  FAM71F2 0.00643 5.34 
Otopetrin 2  OTOP2 0.00006 5.31 
Elongation of very long chain fatty acids (FEN1/Elo2, 
SUR4/Elo3, yeast)-like 3 ELOVL3 0.00012 5.30 
Solute carrier family 7, (cationic amino acid transporter, y+ 
system) member 13  SLC7A13 0.00134 5.30 
Uncharacterized protein C2orf71  C2orf71 0.00177 5.30 
Solute carrier family 14 (urea transporter), member 1 (Kidd blood 
group)  SLC14A1 0.00027 5.21 
RAS guanyl releasing protein 4 RASGRP4 0.00058 5.11 
ATPase, class I, type 8B, member 2 ATP8B2 0.00360 5.07 
Cytochrome P450, family 4, subfamily A, polypeptide 5 CYP4A5 0.00061 5.05 
Pregnancy-zone protein PZP 0.00652 5.02 
ATPase, H+/K+ exchanging, alpha polypeptide (ATP4A) ATP4A 0.00000 5.02 
CD2 molecule CD2 0.00064 4.99 
3-oxo-5-alpha-steroid 4-dehydrogenase 2-like LOC100343882 0.00001 4.99 
Phosphatidylcholine transfer protein PCTP 0.00001 4.96 
Transmembrane emp24 protein transport domain containing 6  TMED6 0.00040 4.96 
Actin-related protein T1 ACTRT1 0.00005 4.94 
Wings apart-like homolog LOC100348678 0.00041 4.94 
Fructose-1,6-bisphosphatase 1 FBP1 0.00050 4.88 
Neuron navigator 2 NAV2 0.00080 4.87 
Potassium channel tetramerisation domain containing 19 KCTD19 0.00123 4.87 
Spermatogenesis associated, serine-rich 1  SPATS1 0.00201 4.83 
Solute carrier family 5 (sodium/glucose cotransporter), member 1 LOC100009262 0.00001 4.80 
Tripartite motif-containing 35  TRIM35 0.00084 4.80 
Cytochrome P450, family 26, subfamily C, polypeptide 1  CYP26C1 0.00224 4.79 
Polymeric immunoglobulin receptor Precursor (Poly-Ig 
receptor)(PIGR)  PIGR 0.00025 4.75 
Ras and Rab interactor-like RINL 0.00135 4.71 
Ubiquitin associated and SH3 domain containing B  UBASH3B 0.00803 4.70 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 13 (GalNAc-T13) GALNT13 0.00000 4.70 
PRP18 pre-mRNA processing factor 18 homolog (S. cerevisiae) PRPF18 0.00144 4.68 
Spinster homolog 3 (Drosophila) SPNS3 0.00049 4.68 
Galactosidase, beta 1-like 3  GLB1L3 0.00003 4.67 
Iroquois homeobox 2  IRX2 0.00052 4.66 
Collagen, type XVII, alpha 1 COL17A1 0.00028 4.65 
Patched 2 PTCH2 0.00005 4.65 
DEAQ box RNA-dependent ATPase 1  DQX1 0.00520 4.60 
Potassium channel, subfamily K, member 1 KCNK1 0.00217 4.58 
Purinergic receptor P2Y, G-protein coupled, 10  P2RY10 0.00197 4.57 
Somatostatin receptor 2 SSTR2 * 0.00077 4.56 
Zinc finger, DHHC-type containing 19 ZDHHC19 0.00241 4.55 
Ret proto-oncogene  RET 0.00036 4.55 
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Oxytocin receptor OXTR 0.00517 4.52 
Serine peptidase inhibitor, Kazal type 1  SPINK1 0.00055 4.50 
Membrane protein, palmitoylated 2 (MAGUK p55 subfamily 
member 2) MPP2 0.00409 4.50 
Solute carrier family 13 (sodium/sulfate symporters), member 1  SLC13A1 0.00325 4.49 
Follistatin-like 5  FSTL5 0.00071 4.49 
Mitochondrial ribosomal protein S15-like LOC100345026 0.00064 4.49 
TERF1 (TRF1)-interacting nuclear factor 2  TINF2 0.00325 4.49 
Keratin associated protein 19-4  KRTAP19-4 0.00044 4.48 
XK, Kell blood group complex subunit-related, X-linked XKRX 0.00051 4.47 
FK506 binding protein 1B, 12.6 kDa FKBP1B 0.00274 4.46 
Phospholipase C, zeta 1  PLCZ1 0.00002 4.45 
CD244 molecule, natural killer cell receptor 2B4  CD244 0.00003 4.44 
Carboxyl ester lipase (bile salt-stimulated lipase) (CEL) CEL 0.00016 4.44 
ADAM metallopeptidase with thrombospondin type 1 motif, 18  ADAMTS18 0.00213 4.43 
UDP-glucuronosyltransferase UGT2C1 0.00035 4.42 
Fms-related tyrosine kinase 3  FLT3 0.00270 4.41 
Mitogen-activated protein kinase binding protein 1  MAPKBP1 0.00003 4.41 
Ammonium transporter Rh type C (Rhesus blood group family 
type C glycoprotein)(Rh family type C glycoprotein)(Rh type C 
glycoprotein) 
RHCG 0.00032 4.41 
Kelch-like 1 (Drosophila) KLHL1 0.00003 4.35 
Leucine rich repeat transmembrane neuronal 4 LRRTM4 0.00002 4.34 
Proteoglycan 3  PRG3 0.00254 4.33 
Ligand of numb-protein X 1-like LOC100343259 0.00568 4.33 
Chymase like protein LOC100008644 0.00060 4.32 
Sex comb on midleg-like 4 (Drosophila)  SCML4 0.00854 4.32 
BMS1-like, ribosome assembly protein LOC100339194 0.00017 4.31 
Uncharacterized protein C2orf61 C2orf61 0.00893 4.31 
Protein FAM55A LOC100009342 0.00326 4.30 
Cyclin-dependent kinase 15  CDK15 0.00129 4.28 
Rac GTPase activating protein 1 pseudogene  RACGAP1P 0.00023 4.27 
Family with sequence similarity 170, member A  FAM170A 0.00008 4.23 
Mitogen-activated protein kinase 4 MAP3K4 0.00788 4.22 
ATPase, H+ transporting, lysosomal 70kDa, V1 subunit A ATP6V1A 0.00397 4.19 
FRY-like  FRYL 0.00291 4.18 
Clusterin-like 1 (retinal)  CLUL1 0.00072 4.17 
Superiorcervical ganglia, neural specific 10 LOC100344464 0.00228 4.14 
Histamine receptor H1  HRH1 0.00001 4.13 
Cingulin (Predicted)  Cgn 0.00236 4.12 
Nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor, delta  NFKBID 0.00103 4.12 
Ribonuclease, RNase A family, 1 (pancreatic) RNASE1 0.00043 4.11 
Nuclear prelamin A recognition factor LOC100344024 0.00002 4.09 
Actin, beta-like 2 ACTBL2 0.00023 4.09 
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Ghrelin receptor LOC100101582 0.00062 4.08 
Olfactomedin 2  OLFM2 0.00385 4.07 
COX10 homolog, cytochrome c oxidase assembly protein, heme 
A: farnesyltransferase (yeast)  COX10 0.00160 4.07 
Ribonuclease L (2',5'-oligoisoadenylate synthetase-dependent) RNASEL 0.00028 4.06 
Keratin associated protein 11-1  KRTAP11-1 0.00013 4.04 
DnaJ (Hsp40) homolog, subfamily C, member 5 beta  DNAJC5B 0.00016 4.03 
Receptor (chemosensory) transporter protein 1 RTP1 0.00012 4.03 
Protocadherin 8 PCDH8 0.00005 4.02 
Ubiquitin specific protease 39 LOC100344046 0.00343 4.02 
Proline/serine-rich coiled-coil 1  PSRC1 0.00571 4.01 
Cadherin 17, LI cadherin (liver-intestine)  CDH17 0.00459 4.00 
HCHT: ‘Hypercholesterolemia plus hypertension’ rabbits. 
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Appendix 18. Downregulated genes in the MCA that are exclusive to 
‘hypercholesterolemia plus hypertension’ rabbits vs. sham operated control rabbits 
with greater than 4-fold change. (Ong et al., 2013) 
 






Somatostatin SST 0.00169 -10.49 
Cellular disintegrin ADAM 6d (ADAM6) ADAM6 0.00009 -9.13 
Prolactin receptor  PRLR 0.00001 -8.55 
ELAV (embryonic lethal, abnormal vision, Drosophila)-like 4 (Hu 
antigen D) ELAVL4 0.00033 -8.49 
Proteolipid protein 1 PLP1 0.00578 -8.28 
Stathmin-like 2  STMN2 0.00129 -7.60 
Olfactomedin 3  OLFM3 0.00005 -6.99 
Pyruvate dehydrogenase kinase, isozyme 4 PDK4 0.00711 -6.98 
Myelin-associated oligodendrocyte basic protein  MOBP 0.00776 -6.94 
Paired box protein Pax-4 (Predicted)  PAX4 0.00001 -5.45 
SPHK1 interactor, AKAP domain containing  SPHKAP 0.00629 -4.99 
Neurogranin (protein kinase C substrate, RC3) NRGN 0.00291 -4.98 
GDNF family receptor alpha 4  GFRA4 0.00025 -4.88 
Sulfotransferase family 4A, member 1 SULT4A1 0.00285 -4.75 
KIAA1549  KIAA1549 0.00019 -4.67 
Zinc finger CCCH-type containing 7B ZC3H7B 0.00176 -4.48 
Inhibin, beta E  INHBE 0.00005 -4.42 
POU class 3 homeobox 4  POU3F4 0.00030 -4.33 
Sema domain, immunoglobulin domain (Ig), transmembrane 
domain (TM) and short cytoplasmic domain, (semaphorin) 4D  SEMA4D 0.00000 -4.16 
Membrane-associated ring finger (C3HC4) 6, E3 ubiquitin protein 
ligase MARCH6 0.00091 -4.11 
ADP-ribosylation factor 4-like LOC100341862 0.00015 -4.11 
Potassium channel, subfamily K, member 18  KCNK18 0.00022 -4.05 
HCHT: ‘Hypercholesterolemia plus hypertension’ rabbits. 
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Appendix 19. Upregulated genes in the ‘hypercholesterolemia plus sham’ rabbits vs. 
sham operated control rabbits that are exclusive to the FC with greater than 10-fold 
change. 
  







Cell death-inducing DFFA-like effector c  CIDEC 0.00008 62.26 
Transcription factor CP2-like 1  TFCP2L1 0.00007 29.15 
Outer dense fiber of sperm tails 2  ODF2 0.00040 29.07 
Ribonuclease L (2',5'-oligoisoadenylate synthetase-dependent)  RNASEL 0.00021 28.98 
Follicle stimulating hormone receptor  FSHR 0.00089 28.24 
Carboxylesterase 3  CES3 0.00125 27.26 
Protein mab-21-like 3 MAB21L3 0.00048 25.83 
Secretoglobin, family 3A, member 1  SCGB3A1 0.00056 20.36 
Fibroblast growth factor binding protein 2  FGFBP2 0.00013 17.99 
Tetraspanin 12  TSPAN12 0.00135 17.91 
Solute carrier family 35 (UDP-GlcNAc/UDP-glucose transporter), 
member D2 SLC35D2 0.00066 17.77 
Leucine rich repeat containing 15  LRRC15 0.00012 17.58 
ASF1 anti-silencing function 1 homolog A (S. cerevisiae) ASF1A 0.00025 15.91 
Fibroblast growth factor binding protein 1-like LOC100353835 0.00042 15.26 
Homeobox A2 (Predicted)  HOXA2 0.00016 15.21 
Protease, serine, 38  PRSS38 0.00030 14.94 
Cytochrome P450 1A2 CYP1A2 0.00036 14.88 
Myosin, heavy chain 6, cardiac muscle, alpha MYH6 0.00023 14.58 
Galactosidase, beta 1-like 3  GLB1L3 0.00067 13.91 
Paired box 1  PAX1 0.00036 13.89 
Uncharacterized protein C2orf71  C2orf71 0.00046 13.74 
Peptide YY PYY 0.00116 13.58 
Beta-carotene 15,15'-monooxygenase 1  BCMO1 0.00039 13.07 
V-set and transmembrane domain containing 1  VSTM1 0.00215 13.03 
Collagen, type II, alpha 1 COL2A1 0.00050 12.63 
Collagen, type VIII, alpha 2  COL8A2 0.00038 12.39 
Pregnancy-zone protein PZP 0.00018 12.27 
Prominin 2  PROM2 0.00014 12.26 
Granulate-macrophage stimulating factor (Predicted)  GMCSF 0.00009 12.03 
G protein-coupled receptor 182  GPR182 0.00021 12.02 
Cytochrome P450 2G1 CYP2G1 0.00056 12.02 
Claudin 16  CLDN16 0.00020 11.99 
ZW10 interacting kinetochore protein ZWINT 0.00005 11.97 
tRNA splicing endonuclease 54 homolog (S. cerevisiae)  TSEN54 0.00106 11.80 
G protein-coupled receptor 156  GPR156 0.00038 11.56 
RAS guanyl releasing protein 4  RASGRP4 0.00361 11.47 
Keratin 84  KRT84 0.00063 11.36 
Phospholipase A2 PLA2G1B 0.00018 11.30 
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Myotilin  MYOT 0.00019 11.18 
Retinitis pigmentosa GTPase regulator interacting protein 1  RPGRIP1 0.00189 11.12 
Iroquois homeobox 2  IRX2 0.00085 11.09 
Cartilage intermediate layer protein, nucleotide 
pyrophosphohydrolase  CILP 0.00052 11.02 
Protease, serine, 16 (thymus)  PRSS16 0.00037 10.91 
Olfactory receptor, family 2, subfamily B, member 11  OR2B11 0.00010 10.85 
Dehydrogenase/reductase (SDR family) member 9  DHRS9 0.00006 10.74 
5-hydroxytryptamine (serotonin) receptor 4, G protein-coupled  HTR4 0.00011 10.69 
Homeobox D11  HOXD11 0.00011 10.46 
Caspase 14 LOC100101622 0.00003 10.46 
Tetratricopeptide repeat domain 28  TTC28 0.00048 10.42 
Cytochrome P450, family 4, subfamily A, polypeptide 5 CYP4A5 0.00022 10.37 
UTP14, U3 small nucleolar ribonucleoprotein, homolog A (yeast) UTP14A 0.00019 10.31 
Double homeobox A  DUXA 0.00110 10.17 
CD38 molecule CD38 0.00013 10.15 
Rac GTPase activating protein 1 pseudogene  RACGAP1P 0.00030 10.09 
Tyrosine hydroxylase TH 0.00116 10.04 
Maestro heat-like repeat-containing protein family member 6 MROH6 0.00034 10.01 
HC: ‘Hypercholesterolemia plus sham’ rabbits. 
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Appendix 20. Downregulated genes in the ‘hypercholesterolemia plus sham’ rabbits 
vs. sham operated control rabbits that are exclusive to the FC with greater than 10-fold 
change.  
 







UDP-glucuronosyltransferase 2B13 UGT2B13 0.00026 -26.47 
Rhophilin associated tail protein 1-like ROPN1L 0.00005 -20.85 
KIAA0513  KIAA0513 0.00020 -20.31 
Protein kinase C, beta PRKCB 0.00128 -19.92 
Gamma-aminobutyric acid (GABA) A receptor, alpha 6  GABRA6 0.00015 -17.62 
ALX homeobox 1  ALX1 0.00019 -17.40 
Matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa 
type IV collagenase) MMP9 0.00028 -16.10 
ELOVL fatty acid elongase 2  ELOVL2 0.00012 -15.72 
Tubulin, beta 1  TUBB1 0.00005 -15.57 
RAB3A interacting protein  RAB3IP 0.00003 -15.36 
Tripartite motif-containing 37  TRIM37 0.00202 -13.86 
Insulin-like 6  INSL6 0.00017 -13.21 
Cerebral cavernous malformations 2 protein-like CCM2L 0.00022 -12.18 
TSR1, 20S rRNA accumulation, homolog (S. cerevisiae)  TSR1 0.00006 -11.63 
Proline, glutamate and leucine rich protein 1  PELP1 0.00025 -10.97 
HC: ‘Hypercholesterolemia plus sham’ rabbits. 
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Appendix 21. Upregulated genes in the ‘hypercholesterolemia plus sham’ rabbits vs. 
sham operated control rabbits that are exclusive to the MCA with greater than 4-fold 
change. 







Family with sequence similarity 46, member C  FAM46C 0.00543 8.51 
Signal-induced proliferation-associated 1 like 3  SIPA1L3 0.00186 8.45 
Uncharacterized protein C11orf71  C11orf71 0.00289 8.33 
Sterol O-acyltransferase 2  SOAT2 0.00235 7.18 
Fc receptor-like A  FCRLA 0.00410 6.76 
CKLF-like MARVEL transmembrane domain containing 2  CMTM2 0.00972 6.28 
Chymotrypsin-like elastase family, member 1  CELA1 0.00112 6.24 
UHRF1 binding protein 1  UHRF1BP1 0.00859 5.70 
Tetraspanin 33  TSPAN33 0.00497 5.61 
REC8 meiotic recombination protein REC8 0.00100 5.52 
Serine incorporator 1 LOC100357075 0.00375 5.37 
Transmembrane protein 149  IGFLR1 0.00128 5.37 
Solute carrier family 9, subfamily A (NHE5, cation proton antiporter 
5), member 5 SLC9A5 0.00351 5.36 
BCL2-like 10 (apoptosis facilitator)  BCL2L10 0.00118 5.34 
Zinc finger, CW type with PWWP domain 2  ZCWPW2 0.00445 5.29 
Mitogen-activated protein kinase 4 MAP3K4 0.00728 5.19 
PSMC3 interacting protein  PSMC3IP 0.00041 5.12 
Testis-specific kinase 2  TESK2 0.00505 5.11 
Double zinc ribbon and ankyrin repeat-containing protein 1 DZANK1 0.00199 5.04 
Nuclear receptor subfamily 1, group D, member 1  NR1D1 0.00824 4.98 
Deltex homolog 3 (Drosophila)  DTX3 0.00457 4.92 
LY6/PLAUR domain containing 5  LYPD5 0.00274 4.70 
4-hydroxyphenylpyruvate dioxygenase-like  HPDL 0.00692 4.68 
Amyloid beta (A4) precursor protein-binding, family B, member 3  APBB3 0.00011 4.66 
BMS1-like, ribosome assembly protein LOC100339194 0.00272 4.46 
Cyclin B3  CCNB3 0.00828 4.39 
Kelch-like 17 (Drosophila)  KLHL17 0.00047 4.38 
PDZ domain containing 3  PDZD3 0.00180 4.38 
WD repeat domain 13  WDR13 0.00765 4.37 
DIS3 mitotic control homolog (S. cerevisiae)-like 2  DIS3L2 0.00729 4.32 
Doublesex and mab-3 related transcription factor 2  DMRT2 0.00319 4.28 
Ribonuclease, RNase A family, 1 (pancreatic)  RNASE1 0.00345 4.26 
Paralemmin 2 PALM2 0.00726 4.26 
O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-N-
acetylglucosamine:polypeptide-N-acetylglucosaminyl transferase)  OGT 0.00075 4.20 
Colony stimulating factor 3 receptor (granulocyte)  CSF3R 0.00224 4.19 
Uncharacterized protein C1orf51  C1orf51 0.00024 4.19 
MORN repeat containing 4  MORN4 0.00031 4.14 
Methyl-CpG binding domain protein 6  MBD6 0.00020 4.11 
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Ankyrin repeat and SOCS box-containing 4  ASB4 0.00967 4.06 
Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase 
epsilon  IKBKE 0.00249 4.04 
Phospholipase C, delta 4  PLCD4 0.00710 4.01 
HC: ‘Hypercholesterolemia plus sham’ rabbits. 
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Appendix 22. Downregulated genes in the ‘hypercholesterolemia plus sham’ rabbits 
vs. sham operated control rabbits that are exclusive to the MCA with greater than 10-
fold change. 







Forkhead box N1  FOXN1 0.00784 -56.89 
Ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide-
like 1  UQCRFS1P1 0.00047 -40.99 
Solute carrier family 9, subfamily A (NHE2, cation proton antiporter 
2), member 2 SLC9A2 0.00019 -36.54 
Tumor protein, translationally-controlled 1 TPT1 0.00008 -26.77 
AHA1, activator of heat shock 90kDa protein ATPase homolog 2 
(yeast)  AHSA2 0.00319 -23.77 
Hhematopoietic prostaglandin D synthase  HPGDS 0.00784 -21.44 
Putative homeodomain transcription factor 2 PHTF2 0.00005 -20.84 
Cytoplasmic beta-actin LOC100009506 0.00078 -20.51 
CD302 molecule  CD302 0.00020 -17.51 
Enabled homolog (Drosophila)  ENAH 0.00247 -16.36 
TIA1 cytotoxic granule-associated RNA binding protein-like 1  TIAL1 0.00478 -13.80 
TTN TTN 0.00118 -13.60 
Sodium channel, voltage-gated, type VII, alpha  SCN7A 0.00130 -12.29 
Complement component 1, q subcomponent-like 3  C1QL3 0.00902 -11.67 
Interferon induced with helicase C domain 1  IFIH1 0.00157 -10.96 
Solute carrier family 2, facilitated glucose transporter member 3 SLC2A3 0.00372 -10.95 
PDLIM1 interacting kinase 1 like  PDIK1L 0.00062 -10.76 
F-box and WD repeat domain containing 7, E3 ubiquitin protein ligas FBXW7 0.00014 -10.71 
Pyrroline-5-carboxylate reductase-like protein C14orf148 (EC 1.-.-.-) NOXRED1 0.00343 -10.49 
Caudal type homeobox 1  CDX1 0.00156 -10.42 
HC: ‘Hypercholesterolemia plus sham’ rabbits. 
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Appendix 23. Upregulated genes in the ‘hypercholesterolemia plus sham’ rabbits vs. 
sham operated control rabbits that are in common between the FC and MCA with 
greater than 10-fold change (in either FC or MCA). 
 











Fc receptor-like 3  FCRL3 0.00022 21.65 0.00784 4.52 
Gonadotropin-releasing hormone receptor  GnRHR 0.00018 18.76 0.00811 5.47 
TAF15 RNA polymerase II, TATA box 
binding protein (TBP)-associated factor, 
68kDa  
TAF15 0.00029 18.25 0.00349 4.71 
Leucine-rich repeat-containing G protein-
coupled receptor 5  LGR5 0.00033 13.08 0.00371 4.14 
Serine proteinase inhibitor, clade B, 
member 2 (Predicted)  SERPINB2 0.00005 12.41 0.00319 6.99 
Kinesin family member 13B  KIF13B 0.00012 11.98 0.00202 6.02 
Interleukin 8 IL8 0.00113 11.66 0.00991 4.87 
Islet amyloid polypeptide IAPP 0.00092 11.39 0.00289 4.17 
Teneurin transmembrane protein 4 TENM4  0.00084 10.72 0.00267 4.31 
Pregnancy-zone protein PZP 0.00036 10.47 0.00245 5.46 
G protein-coupled receptor 52  GPR52 0.00449 10.41 0.00615 4.40 
Potassium channel tetramerisation domain 
containing 19  KCTD19 0.00008 10.32 0.00651 4.40 
Mast cell-expressed membrane protein 1  MCEMP1 0.00014 10.09 0.00935 4.67 
HC: ‘Hypercholesterolemia plus sham’ rabbits. 
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Appendix 24. Downregulated genes in the ‘hypercholesterolemia plus sham’ rabbits 
vs. sham operated control rabbits that are in common between the FC and MCA with 
greater than 10-fold change (in either FC or MCA). 
 











Family with sequence similarity 184, 
member B  FAM184B 0.00001 -116.47 0.00012 -68.05 
Cullin 3  CUL3 0.00001 -80.07 0.00006 -73.37 
Glutamate dehydrogenase 1-like LOC100351029 0.00009 -79.97 0.00009 -55.82 
Transmembrane protein 109  TMEM109 0.00006 -68.30 0.00011 -39.14 
Progesterone receptor membrane 
component 1 
LOC10035709
7 0.00001 -64.16 0.00011 -38.66 
Prefoldin subunit 5  PFDN5 0.00021 -63.30 0.00022 -84.52 
3'(2'), 5'-bisphosphate nucleotidase 1  BPNT1 0.00031 -59.24 0.00003 -52.27 
Heterogeneous nuclear 
ribonucleoprotein C (hnRNP C)  HNRNPC 0.00003 -52.05 0.00050 -12.22 
Transmembrane protein 38B  TMEM38B 0.00002 -47.36 0.00018 -31.53 
Androgen-induced 1  AIG1 0.00005 -43.77 0.00205 -35.48 
Chaperonin containing TCP1, subunit 
2 (beta)  CCT2 0.00009 -40.45 0.00006 -28.67 
Interferon-related developmental 
regulator 1  IFRD1 0.00005 -38.79 0.00028 -51.14 
Ribophorin I  RPN1 0.00128 -36.98 0.00076 -15.81 
Periphilin 1  PPHLN1 0.00006 -33.60 0.00022 -15.71 
Crystallin, alpha A  CRYAA 0.00001 -33.04 0.00001 -60.93 
Zinc finger protein 642  ZFP69 0.00278 -29.17 0.00127 -20.24 
GC-rich promoter binding protein 1  GPBP1 0.00014 -28.51 0.00018 -42.73 
Tyrosine 3-
monooxygenase/tryptophan 5-
monooxygenase activation protein, 
beta polypeptide-like 
LOC10035829
9 0.00016 -28.25 0.00008 -26.07 
IQ motif and Sec7 domain 3  IQSEC3 0.00005 -27.98 0.00180 -8.73 
Proteasome (prosome, macropain) 
26S subunit, ATPase, 6  PSMC6 0.00005 -26.83 0.00010 -22.71 
Nucleolar protein 10  NOL10 0.00003 -25.56 0.00048 -14.02 
Obg-like ATPase 1  OLA1 0.00005 -23.46 0.00006 -35.58 
Endoplasmic reticulum lectin 1  ERLEC1 0.00035 -23.32 0.00007 -34.54 
Solute carrier family 35 (adenosine 3'-
phospho 5'-phosphosulfate 
transporter), member B3 
SLC35B3 0.00014 -22.89 0.00135 -6.60 
Zinc finger protein 638  ZNF638 0.00077 -22.50 0.00006 -22.80 
WW domain containing adaptor with 
coiled-coil  WAC 0.00009 -21.29 0.00060 -13.20 
Uncharacterized LOC100347346 LOC100347346 0.00019 -21.18 0.00107 -13.05 
Microtubule associated tumor 
suppressor 1  MTUS1 0.00001 -21.06 0.00109 -41.71 
Myosin IE  MYO1E 0.00002 -20.09 0.00013 -21.50 
Guanylate cyclase 1, soluble, beta 3  GAPDHS 0.00010 -19.50 0.00083 -11.97 
Manganese superoxide dismutase SOD-2 0.00014 -18.85 0.00013 -46.42 
WD repeat domain 61  WDR61 0.00006 -17.85 0.00350 -8.46 
OTU deubiquitinase 6A OTUD6A 0.00031 -17.62 0.00021 -28.99 
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Upregulated during skeletal muscle 
growth 5 homolog (mouse)  USMG5 0.00009 -16.81 0.00020 -11.86 
Eukaryotic translation initiation factor 
3, subunit M  EIF3M 0.00020 -16.15 0.00006 -10.81 
Secretion regulating guanine 
nucleotide exchange factor  SERGEF 0.00060 -15.87 0.00061 -9.83 
V-Ki-ras2 Kirsten rat sarcoma viral 
oncogene homolog  KRAS 0.00032 -15.13 0.00050 -22.11 
Nuclear transport factor 2-like export 
factor 2  NXT2 0.00047 -14.82 0.00205 -4.22 
Mitochondrial ribosomal protein L1  MRPL1 0.00001 -14.79 0.00033 -15.71 
BRCA2 and CDKN1A interacting 
protein  BCCIP 0.00003 -14.65 0.00021 -13.68 
Nucleolar protein 11 NOL11 0.00034 -14.23 0.00791 -11.98 
Poly(rC) binding protein 3  PCBP3 0.00077 -13.92 0.00234 -6.03 
SWI/SNF related, matrix associated, 
actin dependent regulator of 
chromatin, subfamily a, member 5  
SMARCA5 0.00013 -13.77 0.00046 -19.50 
SWI/SNF related, matrix associated, 
actin dependent regulator of 
chromatin, subfamily d, member 3  
SMARCD3 0.00010 -13.66 0.00015 -11.91 
Cytochrome P450, family 7, 
subfamily A, polypeptide 1 CYP7A1 0.00003 -13.41 0.00146 -9.16 
Tyrosine 3-
monooxygenase/tryptophan 5-
monooxygenase activation protein, 
theta polypeptide 
YWHAQ 0.00008 -13.24 0.00012 -15.13 
Sin3A-associated protein, 30kDa  SAP30 0.00003 -13.11 0.00011 -14.99 
Zinc finger protein 326  ZNF326 0.00171 -12.97 0.00128 -18.36 
RWD domain containing 3  RWDD3 0.00004 -12.93 0.00044 -10.16 
SERTA domain containing 4  SERTAD4 0.00048 -12.85 0.00344 -5.69 
Destrin LOC100358081 0.00015 -12.68 0.00042 -7.84 
MYB binding protein (P160) 1a  MYBBP1A 0.00008 -12.61 0.00009 -4.32 
Mitochondrial ribosomal protein L15  MRPL15 0.00016 -12.53 0.00047 -23.01 
Aryl hydrocarbon receptor nuclear 
translocator ARNT 0.00009 -12.52 0.00018 -13.43 
UDP-glucuronosyltransferase UGT2C1 0.00119 -12.46 0.00054 -12.36 
Zinc finger protein 330  ZNF330 0.00045 -12.39 0.00560 -7.41 
Lupus La protein homolog SSB 0.00114 -12.31 0.00007 -40.45 
Eukaryotic translation initiation factor 
2 subunit 1 EIF2S1 0.00055 -12.06 0.00051 -16.08 
FtsJ homolog 3 (E. coli)  FTSJ3 0.00003 -12.05 0.00091 -5.78 
Proteasome (prosome, macropain) 
26S subunit, non-ATPase, 4 PSMD4 0.00007 -11.96 0.00015 -12.56 
N-myristoyltransferase 2  NMT2 0.00049 -11.89 0.00483 -5.19 
KIAA0305-like LOC100358165 0.00010 -11.86 0.00047 -6.02 
KIAA0513  KIAA0513 0.00253 -11.59 0.00055 -4.14 
ALG9, alpha-1,2-mannosyltransferase  ALG9 0.00002 -11.38 0.00074 -13.51 
Alpha-tubulin N-acetyltransferase ATAT1 0.00017 -11.32 0.00059 -29.43 
DENN/MADD domain containing 1B  DENND1B 0.00091 -11.09 0.00162 -8.81 
DEAH (Asp-Glu-Ala-His) box 
polypeptide 9  DHX9 0.00021 -10.88 0.00021 -7.81 
WD repeat domain 43  WDR43 0.00010 -10.68 0.00106 -9.13 
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Methyltransferase like 10  METTL10 0.00179 -10.49 0.00885 -4.56 
Adaptor-related protein complex 4, 
sigma 1 subunit  AP4S1 0.00001 -10.08 0.00010 -9.37 
Ribosomal protein L36a-like LOC100358069 0.00026 -9.25 0.00219 -14.97 
DCN1, defective in cullin neddylation 
1, domain containing 4 (S. cerevisiae)  DCUN1D4 0.00177 -8.75 0.00070 -18.27 
Amyloid beta precursor protein 
(cytoplasmic tail) binding protein 2  APPBP2 0.00058 -8.36 0.00007 -14.30 
ribosomal protein L26  RPL26 0.00029 -7.01 0.00018 -14.60 
RUN and FYVE domain containing 1  RUFY1 0.00468 -7.00 0.00460 -10.38 
FGGY carbohydrate kinase domain 
containing  FGGY 0.00143 -6.75 0.00073 -16.26 
Insulin induced gene 2  NSIG2 0.00074 -6.32 0.00012 -21.07 
Tumor necrosis factor receptor 
superfamily, member 11b TNFRSF11B 0.00017 -6.27 0.00037 -55.91 
ORM1-like 3 (S. cerevisiae)  ORMDL3 0.00055 -6.17 0.00035 -17.49 
Large subunit GTPase 1 homolog (S. 
cerevisiae)  LSG1 0.00015 -6.11 0.00299 -17.14 
Beta tropomyosin LOC100125984 0.00016 -6.09 0.00020 -97.92 
Lysine (K)-specific demethylase 4A  KDM4A 0.00271 -5.80 0.00011 -10.29 
IQ motif containing GTPase 




6 0.00194 -5.59 0.00022 -26.85 
Cysteine-rich protein 3  CRIP3 0.00064 -5.12 0.00080 -10.99 
Enabled homolog (Drosophila)  ENAH 0.00924 -4.99 0.00116 -16.59 
Ubiquitin specific peptidase 16  USP16 0.00053 -4.88 0.00006 -12.55 
TRAF family member-associated 
NFKB activator  TANK 0.00022 -4.72 0.00071 -20.39 
Solute carrier family 2, facilitated 
glucose transporter member 3 
Fragment (Glucose transporter type 3, 
brain)(GLUT-3)  
SLC2A3 0.00019 -4.05 0.00396 -22.12 
HC: ‘Hypercholesterolemia plus sham’ rabbits. 
 
